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Abstract 
Bovine mastitis continues to pose a major economic challenge to the dairy 
industry worldwide. Critical to the management and control of this condition, is 
the need for prompt and accurate diagnosis in field conditions, therefore a 
search for more sensitive and reliable biomarkers is required. 
In this thesis, studies focused on assessing milk samples from cows with various 
forms of mastitis were undertaken with a view to identifying new biomarkers for 
bovine mastitis.  
Three acute phase proteins (APP); haptoglobin (Hp), mammary associated serum 
amyloid A3 (M-SAA3) and C-reactive protein (CRP) were measured in milk 
samples from composite milk samples of all lactating cows in a commercial dairy 
herd, mastitis cases, submitted to a diagnostic laboratory and following an 
experimental mastitis challenge of cows with Streptococcus uberis. A new 
enzyme linked immunosorbent assay (ELISA) was developed for measuring Hp, 
while commercial ELISA assay kits were used to assay M-SAA3 and CRP. Other 
mastitis related parameters evaluated in the samples included the somatic cell 
counts (SCC) and the presence of pathogens.  
A reliable and sensitive ELISA was developed and optimized for measuring milk 
Hp. A cut off value for Hp of 7.9 µg/ml was established for milk with SCC less 
than 200,000 cells/ml. Pathogen-specific variations were observed in the 
concentration of each APP in mastitic milk. It was observed that the 
environmental pathogens showed higher concentrations of APP compared to 
other pathogens, from the study of mastitis milk samples submitted to the 
diagnostic laboratory. Also, it was possible to distinguish between samples from 
subclinical and clinical mastitis and between samples from subclinical and 
healthy udders using each of the APP (P<0.05). Haptoglobin, M-SAA3 and CRP 
showed corresponding variation with stage of infection during the course of 
experimental mastitis, and specifically CRP was observed to rise earlier than 
other two APP.  
Furthermore, characterization of the profile of these APP in the immediate post-
calving milk samples was carried out to determine how valuable they would be 
in recognizing new mastitis infections arising at the post-partum period. It was 
observed that there is a general moderately-high level of APP in milk 
immediately following parturition which drops a few days later in healthy milk.  
The immunohistochemical localization of Hp in the bovine mammary gland was 
also assessed. It could be concluded from that study that neutrophils and the 
mammary epithelial cells secrete Hp into milk during mastitis. 
Gel and non-gel based proteomics approaches were employed to study the 
protein profiles and variation in mastitic milk from normal samples. Several 
proteins were identified that confirmed previous findings and project new 
mastitis markers, for example, serotransferrin, serpins, alpha-macroglobulin and 
neutrophil gelatinase associated lipocalins. A capillary electrophoresis mass 
spectrometry system (CE-MS) was also employed to elucidate the changing 
peptidome in milk during the course of an experimental mastitis, which lead to 
the generation of a panel of 77 polypeptides, which were able to significantly 
differentiate critical stages of mastitis. Three of these polypeptides were found 
in mastitic milk samples from previous peptidomic analyses thereby indicating 
strong biomarker value. 
Finally, a liquid chromatography mass spectrometry based metabolomics 
approach was used to study the changing profile of small metabolites in milk 
during the course of an experimental infection. Several pathway-based changes 
that highlighted metabolites of potential significance in mastitis diagnosis were 
recognized including lactose synthesis, nitrogen containing compounds such as 
betaine, L-carnitine and lipid metabolites pathways namely sn-
glycerophosphocholine and choline among others. 
Overall, this study has shown the value of APP, milk proteomics and 
metabolomics in bovine mastitis diagnosis; the changing proteins and 
metabolites or their patterns need to be further experimentally and clinically 
validated as specific and sensitive markers of mastitis. Ultimately, the 
applicability of APP, proteins, peptides and metabolites and/or their changing 
patterns as mastitis biomarkers would require their adaptation to rapid (on 
farm) and robust measurement formats.  
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1 General Introduction 
1.1 Bovine mastitis 
Mastitis refers to the inflammation of the udder or mammary gland. This usually 
follows invasion by micro-organisms, although other physical or chemical causes 
such as trauma or harmful toxins/chemicals can also lead to mastitis. There are 
two main forms of mastitis, clinical (CM) and subclinical mastitis (SM). 
1.1.1 Epidemiology and economic Importance 
For a long time, bovine mastitis has remained prominent as one of the most 
costly and prevalent diseases in the dairy industry (Hillerton and Berry, 2005; 
Halasa et al., 2007; Akers and Nickerson, 2011; Hettinga et al., 2008; Awale et 
al., 2012). Losses accrued to mastitis are related to expenses due to cessation or 
reduction of milk production (accounting for up to two-thirds of total losses 
(Akers and Nickerson, 2011), costs of treatment, culling, extra labour, and 
wasted time and discarded milk as well as veterinary costs. It is often difficult to 
estimate the total costs of mastitis due to the myriad of factors that can 
contribute to it during mastitis episodes (Heikkilä et al., 2012). Moreover, drug 
residues in milk, as a result of treatment, pose the danger of antibiotic 
resistance and other public health hazards in milk consumed by humans.  
The cost of mastitis has been said to be highly variable depending on lactation 
stage and other factors (Heikkilä et al., 2012), however, the annual cost of 
mastitis has been estimated to be about 1.8 billion United State dollars (USD) 
(Schroeder, 2012) in the USA and in the United Kingdom (UK) one hundred and 
sixty eight million pounds sterling (£168,000,000) by Bradley (2002). In the 
analysis of Heikkilä et al. (2012), using mastitis on Finnish dairy farms, 209 Euros 
(€209) and €112 were the lowest costs of a CM case in Ayrshire and Holstein-
Friesian breeds respectively while €1006 and €946 was the highest cost for each 
breed.  
Hillerton and Berry (2005) in their study arrived at a total of about £300 million, 
as cost implication of mastitis per annum in the UK. This total was arrived at by 
adding estimated costs of loss in production due to subclinical mastitis, to the 
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average national cost. In the analysis of Schroeder (2012), it was estimated that 
mastitis costs over $200 per annum, per cow. 
Due to a rigorous control programme set up by the National Institute of Research 
in Dairying (NIRD) in the UK, which was adopted in the 1970s, the incidence of 
clinical mastitis in the UK declined. An estimate of the incidence of clinical 
mastitis in herds both within the UK and Wales was put at about 47-65 cases per 
100 cows per annum (Bradley et al., 2007), in another estimate, the average 
incidence of mastitis was put at 40 cases per 100 cows per year in the UK 
(Hillerton and Berry, 2005). This represents a drastic reduction from the former 
150 cases per 100 cows per annum seen in the 1960s-80s (Hillerton and Berry, 
2005). However, in recent decades, there has been a shift in pathogen causes 
and also the prevalence of subclinical mastitis (Bradley, 2002). It has been 
estimated that an average dairy farm has 20-50 % the herd suffering from one 
form of mastitis or the other, per annum. 
Clinical mastitis is characterised by occurrence of the classical signs of 
inflammation on the affected quarter(s) and sometimes with systemic 
involvement. Subclinical mastitis, on the other hand, is characterized mainly by 
an increase in somatic cells in milk, without obvious clinical signs of an 
inflammatory disease. 
1.1.2 Aetiology and risk factors  
Micro-organisms including  bacteria, Mycoplasma, algae and viruses are a variety 
of the pathogens capable of invading the mammary gland and leading to mastitis 
(Nicholas, 2011; Cheville et al., 1984; Tomasinsig et al., 2012; Zaini et al., 2012; 
Wellenberg et al., 2002).  Up to 250 different pathogens have been reported to 
be able to cause mastitis in the bovine species (Sudhan and Sharma, 2010). 
Bacteria are however, the most prevalent cause of mastitis.  Pathogens causing 
mastitis can be generally classified as environmental or contagious pathogens. 
Coliform bacteria namely Escherichia coli (E. coli), Klebsiella pneumoniae (K. 
pneumoniae), Klebsiella oxytoca (K. oxytoca) and Enterobacter aerogenes (E. 
aerogenes) and other bacteria such as Streptococcus uberis (S. uberis) are 
considered environmental pathogens, because, being present in the 
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environment, they cause mastitis opportunistically and are not specifically 
adapted to the host for such a condition. 
New intramammary infections (IMI) with coliforms occur more often in the dry 
period than during lactation (National mastitis council (NMC), 2004). Severity of 
mastitis caused by these groups of bacteria is based on host factors (Zadoks et 
al., 2011). E. coli usually causes severe clinical mastitis that elicits massive 
increases in inflammatory and immune indices, usually resulting in disease which 
can either be rapidly eliminated or can become systemic and consequently fatal 
(Baeker et al., 2002; Pyorälä et al., 2011). 
On the other hand, contagious pathogens are generally considered host adapted 
to cause mastitis and are transmitted from one cow, udder or quarter to the 
other in a herd, and include Staphylococcus aureus (S. aureus), Streptococcus 
dysgalactiae (S. dysgalactiae) and Streptococcus agalactiae (S. agalactiae) 
amongst others. Subclinical or chronic forms of mastitis are usually associated 
with contagious pathogens, because these organisms are adapted to survive for 
long periods in the mammary gland, thus, such infections are difficult to 
eliminate and often lead to a substantial rise in somatic cells in milk (Bradley, 
2002). 
Another group of bacteria, the coagulase negative staphylococci (CNS), which 
are opportunistic gram positive cocci, for example, Staphylococcus chromogenes 
(S. chromogenes), Staphylococcus simulans (S. simulans) and Staphylococcus 
epidermidis (S. epidermidis) which are just a few of up to twelve and possibly 
more different CNS species commonly isolated from mastitis cases in most dairy 
farms (Thorberg et al., 2009; Pyorälä and Taponen, 2009; Simojoki et al., 2009) 
and which characteristically cause more milder forms of subclinical infections 
that develop mostly around the dry period. Coagulase negative Staphylococci 
(CNS) are more commonly isolated from primiparous cows and cause high SCC in 
milk. CNS Infections also exhibit high spontaneous cure rates (Pyorälä et al., 
2011). Corynebacterium pyogenes (C. pyogenes) is a bacterium that causes a 
type of mastitis called summer mastitis which is usually characterised by 
purulent abscess formation. 
In a retrospective study of mastitis cases in Swedish dairy farms by Unnerstad et 
al. (2009), S. aureus, followed by E. coli were the most common pathogens 
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isolated from cases of clinical mastitis between the years of 2002-2003. Other 
pathogens seen in order of prevalence included S. dysgalactiae, S. uberis and 
CNS, Arcanobacterium pyogenes (A. pyogenes) and Klebsiella spp. A similar 
trend was observed in an earlier study in the same region by Nilsson et al. (1998) 
between the years of 1994-1995. Identical pathogens were observed in 
epidemiological studies in other regions of the world including the UK (Bradley 
et al., 2007); United States of America (USA) (Neuder et al., 2003); Canada 
(Olde ReiKerink et al., 2008) and in Norway (Waage et al., 1999). 
In a UK and Welsh survey of dairy herds, S. uberis and E. coli were the most 
prevalent causes of clinical mastitis, while S. uberis, coagulase positive 
staphylococci (CPS) and S. aureus were more frequently isolated from samples 
with high SCC (SM) in order of prevalence (Bradley et al., 2007). 
In a more recent study by Kalmus et al. (2013), S. uberis was the most prevalent 
pathogen isolated from clinical mastitis milk samples containing a single 
pathogen from dairy farms in Estonia, using a molecular diagnostic polymerase 
chain reaction (PCR) kit. These S. uberis CM were however associated with mild 
clinical signs. 
Individual cow factors such as breed and levels of PMN cells in the udder 
increase the risk of a cow developing mastitis, for example there is an increased 
risk in breeds of cows with pendulous udders developing mastitis than cows with 
non-pendulous udders. In a study comparing the innate immune response of 
Jersey and Holstein cows to experimental E. coli mastitis induction, Bannerman 
et al. (2008), however found only slight non-significant differences in temporal 
onset, duration and cessation of some immune variables between the two 
breeds. Findings from this study also agreed with reports of Youngerman et al. 
(2004); Biffa et al. (2005) and Berry et al. (2007). Breed susceptibility to 
mastitis may be related to the selection of features in cows that enhance milk 
production but which at the same time are characteristics that predispose the 
udder to easy invasion and colonization by pathogens. 
The risks of development of new infections as well as the severity of these 
infections are also related to other factors including management systems, type 
of milking system, environmental factors, previous SCC, milk yield, and type of 
treatment(s) and antibiotics used during the dry period treatment programme; 
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this being a common measure of control employed in herds to prevent the 
occurrence of mastitis (O’Reilly et al., 2006; Plozza et al., 2011). 
Occurrence of mastitis also depends on the season and herd location (Awale et 
al., 2012). Lactation stage as well as lactation number (parity) have also been 
shown to be predisposing factors to IMI by studies demonstrating the higher 
susceptibility of primiparous cows to specific pathogens, for example S. 
chromogenes, compared to multiparous cows (Vangroenweghe et al., 2005; 
Thorberg et al., 2009; Heikkilä et al., 2012). Dry period length has also been 
shown to influence the risk of subclinical mastitis and incidence of new cases of 
CM are observed to be highest during the dry and periparturient periods 
(Hillerton and Berry, 2005; Vangroenweghe et al., 2005; Pinedo et al., 2012). 
Cow hygiene is one of the most important risk factors for poor udder health and 
IMI. The use of automatic milking systems (AMS), portends an additional risk 
factor over the conventional milking system as pre-milking cleaning of udders 
that is automated into the system does not discriminatingly clean cows with 
dirtier udders as compared with those with clean ones, and thus, compromises 
udder hygiene during milking. This has been shown to increase the occurrence of 
poor udder health (Dohmen et al., 2010; Santman-Berends et al., 2012). Paduch 
et al. (2013) in their study, found significant associations between the treatment 
of bedding material with an alkaline conditioner and Coliform bacteria counts of 
teat skin and canal, suggesting that pathogen levels in the bedding materials is a 
predisposing factor to the incidence of environmental IMI. 
Position of the gland (whether front or hind quarters), contributes to the 
incidence of mastitis according to the findings of Awale et al. (2012). 
Virulence factors of Major Mastitis organisms 
Coliform mastitis is characterised by a rapid rise in milk SCC and its pathogenesis 
depends largely on the bacterial cell wall lipopolysaccharide (LPS). 
Staphylococus aureus mastitis on the other hand, presents with a milder 
inflammatory signs and lower milk SCC, which leads frequently to subclinical and 
chronic infection of the gland. Staphylococcus aureus mastitis virulence is mostly 
facilitated by peptidoglycans, lipoproteins and lipoteichoic acid (LTA). 
Streptococcus uberis induces a variable type of mastitis by inducing Il-1 and Il-8 
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secretion, through the LTA pathogenic factor (being a gram positive bacteria) 
(Wellnitz and Bruckmaier, 2012; Rambead et al., 2003). 
1.1.3 Transmission and pathogenesis 
Transmission of bacteria that cause mastitis usually occurs through contact of 
teats or udder or cows with contaminated housing or pasture areas, milking 
machines and/or the milker (Hillerton and Berry, 2005). Pathogens access the 
mammary gland via the teat orifice, overcoming the innate immune barriers 
(Wellnitz and Bruckmaier, 2012) of tight teat orifice sphincter muscle, keratin 
layer and antimicrobial long chain fatty acids found around the mammary teat, 
and ascend up into the mammary gland through the teat duct. Exploiting the 
rich nutrient environment provided by milk as well as the optimum temperature 
of the udder, pathogens multiply in the teat and gland cisterns, and 
subsequently rise to and adhere to secretory cells (mammary epithelial cells) 
surfaces within the milk producing tissue. The action of a milking machine during 
milking as well as movement of the cow can aid the spread and establishment of 
microorganisms within the udder. Different pathogens express different degrees 
of virulence which assist their establishment within the gland and determine the 
severity of disease they cause (Blum and Leitner, 2013). 
1.1.4 Acute phase response 
Following pathogen invasion, macrophages present within the gland release 
chemo-attractant compounds that cause the recruitment of polymorphonuclear 
cells (PMC), mainly neutrophils, from the blood into the mammary tissues. There 
is also the release of a number of interleukins (IL); such as IL-6 and IL-8, tumour 
necrosis factor-α (TNF-α) and other chemokines. These compounds 
synergistically achieve an inflammatory response that is also characterized by an 
acute phase response (APR) (Wenz et al., 2010).  The liver and mammary gland 
itself are the sites of synthesis (following cytokine stimulation) of the acute 
phase proteins (APP); these being a group of proteins that are known to be 
further involved the APR (Murata et al., 2004). In cattle the mammary form of 
serum amyloid A (SAA) or mammary-associated serum amyloid A (M-SAA3) and 
Haptoglobin (Hp) are the major APP synthesized and secreted into milk during 
inflammation (Ceciliani et al., 2012).  
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Alpha acid glycoprotein (AGP) is another APP secreted into milk during mastitis, 
although a minor one, and it has been suggested to have immunological roles 
(Ceciliani et al., 2007). 
1.1.5 Clinical signs and pathology 
Following pathogen invasion and establishment in the gland, either of the two 
major forms of mastitis may then result; CM, showing swelling, redness, pain and 
heat (or generalized fever) of the udder or quarter, as well as physical and 
chemical changes in milk such as presence of flakes, clots and blood (physical), 
increased proteolysis of milk caseins, increase in sodium and chloride ions and 
also a decrease in lactose and many more chemical changes. 
Subclinical mastitis occurs with no noticeable physical signs of inflammation, but 
is commonly indicated by an increase in somatic cell counts in milk produced 
from affected quarters due to the migration of leukocytes from blood into milk.  
 Any of these two forms of mastitis may occur as a peracute, acute or chronic 
infection. Clinical mastitis is usually peracute or acute in duration while SM is 
often chronic. When chronic mastitis occurs, it is usually characterized by high 
SCC and reduction in milk production. It is a form of the infection that persists in 
the gland for long periods and from lactation to lactation (Awale et al., 2012). S. 
aureus is the predominant cause of chronic mastitis. 
All forms of mastitis have a negative impact on the quality and quantity of milk 
produced from affected animals; however, it is believed that SM is more costly 
overall than CM (Zhao and Lacasse, 2008). 
The increased migration of neutrophils into the mammary gland as well as the 
penetration and multiplication of pathogens and release of toxins causes varying 
levels of damage to the mammary epithelial cells and renders them less 
secretory, blocks alveolar ducts and can sometime lead to fibrosis in the gland 
(Akers and Nickerson, 2011). In addition, compromise of the udder parenchyma 
and extracellular matrix  (ECM) structural conformation leads to increased 
permeability of the blood-milk barrier membranes resulting in leakage of ions 
and other molecules from serum into milk (Pyorälä, 2003). 
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Polymorphonuclear cells assist in destroying invading pathogens utilizing 
intracellular enzymes systems such as proteases, myeloperodixases and other 
pathogen-destroying reactive oxidants and defensins (Wellnitz and Bruckmaier, 
2012). However, the activities of the PMCs also destroy some of the mammary 
epithelial cells leading to the release of cytosolic enzymes such as lactate 
dehydrogenase (LDH), and N-acetyl-β-D-glucosaminidase (NAGase) from the 
PMCs. The PMCs are later destroyed by apoptosis and engulfed by macrophages. 
Signs of mastitis become severe when PMCs are unable to fight off the pathogens 
leading to massive damage to the epithelial cells; this causes seepage of 
extracellular fluid and blood into milk, which is reflected as an increase in 
electrical conductivity of milk, and change in colour.  Presence of flakes, milk 
clots and blood can also occur in cases of severe pathogenicity. 
Mastitis (clinical, subclinical or chronic) results in loss of vital milk composition 
and protein quality and invariably compromises the technological or processing 
properties of milk (Åkerstedt et al., 2008; Sunderkilde et al., 2012). 
 
1.1.6 Treatment and control 
Antimicrobial agents, chiefly antibiotics, are the drugs of choice for the 
treatment of cows with mastitis. Penicillins, cephalosporins and tetracycline are 
some of the commonly used antibiotics. As part of control measures for mastitis 
in dairy herds, treatment with antibiotics during the dry period of cows is 
routinely carried out. An additional therapeutic practice is the milking out of 
affected quarters/cows and/or even the use of oxytocin to stimulate flow of 
milk in order to get rid of the infected milk and decrease levels of medium 
(milk) of bacterial growth. 
In the early 1970s, a five point mastitis control programme was initiated by the 
NMC which included prompt treatment of all clinical mastitis cases, treatment of 
cows in dry periods to eliminate existing infection and to prevent acquisition of 
new ones, culling of persistently infected cows, use of disinfectant dipping of 
teat after milking and annual testing of milking machinery (Hillerton and Berry, 
2005). This programme was implemented by dairy farms in many countries and 
was successful in greatly reducing the incidence of clinical mastitis in the farms. 
In one study, similar control measures were utilized by Nagahata et al. (2007) to 
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successfully control even a persistent S. aureus mastitis on a farm. Since its 
introduction and adoption, the five point mastitis control plan, has become an 
integral practice in most commercial dairy farms in the western world. 
Adopting hygienic practices in the general dairy farm management and 
especially during milking, represents a very important step in the control of 
mastitis.  Pre and post milking dipping of teats with disinfectants; proper 
sanitation of stalls, litter and bedding materials as wells as milking machines, 
are some of these measures. Precalving antibiotic use has also been considered, 
as mastitis incidence tend to increase around the immediate post calving period 
(Bastan et al., 2010). 
Vaccination has also been employed in the control and prevention of mastitis, 
vaccines against E. coli (J5 vaccine), (Sudhan and Sharma, 2010) and CNS 
(Startvac® by HIPRA) have been introduced. The CNS vaccine is administered 45 
days and 10 days before calving, and then at 52 days post calving to reduce the 
risk of development of CNS mastitis. 
The use of teat sealers, which could be externally or internally applied, to 
occlude the udder from contact with environment during the dry period have 
also been evaluated as a means of mastitis control (Huxley, et al., 2002; 
Dingwell et al., 2003a). Recently, Leitner et al. (2013) have explored the use of 
immunotherapeutic agent, ‘Y-complex’ in the treatment of mastitis. Y-complex 
is made up of a microbead containing immunoglobulins against mastitis-causing-
bacteria and a phagocytosis enhancer. In their study, they found the complex 
effective to clear infections, with no side effect or problem of residues as 
encountered in antibiotic use, and recommend it as a new approach for mastitis 
treatment. 
Despite the stringent control measures, it has been observed that contagious 
pathogens are relatively easier to control than environmental pathogens 
(Rambeaud et al., 2003), and there is a lot of work going on to explore or 
develop measures  for optimum control of environmental pathogens. Prompt 
recognition of mastitis cases especially the subclinical is central to the effective 
control of pathogen-specific mastitis. 
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1.1.7 Diagnosis 
Clinical signs of inflammation of the udder, namely painful swelling, heat, 
hyperaemia and in some cases generalized fever are indicative of CM. In milk, 
the presence of blood clots, flakes and change in colour towards a bloody or 
serum-like appearance, also points to the presence of mastitis. A definite 
diagnosis is usually made by bacteriological culture and isolation of causative 
organisms from milk in combination with somatic cell counts as recommended by 
the International Dairy Federation (IDF). A number of other diagnostic 
procedures are also used, as discussed in the next Sections. 
1.1.7.1 Somatic cell counts 
Rapid migration of leukocytes from blood into the udder in order to help combat 
invading pathogens occurs in mastitis (Leitner et al., 2000). Damage to 
mammary epithelial cells also occurs. Somatic cells are composed of these 
leukocytes and damaged mammary epithelial cells (Wagner et al., 2009) that are 
found in milk during IMI. 
Neutrophils are the predominant type of leukocytes found in milk in acute 
mastitis and macrophages to a lesser extent. The marked increase of these cells 
in milk during the course of mastitis has been shown to affect milk quality and 
composition. Somatic cell counts (SCC) is the estimated number of somatic cells 
in milk and has been used as a gold standard for confirming mastitis in cases of 
SM (NMC, 2001; Pyorälä, 2003) and also used to determining milk quality (Ruegg 
and Pantoja, 2013). Somatic cells, predominantly macrophages, are known to be 
present to a limited extent in healthy udders, forming part of the host innate 
defence mechanisms. Cytokines and other chemoattractants released by these 
macrophages are thought to play a crucial role in the massive recruitment of 
neutrophils from blood following pathogen invasion (Pyorälä, 2003).  The extent 
and magnitude of migration of leukocytes into the mammary gland in mastitis 
varies with host and pathogen virulence factors. 
In a study to characterize the levels of SCC according to the presence or absence 
of mammary infection, an average cell count of 68,000 cells/ml was found in 
milk samples negative for bacteriological infection (by culture), 110,000-150,000 
cells/ml for infections with minor pathogens and 350,000 cells/ml and above for 
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infections with major pathogens (Djabri et al., 2002). It has now come to be 
generally accepted that SCC ≤100,000 cells/ml are consistent for healthy udders 
while ≥200,000 cells/ml could indicate presence of infection (Dufour and Dohoo, 
2012). 
Measurement of SCC can be carried out on herd or cow level, consisting of bulk 
milk SCC (BMSCC), composite or quarter milk SCC. Many dairy farms routinely 
carry out monthly cow composite milk SCC to determine the mastitis status of 
cows. BMSCC is carried out to determine overall milk quality of the herd as it 
relates to the presence of mastitis (Barkema et al., 1998). 
Since it is possible for an individual quarter of a cow's udder to be infected 
without contra-lateral or adjacent quarters of same udder being infected, due to 
the presence of intramammary septa separating each quarter from the other, 
quarter milk SCC (QSCC) is important for isolating the particular infected 
quarter(s) of the udder, as composite milk SCC (CSCC) can be diluted from 
quarters with low SCC (Forsback et al., 2009). 
Dufour and Dohoo’s study (2012) confirmed the usefulness of quarter SCC for the 
determination of incidence and elimination rates of new dry period IMIs and 
their findings agreed with earlier reports of Mollenhorst et al. (2010) of the 
greater sensitivity of quarter milk than cow (composite) milk for monitoring 
udder health, using an online system. 
Frequently used methods for the determination of SCC are direct microscopy 
(also called Breed method) and Fossomatic counter methods which are based on 
fluoro-optical properties. Another method used is the Coulter milk counter by 
counting cells as they flow through an electric field. Recently, a new milk 
somatic cell counter, DeLaval cell counter has been introduced (DCC; DeLaval 
International AB, Tumba, Sweden) (Leslie et al., 2006; Kawai et al., 2013). This 
counter uses a similar principle as the Fossomatic counter, and counts cell nuclei 
stained with a DNA specific dye using an optical digital camera. It is accurate 
when counting SCC of ≤4 x 106 cells/ml, but it has also been shown that samples 
can be diluted to give reliable counts (Kawai et al., 2013). It has the added 
advantage of low initial cost and portability. 
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Given that direct SCC measurement is difficult to adapt to rapid field (on line; 
production milking) detection methods, indirect on line methods exists such as 
the California Mastitis Test (CMT). Another test was developed for the 
determination of SCC based on viscosity properties, and this is frequently used in 
AMS (Kamphuis et al., 2008; Fosgate et al., 2013). More advancement in 
measuring SCC came by way of a developed chip (Choi et al., 2006) that was 
able to detect and measure SCC, pH, antibiotic residues and some bacteria 
pathogens in milk at the same time. Another means of measuring SCC indirectly 
is by analysis of adenosine triphosphate (ATP) (section 1.1.7.6). 
Differential cell counts of milk have also been advocated as an alternative to 
total SCC, and when utilized in the study by Pilla et al. (2013), they showed a 
very high sensitivity and specificity to detect IMI in quarters that otherwise had 
low SCC, using a specified cut off value for neutrophil and lymphocyte ratio. 
Apart from the dilution effect on composite milk samples that compromises its 
reliability for diagnosis of mastitis using SCC, other factors other than IMI can 
affect the levels of SCC in milk such as lactation stage, season, lactation 
number, milking frequency, milking interval and type of milk sample collected 
(foremilk or stripping milk). SCC levels have been shown to remain high in milk 
long after the resolution of a mammary infection/inflammation (Pyörälä and 
Syvajarvi, 1987) thus further compromising its specificity in mastitis diagnosis. In 
addition, SCC has also been questioned and has not been found very dependable 
in its correlation to milk protein quality (Åkerstedt et al., 2008).   
1.1.7.2 California mastitis test (CMT) 
The California mastitis test (CMT) is an indirect estimation of SCC designed by 
Schalm and Noorlander in 1957 (Sargeant et al., 2001), and based on the 
formation of a gelatinous precipitate in milk mixed with a detergent reagent (3 
% w/v sodium lauryl sulphate and bromocresol), as a result of the interaction of 
DNA released from cells with the detergent. Thus, the degree of gel precipitate 
formed can be scored to correlate with different SCC groups. CMT is 
inexpensive, fast and can easily be adaptable as a cow side test. However, some 
variability in detecting abnormal milk using CMT has been reported (Kawai et 
al., 2013). Several studies have been carried out to ascertain the usefulness of 
CMT as a cow side test, in readily recognising samples with IMI for selection for 
Chapter 1, 45 
 
further bacteriological confirmation. In the study of Sargeant et al. (2001), CMT 
was found to be sufficiently sensitive and specific in the mid to late lactation 
stage and early (first week of) lactation respectively.  Dingwell et al. (2003b) 
also confirmed the sufficient sensitivity of CMT in the first week of lactation. 
Good correlations have been found between CMT and  other indicators of 
mammary inflammation such as  SCC and electrical conductivity (EC) (Kaşikçi et 
al., 2012), and Seker et al. (2009) found a significant correlation between CMT 
scores and ultrasonographic teat measurements of different breeds of cows, 
indicating that teat features are possibly  predisposing factors to mastitis 
occurrence. In another recent study, CMT was found to be more sensitive than 
EC in classifying infected samples with SCC above 200,000 cells/ml (Fosgate et 
al., 2013). California mastitis test results are usually scored on the basis of level 
of precipitate formed as described by the CMT kit manufacturers on scales of 
negative, weak positive, strongly positive and so forth (Fosgate et al., 2013). 
 
1.1.7.3 Electrical conductivity 
Measuring electrical conductivity (EC) of milk samples has been shown to 
indicate SM and CM (Milner et al., 1996). This assay relates to the increase in 
milk conductivity of electricity that is enhanced during IMI as a result of leakage 
of extracellular ions such as Na+ and Cl- into milk and the subsequent loss of 
predominantly lactose and K+  (Pyorälä, 2003; Kaşikçi et al., 2012). Electrical 
conductivity was found to show similar sensitivity in detecting SM as did SCC and 
CMT in the study of Kaşikçi et al. (2012). 
Although able to be adapted to an online system for mastitis diagnosis, many 
other factors can affect milk EC, and a lot of false positive rates have been 
associated with use of EC (Mottram et al., 2007) thereby limiting its potentials 
as a diagnostic tool for mastitis detection (Pyorälä, 2003). Hand held meters for 
measuring EC have been used in several countries (Fosgate et al., 2013). It is 
becoming increasingly common to combine EC determination with either quarter 
milk SCC (QSCC) or composite milk SCC (CSCC) for the monitoring of udder 
health (Kamphuis et al., 2008; Mollenhorst et al., 2010), particularly with the 
use of AMS (Mottram et al., 2007). 
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1.1.7.4 Infra-red thermography 
Infra-red thermography (IRT) is a non-invasive method that utilizes heat 
absorbed following emission of infra-red radiation to generate images and can be 
used as an indicator of inflammation (Kotrba et al., 2007). A large and growing 
body of literature has investigated the usefulness of IRT for the detection of SM 
in dairy animals (Polat et al., 2010; Colak et al., 2008; Samara et al., 2013; 
Metzner et al., 2014; Pezeshki et al., 2011). Many of these studies have 
demonstrated its sensitivity in detecting changes in udder skin temperature that 
reflects the presence of mastitis. Kunc et al., (2007) reported that mastitis 
infections cause udder surface temperatures to rise often before other clinical 
signs are observed. On the other hand, studies by Hovinen et al. (2008) and 
Pezeshki et al. (2011) found the use of IRT in SM and early mastitis not to be 
reliable. This study observed that changes in udder skin temperature (UST) 
occurred hours (h) after the appearance of local signs of inflammation, 
indicating that IRT might not be sufficiently reliable enough for the early 
detection of mastitis. 
1.1.7.5 Milk Enzymes 
Certain enzyme levels increase in milk during IMI. Enzymes originating from 
phagocytes, ruptured epithelial cells, and from serum contribute to the change 
in the physical and chemical properties of milk seen during mastitis. 
N-acetyl-β-D-glucosaminidase (NAGase), β-glucuronidase (Nagahata et al., 1987; 
Larsen and Aulrich, 2012) and catalase (Kitchen, 1976) are some lysosomal 
enzymes the activities of which increase in milk as they are released from 
neutrophils to facilitate the phagocytic process on pathogens. Assays of these 
enzymes are an important diagnostic test for mastitis (Polat et al., 2010). 
NAGase is also present in lysosomes of mammary epithelial cells and following 
cell lysis is released into the milk (Zhao and Lacasse, 2008).However much of 
this enzyme still remains within the cytoplasm of cells in milk. Kalmus et al. 
(2013) found a good association between the severity of CM, causative bacteria 
and the concentration of NAGase. A biosensor (electrochemical based) for 
measuring NAGase has been described by Pemberton et al. (2001). 
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Lactate dehydrogenase (LDH) is another enzyme the levels of which in milk, 
have been used as an indicator of inflammatory conditions of the udder. It is a 
cytoplasmic enzyme involved in carbohydrate metabolism that gets released into 
milk following damage to mammary epithelial cells. 
Plasminogen concentration in milk is also increased due to leakage from blood as 
a result of the compromised membrane permeability. This causes proteolysis of 
milk proteins following its activation to plasmin in milk. Other enzymes in milk 
that have been suggested as markers of mastitis include alkaline phosphatase 
(AP) (Babaei et al., 2007; Larsen et al., 2010a; Guha et al., 2012) and acid 
phosphatase (AcP) (Larsen et al., 2010a) whose activity in milk tends to increase 
during IMI due to their release from leucocytes. 
1.1.7.6 Adenosine triphosphate 
Adenosine triphosphate (ATP) is often referred to as the energy currency of the 
body and it is present in all living cells. Its concentration in milk has shown a 
correlation with SCC (Olsson et al., 1986) due to the fact that ATP is released by 
these SCC into milk; its measurement may therefore be useful to monitor IMI 
(Pyorälä, 2003).  ATP level has been successfully used to group milk samples by 
health status, and was also found to correlate with acute phase proteins (APP) 
(Gronlund et al., 2005). 
Measurement of ATP is considered an indirect assay of the SCC and a 
bioluminescent assay of ATP released from SCC was proposed (Emanuelson et 
al., 1988). Frundzhyan et al. (2008), went ahead to improve the bioluminescent 
assay for ATP to measure only non-bacteria ATP, however, measurement of ATP 
for mastitis diagnosis has not found widespread usage, probably because 
measuring ATP requires several sample preparation steps and technical 
machinery just as much as in the measurement of SCC.  
1.1.7.7 Lactose 
Lactose (β-D-galactopyranosyl-D-glucopyranoside) is the predominant form of 
milk sugar, and it is synthesized in the mammary gland secretory cells (Golgi 
apparatus). Since the synthetic ability of the mammary cells is massively 
affected in mastitis due to cell damage, lactose concentrations are known to fall 
(Pyorälä, 2003). Several studies have also demonstrated the correlation of a 
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reduction in lactose concentration with mastitis or SCC (Sharma and Misra, 1966; 
Malek dos Reis et al., 2013). Berning and Shook (1992), however found that the 
change in lactose concentration does not correlate well with SCC and is not very 
indicative of IMI. 
1.1.7.8 Bacteriology 
This entails the culture of milk samples collected in suitable culture media. A 
standard of 0.01 ml of milk sample is plated onto suitable agar and usually 
incubated for 24-48 hours (h) at 37ºC, followed by identification of bacteria 
based on colony morphology, haemolysis and further tests such as catalase, 
coagulase tests. 
Microscopic identification is carried out after gram staining. The NMC has 
stipulated guidelines for the culturing of milk for mastitis diagnosis (NMC, 2004). 
In these guidelines, some factors including presence of organisms of interest 
(mastitis pathogens), number of colonies of these organisms, whether it was 
isolated in pure culture and use of multiple sampling of individual glands is 
recommended for accurate diagnosis of IMIs. In a recent study, triplicate quarter 
samples were determined to be the most specific and sensitive in recognising 
IMIs (Dohoo et al., 2011). However, it has been noted that in up to 30 % of 
clinical mastitis cases, bacteriological tests of milk yields no positive results 
(Hettinga et al., 2008; Bradley et al., 2007). Commonly, cultures where up to 
three different pathogens are isolated are regarded as contaminated and often 
not used in conclusively identifying mastitis aetiology (Randy et al., 1986). 
Bacteriological culture is generally accepted as the most reliable means of 
detecting intramammary infections (Dohoo et al., 2011), however, major 
limitations of being time consuming, expensive and not practically adaptable to 
cow side or on line use, are associated with this method of diagnosis. 
1.1.7.9 Molecular (PCR) diagnosis 
Recently, polymerase chain reaction- single strand conformation polymorphism 
(PCR-SSCP) has been suggested as a useful alternative for the identification of 
pathogenic causes of mastitis, necessitated by increasing observations of 
culture-negative (about 30 %) milk samples from mastitis cows (Schwaiger et al., 
2012). Gurjar et al. (2012) presented several case reports of diagnosis of IMI 
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caused by S. aureus, Mycoplasma bovis, S. uberis and Enterobacter spp in farms 
using the DNA based molecular technique and cited advantages of the diagnostic 
measure in facilitating prompt control and prevention of further spread of 
infection. 
A commercial PCR based mastitis diagnosis kit was introduced recently 
(PathoProof Mastitis PCR Assay; Thermo Fisher Scientific, Espoo, Finland) (Spittel 
and Hoedemaker, 2012) and has been reported to be more sensitive. However, 
even in cases of CM, there have been reports of no pathogens being detected in 
milk samples even with the PCR method (Kalmus et al., 2013), moreover the 
molecular technique is labour intensive, expensive and not easily carried out on 
the complex milk matrix (Hettinga et al., 2008). 
1.1.7.10 Multisensors in automatic milking systems 
Milking by the AMS presents new challenges for the detection of IMI as physical 
indicators of abnormal milk such as colour and presence of flakes, blood or clots 
cannot be seen as in conventional methods, by the milker. This has warranted 
the development and use of sensors for multiple attributes of milk such as yield, 
temperature, and electrical conductivity (Kamphuis et al., 2008; Mottram et al., 
2007). A multisensor also called the ‘electronic tongue’ based on potentiometric 
chemical sensor has been advocated for the detection of clinical mastitis 
(Mottram et al., 2007).  A gas sensor array system (electronic nose) was used to 
differentiate mastitic from non-mastitic milk samples and has been described 
(Eriksson et al., 2005) as offering promise for rapid mastitis detection. 
1.1.7.11 Acute phase proteins 
Following the release of cytokines and other proinflammatory mediators, 
predominantly interleukine -1 (IL-1), interleukine-6 (IL-6) and tumour necrosis 
factor-alpha (TNFα), by macrophages in the mammary gland upon pathogen 
invasion (Tassi et al., 2013), several local and systemic responses are elicited in 
an acute phase response (APR), comprising of the release of acute phase 
proteins (APP) from the liver and the mammary glands into milk, and 
recruitment of other proinflammatory cells from the blood  amongst many other 
systemic and local responses (Jensen and Whitehead, 1998). Figure 1-1 shows a 
schematic diagram of the pathway for secretion of APP. 
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Acute phase proteins are a group of proteins predominantly produced in the 
liver, that are changed (usually increased or decreased) by over 25 % during 
inflammation, infection or stressing conditions, and released into blood 
(Lomborg et al., 2008; Ceron et al., 2005; McDonald et al., 2001). Elevated 
levels of APP in serum are generally used as non-specific indicators of 
inflammation and have been widely used in human clinical diagnosis for a long 
time (Eckersall and Bell, 2010). The use of APP as inflammation indicators has 
become important over the last few decades. 
 
Figure 1-1: Schematic representation of the acute phase response leading to secretion of 
acute phase proteins. 
 
There are three major classes of APP; including major, minor and negative APP. 
Major APP are proteins whose levels in serum increase by 1000 folds from 
baseline values during inflammation; haptoglobin (Hp) and serum amyloid A 
(SAA) are major APP of cattle. Moderate APP concentration increase less 
dramatically during inflammation (2-10 fold) and examples in cattle are alpha 1-
glycoprotein and inter α-trypsin inhibitor H (ITIH), while minor APP increase in 
less than 2 fold proportion for example C-reactive protein (CRP) and negative 
APP whose synthesis are down regulated during APR for example albumin (Uhlar 
and Whitehead, 1999; Murata et al., 2004). 
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Several studies have revealed the occurrence of APP not just in serum, but in 
other body fluids such as milk, colostrum, nasal secretion, abdominal fluid, 
synovial fluid (Eckersall et al., 2001; McDonald et al., 2001; Molenaar et al., 
2009). Bovine serum albumin and alpha1-trypsin inhibitor (A1TI) have been 
measured in milk as indicators of mastitis (Sandholm et al., 1984 in Pyorälä et 
al., 2011). 
Of late, a large and growing body of literature has examined the relationship 
between the major bovine APP in milk with IMI and other indicators of 
inflammation (Viguier et al., 2009). Eckersall et al. (2001) first reported the 
correlation of major APP; SAA and Hp in milk with presence mastitis. Many other 
workers have demonstrated the correlation of major bovine APP with other 
inflammatory indices (particularly SCC) during mastitis (Nielsen et al., 2004; 
O'Mahony et al., 2006; Åkerstedt et al., 2008; Pyorälä et al., 2011) and even 
with milk composition and protein quality (Åkerstedt et al., 2008; Åkerstedt et 
al., 2009) and with severity of the IMI (Pyorälä et al., 2011). To further 
emphasize the advantage of these major APP in mastitis detection, only a small 
variation in their levels were observed in healthy cow’s milk over 42 consecutive 
milkings, which shows that these APP are stable and able to discriminate 
between healthy and inflamed tissues reliably (Åkerstedt et al., 2011).  
Alpha1-acid glycoprotein and alpha1-trypsin inhibitor are moderate APP in cattle 
which increases in chronic conditions (Eckersall et al., 2001; Pyörälä, 2003) 
therefore they are less effective in diagnosis or prognosis of mastitis in cows. 
Bovine serum albumin (BSA) is a negative APP in cattle and does not show 
significant changes with subclinical mastitis in the acute phase to be of 
diagnostic value.  
Wenz et al. (2010) evaluated the usefulness of Lipopolysaccharide binding 
protein (LBP), another APP, for mastitis diagnosis. In studies by Suojala et al. 
(2008) LBP in serum and milk was found to increase in association with the 
course of an experimental E. coli mastitis infection, especially in milk.  
It is now established that the major bovine APP (Hp and SAA) are synthesized  in 
the mammary gland (Eckersall et al., 2001; Eckersall et al., 2006; Hiss et al., 
2004; Lai et al., 2009; Theilen et al., 2007). It has also been shown that Hp is 
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synthesized by the neutrophils that migrate into the gland during inflammation, 
but it is not clear if this is the only source of Hp in milk during mastitis. 
Soyeurt et al. (2012) explored the use of mid-infrared spectrometry for the 
measurement of lactoferrin, an important immune glycoprotein in milk, 
developing an equation to quantify its level in milk and they also found that 
using Lactoferrin and SCC improved the predictability for mastitis over using SCC 
alone. Different pathogens have been shown to elicit differences in the level and 
time of onset of APP secretion (Suojala et al., 2008) and this was shown in a 
study by Pyörälä et al. (2011) and Kalmus et al. (2013) where coliforms had 
higher levels of APP (inflammatory response) than other pathogens assessed. 
Major acute phase proteins of bovine milk  
Serum amyloid A (Mammary associated serum Amyloid A3) 
Serum amyloid A is an apolipoprotein made up of two major classes. The acute 
phase SAA (A-SAA), this is primarily produced in the liver in response to an acute 
phase stimulus, under the influence of inflammatory cytokines, mainly IL-1, IL-6 
and TNFα. A-SAA is then released into the blood stream where it binds 
predominantly to the high density fraction of lipoproteins (HDL). Secondly, the 
constitutive SAA (C-SAA) is constitutively expressed in many tissues (Uhlar and 
Whitehead, 1999; Berg et al., 2011; Lecchi et al., 2012; Kovačević-Filipović et 
al., 2012), especially cells lining tissues that communicate with the external 
environment for example the gastrointestinal tract (GIT) and respiratory tract. 
A-SAA is reported to be able to bind to and transport cholesterol at its amino 
terminal region by a structural modification (diminished α-helical structure) that 
makes them different from the C-SAA, which does not bind cholesterol (Liang et 
al., 1996). This amino terminal of A-SAA molecules provides the HDL-binding 
domain comprising of the last 10 amino acids (Yamada, 1999). 
It is a highly conserved protein in most vertebrates and invertebrates and has 
been shown to be a major and highly sensitive APP, the concentrations of which 
rise from basal to up to a thousand fold increases in serum shortly following 
inflammatory or stressor stimuli, in most mammalian species (Wilkins et al., 
1994; Eckersall and Bell, 2010). It is a small protein, having a molecular weight 
between 11-14 kDa and about 104-112 amino acid residues (Rossevatin et al., 
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1992; Yamada, 1999). The role of SAA in inflammation and immunity is not fully 
understood but it is thought to be involved in lipid transport and repair of 
damaged tissues (Takahashi et al., 2009), and also thought to have antibacterial 
activity (Hari-Dass et al., 2005; Molenaar et al., 2009). Other speculated effects 
of SAA include functional modulation of immune response cells such as 
neutrophils (Gatt et al.,1998) and induction of secretion of mucin in the 
intestinal lining by the mammary associated isoform (SAA3), thereby preventing 
adhesion of pathogenic bacteria (Larson et al., 2003). SAA has been speculated 
to have both pro and anti-inflammatory roles.  
There are different isoforms of SAA and these are known to be heterogeneous in 
their amino acid sequences, and isoelectric points (Horadagoda et al., 1993; 
Alsemgeest et al., 1995; Kovačević-Filipović et al., 2012). Major isoforms include 
SAA1, SAA2 and SAA3 (which are encoded for by the SAA1, 2 and 3 genes to form 
the A-SAA) and SAA4 which is encoded for by the SAA4 gene and comprise the C-
SAA (Upragarin et al., 2005). The SAA1, SAA2 and SAA4 are produced in the liver. 
SAA3 is the predominant isoform produced in extrahepatic sites and is the form 
found in colostrum and mastitis milk; it is also called mammary associated serum 
amyloid A (M-SAA3) or milk amyloid A (MAA)(Eckersall et al., 2001; McDonald et 
al., 2001; Nielsen et al., 2004; Molenaar et al., 2009). Serum amyloid A3 has 
also been shown in the equine synovial fluid (Jacobsen et al., 2006) adipose 
tissue (Mukesh et al., 2010) and gastric epithelial cells (Dilda et al., 2012).  
It was specifically demonstrated by Molenaar et al. (2009) using in situ 
hybridization, that the mammary secretory epithelial cells were responsible for 
the production of SAA3 during episodes of mammary infection. Several other 
isoforms (apart from SAA1 and SAA2) have been demonstrated in bovine serum 
by Takahashi et al. (2009) having pIs ranging from 5.2 to 8.6.   
Moreover, multiple isoforms have also been demonstrated in milk including a 
three very alkaline forms (pI > 9.3) during mastitis which were not found in 
serum (Jacobsen et al., 2005; Kovačević-Filipović  et al., 2012; Larson et al., 
2005; Weber et al., 2006). The SAA isoform demonstrated in colostrum was also 
of very high alkaline pI and molecular weight (Mw) of 12.6 kDa (McDonald et al., 
2001). Serum AA exists mainly as complexes with high density lipoproteins (HDL) 
in serum and during periods of prolonged high concentration of SAA in the blood, 
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deposition of amyloid fibrils usually occurs causing a condition called amyloidosis 
in many species (Takahashi et al., 2007; Murakami et al., 2014).  
Prolactin is a major physiological stimulus for the M-SAA3, and Larson et al. 
(2005) showed that, M-SAA3 is the main isoform synthesized by the mammary 
epithelial cells in response to prolactin and lipopolysaccharide (LPS) stimulation, 
suggesting a specific role of that isoform in the gland. Van Der Kolk  et al. (1992) 
however demonstrated that adrenocorticotropic hormone failed to induce 
hepatic synthesis of SAA. Serum amyloid A has been described as a useful 
nonspecific marker of inflammation, which can also be used to monitor 
progression or prognostics of disease in Veterinary Medicine (Eckersall and Bell, 
2010). According to Humblet et al. (2006), SAA (and Hp) measurement in serum 
within a 6 months study period was able to classify clinically diseased cows with 
higher specificity (though less sensitivity) than clinical examination. 
The increase in serum of acute phase SAA during inflammation occurs rapidly 
and up to 1000 fold, hence it has been exploited as a useful biomarker of 
inflammation in man and animals and is designated a major APP in most species. 
Serum amyloid A is expressed in all animal species and their expression is highly 
conserved, suggesting its importance and functional integrity in all species. It 
has also been demonstrated to be synthesized in histologically normal 
extrahepatic tissues such as lungs, mammary gland, uterus and the 
gastrointestinal tract, supporting the hypothesis that this apolipoprotein plays a 
role in innate defence of the body against pathogen invasion (Berg et al., 2011).  
These M-SAA3 isoforms are made up of about 113 amino acids and a molecular 
weight of between 12-14 kDa (Takahashi et al., 2009; Yamada, 1999 Rossevatn 
et al., 1992) whereas the human A-SAA has 104 amino acids and a molecular 
weight of about 12 kDa (Uhlar or Whitehead, 1999). Moreover, the various serum 
A-SAA and the milk specific isoform of SAA, have been identified as having 
different isoelectric points (pI), with the M-SAA3 being highly alkaline (pI = 9.6) 
as compared with other isoforms (McDonald et al., 2001; Jacobsen et al., 2005). 
Data from several sources have demonstrated the correlation of M-SAA3 to other 
established inflammatory indices of intramammary inflammation (IMI) (O'Mahony 
et al., 2006; Jacobsen et al., 2005; Gerardi et al., 2009; Kovačević-Filipović et 
al., 2012). M-SAA3 has been found to be more sensitive to changes in the 
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inflammatory condition of the mammary gland than its serum counterpart 
(Eckersall et al., 2001; O'Mahony et al., 2006; Jacobsen et al., 2005). 
Larson et al. (2006) and Molenaar et al. (2009) also demonstrated in their study 
that M-SAA3 is synthesized locally by the mammary epithelial cells, thereby 
improving the potentials of M-SAA3 as a biomarker for subclinical mastitis. 
The presence of SAA in colostrum of healthy animals has suggested a role for 
these APP in conferment of some immunological characteristics on the new-born 
(McDonald et al., 2001), or a role in the maintenance and remodelling of the 
mammary gland tissue during lactation.  Moreover it may also be related to the 
stress induced APR on the cow during the process of parturition, as APP levels 
remain elevated only for a few days and then drop. 
Assay of SAA has been predominantly by immunoassays such as ELISAs. Obtaining 
monoclonal as well as polyclonal antibodies for SAA has been known to be 
particularly difficult due to the fact that SAA is highly hydrophobic (thus binding 
to HDL in serum) and the high homology of individual species SAA isoforms 
(Yamada, 1999; Kho et al., 2000). However a method for production of 
monoclonal antibodies against SAA has been described by McDonald et al. (1991) 
and has now been used to produce a commercial immunoassay format for the 
measurement of multispecies SAA (Tridelta Development Co., Ireland). 
The usefulness of SAA (mammary associated serum amyloid A3) in diagnosis and 
prognosis of mastitis, particularly SM has also been investigated by various 
groups in the bovine species (Pyörälä et al., 2011; Kovačević-Filipović et al, 
2012; Szczubial et al., 2012; Gerardi et al., 2009; Suojala et al., 2008) and in 
other species including ovine (Winter et al., 2006; Miglio et al., 2013). Using 
both experimental models (Eckersall et al., 2001; Nielsen et al., 2004; Jacobsen 
et al., 2005;  Gronlund et al., 2005; Eckersall et al., 2006) and field conditions 
(Pyörälä et al., 2011; Kovačević-Filipović et al., 2012; Kalmus et al., 2013) the 
potentials of M-SAA3 in mastitis detection, assessment of severity of infection 
and prognostic evaluation of cases, has been identified. 
The effect of sample storage temperature and conditions on SAA values was 
recently investigated by Tothova et al. (2012) who found that duration and 
storage temperature of milk and serum samples from dairy cows could affect SAA 
Chapter 1, 56 
 
(reducing) values significantly. 
Haptoglobin 
Haptoglobin (Hp) was discovered in the late 1930s by Polonovski and Jayle 
(Rowe, 1962). The name haptoglobin derives from two words ‘hapto’ (to bind) 
and 'globin', suggesting its role (Sadrzadeh and Bozorgmehr, 2004) in binding to 
haemoglobin (Hb). Haptoglobin is a major APP in cattle, a tetrameric 
glycoprotein  having two α (alpha) and two β (beta) chains linked by disulphide 
bonds. It is often found in polymeric (2-20 units) forms in bovine serum.  The 
two α chains are different, with α 1 weighing approximately 8.9 kDa, and α 2 
about 16 kDa; these correspond to the light chain of the human H2 haptoglobin.  
The two β-chains, however, are identical and have molecular weights (Mw) of 
about 40 kDa and corresponding to the heavy chain of human Hp (Morimatsu et 
al., 1991a; Sadrzadeh and Bozorgmehr, 2004). Recently Andersen and co-workers 
elucidated the structure of the Hp-Hb (porcine) complex (Figure 1-2) after 
purification and crystallization by employing the use of ultra-visible and Raman 




Figure 1-2: Crystal structure of porcine haptoglobin-haemoglobin complex.  
Hp is coloured blue and cyan, αHb and βHb are orange. Haem groups are shown as dark grey 
sticks. Red spheres represent Fe ions. Glycosylations are shown as light grey sticks and disulphide 
bridges as yellow sticks.  
Source; Andersen et al; Nature 489, 456–459 (20 September 2012) doi:10.1038/nature11369 
Haptoglobin binds to free haemoglobin with very high affinity; the β-chains carry 
the haemoglobin binding portion and have sequences which are highly conserved 
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in most species. Haptoglobin also has broad anti-inflammatory activities and is 
involved in angiogenesis (Arredouani et al., 2003; Tseng et al., 2004; Sadrzadeh 
and Bozorgmehr, 2004). Potent antioxidant activities are associated with Hp, not 
only through its haemoglobin binding capabilities which serve to prevent the 
damaging oxidative effects of iron released from free haemoglobin to the body, 
but possibly through other structural conformation changes (Tseng et al.,2004). 
Roles in lipid metabolism have been suggested (Dobryszycka, 1997), while others 
have suggested immunomodulatory activities (Morimatsu et al., 1991a; 
Arredouani et al., 2003). The binding of Hp to Hb is particularly useful in 
preventing the growth and multiplication of pathogenic bacteria that require 
iron, thus Hp can be said to have antibacterial activity (Sadrzadeh and 
Bozorgmehr, 2004). 
Haptoglobin is synthesized mainly by the hepatocytes in liver, following 
proinflammatory cytokine; IL-6 and TNFα stimulation during inflammation or 
infection. Extrahepatic synthesis has been demonstrated in several other sites 
including lungs (Abdullah et al., 2012), skin (Li et al., 2005) spleen, intestine 
(D'Armiento et al., 1997), female reproductive organs in bovine (ovary and 
oviduct) (Lavery et al., 2003), adipose tissue (Saremi et al., 2012) and also in 
the mammary gland (Hiss et al., 2004; Thielen et al., 2005; Cooray et al., 2007). 
Macrophages, epithelial cells, and granulocytes have also been reported to 
synthesize Hp (Mao et al., 2001; Cooray et al., 2007). Haptoglobin synthesis can 
also be stimulated by glucocorticoids as well as through cytokines. 
Increased synthesis of Hp leads up to a thousand fold change in serum levels, 
and Hp has also been detected in several other body fluids including saliva 
(Gutierrez et al., 2009), oviductal fluid (Lavery et al., 2003), nasal secretion 
(Ghazali, personal communication (pers. comm.), synovial, cerebrospinal, ascitic 
and pleura fluids, urine (Sadrzadeh and Bozorgmehr, 2004) and in milk (Eckersall 
et al., 2001; Gronlund et al., 2003; Pedersen et al., 2003; Eckersall et al., 
2006), with milk Hp level shown to rise dramatically in episodes of mastitis. 
Increased milk Hp in IMI was initially thought to occur only as a result of 
increased permeability of blood milk barrier during udder infections (Eckersall et 
al., 2001), however Hiss et al. (2004), Thielen et al. (2005) and Lai et al. (2009), 
have demonstrated the synthesis of Hp in mammary epithelial cells as well as in 
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milk somatic cells predominantly neutrophils. Measuring milk Hp has been shown 
to be a more sensitive indicator of mastitis than serum Hp, as Hp in milk 
increases several more folds during IMI than serum (Eckersall et al., 2001; 
Gronlund et al., 2005), and the increases appear earlier than in serum, for 
example a rise by just 3 h post challenge in milk as against 9 h in serum, 
following an intramammary LPS challenge in the study by Hiss et al. (2004). This 
was also demonstrated in the study by Eckersall et al. (2006). 
Several isotypes of Hp were demonstrated in the study of Cooray et al. (2007) in 
the granules of granulocytes of healthy cattle indicating it is constitutively 
expressed with the different isotypes possibly being due to post translational 
modifications. Isoelectric points (pI) ranging from 8-9.5 for the 40 kDa (β) 
subunit and ranging from 6 to 8 for the 20 kDa (α) subunit of Hp, were also 
shown. 
Unlike humans and rats, non-acute phase sera in cattle rarely contains 
detectable levels of Hp, but following an inflammatory stimulus, Hp is known to 
rise steadily from about 10 to 24 h after exposure and peaks by the 3rd to 4th day 
and then gradually drops by the 11th day (Conner et al., 1988 in Jawor et al., 
2010; Eckersall et al., 2006). This therefore enhances the potential of Hp in 
indicating inflammation in cattle. 
Haptoglobin has also been described as a bovine adipokine, which is not 
confounded by varying degrees of adiposity when used as an inflammatory 
marker (Saremi et al., 2012). It was also suggested that parturition may elicit a 
higher APR in primiparous cows than in multiparous. The potential usefulness 
and applications of serum Hp measurement in cattle continues to grow 
especially in the areas of clinical diagnosis, monitoring herd health and 
management, pre slaughter meat inspection, evaluating responses to stress and 
so on (Skinner et al., 1991; Alsemgeest et al., 1994; Nazifi et al., 2009; Cooke et 
al., 2012; Holland et al., 2011; Blagojevic et al., 2011; Eckersall and Bell, 2010). 
Blagojevic et al. (2011) investigated the possibility of using serum Hp levels 
assayed during pre-slaughter ante-mortem meat inspection of cattle and pigs, to 
determine and establish values and cut off points that could be used for 
discriminating animals with abnormalities from those without abnormalities in 
order to reduce the needs for hands on meat inspection. This is in accordance 
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with previous studies (Saini et al., 1998), which showed that there was a 
significant difference between Hp of group(s) of cattle having abnormalities 
compared with those without; however there were no difference observed at 
individual cow level.   Crawford et al. (2005), also found serum Hp assessment 
useful for indicating inflammatory disease and other stressing factors in post 
calving dairy cows. It has been suggested that prolonged increases in serum Hp 
may lead to immunosuppression (Crawford et al., 2005; Murata and Miyamoto, 
1993) and could thus be used to identify cows due for culling. 
Serum Hp has been used to assess the severity of inflammation and also as a 
prognostic marker; in the study of Hisaeda et al. (2011), both serum and whey 
Hp showed prognostic value in predicting recovery from naturally occurring 
peracute Klebsiella pneumoniae mastitis in dairy cows. 
Milk Hp has also been evaluated by several studies for its ability as a diagnostic 
marker for subclinical mastitis (Nilgun et al., 2012), although the authors did not 
find Hp analysis in both samples useful in diagnosing and evaluating treatment of 
SM and clinical mastitis (Wenz et al., 2010), as well as other conditions such as 
metabolic status during early lactation (Hiss et al., 2009). Milk Hp has been 
found to be elevated in the early pre-partum period (Crawford et al., 2005; Hiss 
et al., 2009). In the study of Kalmus et al. (2013), milk Hp performed better as 
an indicator of IMI than MAA, due to the fact that MAA was not able to correctly 
identify inflammation by Arcanobacterium pyogenes, the cause of a purulent 
acute form of mastitis. 
Assays for Hp are based predominantly on two principles; the binding of Hp to 
antibodies as in immunoassays and on the high affinity of Hp for haemoglobin to 
form a Hb-Hp complex (Owen et al., 1960), which has innate peroxidase activity 
that can be measured using suitable substrates such as guaiacol. The level of Hb-
Hp is proportional to the concentration of Hp. In addition a nephelometric assay 
for human Hp measurement was described by Vanlente et al. (1979).  A high 
performance liquid chromatography method for determining serum Hp levels has 
also been described (Salonen et al., 1996). 
A number of immunoassays and Hb binding assays for Hp have been developed 
and described in literature. Single radial immunodiffusion assay (SRID) was 
described by Morimatsu et al., (1992), ELISAs for Hp determinations which 
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maybe direct or indirect, sandwich or competitive ELISA have been developed 
and utilized (Sheffield et al., 1994; McNair et al., 1995; Jawor et al., 2010). 
Immunoassays are more specific in determining Hp concentration in samples 
(McNair et al., 1997). In bovine serum, sulphhydryl compounds have been 
employed to reduce polymerization of Hp before measurement (Morimatsu et 
al., 1992; Eckersall and Conner, 1990). McNair et al. (1995) described a 
competitive time resolved fluorometric immunoassay that utilized a bovine 
specific mouse monoclonal antibody and had improved sensitivity as a result of 
use of lanthanide labelling. 
The Hp-Hb binding assay described by Owen et al. (1960) was modified by Jones 
and Mould (1984), for use in a microtitre plate format. Eckersall et al. (1999) 
further modified the assay to take care of the confounding effects of serum 
albumin on the assay. Slocombe and Colditz (2012) were able to derive an 
equation to correct for the effect of haemolysis, which frequently occurs during 
blood sample collection especially from the coccygeal vein in cattle, on 
biochemical assays of serum Hp. 
Haptoglobin-haemoglobin binding assays have the advantage of being cheap and 
suitable for measurement of Hp from all species, and unlike immunoassays, 
being less time consuming. However, measuring Hp using the Hb binding, 
presents the difficulty of interference by haemolysis and serum albumin and 
other factors that can affect peroxidase activities (McNair et al., 1995; 
Slocombe and Colditz, 2012; Eckersall et al., 1999) in blood samples. Indeed, 
Cooke and Arthington (2013) compared the Hb binding assay for measuring Hp in 
plasma to an ELISA and found significant correlations between the two different 
assay techniques. Although Slocombe and Colditz in their study were able to 
derive an equation to correct for the effect of haemolysis on blood Hp assay, in 
milk, it was observed that innate milk lactoperoxidase could compromise the 
assay of Hp using the biochemical method (peroxidase activity of Hb-Hp 
complex) (Eckersall et al., 2001; Åkerstedt et al., 2006).   
Milk Hp is measured by immunoassays, especially ELISAs. An immunodiffusion 
assay was used by Eckersall et al. (2001), while Pedersen et al. (2003) utilized a 
sandwich ELISA to measure milk Hp. Hiss et al. (2004) also described an ELISA 
using purified bovine Hp and polyclonal antibody raised against the bovine Hp, 
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both assays had sensitivities of 11.5 µg/ml and 0.07 µg/ml respectively.  ELISA 
however has the limitation of being time consuming, and the need for rapid on 
line diagnosis of udder infections is of paramount importance in its control. 
A rapid format biosensor assay to determine Hp concentration in milk was 
described by Åkerstedt et al. (2006); the assay was based on the high affinity of 
Hp for haemoglobin and was a competitive (indirect) assay. Although not as 
sensitive as the ELISA, some level of success was achieved with this biosensor 
assay. However, this assay requires expensive machinery and well trained 
personnel to operate it. 
Another attempt to adapt Hp determination to rapid field on line format 
explored the use of an amperometric immunosensor assay for detection of SM 
milk samples and had a sensitivity of 0.63 mg/l and agreed well with values for a 
commercial ELISA kit used to measure Hp in same samples, although above a 
certain concentration of Hp, the test became less reliable (Tan et al., 2012). 
In addition to the need for an on farm format for measuring these APP, it is 
important to determine reference values of these compounds in milk under 
different physiological conditions and in health. Other factors that could 
influence variations in the concentration of these parameters in milk other than 
disease need to be identified. 
C-reactive protein 
For a long time, C-reactive protein has been categorized as a minor APP of the 
bovine species (Eckersall and Conner, 1988). In canine and porcine however, it is 
a major APP that has found wide usage for the diagnosis and monitoring of 
numerous inflammatory and infectious conditions (Eckersall and Bell, 2010; 
Petersen et al., 2004). It is also secreted from the liver in response to cytokine 
stimulation and known to play roles in activating phagocytosis by binding to 
phosphocholine portions of pathogens or dying cell membranes, complement 
activation, opsonisation of pathogens and binding to immunoglobulin receptors 
(Black et al., 2004). 
C-reactive protein has a molecular weight of about 115 kDA and consists of 5 
identical subunits linked together non-covalently (Black et al., 2004). It was first 
identified based on its ability to bind to pneumococcal phosphocholine. The 
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name C-reactive protein (CRP) was given to a pentameric protein which was 
found to increase greatly in plasma following inflammation and infections, bind 
to pneumococcal C-polysaccharide  and was discovered by Tillett and Francis in 
1930 (Clyne and Olshaker, 1999). Figure 1-3 is a model of human CRP showing its 
5 subunits in the shape of a pentagon with a central core. 
 
 
Figure 1-3: Model of C-reactive protein, showing the 5 subunits forming a pentamere 
Source; protein data base www.pdb.org entry 1GNH for human CRP 
 
It has since been established that CRP is an acute phase protein, which is a 
member of the pentraxin family of proteins, is a pattern recognition receptor 
(PRR) and is synthesized mainly in the liver (Darren et al., 1999; Hirschield and 
Pepys, 2003). It is a cyclic pentamere (containing five identical subunits) with a 
core at the centre. 
It is synthesized in response to cytokine (predominantly IL-6) stimulation, and 
has been shown to bind to phosphocholine (in a calcium dependent mechanism), 
one of the components of lipid bilayer of cell membranes, specifically in dying or 
dead cells leading to the activation of complement system needed for  
phagocytic clearing of cellular debris (Agrawal, 2005). It has also been 
demonstrated to be involved in the opsonisation of bacteria and modulation of 
platelet aggregation (Cheryk et al., 1996). 
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C-reactive protein is a very important APP in humans and is frequently evaluated 
to monitor most inflammatory and infectious conditions as well as response to 
therapy (Darren et al., 1999). CRP has been identified in several other body 
fluids including cerebrospinal and arthritic fluid, as well as in human breast milk 
and colostrum (Fetherston et al., 2006). It is not however clear if human milk 
CRP is sourced locally as well as or entirely from the circulation. It is a very 
commonly used marker of inflammation in human medicine particularly also 
because of its short half-life. 
In animals, CRP is a major APP in dogs and pigs. CRP is the most sensitive APP in 
dogs and frequently used in canine and porcine medicine for diagnosis and 
monitoring of inflammatory and infectious conditions (McGrotty et al., 2004; 
Eckersall and Bell, 2010). Only a few studies have reported any relationship 
between bovine serum or milk CRP and any disease such as mastitis (Schrodl et 
al., 1995; Hamann et al., 1997; Kruger and Neumann, 1999; Lee et al., 2003; 
Shcroedl et al., 2003; Ozmen, 2009). However, Maudsley et al. (1987) were able 
to isolate two bovine serum pentraxins (confirmed by electron microscopic 
appearance) of which one was identified as bovine CRP, using a calcium 
dependent affinity chromatography. Furthermore, Morimatsu et al. (1989) were 
able to characterize bovine CRP after isolating it from a large quantity of bovine 
serum as being glycosylated and having a molecular weight of about 100,600 
Daltons and having 23 kDa subunits.   
Although, CRP is said to be a minor APP in the bovine species, some studies have 
demonstrated the presence of CRP in serum and milk of cows showing 
correlation with health conditions and even mastitis (Schrodl et al., 1995; Lee et 
al., 2003; Schroedl et al., 2003). In the study by Lee et al. (2003) a correlation 
between bovine serum CRP and lactation status as well as body condition score, 
general animal health and the ability of CRP to identify inflammatory and 
stressing conditions by its increasing levels in serum was shown.  
In earlier studies, Morimatsu et al. (1991b) showed an association between the 
levels of bovine serum CRP with lactation in Holstein cows. Schroedl et al. 
(2003) showed a significant rise in CRP in blood of calves one day after receiving 
colostrum, suggesting a passive transfer of CRP from colostrum (CRP was earlier 
demonstrated to be present in colostrum by the same researchers) into the 
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blood of calves and suggesting its role in the elimination of bacteria and 
importance in the innate immune protection of the new born.    
C-reactive protein is typically measured using immunoassays such as ELISAs, 
immunodiffusion and agglutination tests and immunoturbidimetric assays (Kim 
CH et al., 2013; Sarikaputi et al., 1992; Deegan et al., 2003). 
Immunoturbidimetric analysis such as nephelometry, are based on the reaction 
of CRP with antibodies and measuring of the turbidity of the resultant antigen-
antibody complex. Recently Lin et al. (2013) demonstrated the success of using 
magnetic nanoparticles in combination with capillary electrophoresis (CE) and 
laser-induced fluorescence detection technique for CRP. The high affinity of CRP 
to phosphocholine has also been exploited as generic quantitative technique for 
assay of multispecies CRP by conjugating phosphocholine to bovine serum 
albumin and linking the conjugate to HRP, and this is then used in a CRP-ELISA or 
turbidimetric assay format (Deegan et al., 2003). Recently the Life Diagnostics 
Inc. laboratories have produced a new sandwich ELISA for measuring bovine CRP, 
which is reported by the manufacturer to be sensitive enough to measure bovine 
milk CRP. 
1.1.7.12 Other biomarkers for bovine mastitis 
A biomarker is a molecule used to measure or indicate the effects or progression 
of a disease, condition, or treatment (Metzger et al., 2009). Biomarkers have 
also been described as a measurable entity that sensitively, specifically and 
without bias indicates the presence, progression or absence of a disease 
(Leichtle et al., 2013).The need for biomarkers in the management of bovine 
mastitis has become a necessity in order to complement the role of somatic cells 
in the diagnosis of bovine mastitis, particularly of the subclinical forms. In the 
search for biomarkers, major considerations include sensitivity, specificity, 
accuracy and avoidance of bias. Other characteristics of a good biomarker 
include ability to remain unchanged in other conditions not related to the 
disease and be reproducibly measured and quantified. 
It has also been suggested that as well as a biomarker molecule, biomarker 
profile (s) of compounds may be harnessed for use as sensors for rapid detection 
of mastitis especially on line in an AMS farm (Boehmer, 2011). 
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Some examples of biomarkers which have been suggested for bovine mastitis 
includes the major APP (SAA and Hp) discussed above, and other milk 
compounds, for example lactoferrin (Lf). Lactoferrin is a soluble protein that 
plays a role in host defence against pathogens by facilitating the destruction of 
invading pathogens (Wellnitz and Bruckmaier, 2012). Lactoferrin is present in 
milk, it acts by sequestering iron and thus makes it (iron) unavailable to bacteria 
to use, hence its antibacterial action.  It is also considered an APP released from 
PMN during inflammation and its usefulness in indicating metabolic stress in 
early post-parturient cows has been investigated by Hiss et al. (2009).  Arnould 
et al. (2009) evaluated the genetic content of lactoferrin in milk and found some 
correlation between mid-infra-red spectrometry predicted Lactoferrin values 
and somatic cell scores.  
In recognition of its potential as a marker of mastitis and also nutritional value 
of milk Soyeurt et al. (2012) went further to derive an equation to measure Lf 
using mid-infrared spectrometry in milk, more rapidly than using ELISAs or SRID. 
However the sensitivity and specificity of Lf for bovine mastitis still requires 
detailed studies and validation. 
Interleukin 6 is another protein the potential of which as a mastitis biomarker 
has also been investigated (Sakemi et al., 2011). Milk cathelicidins have also 
been proposed as markers of bovine mastitis by Smolenski et al. (2011). These 
are a group of polypeptide markers of inflammation that have shown 
antimicrobial properties (antimicrobial peptides) and originate from lysosomes 
of macrophages, PMN and other cells. The authors did not however find a very 
good correlation between milk Cathelicidins and SCC in natural infections of 
mastitis as was in the case of experimental infections (Smolenski et al., 2011).  
Several proteomic studies have been able to identify several low abundance 
proteins related to bovine mastitis (Danielsen et al., 2010, Boehmer et al., 2008, 
Boehmer et al., 2010, Smolenski et al., 2007 and Hogarth et al., 2004). For 
example, the study by Boehmer et al. (2010) identified some specific proteins, 
namely inter-alpha-trypsin inhibitor heavy chain4 (ITIH4) (heavy chain-4), 
apolipoproteins, kininogen-2 and clusterin, previously unreported in milk but 
which showed a typical biomarker trend with mastitis. 
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The need for early diagnosis of mastitis for prompt and efficient treatment to be 
effected cannot be overemphasized. Moreover, it has also been reported that 
treatment of cows or udders prior to development of classical signs of CM (given 
that occurrence of CM could be predicted by appropriate diagnostic indices in a 
rapid way), would drastically reduce the severity and duration of cases (Hillerton 
and Berry, 2005). There is therefore a need for more sensitive and robust 
markers of mastitis that may even enable pathogen specific identification of IMIs 
(Danielsen et al., 2010). Advances in bioinformatics and mass spectrometry have 
enabled the development of new tools that can be used for biomarker discovery, 
together with the new ‘omics’ technologies such as peptidomics and 
metabolomics, as well as the earlier proteomics. 
1.1.7.13 Proteomics 
Proteomics is the comprehensive study of a specific proteome, including 
information on protein abundances, their variations and modifications, along 
with their interacting partners and networks, in order to understand cellular 
processes (NCI, 2014). The ‘proteome’ refers to the entire complement of 
proteins that can be found within a biological system.  
Most disease states are associated with changes in the protein constituents 
and/or concentrations within a biological system. Thus comparing the protein 
profile in health and disease are potential sources of biomarkers and therapeutic 
targets (Scrivener et al., 2003).  
Protein analysis in samples has been carried out for decades using immuno and 
biochemical assays, but these assays are usually limited to detection of a 
particular protein or quantitative analysis such as total protein (Ceciliani et al., 
2014) and often require the use of antibodies. With the evolution of mass 
spectrometric techniques and advances in bioinformatics such as the sequencing 
of the whole genome of some species in the late 1990s, the next major omics 
technology emerged, which was proteomics (Vaudel et al., 2014). This 
technology has enabled the characterization of protein profiles in various 
biological systems, under different conditions, helping to understand the role of 
complex proteins in cellular and molecular mechanisms; it has also facilitated 
the discovery of biomarkers for disease diagnosis.  
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Current approaches to proteomic studies include gel based and non-gel based 
methods and has additional advantages over the immuno and biochemical assay 
techniques in identifying a wider panel of proteins within a single experiment 
without the need for specific antibodies (Boehmer et al., 2010). They have also 
enabled the elucidation of post translational modifications (PTMs) as well as 
quantification of proteins. Two fundamental principles underlie modern 
proteomics studies; these are the separation of individual proteins from a 
complex mixture of proteins (fractionation) and the identification or 
characterization of these proteins (Ceciliani et al., 2014). 
Gel based proteomics 
The gel based methods are based on the use of an electric field (electrophoresis) 
for the separation of protein samples loaded onto gel matrix commonly sodium 
dodecyl sulphate (SDS) polyacrylamide gels followed by the application of an 
electrical field i.e. separation by electrophoresis. In such gels, molecules can be 
separated on the basis of either their molecular weight or isoelectric points (1 
dimensional electrophoresis (1DE), isoelectric focusing (IEF) or based on both 
properties (2 dimensional electrophoresis (2DE) (Roncada et al., 2013).  
The 2DE was first described in the 1970s (O’Farrell, 1975), here samples are first 
separated based on their pI in a pH gradient on an IEF gel strip. This is then 
loaded onto a SDS-PAGE gel and separated according to mass, resulting in the 
generation of protein spot patterns which are visualized following staining with 
gels dyes (Hogarth et al., 2004).  One dimensional gel electrophoresis has poor 
resolution power although is robust, while 2DE has been able to resolve up to a 
few thousands of protein spots which can be excised, digested and characterized 
using mass spectrometry (MS). It has major advantages of being able to 
characterize some post translational modifications in proteins and represents the 
most powerful tool for separating complex mixtures of intact proteins (Roncada 
et al., 2012).   
Difference gel electrophoresis was first described by Unlu et al. (1997) and was 
developed in order to overcome the problem of lack of reproducibility in 2DE. It 
utilizes different fluorescent dyes to label proteins in different samples and an 
internal standard (pool of samples) also labelled with another dye; these 
samples are then electrophoresed in combination within a single 2D gel.  
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Dyes which were originally designed and used in DIGE comprise of cyanine dyes; 
propyl-Cy3-NHS and methyl-Cy5-NHS (Cy3 and Cy5) and an additional amine-
reactive dye, Cy2 that was targeted to bind to lysine residues. Later dyes which 
targeted cysteine residues were produced (Minden, 2007). Lysine targeting dyes 
are used for minimal labelling strategies in cases of protein concentration >100 
µg/sample while saturation labelling strategies utilize the cysteine targeting 
dyes, for low abundance protein samples.  
After labelling samples with dyes, they are pooled and run according to a 
standard 2DE protocol. The gel is viewed using a florescent imager with different 
excitation wavelengths for the separate dyes, thus up to 3 images are produced 
which can be assessed for differences and proteins quantified relative to an 
internal standard (Minden, 2007). 
Non-gel based proteomics 
Non-gel based proteomics involves the use of non-gel methods such as liquid 
chromatography (LC) and capillary electrophoresis (CE) for separation of 
proteins in a complex mixture prior to mass spectrometry analysis. Liquid 
chromatography entails the migration of molecules in a liquid phase, the 
migration can be based on ion migration speed (size exclusion chromatography), 
electrical properties (ion exchange chromatography), hydrophobicity (reversed 
phase chromatography) and binding with ligands (affinity chromatography). 
Capillary (zone) electrophoresis entails the movement of molecules through a 
capillary tube filled with electrolytes upon the addition of an electric field. 
Two different approaches may then be used for detection of proteins, firstly 
detection of intact proteins after ionisation (with the retention of all PTMs in 
the proteins) and secondly detection of peptides after tryptic digestion of the 
proteins also called bottom up proteomics. Proteolytic digestion of intact 
proteins to peptides can be coupled to on-line ionisation phase by a mass 
spectrometer (MS) for detection of peptide fragments. Over the years, many 
different approaches to the ionisation of separated molecules prior to detection 
on an MS machine have been developed. Some of these methods include electron 
ionisation (a gas phase ionisation), chemical ionisation (CI), electrospray 
ionisation (ESI), matrix assisted laser desorption ionisation (MALDI), nanospray 
ionisation (NSI) and atmospheric pressure chemical ionisation (APCI). Each of 
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these methods has their specific benefits and limitations and choice of ionisation 
methods to be used is usually based on type of molecule to be analysed. MALDI is 
commonly used in proteomics studies. Electrospray ionisation (ESI) and matrix 
assisted laser desorption ionisation (MALDI) are some of the most frequently used 
methods for ionising peptides in proteomic experiments and ESI is increasingly 
used for ionisation of peptides and intact proteins (Catherman et al., 2014). 
Ionised peptides are then passed through a mass analyser where the various ions 
are separated based on mass and charge and subsequently detected   
A secondary fragmentation of peptides can be carried out; tandem mass 
spectrometry (MS/MS) and this can be achieved through collision induced 
dissociation (CID) or electron transfer dissociation (ETD) and this permits protein 
sequencing. A multidimensional Protein Identification Technology (MudPIT) 
utilizes the separation of peptide content of complex protein samples in a liquid 
phase in two dimensions (2D-LC); by reversed phase and ion exchange 
chromatography in a micro-capillary column, followed by a MS/MS with 
secondary peptide fragmentation by CID and searching and matching with 
sequence databases (Delahunty and Yates III, 2007; Schirmer et al., 2003). This 
method is sensitive, robust and valuable for both qualitative and quantitative 
proteomics. 
Non-gel based methods are becoming increasing popular as they can be adopted 
into (by coupling the protein separation technique to mass spectrometric 
identifications) an on-line proteomics experiment (Roncada et al., 2012), 
utilizing the high throughput separation procedures of LC and CE. 
Database searching 
Ultimately, detected ions are represented in a spectrum and converted from raw 
data to proteomic file formats (for example mzXML, mzML, mzData, dta, mgf 
and so on) that can be searched in databases (Swiss Institute of Bioinformatics 
(SIB); http://www.isb-sib.ch/aboutsib/mission.html, 2009). 
Protein database search engines such as Mascot, SEQUEST, ProteinPIlot are 
applied for searching and matching of MS generated-peptide spectrums with that 
of databases for example UniProt, Swiss-Prot, Proteomics identifications 
database (PRIDE), Protein Data Bank (PDB). Protein scores are then computed for 
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every protein match and false discovery rate (FDR) is also assessed. It is also 
possible to search the spectra obtained from experiment through a library of 
mass spectra which has been made available (SIB, 2009). 
A typical work-flow for proteomics analysis involves initial sample preparation 
and separation in gel electrophoresis, excision and digestion of proteins of 
interest by a known protease (usually trypsin) into peptides and the subsequent 
identification of peptides on a mass spectrometer. After ionisation of molecules 
in the mass spectrometer, mass to charge (m/z) ratio of the molecule is then 
measured and used to plot a mass spectra that is then searched in a relevant 
database to match obtained masses. Of late, however there has been a focus on 
non-gel based methods of separating the protein constituents of samples prior to 
mass detection on the spectrometer, with liquid chromatography tandem mass 
spectrometry (LC-MS/MS) being the most widely utilized means of proteomic 
analysis. 
Quantification of proteins  
In order to quantify detected proteins in a proteomics experiment, several 
approaches have been developed and utilized including labelling techniques and 
label–free approach. In the labelling approach, several approaches are possible 
such as, DiGE, a gel based method earlier mentioned, and that can be employed 
for quantification of intact proteins. Chemical labelling of peptides with isobaric 
tags (iTRAQ) or dimethyl groups, and metabolic labelling with stable amino acid 
isotopes (stable incorporation of labelled amino acids in culture- SILAC) are non-
gel labelling approaches for protein quantification on MS (Lengqvist and 
Sandberg, 2013). Spectral counting is an example of a label-free approach to 
protein quantification in proteomics (Nissen et al., 2013; Wong and Cagney, 
2010). 
Milk is composed of two major groups of proteins, the insoluble caseins (high 
abundance proteins) and soluble whey proteins. There are several types of 
caseins including α-caseins (α-CN), β-CN and κ-CN; all these constitute about 80 
% of the total milk proteins. The remaining 20 %, whey proteins (low abundance 
proteins) are made up of  -lactoglobulin,  -lactalbumin, immunoglobulins, 
bovine serum albumin, bovine lactoferrin, lactoperoxidase as well as cytokines 
and other immune proteins (Pepe et al., 2013). The low abundance milk proteins 
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present a repertoire of proteins from which likely biomarkers of disease 
conditions of the mammary gland can be found.  
In order to overcome the effect of high versus low abundance protein, 
fractionation steps are often carried out on milk samples and can vary from 
centrifugation, acidification, and filtration to the use of peptide ligand libraries 
as well various precipitation methods to rid the samples of the high abundance 
proteins (Nissen et al., 2013; D’Amato et al., 2009). These recent advances in 
fractionation techniques have helped to resolve the limitation posed by presence 
of high abundance proteins (Boehmer et al., 2010). Different fractions of milk 
proteins, for example whey, have been studied using proteomics. Another major 
fraction of milk that has been studied using proteomics is the milk fat globule 
membrane (MFGM) (Reinhardt and Lippolis, 2008) where new proteins not 
previously known to be in milk were identified. 
Mass exclusion filters, 1DE and commercial depletion kits are also available for 
this purpose of fractionating milk proteins prior to proteomic analysis (Boehmer, 
2011). In the study by Nissen et al. (2013), centrifugation at a very high speed 
compared other milk proteins fractionation techniques such as acidification or 
filtration, before carrying out a proteomics experiment, was found to be the 
most reproducible and robust method of obtaining the milk proteome.  
Recently, the use of combinatorial peptide ligand libraries has been developed 
and was successfully employed for fractionation of peptides and identification of 
new proteins (D'Amato et al., 2009). Enrichment for example by cysteine-tagging 
has also been used to enhance the identification of low abundance caseins in 
milk containing cysteine as against the abundant α- s1 CN and β-CN that do not 
(Holland et al., 2006). Proteomics methodologies in recent years have been 
adopted for the discovery of biomarkers of bovine mastitis. Some measure of 
success has been achieved with up to about 80 different proteins identified that 
vary in milk in response of the host to pathogen infection of the mammary gland 
(Viguier et al., 2009), although most of these have not been validated.  
A recent application of proteomics has been established for non-culture 
identification of mastitis- causing bacteria in milk using a matrix assisted laser 
desorption ionisation – mass spectrometry (MALDI-MS) (Barreiro et al., 2012). 
This method employs bacterial ribosomal proteins as fingerprinting markers to 
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identify specific micro-organisms, from a dedicated MALDI biotype reference 
library after a pre-concentration step. However, a high bacteria count is 
required for accuracy and only a few species of bacteria have been evaluated in 
milk using this method. 
By and large, proteomics is a promising technique that can be used to identify, 
validate and screen biomarker candidates for bovine mastitis (Boehmer et al., 
2010; Lippolis and Reinhardt, 2010; Bendixen et al., 2011; Eckersall et al., 2012; 
Bassols et al., 2014), but further work needs to be carried out using different 
models of mastitis, including both field and experimental models as well as 
mastitis caused by different pathogens, and representing diverse clinical phases. 
1.1.7.14 Peptidomics 
The peptidome, in analogy with the proteome, is the collection of all peptides 
within a biological system at a given time. Peptidomics is one of the newly 
emerged 'omics technologies and is a subset of proteomics. It is the detection, 
identification and quantification of all peptides with their post translational 
modifications within a cell, tissue organism or biological sample. Developments 
in mass spectrometry as well as high resolution separation techniques for 
biological sample constituents heralded this new technology. Due to the fact 
that peptides represent a very important class of biological compounds that have 
been demonstrated to play crucial roles in many processes in the body especially 
as neurotransmitters in the nervous system, peptidomics technology has proven 
useful in the areas of neuroendocrine research, biomarker and drug discovery 
(Menschaert et al., 2010; Schulz-Knappe et al., 2001). 
Peptidomics primarily focuses on the simultaneous identification of 
endogenously derived peptides within a biological fluid/system, however often 
encompassing peptide products of protein degradation. It can be used to 
elucidate proteolytic regulation of bioactive peptides as a key to understanding 
the physiology and identifying possible drug targets of these peptides (Kim YJ et 
al., 2013). 
Peptidomic analysis depends largely on mass spectrometry techniques such as 
MALDI-time of flight (TOF) or electrospray ionisation (ESI) combined with tandem 
mass spectrometry (MS/MS). Separation technologies for peptides within 
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complex mixtures comprise chromatographic techniques such as liquid 
chromatography, reversed-phase high pressure liquid chromatography (HPLC), 
capillary electrophoresis and ion exchange chromatography (Schrader and 
Schulz-Knappe, 2001). Capillary electrophoresis- mass spectrometry (CE -MS) has 
been used for high throughput analysis of urine samples with successful turnover 
of biomarker candidates with high reproducibility (Soloviev and Finch, 2006; 
Balog et al., 2009). Surface-enhanced laser desorption ionization time- of-flight 
mass spectrometry (SELDI-TOF-MS) another commonly employed method in 
peptidomics has been specifically used for urine. Another method has also been 
used for peptidomics analysis is liquid chromatography/electrospray ionisation 
tandem mass spectrometry (LC/ESI-MS/MS), which was applied by Guarino et al. 
(2010) to detect adulteration of goat milk with sheep milk for making cheese, 
involving identification of a particular casein plasmin-hydrolysis peptide of sheep 
cheese, used as a marker. 
Milk Peptidomics  
A number of discoveries about peptides in milk have been made possible as a 
result of milk peptidomics. Antimicrobial peptides amongst other peptides 
exhibiting diverse properties such as immunomodulation have been identified 
following endogenous proteolysis of the major milk proteins (caseins and 
lactalbumin) in human milk (Dallas et al., 2013). In a similar study Wan et al. 
(2013) also elucidated the peptidome of human term and preterm milk, but 
found many peptides to be quantitatively diverse between the two classes of 
milk samples. 
Several antimutagenic properties have also been associated with peptides 
obtained after hydrolysis of milk protein constituents such as caseins and 
lactalbumin (Larsen et al., 2010b).  
Peptides in milk increase during episodes of mastitis, not least as a result of the 
action of proteases such as plasmin, elastase, cathepsins A and B.  
Aminopeptidases, in addition to these proteolytic enzymes may leak into milk 
from blood through a disrupted blood milk barrier, or be secreted into milk by 
somatic cells or mammary epithelial cells as a tool for killing bacteria, or arise 
from microorganisms metabolism. Proteases originating from leucocytes that 
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increase in the mammary gland during episodes of inflammation also abound and 
may be considered as endogenous non-native proteases that could account for 
most of the proteolytic activity in high somatic cell count milk (Napoli et al., 
2007). The proteolytic activities of enzymes in milk ultimately result in loss of 
milk caseins which compromises the quality and technological properties of milk 
such as in cheese formation (Larsen et al., 2010b). Mass spectrometry based 
peptidomics has enabled the identification of a great number of peptides in milk 
samples from which biomarkers might be discovered. 
Larsen et al. (2010b) utilized capillary reverse-phased–HPLC to study the peptide 
profile of milk following a LTA challenge of quarters; spectral peaks were 
subsequently identified using tandem MS, following ionisation by MALDI-TOF.  In 
a recent study, Mansor et al. (2013), identified up to 31 polypeptides which 
could differentiate healthy from mastitic milk samples and up to 14 polypeptides 
that were able to distinguish between different pathogens responsible for 
infections. 
1.1.7.15 Metabolomics 
General Metabolomics   
Metabolites are small molecules which are intermediates and products of 
metabolism, and exist in a dynamic state within the body. The word 
‘metabolome’ was first used by Oliver et al. (1998) in relation to the metabolic 
analysis control aspect of the yeast genome sequencing, in reference to 
measurement of the change in the relative concentrations of metabolites as a 
result of the deletion or over-expression of a gene. Since then, the word has 
evolved to be used to describe the complete collection of all low molecular 
weight (MW) metabolites in a cell, which are involved in growth, maintenance 
and normal functioning of the cell (Dunn and Ellis, 2005).  
Metabolomics is the study of the composition, relative abundances, interactions 
and dynamics of the metabolome in response to change of environment of 
metabolites within a biological system (Osorio et al., 2012). It entails the use of 
sophisticated analytical techniques in non-biased identification and 
quantification of all metabolites in a biological system (Dettmer et al., 2007). 
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Since the metabolites that can be measured, are directly responsible for health 
and changeable by physiologic or pathologic interventions; their qualitative and 
quantitative measurement within a biological system is a potentially useful tool 
for understanding the phenotype (Watkins and German, 2002). 
The range of metabolites that can be analysed in a metabolomics experiment is 
remarkably diverse and cuts across all possible biochemical pathways within a 
living system, therefore analysis of molecules extending from very low MW-polar 
to much larger MW non-polar compounds is the norm in a typical metabolomics 
experiment (Dettmer et al., 2007). Metabolomics procedures involve controlled 
sample collection and preparation, instrumental analysis, data processing and 
data interpretation (Dunn and Ellis, 2005). 
A variety of samples can be used for metabolomics studies ranging from blood 
(serum or plasma), urine, cerebrospinal fluid, saliva, milk, organ effusions and 
even tissue (Dettmer et al., 2010). Most metabolomics studies are carried out 
for either of or both of two major reasons; first to understand the biological 
process at any given time, and second to detect and identify biomarkers (Xia et 
al., 2013). Three major approaches to metabolomics studies are metabolic 
profiling, metabolic fingerprinting and metabolic foot printing. 
Metabolic profiling is usually hypothesis driven and involves the analysis of a 
given set (targeted) of metabolites based on class or pathway while metabolic 
fingerprinting does not target a particular set of metabolites but aims to identify 
all metabolites present within the given biological system as they relate to 
changes in genes or phenotype (Courant et al., 2013). In metabolic foot printing 
naturally secreted or excreted biofluids such as urine, saliva and milk are 
studied to determine what is going on within the biological system under 
different conditions (Kell et al., 2005). Also referred to as the ‘exometabolome’, 
metabolic footprints offer a convenient strategy to understand and characterize 
the cellular metabolic pathways and biochemistry. Metabolomics has the 
particular advantage over other omics technologies of being the most reflective 
of current status of the biological system and comparatively less expensive to 
perform. 
Metabolomics can be carried out by the use of mass spectrometry (MS), Fourier 
transform infrared spectroscopy (FTIS) or nuclear magnetic resonance (NMR) 
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spectrometry. Mass spectrometry is usually combined with separation techniques 
such as liquid or gas chromatography (LC-MS; GC-MS) or less commonly capillary 
electrophoresis (CE-MS). Added resolution in the separation technique may also 
be achieved by the use of either high pressure liquid chromatography (HPLC) or 
ultrahigh pressure liquid chromatography (UPLC). 
Mass spectrometry provides a more sensitive (than NMR) qualitative and 
quantitative identification of metabolites being able to assess to the picogram 
(pg) level (Atzori, et al., 2009) and is the most commonly used technique in 
metabolomics. The basic principle in mass spectrometric analysis involves the 
ionisation of molecules, separation of these molecules based on mass to charge 
ratio within an electrical field and detection of the each separated ions, which is 
then used to generate a mass spectra.  
Direct injection MS (DIMS), is an MS technique where no prior separation of 
samples is done before loading onto the mass spectrometer. This form of 
analysis is commonly used for screening as against quantitative analysis (Dunn 
and Ellis, 2005). 
Several MS instruments are obtainable such as quadrupole, triple quads, ion 
traps, and time-of-flight mass analysers. An orbitrap analyser is another form of 
MS that is able to detect ion mass with greater accuracy (Gowda et al., 2008). 
Mass spectrometry has several drawbacks despite of its high sensitivity which 
includes the need for thorough sample preparation (especially in GC-MS) and is 
also time consuming to perform. In addition, with metabolomics experiments 
carried out using LC-MS, batch to batch variations of analytes are commonly 
encountered. This may occur as a result of variation in the extent of sample 
preparation or as a result of the instrument selectivity. New improvements in MS 
methods are also being introduced which tackle the problems of sample 
preparation and analysis time. 
In a typical metabolomics experiment, hundreds and sometimes thousands of 
spectral signals can be generated representing hundreds and thousands of 
metabolites. This data needs to be properly processed in order for the results to 
be biologically interpretable. Briefly, data analysis entails file conversion of raw 
data, peak or feature detection, data alignment and then normalization (or data 
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binning and scaling), multivariate analysis, metabolite identification using 
standard (public) database searches and the use of calibrated data matrix for 
further data (statistical) analysis (Sugimoto et al., 2012). 
Statistical analyses using multivariate techniques are often employed in 
metabolomics as large data sets are generated from these experiments, in order 
to determine changes in metabolome between different sample-sources 
following generation of their metabolic profiles (Gowda et al.,2008; Courant et 
al., 2013). These multivariate techniques include supervised approaches where 
prior knowledge of the sample category (e.g. control or diseased) is unknown; an 
example of this method includes principal component analysis (PCA) and 
hierarchical cluster analysis (HCA); and supervised approach, where the 
categories of samples are known, for example partial least squares discriminant 
analysis (PLS-DA), orthogonal signal correction (OSC) and random forest (RF) 
(Gowda et al., 2008; Sundekilde et al., 2013).  
Metabolomics is useful for the discovery of biomarkers of diseases such as 
cancers and metabolic disorders like diabetes, determination of biochemical 
effects of various interventions such as drugs or environmental stressors, cellular 
characterisation and health assessment (Suhre, 2014; Nair et al., 2014; Bonvallot 
et al., 2013). It is being increasingly utilized in pharmacological studies, 
understanding neurological diseases (Zhang et al., 2013), food and nutrition 
science, neonatal screening, clinical chemistry, and plant biotechnology 
(Okazaki and Saito, 2012) as well as in microbiology (Sundekilde et al., 2013; 
Sugimoto et al, 2012).  
The metabolome has been described to be the most predictive of the ‘omics’ 
technologies for the phenotype; hence a major advantage of metabolomics over 
proteomics, transcriptomics or genomics is that it reflects the state of the cell 
more accurately. Changes in function of the cells are also more amplified in 
metabolite profile, since these molecules are the products of on-going chemical 
reactions. Metabolomics is also said to be far less expensive than other ‘omics 
technologies (Dunn and Ellis, 2005; Kell et al., 2005). The first web human 
metabolome database was developed by Smith et al. (2005). Since then, the 
benefits of metabolomics in clinical diagnosis particularly in oncology have been 
emphasized (O’Connell, 2012). 
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Metabolomic investigations however have a few hurdles to overcome including 
lack of standardized procedures and bioinformatics modules especially for 
handling of the large quantities of data generated, as well as problems with 
identification of metabolites due to incomplete databases of many species. A 
number of limitations to biomarker discovery using metabolomics have 
encompassed issues of sensitivity, specificity and avoidance of bias as well as 
challenges with data processing (Leichtle et al., 2013). Nevertheless, constant 
improvements in multivariate analysis, instrumentation as well as 
standardization of methodology and sample preparation techniques are showing 
promise for overcoming these limitations. 
Metabolomics  studies in Bovine  species 
Metabolomics has been valuable in several areas of study in the bovine species, 
in particular diagnostics of animal health and food safety as well as management 
practices geared to improvement of animal production. Numerous metabolomic 
studies have already been carried out in cattle and the bovine metabolome 
database (BMDB) is available on http://www.cowmetdb.ca/. This database 
comprises information on metabolites of dairy and beef cattle obtained by 
experiment on blood, meat, urine, milk and ruminal fluid (Hailemariam et al., 
2014; Wishart Research Group 1996 —2013).  
Targeted evaluations of the metabolic profile (of known metabolites) in bovine 
samples such as urine, serum, plasma and milk have been frequently carried out. 
However untargeted approaches that aid in detecting new metabolites are 
gaining importance especially with new innovations in bioinformatics and mass 
spectrometric techniques. 
Some metabolomic studies which have been conducted in the bovine species 
include studies by Rijk et al. (2009) who utilized an untargeted UPLC-TOF MS to 
identify biomarker-candidates for the use of anabolic steroid prohormones; 
dehydroepiandrosterone (DHEA) and pregnenolone in cattle urine. Similar studies 
were also carried out by Regal et al. (2013) for assessing two other anabolic 
steroids, estradiol-17β and progesterone, this time using serum samples. They 
utilized HPLC coupled to an Orbitrap spectrometer and found significant 
differences that discriminated use and non-use of these hormones. With the 
same focus, a targeted approach for the detection of markers of natural steroids 
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and 4-androstenedione abuse in urine of cattle was explored by Anizan et al. 
(2011). Phase II metabolites of steroid detoxification (glucuronides and 
sulphates) in urine were the focus of both experiments and a UPLC-MS/MS 
technique was applied. All these studies resulted in the detection of several 
compounds which were not previously recognized and which once properly 
validated could serve as markers for screening of animals for steroid abuse. 
In trying to ascertain which blood sample type would be most suitable for 
assessing the blood metabolome, Dettmer et al. (2010) compared the 
metabolomic profiles of blood collected from bovine into; EDTA-plasma only and 
EDTA-plasma with acetyl salicylic acid, and blood collected and allowed to clot 
without addition of anticoagulants (serum) using a GC-TOF-MS. Differences were 
observed in the fingerprints from these three different types of blood sampling. 
Trabi et al. (2013) also used NMR based metabolomics to investigate the effect 
of long term storage on the metabolite profile of bovine plasma samples. 
Bender et al. (2010) observed significant differences in metabolites in follicular 
fluid of heifers compared to those of lactating cows using GC-MS, and also 
between dominant and subordinate follicles; these discrepancies were suggested 
to be able to give an insight into increasing incidences of low fertility and 
variances in fertility level between these two groups of cows.  
Additional metabolomics studies by Osorio et al. (2012)  aimed at elucidating 
biomarkers that could be applied to discriminate between beef produced under 
different pasture and concentrate-based production systems; creatinine, 
glucose, hippurate, pyruvate, phenylalanine and phenylacetylglycine, were 
observed to have promise in differentiating beef cattle based on these 
parameters. 
Metabolomics studies have also shown that differences in the concentration of 
up to 19 metabolites are potentially able to distinguish subclinical ketosis from 
normal serum samples, whilst up to 31 differentiated clinical ketosis from 
normal. Eight metabolites were also found to vary between subclinical ketotic 
and normal serum samples. These metabolites are thus potential biomarkers of 
ketosis in dairy cows (Zhang et al., 2013). 
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More research using metabolomics is still on-going in a variety of aspects dealing 
with cattle farming management and health. Thus the metabolomics approach is 
finding diverse and growing applications in cattle. The bovine ruminal fluid 
metabolome was elucidated by Saleem et al. (2013), using a combination of NMR 
spectroscopy and GC-MS, along with literature searches. A database containing 
the metabolites to use in this study has been made available at 
http://www.rumendb.ca. 
1.2 Proposed research 
Despite the enormous problem and economic impact of mastitis on dairy farming 
globally, there is as yet no definitive ‘parameter' the measurement of which in 
milk can be reliably used as a 'gold standard' for the confirmation of subclinical 
mastitis in a rapid on-farm tests (Uhler, 2009). The commonly used indicator, 
SCC, cannot be directly measured on the farm especially with the newer AMS in 
dairy farms. In addition, SCC has shown marked variation with other factors 
other than diseases of the mammary gland. This situation often results in false 
negatives that can subsequently lead to uncontrolled spread of contagious 
mastitis pathogens in a dairy herd. 
Furthermore, a major limitation to the use of SCC is its inability to be measured 
directly rapidly on line, while indirect measurements of SCC are less sensitive. 
Recently there has also been the focus on the need for pathogen-specific 
diagnosis of mastitis online to facilitate quick treatment intervention measures 
(Taponen et al., 2006; Hettinga et al., 2008). This would require markers 
specific for particular causative organisms, which as yet have not been reported 
for any of the major causative agents of bovine mastitis. 
Also, other parameters that have been brought to the fore over the years for use 
in mastitis detection, for example the APP, but have not received justifiable 
investigation of their potentials in on-farm use whereas others have had several 
shortcomings or poor exploration and validation of their prospects.  
Recent developments in technologies such as proteomics has allowed their use 
for better understanding of the mechanisms of disease well as in the discovery of 
marker compounds of bovine mastitis (Ferreira et al., 2013). In the last decade, 
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more omics applications have played and continue to play a crucial role in 
biomarker discovery from biological samples. 
However, there have been few studies focusing on the use of the newer omics 
(peptidomics and metabolomics) analyses for bovine mastitis biomarker 
identification, although more attention has been drawn to its use in 
characterizing the technological properties of milk such as SCC, which are 
related to mastitis. The few studies which have investigated the properties of 
milk in relation to disease using the omics technologies have shown the 
possibility of discovering new mastitis markers (Boehmer, 2011; Ferreira et al., 
2013). 
1.3 Aims and objectives  
It is the aim of this study to further elucidate and assess the potentials and 
applicability of the major bovine milk APP (Hp and M-SAA3) in specifying 
inflammatory conditions of the mammary gland. Reference levels, including 
baseline values in milk samples from uninfected quarters/cows, variations and 
dynamics of the APP under different physiological conditions affecting the dairy 
cow, in particular, the puerperal period, and other factors other than IMI that 
can alter APP levels will be explored. Characterization studies of Hp to 
determine its source in milk, from the mammary gland will be carried out. 
Analysis of these APP will also be carried out to further validate their levels of 
significant correlation with onset, progression, peak and resolution stage of an 
IMI using an experimental mastitis model. Furthermore how the major APP vary 
in milk with different mastitis causative pathogens will be examined.  
Following previous reports on the mastitis biomarker potential of bovine milk 
CRP (discussed above) and with the new experimental evidence and validation of 
this erstwhile minor bovine APP as a possible marker of mastitis, studies in this 
work will attempt to determine the value of CRP as a mastitis indicator under 
various conditions as detailed above for Hp and M-SAA3.  
In addition, because sample treatment or preparation is an important factor that 
can alter target indices within samples, analyses of the effects of some 
frequently used milk-sample storage-related treatment protocols; heat 
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treatment, preservation at different cold temperatures for various durations of 
time and use of chemical preservatives in milk samples, will be assessed.  
Using current approaches to proteomics, peptidomics and metabolomics, 
another major objective of this study, will be to identify compounds, 
metabolites, traits or biological features and patterns of compounds in milk that 
are discrepant between health and disease states of the mammary gland.  An 
aim to identify reliable markers which eventually can be applied or adapted to 
rapid on-line diagnosis of IMI will be targeted. Particular attention will be paid 
to detecting biomarkers which can sufficiently discriminate pathogen-specific 
causes of mastitis episodes. Adopting an experimental host-adapted S. uberis 
mastitis as a model, and covering a period of 0 to 312 h, which spans the pre-
infection to resolution stage of the acute mastitis model, it is aimed that profile 
of the proteome, peptidome and metabolome of milk as it varies with the 
progress and remission of infection will highlight compounds that will be of value 
in discriminating mastitis generally and S. uberis mastitis specifically. This study 
will attempt to fill the gap in knowledge of mastitis resolution metabolic 
markers specific for S. uberis.  
1.4 Justification  
Justification for this study comes from the growing impact of bovine mastitis as 
an economic and welfare issue in the dairy industry, the recognition of major 
the limitations to its control and management being the lack of its rapid 
definitive and causal-specific diagnosis.  
With the added complexity that AMS introduces to existing diagnostic measures 
such as CMT that would otherwise have been uncomplicated with conventional 
milking methods, the need for newer techniques or parameters whose 
measurements can be easily adjusted to work with the milking system, is 
warranted. 
This PhD research is therefore channelled to addressing and attempting to 
answer some of these pertinent problems and questions, confronting the 
management (diagnosis) of bovine mastitis using the tools of acute phase 
proteins analyses, proteomics and metabolomics of milk samples.  
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2 Acute phase proteins in a commercial dairy farm 
2.1 Overview 
In this chapter, the development of an assay for measuring milk haptoglobin 
(Hp), its optimization and validation as well as its use in assaying the profile of 
Hp in milk from a dairy herd in the west of Scotland is described.  Mammary 
associated serum amyloid A3 (M-SAA3) as well as C-reactive protein (CRP) were 
also measured using commercially available ELISA kits adapted for use in milk M-
SAA3 and CRP assays respectively and are also reported. In addition, a range of 
sample treatment protocols were examined to determine their effect on milk Hp 
and M-SAA3. An in-house, relatively inexpensive assay was developed and 
validated for the measurement of milk Hp. All samples were analysed for milk 
Hp, whereas only herd composite samples and some of the sample treatment 
protocols were analysed for M-SAA3. For the same reason, only composite milk 
samples from the dairy herd were assayed for CRP. 
2.2 Introduction 
2.2.1 Milk haptoglobin 
Haptoglobin can be assayed directly by antibody detection using immunoassays 
such as enzyme linked immunosorbent assay (ELISAs) and single radial 
immunodiffusion (SRID) as described by Morimatsu et al.(1992), as well as 
indirectly by measuring the peroxidase activity of the haemoglobin (Hb)-
haptoglobin complex, exploiting  the high affinity binding of Hp to free Hb 
(Eckersall et al., 1999). Direct immunoassays using antibodies have an advantage 
of higher sensitivity than assays using Hb binding assays which are also subject to 
interference.  
Haptoglobin has also been measured in bovine serum using high performance 
liquid chromatography (HPLC) as described by Salonen et al. (1996). In this 
method, Hp was first separated from serum by binding to cyanomethaemoglobin 
(HbCN) step after being depolymerised; gel filtration using the HPLC was then 
used to separate the HbCN. This method of assay was sufficiently sensitive to 
measure baseline levels of Hp. 
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A capillary zone electrophoresis method for measuring serum Hp was also 
described by PIrlot et al. (1999). This was also based on the capacity of Hp to 
bind to Hb, though the assay did not work well for bovine serum Hp. 
Since the discovery of Hp in milk and the reports of its increases in relation to 
mastitis, the measurement of milk Hp as a potential tool for diagnosing mastitis 
has been explored by several researchers (Eckersall and Bell, 2010). The need 
for a corresponding assay specifically adapted to detect milk Hp has also been 
highlighted. It was recognized by Eckersall et al. (2001) that the presence of 
milk (lacto) peroxidase could interfere with the measurement of Hp using the 
peroxidase activity of an Hp-Hb complex, thereby ruling out the use of that 
biochemical assay for measuring milk Hp.  
A number of commercial Hp assay kits exist for the measurement of Hp and a 
commercial SRID assay has also been used (Takahashi et al., 2007); however 
these kits are not be specifically optimized for measurement of milk Hp. Some 
workers have also developed assays specifically for milk Hp measurement (Hiss 
et al., 2004; Yang et al., 2011) whilst other workers have also attempted to 
adapt Milk Hp assays to rapid on-farm detection of mastitis methods, with 
varying levels of sensitivities (Åkerstedt et al., 2006; Tan, et al., 2012). 
An immunoassay is a method of detection of a compound or macromolecule 
(usually proteins or polysaccharides which are immunogenic) by the use of 
immunoglobulins or antibodies. The underlying principle of all types of 
immunoassays is the inherent ability of antibodies to bind to specific antigen. 
Engvall and Perlmann (1971) were the first to originally describe the enzyme 
linked immunosorbent assay (ELISA), one form of immunoassay that utilises the 
labelling of antibodies with enzymes and adsorption of analyte to a solid phase. 
The use of ELISAs became predominant in the seventies having evolved from 
radioimmunoassay (RIA). Since then, they have been found to be very useful for 
assay of large numbers of samples as they are reliable, sensitive and relatively 
inexpensive.  
There are several formats of ELISAs including direct, indirect and sandwich or 
capture ELISA, but generally all formats involve the coating of a solid support 
with the antigen or analyte (directly or indirectly), blocking of unoccupied sites 
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on the solid phase with non-reactant protein or other molecules and washing off 
unbound compounds. Antigen/analyte specific antibodies are then used to 
detect or probe the antigen, with a signal based on enzyme-substrate interaction 
of enzymes tagged to either the antigen-specific-antibody or a secondary 
antibody (to the primary antibody). This is subsequently measured 
spectrophotometrically to quantify the product of the enzyme substrate reaction 
which is used to interpolate the concentration of the analyte in samples.  
Competitive ELISAs utilize the principle of competition between reference 
antigens and the antigens in a test sample with a small amount of antibodies. In 
this format either the reference antigens or the antibodies may be labelled and 
the signal is inversely proportional to the amount of antigens in the test sample.  
A number of ELISAs have been described for the assay of Hp in biological samples 
(Sheffield et al., 1994; Young et al., 1995; Saini et al., 1998; Hiss et al., 2004; 
Flanagan et al., 2014 ) and there are also several commercial ELISAs for Hp now 
available (Wenz et al., 2010; Giannetto et al., 2011). 
A sandwich or capture ELISA is one in which a primary or capture antibody is first 
immobilized onto the solid support phase (in a process called coating) in order to 
enhance the specific adsorption of the antigen of interest. The addition of 
antigens follows after washing off unbound primary antibodies and blocking of 
unoccupied sites in the wells. 
A secondary or signal antibody which would bind to a different site on the 
antigen from the capture antibody is then incubated to detect or probe the 
antigen. Usually the signal antibody is tagged with an enzyme, the substrate for 
which is subsequently added to generate a signal that can be measured, based 
on chromogenic, chemiluminescent or fluorometric properties of the enzyme-
substrate product. 
Different antibodies, but which are specific to the analyte antigen, are often 
used for the capture (primary) and signal (secondary) in sandwich ELISAs. Usually 
monoclonal antibodies are preferred for coating and polyclonal antibodies for 
signal detection. It is also possible to use the same antibody type for both 
capture and signal (Leng et al., 2008). 
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This is a highly specific ELISA format as only the specific antigen is ‘captured’ to 
the surface of the wells and no other sample proteins due to the presence of the 
coating/primary antibody. Sandwich ELISAs are useful to detect antigens which 
are present at a low level in samples or within a complex mixture (KPL ELISA 
technical guide, Thermo scientific, 2013). 
2.2.2 Mammary associated serum amyloid A3 
Due to its hydrophobicity and high affinity for the lipoprotein fraction in serum, 
SAA is difficult to purify from blood and this poses many technical problems in 
the production of its stable antibodies (Yamada et al., 1999). In addition, the 
SAA molecule is poorly immunogenic (Wilkins et al., 1994). 
SAA is also known to adhere to the surface of plastic (sample) tubes leading to 
potential loss of SAA during sample concentration (Yamada, 1999), the reduction 
in alpha helical structure found in the last 1-11 amino acid residues of the amino 
terminal in A-SAA has been suggested to enhance the binding of SAA to 
polystyrene surfaces (Liang et al., 1996). It also sometimes shows a high 
tendency to aggregate or form multimeres once elution buffer was removed and 
after episodes of freeze thawing or in the presence of calcium (human samples); 
thus immunoreactive bands at about 66 kDa were noticed in 1D SDS-PAGE, and 
these were thought to be 5-unit multimeres of SAA molecules (Molenaar et al., 
2009). This attribute is another contributing factor to the difficulty commonly 
encountered in developing assays for SAA. Also, because SAA is often found 
bound to HDL in serum, denaturing techniques need to be applied to the sample 
often in order to facilitate reaction of the molecule to its antibody (McDonald et 
al.,1991). Storage at different temperatures and conditions was recently shown 
to affect the concentration of SAA and its mammary associated isoform in serum 
and milk samples (Tóthová et al., 2012), with a tendency to decrease with time 
of storage. 
SAA has been purified from serum by isolating the HDL fraction and then 
performing ultracentrifugation and delipidation steps (Smith and McDonald, 
1991), but very low recoveries were encountered. By using hydrophobic 
interaction chromatography, Smith and McDonald (1991) were able to get up to 
56 % recovery of SAA. A number of other researchers have also been able to 
purify SAA and antibodies against it for use in SAA immunoassays.  Horadagoda et 
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al. (1993) were also able to purify bovine SAA and applied it in an indirect ELISA 
for the quantification of SAA in serum of diseased calves. 
Serum amyloid A is measured predominantly using immunoassays particularly 
ELISAs and less frequently western blotting (Weber et al., 2006; Wells et al., 
2013), radial immunodiffusion assay (Chambers and Whicher, 1983) and 
radioimmunoassay (Eriksen and Benditt, 1986). A dot-blot immunoassay was also 
described (Ogata, 1989) and is based on the reaction of samples with a dot of 
commercially available hyper immune serum to SAA. 
McDonald et al. (1991) developed a sandwich ELISA using monoclonal antibodies 
from rat raised against human SAA, and this assay formed a basis for the 
development of a commercial SAA multispecies sandwich ELISA kit by Tridelta 
Development Co. (Kildare, Ireland) which is the most frequently used method of 
assay for SAA in animal studies. 
In the present study, several attempts were made to develop an ELISA for 
measuring M-SAA3 with antibody previously produced in the laboratory (Prof 
Eckersall, pers. comm.) but were not successful; hence the commercial ELISA kit 
by Tridelta Development Co. (Kildare, Ireland), was used for measuring M-SAA3.  
2.2.3 C - Reactive protein 
Generally, CRP has received very little attention as an APP in serum or milk of 
the bovine species that may be useful for diagnosis or prognosis of any 
inflammatory condition. The use of CRP as a parameter for mastitis has not been 
the subject of much investigation, even though there has been a small number 
of earlier reports of its potentials in this regard (Schrodl et al., 1995; Kruger and 
Neumann, 1999; Lee et al., 2003). A probable reason for this could be due to the 
narrow range of CRP in milk as reported in one study, where CRP was not found 
useful in differentiating milk from healthy and SM milk samples, therefore 
lacking adequate sensitivity (Hamann et al., 1997). Similarly in human milk, CRP 
was reported to have a narrow range, thus it was not feasible to utilize it to 
make a differential diagnosis of infective and non-infective forms of mastitis 
(observed in the human subjects of that study) (Fetherston et al., 2006).  
Recently, studies at the Life Diagnostic Inc. laboratory (West Chester, USA), 
using a newly developed ELISA for measuring bovine CRP, that utilized antibodies 
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raised specifically for cow CRP, showed that a range of 3.1 ± 2.8 ng/ml existed 
in normal milk (n=17), while a range of 4218 ± 2658 ng/ml existed in milk from 
mastitic cows (cow C-reactive protein, Life Diagnostics ELISA kit instruction 
manual, 2014). This new and promising report in the range and sensitivity of CRP 
in healthy and mastitis milk for diagnosis of mastitis may have resulted from the 
use of a more sensitive assay, which was able to measure a wider range of CRP, 
even in normal (healthy) milk samples.  
In view of the overall objective of this PhD research to identify new and more 
reliable biomarkers of bovine mastitis, the value of bovine milk CRP, which has 
only been reported in a few studies as yet, was investigated as a useful 
parameter of bovine mastitis.  
2.2.4 Study of acute phase protein profiles on farms 
The importance of APP for herd diagnosis of various disease conditions have 
been shown (Humblet et al., 2006). There are numerous reports of the profile of 
APP in bovine serum and their value in recognizing disease conditions on a herd 
basis (Murray et al., 2014; Abuelo et al., 2014; Trevisi et al., 2014).  
There are also a few reports on the profile analysis of milk APP in samples 
encompassing entire dairy farms (Petersen et al., 2005 and Åkerstedt et al., 
2007). Petersen et al. (2005) examined the MAA profile in five herds, and 
correlated findings with the SCC, presence or absence of clinical mastitis and 
bacteriological agents. They found no correlation between SCC and MAA. 
Åkerstedt et al. (2007) looked at samples from healthy cows from three 
different herds and related the APP profiles to the type of milk sample (quarter, 
composite or bulk tank milk), and to the SCC level. The dairy herds were of the 
Swedish dairy herd breeds and the two major APP, Hp and SAA were evaluated, 
and significant correlations discovered between SAA, Hp and SCC in quarters and 
composite milk but only between SAA and SCC in the bulk tank. The finding of 
this correlation between APP and SCC in samples from apparently healthy cows 
indicates that APP cut off points maybe adapted to determine mastitis status of 
cows or herds. Therefore it would be useful to evaluate the APP profile in a 
dairy herd, with the aim of determining cut off values for each in relation high 
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and low SCC levels. Such knowledge would enhance their potential for their 
future use on farms.  
2.2.5 Stability of acute phase proteins in milk under different 
sample treatment conditions 
Samples for diagnostic procedures often require some form of preparation, 
preservation or safe handling for transportation prior to analysis in the 
laboratory.  This is especially true for milk samples which frequently need the 
use of preservatives to retain milk composition as close to freshly collected 
samples as possible. Chemical preservation is used to avoid cellular degradation 
prior to somatic cell count or progesterone analysis. Another form of treatment 
is milk fat and casein removal to expose ‘milk serum’ preceding some analytical 
techniques such as proteomics, and where samples are not to be immediately 
assayed, storage at freezing temperatures of between -20°C and -80°C is 
common.  
In addition, as a requirement for the safe transfer of biological samples across 
international borders, some national regulations that demand heat treatment of 
liquid samples in order to inactivate harmful pathogens in the samples have 
been put in place (Council directive 82/894/EEC of 21 December 1982, under the 
European Communities Act 1972). However, high temperature is known to 
denature proteins and to influence the concentration and immunologic activities 
of some serum proteins (Hausen et al., 2012; Ahmed and Saunders, 2012). Heat 
treatment has also been shown to result in irreversible changes in the structure 
of milk proteins (Raikos, 2010). 
In the handling of milk samples for chemical analyses, the use of preservatives 
has become a requirement for some tests due to distances of laboratories from 
the farms where samples are obtained. Potassium dichromate (K2Cr2O7) is a 
corrosive and toxic biocide which is often used in the preservation of milk 
samples in order to maintain milk composition from time of collection to 
analyses. It is known to be effective as a milk preservative (Barbano et al., 
2010), and is used to maintain progesterone levels in milk for pregnancy 
diagnosis. Other preservatives that have been used in milk samples include 
Mercury chloride (HgCl2), Sodium azide and Bronopol (C3H6BrNO4; 2-bromo-2-
nitro-1, 3 propanediol) (Luck, 1975; Kvapilik and Suchanek, 1974). Unlike 
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potassium dichromate, Bronopol is reported to have no harmful effects and is 
often used in milk preservation (Chalermsan et al., 2004), particularly for 
preserving SCC prior to analysis through its action as an antimicrobial agent. 
However it is not known if such commonly used milk preservatives or heat 
treatment used to inactivate pathogens before international transit, have an 
effect on the concentration of milk APP but it is important to be aware of such 
effect if milk APP are to be performed on samples treated with these methods.  
One of the aims of this study was to evaluate the effect of some sampling and 
storage variables on milk Hp concentration. This consisted of the assessment of 
milk Hp following the use of milk preservatives such as potassium dichromate 
(Lactab Marks III; Thompson & Capper Ltd, Cheshire, UK) and Bronopol (Broad 
spectrum Microtab® II; Advanced instruments, Inc., Massachusetts, USA), which 
are used to preserve milk composition from collection to analysis of for example, 
SCC or progesterone for pregnancy diagnosis.  
This study also explored the possible effect on milk APP when samples were 
heated to pathogen destroying temperatures. Storage of samples at different 
durations of freezing temperature, on milk APP profile was also examined. 
2.2.6 Study objectives 
The objectives for this chapter were the following; 
 The first aim of this study was to develop, optimize and validate an 
immunoassay of a sandwich ELISA format which would be sensitive and 
reliable for the measurement of milk Hp.  
 Studies were carried out to evaluate the effect of sampling and storage 
variables on milk Hp and M-SAA3 concentration. This consisted of the 
assessment of milk Hp and M-SAA3 following the use of the milk 
preservatives; potassium dichromate (Lactab® Marks III) and Bronopol 
(Broad spectrum Microtab® II) for milk Hp only, which are used to 
preserve milk composition from collection to analysis (to preserve milk 
meant for somatic cell counts (SCC) and progesterone measurement 
respectively). This study also explored the possible effect on the milk 
APP, when samples were heated to pathogen destroying temperatures. 
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Storage of samples at different temperatures for different durations of 
time was also examined in relation to the APP. 
 To evaluate the profile of milk Hp, M-SAA3 and CRP in samples from a 
commercial dairy herd and to compare the results with some commonly 
measured milk traits such as SCC and cow factors such as parity and stage 
of lactation of each cow.  
2.3 Materials and methods  
2.3.1 Reagents 
General chemicals were obtained from Sigma-Aldrich, Poole, UK, except where 
otherwise stated. In all experiments, milli Q water was used.  
2.3.2 Haptoglobin ELISA development 
2.3.2.1 Assay Protocol 
Antibody conjugation 
Purified rabbit anti bovine haptoglobin (RABHp) (Life Diagnostics, West Chester, 
USA) was conjugated with alkaline phosphatase (Innova Biosciences, 
Cambridgeshire, UK) according to manufacturer’s instruction. An aliquot of 3.7 
µl of LL-Modifier was added to lyophilized product (alkaline phosphatase-AP) in 
the vial and gently mixed by pipetting up and down. 37 µl of the RABHp IgG 
(immunoglobulin G) (0.1 mg) was then added into the vial, gently mixed and left 
at RT overnight. 3.7 µl of LL-Quencher was added the next day to stop the 
reaction.  
The conjugate was ready for use after 30 minutes (min). 200 µl of phosphate 
buffered saline (PBS) was added to the conjugate to give a final volume about 
244 µl, and an antibody concentration of 0.4 mg/ml. This was stored at 4oC until 
used. The success of the conjugation of the rabbit anti bovine Hp to alkaline 
phosphatase was assessed by western blotting (of SDS-PAGE of milk and serum 
samples with varying concentration of Hp) incubation with the conjugated 
antibody and staining with 1-Step™ NBT/BCIP (alkaline phosphatase substrate for 
immunoblotting; Thermo scientific, Rockford, USA). 
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Sandwich ELISA procedure 
Unconjugated rabbit anti bovine Hp was diluted to give a series of 
concentrations of 1 - 0.125 µg/ml in coating buffer (0.05 M NaHCO3 pH 9.6). 100 
µl aliquots were dispensed into individual wells of Nunc-Maxisorp 96 MicroWell™ 
plate (Nunc International, Rochester, New York, USA) and incubated at 4oC 
overnight. After discarding the antibody coating solution, each well was washed 
using 250 µl wash buffer; 250 µl of 0.02 M Tris-HCl containing 0.05 % (v/v) 
Tween-20 (pH 7.4), per well, four times. Unoccupied binding sites were blocked 
by adding 250 μl of 10 % (w/v) Marvel milk protein in wash buffer, per well and 
incubated at 37oC for 60 min. 
After washing, standard bovine Hp (1.64 mg/ml, Life Diagnostics Inc., West 
Chester, USA) was diluted to a concentration of to 1025 ng/ml in wash buffer 
and then double dilutions made from 1025 - 8 ng/ml, in order to generate a 
standard curve. Milk samples were also diluted in wash buffer (1:200, 1:400, 
1:800, 1:1600 or 1:3200). 100 μl of each standard bovine Hp and diluted milk 
samples were added into duplicate wells and incubated at 37 °C for 60 min with 
gentle shaking. 
Wells were washed, and 100 µl of the alkaline phosphatase-conjugated antibody 
(section 2.1.1) diluted 1:1000, 1:5000 and 1:10,000 in wash buffer, were 
dispensed into each well of the ELISA plate and incubated at room temperature ( 
RT) for 60 min with gentle shaking.  After washing, substrate solution, 
BluePhos® Microwell phosphatase substrate system by KPL (KPL laboratories, 
Inc., Maryland, USA) was made up according to manufacturer’s instruction and 
100 µl was added into each well for colour development taking approximately 10 
min. APstopTM solution (KPL laboratories, Inc., Maryland, USA) was used by 
adding 100 µl per well, to stop further colour development after the optimum 
was reached. 
The absorbance was read at 595 nm using FLUOstar OPTIMA plate reader (BMG 
Labtech Ltd, Bucks, UK) and the results analysed and calculated using the 
associated MARS (Optima) data analysis software (BMG LABTECH, program 2.40) 
with a 4 parameter logistics (4PL) standard curve plotted on a log-linear scale. 
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In order to obtain a better intra assay coefficient of variance (CV) per ELISA 
plate (where the intra assay CV was above 15 % probably due to instrument 
error), absorbances for some plates were also read using the built-in Triturus® 
ELISA plate reader at wavelength of 600 nm. Better intra and inter assay CVs 
were obtained using this reader. So for subsequent readings of samples 
described in chapters 4 and 5 of this thesis, the Triturus® reader was used. A 
4PL standard curve was selected and concentration and validation calculations 
were carried out by the Triturus® software. 
2.3.2.2 Assay validation 
Precision 
Precision of the assay was determined by calculating the intra assay and inter 
assay coefficient of variance (CV). Intra assay was determined by the mean CV of 
40 duplicate samples while inter-assay was calculated by the mean CV of 
repeating 2 different samples (high and low Hp milk) in 10 different assays.  
Limit of detection  
Minimum detection limit was taken as the haptoglobin concentration of mean of 
absorbance reading 4 blank samples plus 3 standard deviations (SD) being the 
concentration that could be differentiated from zero.  
Specificity 
Specificity of the assay was assessed by western immunoblotting of milk samples 
containing varying concentrations of Hp and samples of commercial milk spiked 
with known concentrations of purified bovine Hp with the alkaline phosphatase 
labelled anti bovine Hp as antibody (the western blotting procedure is described 
in details in Section 3.3.1.3.2). 
Accuracy  
Accuracy was determined by percentage recovery of Hp concentration, from 
spiked milk samples, using the ELISA assay. Spiked samples were prepared from 
separate aliquots of a commercial milk (with no measurable level of Hp) to 
which standard bovine Hp (Life Diagnostics Inc., West Chester, USA) was added 
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to gain a final concentration of 100 µg/ml, 50 µg/ml, 25 µg/ml and 0 µg/ml (not 
spiked), followed by gentle mixing at 4°C overnight. 
 
2.3.3 Mammary associated serum amyloid A3 assay 
2.3.3.1 ELISA kits 
Tridelta Development Ltd supplied the Phase™ Range SAA ELISA kit (sandwich 
ELISA kit for measuring multispecies SAA, Phase™ Range by Tridelta Development 
Ltd (Kildare, Ireland). 
2.3.3.2 Reagent preparation 
Diluent buffer and wash buffer (1x) were prepared from the stock of 10x and 20x 
respectively using milli Q water, according to the manufacturers’ instructions. 
The calibrator for the assay was reconstituted by adding 1 ml of 1x diluent 
buffer to the lyophilized SAA standard and vortexed vigorously. Aliquots of the 
top calibrator were made and stored at -20ºC. Serial dilutions of the top 
standard were made to achieve 6 standards per assay (300 – 0 ng/ml), which 
were run in duplicates. Milk Samples were diluted in 1x diluent buffer. 
2.3.3.3 M-SAA3 assay protocol 
Samples were diluted to 1:50 or 1:500 and 50 µl of each sample, as well as of 
the standards (calibrators), were dispensed into wells of a pre-coated 96-well 
plate to which 50 µl of anti SAA-HRP conjugate had been previously added. ELISA 
plates were gently tapped to mix the contents and then incubated at 37°C for 60 
min.   
Wells were washed four times with 1x wash buffer, after the last wash the plate 
was tapped dry on absorbent paper. Substrate for HRP; tetramethyl benzidine 
(TMB) solution, was added (100 µl/well) and incubated for 15 min at RT in the 
dark. The reaction was stopped by adding 100 µl of the stop solution provided in 
the kit, and absorbance read at 450 nm using FLUOstar Optima ELISA plate 
reader at wavelength of 450 nm. A 4-parameter logistics (4PL) standard curve 
was used to plot the standards; sample concentration interpolations were 
calculated using the MARS (Optima) analysis software (v. 2.40, BMG Labtech). 
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Concentrations of samples were interpolated from the linear portion of the 
standard curve generated.  
2.3.3.4 M-SAA3 assay validation 
The limit of detection (LOD) was determined from the mean plus 2 standard 
deviations of 4 blank samples while the specificity and accuracy of the assay 
were based on the data supplied by the manufacturer (Phase™ Range, 
Instructions for use, 2014).   
Intra assay precision was evaluated from the mean coefficient of variance (CV) 
for 42 samples ran in duplicates, while inter assay precision was calculated from 
the mean CV of 5 repeats of high and low quality control samples. 
2.3.4 CRP assay 
2.3.4.1 ELISA kits  
Cow C-reactive protein (CRP) ELISA kits for assay of milk CRP were supplied by 
the Life diagnostics Inc. (West Chester, USA). The assay was based on solid phase 
sandwich ELISA format, and comprised of a primary anti-bovine CRP antibodies 
immobilized to the wells of a 96-well microtitre plate and secondary antibodies 
against the anti-bovine CRP conjugated to HRP. 
2.3.4.2 Reagent preparation 
Diluent buffer and wash buffer were prepared from the stock of 10x and 20x 
solution respectively, using milli Q water according to the manufacturer’s 
instruction. 
CRP standard was reconstituted by adding 1 ml of the 1x diluent buffer into the 
vial of lyophilized standard and vortexed vigorously. 14.25 µl of the 
reconstituted standard was added to 485 µl of diluent buffer to give the top 
standard with a concentration of 62.5 ng/ml. The top standard was then serially 
diluted to give 6 other standards with concentrations ranging to 0.98 ng/ml. 
Plain diluent buffer was used as the blank (0 ng/ml). Milk samples were diluted 
initially at 1:250 in 1x diluent buffer, but for samples with higher CRP 
concentrations, a dilution of 1:2000 was re-used and for sample with very low 
CRP concentration a lower dilution of 1:5 was used. 
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2.3.4.3 CRP assay protocol 
Diluted samples and standards were mixed thoroughly and 100 µl of each sample 
or standard was dispensed into duplicate wells of the 96-well microtitre plates 
provided.  This was then incubated on an orbital microplate shaker at 150 
revolutions per minute (rpm) at RT for 45 min. Contents of the wells were then 
discarded and wells washed five times each using 1x wash buffer. After ensuring 
all residual droplets in the wells were removed by striking plates onto absorbent 
paper, 100 µl of the secondary antibody-HRP conjugate was then dispensed into 
each well and incubated on the shaker at RT for 45 min. The wash step was 
repeated and 100 µl of TMB reagent (HRP substrate) was dispensed into wells 
and colour development was allowed to proceed for 20 min on the shaker at RT. 
The reaction was stopped by adding 100 µl of stop solution per well into the 
wells. Absorbance was read using a FLUOstar Optima plate reader at 450 nm 
within 15 min of stopping the reaction. A four parameter logistic curve (4PL) was 
used to plot the standard curve, and concentrations of samples were 
interpolated from the linear portion of the standard curve. 
2.3.4.4 CRP assay validation  
The limit of detection of the CRP ELISA was determined as the mean plus 3 
standard deviations of the concentration value of 4 blanks. The specificity and 
accuracy of the assay was based on the data supplied with the kit (Life 
diagnostics, Inc., catalog number 2210-8, instruction manual).  Intra assay and 
inter assay precision was calculated from the mean CV of 40 samples ran in 
duplicates and that of 5 repeats of 2 QC samples (high and low CRP 
concentration) respectively. 
2.3.5 Assayed samples   
2.3.5.1 Effect of sample treatment on milk APP 
Milk samples with a varying range of APP concentration were obtained from the 
University of Glasgow Cochno Research Farm dairy herd and from Veterinary 
Diagnostic Services (VDS), University of Glasgow. Several 500 µl aliquots were 
made from each sample with aliquots treated to assess for;  
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 Effect of heat treatment by subjecting one set of aliquots (500 µl per 
aliquot)  to heat treatment (56°C, for 30 min in a water bath); Hp (n=38), 
M-SAA3 (n=20).  
 Effect of use of preservatives by adding and mixing to one set of aliquot 
each; 
o 1 tablet (30 mg) of potassium dichromate (Lactabs® Mark III, 
Thompson and Capper Ltd, Cheshire, UK) per 10 ml of milk 
samples; Hp (n=35), M-SAA3 (n=8);  
o 1 tablet (8 mg Bronopol + 0.30 mg Natamycin) per 40 ml of milk 
sample of Bronopol (Broad spectrum Microtabs® II, Advanced 
instruments, Inc., Massachusetts, USA);  Hp (n=33)  
 For evaluation of effects of different storage temperatures and duration 
on milk APP, separate sets of aliquots of fresh milk samples (n=6) 
collected from Cochno Dairy, were stored at 4°C for 24 h; -20°C for 7 
days and -20°C for 21 days, after which they were all assayed for Hp and 
M-SAA3. Control aliquots of the samples were analysed for Hp and M-SAA3 
on the day of collection, before any form of storage. 
 
2.3.5.2 Milk Samples from cows at Cochno dairy 
Composite and quarter milk samples were collected during the morning (6:00 
am) and afternoon milking (3:00 pm) respectively, from all lactating Holstein–
Friesian cows at Cochno dairy farm, Glasgow between the period of September 
and October 2012. Sample collection was carried out with the assistance of Mr 
Ian Cordner (Cochno Dairy farm, University of Glasgow) and Mary Waterston 
(Institute of Infection, Immunity and inflammation, University of Glasgow). 
The health statuses of the cows were confirmed by routine veterinary records 
maintained for each cow. Cows were milked twice daily, housed in pens and fed 
a standard diet. Just before application of milking machine clusters to the 
udder, teats were wiped with an iodine based disinfectant, the first few jets of 
milk were discarded, and approximately 50 ml milk per quarter was expressed 
into sterile Falcon tubes and labelled. Composite milk samples were obtained 
after application of the milking machine cluster to the teats of functional 
quarters of each cow, ~50 ml of sample was then collected from a milk tube 
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linked to the claw of the milking machine, into sterile tubes. Samples were later 
aliquoted (~15 ml, 3 aliquots) and stored -20°C until analysed. 
One hundred and forty nine (149) quarter and fifty four (54) composite milk 
samples collected from Cochno Dairy farm were assayed for Hp, while only 
composite milk samples (n=54) were analysed for both M-SAA3 and CRP. Samples 
were thawed at RT, thoroughly mixed by vortexing, and diluted in diluent/wash 
buffer. They were then assayed using the respective sandwich ELISAs for each of 
the APP as described above.  
Data of SCC, percentage fat and percentage protein in milk samples as well as 
lactation number (number of times cow had calved) and days in milk (DIM) of the 
cows were obtained from farm records (SCC, fat and protein tests were carried 
out by the National Milk Records Company (NMR Co.), Hillington-Park, Glasgow.  
Somatic cell counts were categorized into high (>200,000 cells/ml) and low 
(≤200,000 cells/ml), based on suggestions by Pantoja et al. (2009). Cut off 
values for SCC to determine subclinical mastitis have been a subject of debate 
(Åkerstedt et al., 2011), therefore in this study a second categorisation level for 
SCC was used based on suggestions of Schwarz et al. (2011) and Berglund et al. 
(2007) (healthy samples- SCC<100,000 cells/ml; subclinical mastitis (SM)-SCC 
101,000 -200,000 cells/ml; clinical mastitis (CM)-SCC>200,000 cells/ml). The APP 
distributions were compared between these various SCC categories.  
Lactation stage was determined from DIM as: 0-60 days= early lactation, 61-240 
days=mid lactation; 241-305 days=late lactation; 306 and above=dry period) and 
distribution of each APP was across lactation stages were compared. Correlations 
between the APP, lactation number, percentage (%) fat and % protein were 
examined. 
2.3.6 Statistical analyses  
Results obtained were initially stored in Excel (Microsoft 2007) and simple 
descriptive statistics were obtained. Data were later exported to IBM statistical 
package for social sciences (SPSS) statistical software; version 21 (IBM 
Corporation, 2012) for further analysis. 
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Tests for normality were run on the APP values using Kolmogorov–Smirnov and 
Shapiro–Wilk test along with normal probability plots and quantile-quantile (Q-Q) 
plots. To analyse effects on milk APP of heat treatment, Lactab® and Microtab® 
use, different storage conditions and milk defatting and casein removal, the 
Wilcoxon signed ranks test for non-parametric data was used to compare the two 
groups (treated or untreated), significance level of P was taken as <0.05. Non-
parametric correlations test (Spearman’s rho) was carried out to determine 
correlations between APP in the different groups. 
For variables which were not normally distributed, non-parametric tests (Mann-
Whitney’s test for two groups and independent Kruskal-Wallis test for more than 
2 groups) were used to evaluate the differences between groups (SCC categories 
and lactation stage). Bivariate correlation analyses (Spearman’s rho for non-
normally distributed data) were carried out between each APP, SCC, lactation 
number, % fat and % protein of Cochno composite milk samples. P-value was 
considered significant at <0.05. The Stata® statistical package (version SE/12.1, 
StataCorp, USA) was used to calculate reference values for the APP in relation to 
high and low SCC categories (>200,000 and <200,000 cells/ml) of the composite 
milk samples from Cochno dairy farm. 
2.4 Results  
2.4.1 Milk haptoglobin 
2.4.1.1 Hp ELISA optimisation and validation 
Coating Antibody 
A final concentration of 0.125 µg/ml of the primary antibody in coating buffer 
(100 µl/well) was used as the optimized capture solution. This value was 
selected as it produced the best signal to noise ratio absorbance on the ELISA 
plate wells and contributed to standard curve with the lowest blanks and 
sufficiently steep, after trying concentrations of 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml 
and 0.125 µg/ml. Figure 2-1 shows standard curves obtained using different 
concentration of coating antibody. 
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Figure 2-1: Optimization of the coating antibody solution for the ELISA showing curves 
obtained for various coating antibody concentrations.  
The 0.125µg/ml solution gave the steepest curve with lowest blank and was therefore adopted for 
the ELISA. 
 
Standards and sample dilution 
A range of concentrations of bovine Hp standard from 1025 ng/ml double-diluted 
to 8 ng/ml (in wash buffer) gave the range of steepest 4PL curve (on the log-
linear scale as seen in Figure 2-2). 
Samples were diluted to 1:400, 1:800, 1:1600 or 1:3200 in wash buffer 
depending on the concentration of Hp in order for the measured value to fall 
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Figure 2-2: Example of 4PL standard curve generated for standard bovine Hp. 
Dilutions were from 1025-8 ng/ml, from which sample concentrations (n=21) were interpolated. 
Points are mean ± standard deviation (SD) of standards. 
 
Signal antibody 
A final dilution of 1:10,000 of the conjugated antibody (alkaline phosphatase 
labelled RAB-Hp) in wash buffer (0.4 µg/ml) gave the optimum concentration of 
signal for the determination of Hp levels in the milk samples compared to 1:1000 
and 1:20,000 and was thus adopted as the optimized concentration of signal 
antibody for the assay. Figure 2-3 shows standard curves generated for the three 
different signal antibody concentrations used. 
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Figure 2-3: Optimization of signal antibody (RAB-alkaline phosphatase conjugate) for 
developed ELISA. 
Standard curves generated using signal antibody concentrations of 1:1000, 1:10,000 and 1:20000. 
The 1:10,000 signal Ab concentration was choosen because it had a lower blank and at the same 
time suffienctly steep curve than the other concentrations. 
 
Precision 
The intra assay CV was 5.74 %, while inter assay CV was 26.92 %. Table 2-1 shows 
the concentration (mean of duplicates) and calculated standard deviations (SD) 
and CV used to arrive at the inter assay precision. 
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Table 2-1: Haptoglobin concentrations determined by the developed ELISA in two quality 
control (QC) samples 
Samples 97FL (high Hp) and 43FL (low Hp) in 11 different plate assays, read using the FLUOstar 
optima plate reader, an inter assay precision of 30 % and 23 % for the high and low QCs 
respectively was obtained. 
 Hp (µg/ml) 
TEST High QC Low QC 
1 30.2 3.67 
2 21.3 5.65 
3 18.58 7.33 
4 17.86 7.31 
5 33.68 7.17 
6 34.4 8.69 
7 23.74 9.06 
8 25.1 7.07 
9 17.22 5.85 
10 15.05 6.95 
11 16.26 4.97 
Mean 23.04 6.70 
SD 7.01 1.57 
    % CV  30.44,  23.4 
Average % CV (interassay CV) =26.92 %,  
In order to further optimize and improve the precision of the Hp ELISA, standard 
dilutions were later made from 512.5 ng/ml to 4 ng/ml and assays were run on 
an automated ELISA equipment robot (Triturus® ver. 4.01 by Diagnostic Grifols, 
Spain).  
Absorbances were then read using the built-in Triturus® ELISA plate reader at 
wavelength of 600nm. Standard curve plotting, concentration calculations and 
validation calculations were carried out by the Triturus® software. Calculated 
intra assay CV was 1.6 % (mean of CVs of 40 samples run in duplicates) and inter 
assay CV (mean) was 15.6 % after these adjustments. Table 2-2 shows the mean 
and calculated SD and % CV of 10 repeats of the controls used to determine the 
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Table 2-2: Haptoglobin concentrations of 2 QC samples (high and low Hp milk) in 10 
repeats. 
Determined using the developed ELISA after modifications on standards’ concentration range and 
by the use of Triturus® ELISA plate reader. 10 different ELISA analyses were carried out giving an 
inter-assay precision of 14 % and 17 % for the high and low Hp milk respectively. 
TEST High QC  Low QC  
1 18.8 4.6 
2 15.56 5.28 
3 14.36 4.88 
4 21.84 6.84 
5 18.08 6.04 
6 16.48 5 
7 16.08 4.68 
8 21.84 5.8 
9 16.7 5.9 
10 17.04 7.52 
Mean  17.67, 5.65 
SD 2.51,   0.96 
CV 0.14,   0.17 
% CV 14.22,  17.03 
AVERAGE % CV=15.62 % 
 
Limit of detection 
The limit of detection (LOD) which was determined from the concentration of 
the mean of four blank samples plus 3 standard deviations was 2 ng/ml (0.002 
µg/ml) for milk samples after dilution which allowing for the minimum dilution 
of 1:200 gave a limit of 0.4 µg/ml for the lowest concentration that could be 
measured in milk.  
Accuracy 
The calculated accuracy of the assay was determined from recovery 
concentration of spiked samples and this was 96 %, shown in Table 2-3. 
Table 2-3: ELISA determination of haptoglobin concentrations in Hp-spiked milk samples;  









C100 100 76.17 76 
C50 50 44.04 88 
69BR 10 10.63 106 
69BR 40 37.51 94 
69BR 20 23.86 115 
Mean Recovery = 96 % 
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Accuracy was also determined by evaluating the linearity of 3 different milk 
samples of varying Hp concentration after serial dilutions of the samples at 
1:400, 1:800 and 1:1600, Figure 2-4 is a chart showing the linearity of the 
samples. 
 
Figure 2-4: Linearity of 3 milk samples’ (A1, B1 and C1) Hp after dilution of the samples at 
1:400, 1:800 and 1:1600 
 
Specificity 
The western blot assessment of the specificity of the assay using milk samples 
spiked with known concentrations of standard bovine Hp and is shown in Figure 
2-5. Figure 2-6 shows a western blot of serum and milk samples having naturally 
high or low haptoglobin and shows bands developed in high Hp containing 
samples. In both spiked samples and those with naturally elevated Hp, the β-
chain of Hp around 40 kDa reacted with the labelled antibody used in the Hp 
ELISA and no other protein. 
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Figure 2-5: Western immunoblotting of milk samples spiked with Bovine Hp. 
Lane 1, 2 and 3 having samples spiked with 100 µg, 50 µg and 25 µg Hp respectively showing 
increased intensity of bands with higher Hp concentration) and lane 4 not spiked and having no 




Figure 2-6: Western blot of serum and milk samples using RABHp with varying Hp 
concentration.  
Serum samples (1-9) with low (1-3, 6 and 9) and high Hp (4, 5, 7 and 8) and milk samples (10-15) 
with low (12, 13 and 14) and high Hp (10 and 11), showing the β-chain band of Hp in the high Hp 
samples. 
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2.4.1.2 Effect of different sample treatment on milk haptoglobin. 
Significant differences were found in the milk Hp levels of heat treated and non-
heated samples (P=0.03). Heated samples (56ºC for 30 min) showed an average 
11 % reduction in milk Hp compared with unheated samples. However there was 
a high correlation between the heated and unheated samples (r = 0.97). Table 2-
4 shows the related samples Wilcoxon signed ranks test of comparison between 
the two sets of samples (heated and unheated), and in Figure 2-7 is a scatter 
plot of the heated and unheated samples is depicted. 
There was no significant difference in milk Hp with use of the preservative, 
potassium dichromate (Lactabs® Mark III) compared with controls (P=0.08, 
r=0.98) (scatter plot shown in Figure 2-8). No significant differences were also 
observed for use of Bronopol (Broad spectrum Microtabs® II) (P=0.796, r=0.88) 
(scatter plot shown in Figure 2-9) compared to controls. Samples stored at 
different storage temperatures ranging from 4ºC for 24 h and -20ºC for 21 days 
did not show any significant difference in their Hp levels (supplementary data).  
 
Table 2-4: Wilcoxon signed ranks test of comparison of milk Hp in heated and unheated 
samples 
Negative ranks indicate samples in which heated samples had Hp concentration less than in 
unheated samples.  
Ranks 








26a 17.17 446.50 
Positive 
Ranks 
9b 20.39 183.50 
Ties 3c   
Total 38   
a. heated < unheated 
b. heated > unheated 
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Figure 2-8: Scatter plot of samples preserved and non-preserved with Potassium 
dichromate 
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2.4.1.3 Haptoglobin profile of Cochno dairy farm milk samples 
Quarter milk samples 
Haptoglobin concentration in quarter milk samples (n=149) collected from 
Cochno Farm ranged from <0.4 µg/ml to 420 µg/ml and had a skewed rather 
than normal distribution (Figure 2-10). The median was 36 µg/ml. Figure 2-11 
shows the distribution of quarter samples having Hp below 100 µg/ml. 
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Composite milk samples Haptoglobin 
Descriptive statistics of Hp and relevant data from the NMR Co. in composite 
milk samples are presented in Table 2-5, while the frequency distribution is 
shown in Figure 2-12. Hp concentration ranged from 0.4-55.46 µg/ml and a 
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Table 2-5: Descriptive statistics’ of composite milk samples APP (n=54). 
 Hp (µg/ml) M-SAA3 (µg/ml) CRP (ng/ml) SCC cells/ml Parity % fat % Protein DIM (days) 
Mean 6.97 3.87 32.64 485 3 11.75 3.47 222.20 
*SEM 1.47 1.08 5.00 159 0.28 7.55 .06 20.11 
Median 3.46 1.17 24.56 96 3 4.28 3.44 188.50 
SD 10.82 7.95 36.76 1170 2 55.50 .41 147.79 
Minimum <0.4 <0.6 <1.80 9 1 2.79 2.71 11.00 
Maximum 55.46 50.13 172.47 6154 10 412.00 4.84 565.00 














Figure 2-12: Frequency distribution chart of Haptoglobin in composite milk samples on Cochno dairy farm (n=54). 
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Data were not normally distributed. Therefore non-parametric tests were used.   
There were significant correlations between Hp concentration and SCC (P<0.01) 
and Hp and lactation number (P=0.009). SCC and lactation number were also 
significantly correlated (P<0.05). Significant differences were observed in the Hp 
concentrations of the SCC categories (high and low; P=0.001). Figure 2-13 shows 
the box plot of Hp concentration in the high and low SCC categories. Table 2-6 
gives the median and range values of Hp concentration in the two SCC 
categories. There was however no significant difference between the Hp 
concentrations of the second set of SCC categories of healthy (≤100,000 
cells/ml), SM (101,000-200,000 cells) and CM (>200,000 cells/ml). No significant 
difference was observed between Hp of the different stages of lactation, or SCC 
and stage of lactation (P>0.05). No correlations were also found between Hp and 
M-SAA3, Hp and CRP, Hp and percentage fat, and Hp and percentage protein 
(Table 2-13).     
 
 
Figure 2-13: Box plot showing two categories of SCC and the Hp concentrations (bars) of 
composite milk samples  
   * indicate extreme values, ° indicates outlier subject 




Table 2-6: Showing values for Hp in two different categories of SCC, high (>200,000cells/ml) 
and low (≤200,000 cells/ml) 
 
In order to determine reference values for Hp in composite milk samples from 
healthy, subclinical mastitis cows and clinical mastitis, SCC was further 
categorized into healthy (<100,000 cells/ml), subclinical mastitis (101,000-
200,000 cells/ml) and clinical mastitis (<200,000 cells/ml) based on another 
suggested SCC cut off values by Berglund et al. (2007) and Madouasse et al. 
(2010), and the median and range values of Hp in these categories are shown in 
Table 2-7.  
Following the use of the Stata® package (version SE/12.1, StataCorp, USA), the 
area under curve (AUC) of receiver operating characteristic (ROC) for Hp optimal 
cut off was determined to be 7.92 µg/ml (AUC=0.78, P=0.001) with a specificity 
of 94.59 % and a sensitivity of 52.94 % based on high and low SCC categories 
(>200,000 and <200,000 cells/ml). 
To obtain reference values based on SCC >100,000 cells/ml, an AUC of 0.75 was 
obtained for Hp with cut off between 3.33 to 3.52 µg/ml (sensitivity of 74 % and 
specificity of 69.44 %). 
Table 2-7: Showing median and range of haptoglobin in healthy, SM and CM range of SCC in 
composite milk 
SCC Haptoglobin (µg/ml) 
Category N Median Range 
Healthy (SCC<100 x 10
3
 cells/ml) 29 2.96 <0.4-13.74 





 cells/ml) 8 4.02 <0.4-5.28 
Clinical mastitis (SCC>200 X 10
3
 
cells/ml) 17 6.40 2.08-55.46 
 
 
SCC Haptoglobin (µg/ml) 
(cells/ml) Mean Median Minimum Maximum N 
Low (≤200 x 10
3
 cells/ml) 3.60 3.08 <0.40 13.74 37 
High (>200 x 10
3
 cells/ml) 15.04 6.40 <0.40 55.46 17 
Chapter 2, 118 
 
2.4.2 Mammary associated serum amyloid A3  
2.4.2.1 M-SAA3 Assay validation 
Sensitivity of the SAA ELISA determined from the LOD (calculated from mean of 
four blanks plus 2 standard deviations) was 0.012 µg/ml and to allow for a 
minimum dilution of 1:50, the LOD is 0.6 µg/ml. The calculated intra assay 
precision (mean CV of 40 samples assayed in duplicate) was 7 %. Inter assay 
precision (mean CV of 2 QC samples in 5 different assays) was 33 %, values of 
each QC sample per assay, used to calculate the inter assay precision (CV) as 33 
% (Appendix Chapter 2).   
2.4.2.2 Effect of different samples treatment on milk M-SAA3 
For heat treatment effect, twenty pairs of samples were assayed; however, the 
results of one pair were excluded from further analysis because the difference 
between the two Hp values was more than 100 % indicating experimental error. 
There was a significant difference observed in the median M-SAA3 of heated milk 
samples and unheated milk samples (Wilcoxon signed rank test of related 
samples, P= 0.000), but the two groups of samples (heated and unheated) were 
significantly correlated (r=0.87). M-SAA3 concentrations in heated samples were 
approximately 36 % lower than those recorded from the unheated samples. 
Table 2-8 displays the ranks for statistical comparison of M-SAA3 in heated and 
unheated samples using the Wilcoxon signed ranks test; N-samples with negative 
ranks represent samples in which unheated samples had a higher M-SAA3 value 
than in heated pair while positive ranked samples indicate the number of 
samples with M-SAA3 lower in unheated than in heated. Figure 2-14 displays the 
scatter plot of M-SAA3 in the heated versus unheated samples and shows the 
equation and R2 of the curve.  
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Table 2-8: Wilcoxon Signed Ranks Test showing ranks of heated versus unheated milk M-
SAA3 
Negative ranks indicate samples in which unheated samples had higher M-SAA3 than in the 
heated pair, while positive ranks are samples in which the unheated samples had less M-SAA3 
than in their heated pairs. 
Ranks N Mean Rank Sum of Ranks 




2a 4.50 9.00 
Positive Ranks 18b 11.17 201.00 
Ties 0c   
Total 20   
a. Unheated M-SAA3 < heated M-SAA3 
b. unheated M-SAA3 > Heated M-SAA3 





Figure 2-14: Scatter plot of heated versus unheated milk sample M-SAA3 concentration.  
 
 
There was no significant difference in M-SAA3 between the samples preserved 
with potassium dichromate (Lactabs® Marks III) and those not preserved (P=0.75, 
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correlation coefficient (r) = 0.97). A scatter plot comparing M-SAA3 in potassium 
dichromate preserved and unpreserved samples is shown in Figure 2-15.  
No differences in M-SAA3 distribution were seen between samples frozen for 7 or 










2.4.2.3 Cochno composite milk M-SAA3 
The frequency distribution of M-SAA3 concentration in Cochno composite milk 
samples from 54 cows is shown in Figure 2-16. Values were skewed to the right 
with a range of <0.6 -50.13 µg/ml and a median of 1.17 µg/ml. There was no 
significant difference observed between the M-SAA3 of the high and low SCC 
categories (categories defined in Section 2.3.5.2) (P=0.174). There was also no 
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significant difference in M-SAA3 concentrations between the healthy, SM and CM 
categories of SCC values (categories defined in Section 2.3.5.2) of composite 
milk (P=0.166). Furthermore no correlation existed between M-SAA3 and Hp or 
M-SAA3 and any of the other composite milk or cow factors considered. The 
descriptive values of M-SAA3 concentration in the high and low SCC categories 










Table 2-9: Descriptive values of M-SAA3 for two different categories of SCC. 
High (>200,000 cells/ml) and low (≤200,000 cells/ml). 
 
SCC M-SAA3 (µg/ml) 
(cells/ml) Mean Median Minimum Maximum N 
Low (≤200X10
3
 cells/ml) 3.85 0.96 <0.6 50.13 37 
High (>200X10
3
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The AUC of the ROC for M-SAA3 SCC level (>200,000 cells/ml) was not significant 
(AUC=0.57, P= 0.180), therefore cut off values could not be obtained. Further 
categorisation of milk into healthy, SM and CM samples based on SCC levels 
(defined in Section 2.3.5.2), did not result into any significant difference in the 
M-SAA3 across the categories, the median and range values of M-SAA3 in these 
categories are shown in Table 2-10. 
 
Table 2-10: Median and range of M-SAA3 in healthy, SM and CM range of SCC milk. 
 
 M-SAA3 (µg/ml) 
Somatic Cell Counts Median Range 
Healthy (<100 x 10
3








CM (>200 x 10
3
 cells/ml) n=17 0.60 0.60-24.81 
 
 
2.4.3 C-reactive protein 
2.4.3.1 Assay validation 
The limit of detection of the assay was calculated to be 0.18 ng/ml (mean +3 SD 
of 4 blank samples), and allowing for a minimum dilution of 1:5, the lowest 
detectable CRP concentration in milk (different from zero) was 1.8 ng/ml. Intra 
assay precision (mean CV of 30 samples ran in duplicates on a single ELISA plate) 
was 4 % while the inter-assay precision calculated from 5 repeats of two QC 
samples (high and low CRP concentration) was 7 %. 
2.4.3.2 Cochno composite CRP 
The range of concentration of CRP in composite milk from the dairy farm was 
<1.8 to 172.47 ng/ml with a median value of 24.56 ng/ml (Histogram showing 
the frequency distribution of CRP in Cochno composite milk is shown in Figure 2-
17). A compilation of some descriptive statistics of these samples, categorized 
based on SCC categories described in Section 2.3.5.2, are shown in Tables 2-11 
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Figure 2-17: Frequency distribution of CRP in Cochno dairy composite milk samples (n=54). 
 
 
Table 2-11: Descriptive values of CRP for two different categories of SCC. 




SCC  Mean Median Minimum Maximum N 
Low (≤200X10
3
 cells/ml) 27.68 22.40 <1.80 136.73 37 
High (>200X10
3
 cells/ml) 43.42 27.12 6.44 172.46 17 
 
Concentrations of CRP across the high (>200, 000 cells/ml) and low (<200, 000 
cells/ml) SCC categories and across the healthy, SM and CM SCC categories were 
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not statistically different (P=0.133 and 0.272 respectively). The AUC of the ROC 
for CRP for the different SCC levels was not significant (AUC=0.63, P= 0.078).  
 
 
Table 2-12: Median and range of CRP in healthy, SM and CM range of SCC milk. 
 
 CRP (ng/ml) 
Somatic Cell Counts Median Range 
Healthy (<100 x10
3
 cells/ml) n=29 22.40 <1.8 - 136.73 




 cells/ml) n=8 30.63 <1.8-108.84 
CM (>200 x 10
3
 cells/ml) n=17 27.11 6.44-172.46 
SM-subclinical mastitis, CM-clinical mastitis, SCC-somatic cell counts.  
 
There was no correlation between CRP and Hp or between CRP and M-SAA3. 
Neither was there any correlation between CRP and SCC, nor CRP and parity. 
However significant correlations were found between CRP and percentage fat 
and protein contents of the milk samples. Table 2-13 shows the results of tests 
for correlation of the dependent variables (APP, SCC and lactation number), 
with the significant correlations highlighted in light blue. 
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                     Table 2-13: Tests for correlation between APP and other variables. 
                     Variables with significant correlation highlighted in light blue. 
 M-SAA3 CRP Hp SCC Lactation 
number 























SAA Correlation Coefficient 1.000 .228 .062 .244 .205 .054 .089 
Sig. (2-tailed) . .098 .658 .075 .137 .698 .523 





Sig. (2-tailed) .098 . .198 .072 .377 .002 .001 




 .164 .186 
Sig. (2-tailed) .658 .198 . .001 .009 .236 .178 




 -.021 .090 
Sig. (2-tailed) .075 .072 .001 . .013 .883 .517 
Lactation 
number 




 1.000 -.046 -.038 
Sig. (2-tailed) .137 .377 .009 .013 . .741 .786 
 % fat 
Correlation Coefficient .054 .414
**
 .164 -.021 -.046 1.000 .512
**
 
Sig. (2-tailed) .698 .002 .236 .883 .741 . .000 
% protein Correlation Coefficient .089 .422
**
 .186 .090 -.038 .512
**
 1.000 
Sig. (2-tailed) .523 .001 .178 .517 .786 .000 . 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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2.5 Discussion  
2.5.1 Haptoglobin 
2.5.1.1 Milk haptoglobin ELISA 
A reliable and specific assay was developed and validated and shown to be 
sufficiently accurate and reproducible to measure the concentration of Hp in 
milk from cows in a dairy farm. 
Using the FLUOstar Optima ELISA reader, deviations were observed in readings of 
between replicates of sample and standard (duplicate or triplicate) leading to a 
higher inter and intra assay precision (CVs). This was suspected to be an 
instrument based error; hence an alternative ELISA reader was utilized in order 
to check/correct for this variation. The Triturus® (ver. 4.01 by Diagnostic 
Grifols, Spain) was utilized 10 ELISA plates with varying concentration of milk 
samples and standards. It was observed that with readings by the Triturus®, 
intra assay CVs (between sample duplicates or triplicates) fell within a range of 
0-5 % and only rarely (very few samples) went above 5 % and such samples were 
repeated and subsequently gave a lower CV. When the same ELISA plates were 
read on the 2 different ELISA readers (FLUOstar Optima and Triturus®) within 10 
min of each reading, it was also observed that considerably higher variations in 
the replicates existed in the absorbance readings of the FLUOstar Optima (>5 %) 
compared to the Triturus® reader (<5 %).  After this observation, it was 
concluded that the Triturus® reader was more reliable for reading the 
absorbances of the Hp ELISA plate and was used for all remaining ELISA Hp 
absorbance readings. However the data generated in the ELISA plates read by 
the FLUOstar Optima were included in the study (for examples analysis of 
quarter milk samples from Cochno (149) because intra-assay CVs calculated was 
below 20 % and considered sufficiently low for an immunoassay.   
The ELISA is a direct assay of milk Hp requiring little sample preparation. Hiss et 
al. (2004) in their study demonstrated an ELISA that was developed to measure 
milk Hp from healthy quarters (basal levels) with sensitivity (limit of detection) 
of 0.07 µg/ml. The ELISA developed in the present study had a sensitivity of 
0.002 µg/ml in the diluted samples and was able to determine milk Hp 
concentrations in many milk samples from healthy quarters (low SCC). The 
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present assay utilizes bovine specific anti-Hp antibodies conjugated to the 
enzyme alkaline phosphatase (AP), a previously reported enzyme-based bovine 
milk Hp ELISA (Hiss et al., 2004) and commercial ELISAs (Life Diagnostics Inc., 
West Chester, USA; Tridelta Development Limited, Kildare, Ireland) have utilized 
the horse radish peroxidase enzyme system or Hb-Hp peroxidase activity for 
substrate detection. Yang et al. (2011) in their study also used an AP enzyme 
system, from their results and results of the present study it can be concluded 
that the alkaline phosphatase system is an equally suitable enzyme-antibody 
conjugation system offering optimum sensitivity and specificity in milk Hp ELISA.  
ELISAs are generally known to be cost effective and easy to perform, and 
sandwich ELISAs have the added advantage of being more specific and sensitive 
than other immunoassay formats such as SRID. However, ELISAs are time 
consuming and difficult to adapt to an on-farm format. A biosensor assay that 
utilizes the Hp binding to haemoglobin principle has been described by Åkerstedt 
et al. (2006). Although a rapid method of testing for milk Hp, it also requires 
technical equipment, namely an optical biosensor.  
More recently an immunosensor assay for detection of Hp milk was also 
described by Tan et al. (2012). The assay was reproducible and has the potential 
for on farm measurement of milk Hp for detection of mastitis. The detection of 
Hp was coupled to generation of an electrical response following the reaction of 
milk Hp with anti Hp antibodies mounted on an electrode, and though a 
sensitivity of 0.63 mg/l was reported, a more sensitive assay would be desirable 
to distinguish subclinical from healthy milk samples. 
Given the sensitivity of the ELISA in the present study it is anticipated that a 
lateral flow immunoassay format of the assay would be equally as sensitive. 
2.5.1.2 Effect of different Sample treatments on milk haptoglobin 
The significance of the findings that use of two common milk preservatives did 
not affect milk Hp in this study is that these sample preservation methods can 
be used in milk without confounding the values obtained for milk Hp assay. 
Therefore samples being collected for SCC or for progesterone analysis can also 
be used for determination of Hp concentration. 
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However in this study, an extended time lapse (post preservation) was not 
employed and may become an important factor that could affect milk 
composition preserved using such chemicals as observed by Chalermsan et al. 
(2004). Therefore, it is recommended that samples needing to be transported 
over long distances without any means of cold-chain storage, can be preserved 
using either potassium dichromate (Lactabs® Mark III) or Bronopol (Broad 
spectrum Microtabs® II), but should be analysed as soon as possible. It would be 
interesting to examine the effect of prolonged storage of milk with preservatives 
on milk APP for example Bronopol is said to be able to preserve milk samples at 
RT for up to 14 days. Since storage at different temperatures and for different 
durations did not affect the Hp concentration, this would allow for posting with 
an ice pack from farms to laboratories and will keep Hp without loss. 
Heating caused a significant decreased in Hp concentration of milk; this is 
probably as a result of a denaturation effect of heat on the protein moiety 
(Hausen et al., 2012) and/or structure of Hp that could probably affect its 
antibody binding ability. This finding should therefore be taken into 
consideration when assaying for Hp in samples which have undergone heating as 
a result of international transfer regulations involving heat treatment of 
biological samples. In such studies, control samples should be treated in the 
same manner as experimental samples or a correction factor, for example 26 % 
reduction in the mean Hp concentration, based on the findngs from this study 
can be applied.  
2.5.1.3 Haptoglobin profile of Cochno dairy milk Samples 
Haptoglobin from individual quarter milk samples of cows in the herd were not 
normally distributed, but skewed to the right with a higher percentage of 
samples falling within the low Hp category. Many factors such as lactation stage, 
stressing conditions, presence or absence of mammary infections/inflammation; 
stage and severity of such infections, pathogenic factors related to mammary 
infections, and other physiological factors may contribute to differing Hp levels 
in milk.  
Somatic cell count values for each quarter were not obtained as only composite 
sample SCC were possible, therefore it was difficult to relate the quarter Hp 
values to SCC (composite), bearing in mind the dilution effect that often results 
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from the combination of milk from uninfected quarters (with low Hp 
concentrations), on high Hp containing milk quarters. Hp range in quarter milk 
(<0.4-420 µg/ml) was higher than composite milk (0.4-55 µg/ml) presumably also 
due to this dilution effect (Reyher and Dohoo, 2011). 
At the time of sampling, all quarters were considered healthy with no signs of 
inflammation (the cows were under veterinary and handler observations and 
considered apparently healthy enough for commercial milk production) but from 
the SCC of the composite sample, it can be inferred that subclinical mastitis 
existed in the herd as some composite milk samples showed levels far above 
200,000 cells/ml, the suggested cut off for discriminating healthy milk samples 
from mastitis samples (Pantoja et al., 2009; Dufour and Dohoo, 2012). The SCC 
cut off points for SCC to determine mastitis has been a subject of debate, with 
other SCC cut-off values being advocated to distinguish healthy, subclinical and 
clinical mastitis samples (Schwarz et al., 2011; Berglund et al., 2007). In this 
study, no bacteriological tests were carried out to confirm SM, therefore SCC 
was used as the sole indicator of an IMI, and 2 different cut off ranges for SCC 
were assessed in order to cover discrepancies that may result from use of 
different SCC cut off values.   
The percentage of composite samples with SCC below 200,000 cells/ml out of 
the total number of sampled cows (n=54) was 69 % indicating a prevalence rate 
of 31 % of subclinical mastitis on the herd. There was a significant correlation 
between SCC and Hp concentration in the composite samples; which agrees with 
studies by Thielen et al. (2005) and Lai et al. (2009) who demonstrated that Hp 
in milk could originate from neutrophils (major component of SCC) and 
mammary epithelial cells during mastitis. Therefore it is expected that as SCC 
increases, Hp in milk would also increase, although the possibility of direct Hp 
leakage from serum into milk exists. The correlation of Hp with SCC and 
mastitis, as is our observation in this study agrees with a number of other 
studies, which highlights the promise of Hp in diagnosis of IMIs (Eckersall et al., 
2006; Hiss et al., 2004; Hiss et al., 2007; Pyörälä et al., 2011; Medvid et al., 
2011 and Kalmus et al., 2013 amongst others).  
Significant correlations were also observed between parity (lactation number) 
and milk Hp, with multiparous cows tending to have higher Hp values. SCC values 
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in healthy quarters have been suggested to be higher in multiparous cows which 
may have been exposed to previous episodes of mastitis compared to 
primiparous or first lactation cows (NMC, 2001) presumably due to carryover 
effect. The observation of correlation between parity and Hp as well as parity 
and SCC in this study may be a reflection of this effect. In a study by Kalmus et 
al. (2013), that compared APP profile, in samples from different pathogen-
caused mastitis, with other cow factors, no association was observed between 
APP profile and parity of cows. Given that a larger sample size was used in that 
study (n=253) our observations in the current study may have been influenced by 
the smaller sample size (n=54). 
2.5.2 Mammary associated serum amyloid A3 
2.5.2.1 Effect of different sample treatment on milk M-SAA3  
Heat treatment 
Treatment with heat at 56ºC for 30 min was found to have a significant reducing 
effect on the apparent M-SAA3 concentration in milk samples. This may be due 
to the denaturing activity of high temperature on protein structure (Hausen et 
al., 2012). Values of Hp in the heated and unheated samples were however 
significantly correlated.  
The significance of this finding, similar to that of Hp, applies for diagnostic or 
research milk samples that need to be transported across international borders 
and require mandatory heat treatment for inactivation of pathogens that maybe 
contained within such biological samples, a prerequisite specified in the 
regulation concerning such samples’ transfer for example the; European 
Communities Act (1972). It is therefore imperative that the effect of heat 
treatment be taken into account and corrected for using a factor of 36 % as 
observed in this study or by treating controls the same way as experimental 
samples, in M-SAA3 analysis of heat treated samples.  
Preservative treatment 
Preservation with Lactabs® Marks III did not affect milk M-SAA3, therefore it can 
be concluded that samples preserved with this reagent can be reliably assayed 
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for M-SAA3. Effect of Bronopol on milk  M-SAA3 have not been performed in this 
study and would require experimental verification.  
Duration of storage 
Contrary to the findings of Tóthová et al. (2012), no differences were observed 
in the present study between samples analysed on collection day and those 
stored at -20°C for either 7 days or 21 days. Reasons for this discrepancy is not 
known, but could likely be due to the freeze-thawing cycles, which the samples 
stored at -18°C had to undergo at 2, 7, 14 and 21 days after storage in the 
Tóthová et al. (2012) study. In the present study, separate aliquots were stored 
for 7 days, and 21 days, thus re-freezing samples to analyse at a later date was 
not required, and this may have contributed to retaining the levels of M-SAA3 
concentration of milk in the separate sets of aliquots. Generally, however, the 
sample size of milk samples (n=6) used in both studies can be considered small 
and may not give a very accurate picture of response of M-SAA3 to duration of 
freezing storage. 
2.5.2.2 M-SAA3 in Cochno composite milk 
Åkerstedt et al. (2007) reported the profile of M-SAA3 (as well as Hp) in quarter, 
composite and bulk tank milk samples and demonstrated the correlation of 
quarter, composite and bulk tank M-SAA3 to SCC. In the present study, we found 
no significant correlation between the composite milk M-SAA3 and the SCC. This 
observation may be due to the sample size (n=54) as against n=165 used in the 
Åkerstedt et al. (2007)’s study and may also be due to the fact that SAA was 
divided into two broad categories (detectable and undetectable) in that study. 
These observations could also suggest that SCC assay may not be consistent 
between laboratories even if the same commercial ELISA was used in both 
locations. 
There was no correlation observed between the Hp and SAA in composite milk 
samples. This could be due to the fact that the two different APP, Hp and M-
SAA3 have been shown to be produced from different sites in the mammary 
gland (Molenaar et al., 2009; Hiss et al., 2004; Thielen et al., 2007). Differences 
in the site of production and portal of release of these APP into milk have the 
potential of influencing APP concentration in milk at any specific time point. 
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Furthermore, depending on which mastitis-causing- bacteria is responsible for an 
IMI, levels of secretion into milk of the different APP may vary as different 
virulence factors can stimulate different cytokine responses, and also cause 
tissue injury to the mammary gland that is different in natures and extent. 
The range of M-SAA3 values observed for these composite milk sample can be 
considered as low when compared to values obtained from individual mastitis 
affected quarters in the challenge study and even values recorded in colostrum 
(day 1 post-calving). This may be due to dilution effects.  
2.5.3 CRP in Cochno composite milk 
From this study, a range of 1.8 (lower limit of detection of assay) to 172 ng/ml 
was shown to exist in the composite milk samples from the dairy farm. This 
confirms the presence of detectable levels of CRP in bovine milk as reported by 
(Schrodl et al., 1995; Lee et al., 2003). In the herd examined, there was no 
reported case of clinical mastitis as at sampling time, therefore the maximum 
value seen in this study may only be reflective of the CRP values during SM. 
Although, milk samples with SCC of above 200,000 cells/ml were categorized as 
‘clinical mastitis’, no clinical signs of mastitis was seen in the milk or cows, but 
classification was just for the purpose of identifying cut off range as suggested 
by Berglund et al. (2007) and Madouasse et al. (2010).  
In this study, a minimum dilution of 1:5 was used for assaying samples of low 
CRP concentration. Milk CRP showed no correlations with SCC, Hp or with M-
SAA3, but significant correlations with fat and protein content of milk. The 
reason for is correlation with fat and protein is not known and could be a subject 
of future investigation. Non-significant correlations seen between the three APP 
may be due to the individual dynamics of each of the APP. Most samples had low 
levels of CRP (< 50 ng/ml), which may reflect the general low mastitis incidence 
on the farm, if CRP can be considered a reliable indicator of IMI. However the 
lack of correlation between the APP may increase the value of assays for the 
entire APP as they may reflect differing stages of mastitis or differences in the 
pathogens causing the disease. 
In an early study by Hamann et al. (1997), milk CRP compared to the SCC and 
health status in 47 cows over time, showed a negative correlation between SCC 
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and CRP (r=0.32) and a threshold value of 123 ng/ml of CRP in normal milk. 
These findings are similar to the results of the present study. Further 
classification of samples based on CRP concentration into different health status 
(healthy, mastitis or subclinical infection) in the Hamann et al. (1997) study 
using an  SCC cut off of >100,000 cells/ml produced a poor sensitivity (55 %), as 
also observed in this study. Therefore it can be inferred that the secretion of 
CRP into milk does not follow similar dynamics with SCC or Hp, and could suggest 
local production of CRP in the mammary gland just as M-SAA3, under the 
influence of explicit signalling pathway(s). This should be subject of future 
evaluation. 
It is probable that the observed correlation between CRP and fat content of milk 
samples may be due to the binding afintiy of CRP to phosphocholine which forms 
a major component of the lipid constituent of membranes. It is not however 
clear why a significant  correlation existed between CRP % protein of samples.  
No clear conclusions can be drawn from the observed profile of CRP from this 
study as sample size was small, but there appears to be some prospects for its 
use as a marker of mammary inflammation. Evaluation of a larger set of samples 
would be of additional value to give better understanding of the worth of CRP 
and its association with other common mastitis defining parameters.  
2.6 Conclusion 
2.6.1 Haptoglobin 
A robust and reproducible ELISA for measuring milk Haptoglobin was developed. 
Studies have demonstrated that Hp is a reliable marker for bovine mastitis 
through good correlations between milk Hp and SCC. Parity of cows was seen as 
a possible confounding factor in an on farm diagnosis of mastitis using Hp. High 
temperature was recognized to have a significant reducing effect on milk Hp. 
2.6.2 Mammary associated serum amyloid A3 
This study has shown the significant effect that high temperature has on the 
concentration of M-SAA3 in milk samples; in addition the profile of M-SAA3 in 
composite milk from a commercial dairy herd was demonstrated. 
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2.6.3 C-Reactive protein 
C-reactive protein has shown some potentials as an acute phase protein in 
bovine milk, able to differentiate between milk with high SCC and low SCC, 
further investigations of this potential in actually discriminating mastitis (clinical 
and subclinical) from non-mastitic, and clinical from subclinical mastitis 
samples, needs  to be carried out. 
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3 Investigations of acute phase proteins in 
periparturient milk and in the mammary gland. 
3.1 Overview 
In this chapter, acute phase proteins and proteomic investigations on milk 
samples collected within ten days post-partum from calving cows, in a dairy 
farm are described. Antibody to bovine Hp was used for western blot analysis of 
these samples. Furthermore, studies with the same antibody in 
immunohistochemical studies of Hp in healthy versus mastitis bovine mammary 
glands are reported.  
3.2 Introduction 
3.2.1 Post-calving milk APP 
The periparturient period is one of the most critical periods, health wise, in the 
productive life of a dairy cow characterized by an increased susceptibility to 
diseases (Trevisi et al., 2010). This has been attributed to negative energy 
balance (NEB) and the associated immune suppression at the puerperal period 
(Waldron and Revelo, 2008; Hiss et al., 2009). Related to this periparturient 
immune suppression is the occurrence in serum of increased levels of metabolic 
and endocrine markers such as prostaglandins (Yuan et al., 2014), cortisol, 
ketone bodies (for example α-butyric acid) and non-esterified fatty acids (NEFA). 
Hypoglycaemia and hypocalcaemia have also been defined as markers of 
metabolic stress during this period in dairy cows (Esposito et al., 2013; Waldron 
and Revelo, 2008). Some studies have also shown inflammatory markers such as 
the acute phase proteins, Hp and SAA to be increased in serum during the 
periparturient period (Trevisi et al., 2012). This has been attributed to diseases 
of inflammatory aetiology characteristic of the period.  
In addition, Morimatsu et al. (1991b) demonstrated an increase in bovine serum 
CRP in association with onset of lactation in Holstein cows and Schrodl et al. 
(1995) also showed the presence in bovine colostrum and milk of the APP CRP, 
and this was suggested to be passively transferred to colostrum fed calves 
(Schroedl et al., 2003). In humans CRP has been shown to be increased in serum 
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at the post-partum period and this has been attributed to the trauma associated 
with childbirth, with concentration dropping back to baseline values by the 5th 
day post-partum (Fetherston et al., 2006). 
It is well established that colostrum and milk in the immediate post-partum 
period contains a large repertoire of immunological proteins including 
predominantly IgG and other Igs. Recently, the APP, M-SAA3 and AGP have been 
observed to be high in milk during the immediate post-partum period (McDonald 
et al., 2001 and Ceciliani et al., 2005) and this has been suggested to be due to 
physiological roles of these proteins in conferring immunity to the new-born. 
Hiss et al. (2009) also showed from their study that Hp is high in milk of 
metabolically stressed transition dairy cows. In that study weekly milk samples 
were used to determine the profile of Hp in the periparturient cow milk for up 
to 12 weeks post-partum.  
Mastitis is one among many conditions in which new infections frequently arise 
during the periparturient period more than during any other period of a diary 
cow’s life (Waldron and Revelo, 2008). With APP in milk gaining prominence as 
markers for mastitis diagnosis in dairy cows, it would be important to evaluate 
their usefulness in recognising new mastitis developing in the periparturient 
period.  Due to the fact that there is the general physiological increase in 
inflammatory markers in the circulation during this period, and also the fact that 
post parturient milk (colostrum especially), contains high immune protein 
concentration, there is the challenge of readily diagnosing new infections in the 
mammary gland with regards to differentiating the physiological from the 
pathological increases of marker proteins. Obtaining reference values that can 
differentiate the physiological increases from pathological ones, during the 
periparturient period would be of immense value in readily identifying new 
mastitis conditions developing in post-partum cows in order to promptly institute 
treatment. 
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3.2.2 Immunohistochemical localization of Hp in the bovine 
mammary gland 
Immunohistochemistry (IHC) is a method applied for the localisation of antigens 
of interest in body tissues based on the principle of the reaction of such antigens 
with their specific antibodies. Enzymes are usually conjugated to a primary or 
secondary antibody for chromogenic detection after substrate reaction or by 
fluorescent detection when a fluorophore is conjugated to the antibodies, under 
microscopy (Brandtzaeg, 1998).  
The bovine mammary gland becomes fully developed during gestation, when 
mammary epithelial cells grow extensively into a network of ductules that 
terminate as alveoli (Sobolewska et al., 2011). The mammary gland alveolus is 
the basic functional unit of the gland; milk is produced by the epithelial cells, 
passes into the lumen of the alveolus from where it is propelled by contractile 
activity of the myoepithelial cells into collecting ducts of the gland (Alkafafy et 
al., 2012). The gland cells typically undergo periods of proliferation, 
differentiation and regression, corresponding to the period of preparation for 
lactation (pregnancy), onset of lactation  and cessation of lactation (dry period) 
of a cow, all tightly regulated by growth factors and hormones. 
The IHC technique has been used in a number of studies involving the bovine 
mammary gland; localization of protothecal mastitis (Corbellini et al., 2001), 
localization of immune cells and their characteristic distribution during a chronic 
S. aureus mastitis (Leitner et al., 2003). Also, localization of growth factors such 
as activin-like protein (Bloise et al., 2010) and in studies of the different stages 
of cellular maturation of the gland during lactation (Hodgkinson et al., 2007), 
distribution of adhesion molecules in the gland in mid-lactation cows (Simon et 
al., 2007) and even in the general assessment of the structural proteins of the 
gland (Alkafafy et al., 2012). 
Immunocytochemical (ICC) localization and differential expression of the APP M-
SAA3 was also carried out on bovine mammary gland after an experimentally 
induced subclinical S. aureus mastitis (Eckersall et al., 2006). In that study it 
was observed that M-SAA3 was located most in the secretory mammary epithelial 
cells (MEC), gland cistern, and, to a lesser extent, teat canal. 
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Another APP, α-acid glycoprotein (AGP), a lipocalin, was immunohistochemically 
identified in all areas of a section of normal bovine mammary gland and it has 
been suggested production occurs in the alveoli (Ceciliani et al., 2007). 
Noteworthy is the fact that while IHC deals with localization of proteins in whole 
tissues, maintaining as much as possible the normal architecture, ICC is 
distinguished by dealing with cells, although these two terms are often used 
interchangeably.  
The liver has long been established as the major site of serum Hp synthesis in 
ruminants (Eckersall and Bell, 2010). However, the study of Lavery et al. (2003), 
suggested that Hp is constitutively expressed by the female reproductive organs 
in the bovine species. Hp found in milk was initially thought to be from 
extravasation from serum due to compromised blood milk barrier during mastitis 
(Eckersall et al., 2001), however in studies by Hiss et al. (2004), the qualitative 
and quantitative detection of Hp mRNA in mammary gland tissue indicated that 
milk Hp was probably sourced from the mammary gland (alone or in combination 
with serum seepage of Hp). It was later confirmed by immunohistochemical 
analysis of mammary gland sections following experimental mastitis, that Hp was 
synthesized in portions of the mammary gland (Hiss et al., 2005), although in 
that study, a significant difference between control and infected glands in the 
IHC staining of Hp, was not found. Further studies by Lai et al. (2009), using ICC 
along with RT-PCR, demonstrated that neutrophils and mammary epithelial cells 
(MEC) were major sites of Hp synthesis. 
3.2.3 Proteomics 
Proteomics methodologies and its applications in the search for bovine mastitis 
biomarkers has been discussed in the introductory chapter of this thesis and 
furthermore in section 5.2.3. 
3.2.4 Objectives of the study 
The studies carried out in this chapter had several objectives which includes; 
 To determine the profile of Hp, M-SAA3 and CRP immediately following 
parturition and to investigate the potential of these APP for detecting 
new IMI during the periparturient period. The APP were measured in daily 
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milk (from the first to the tenth day post-partum) in calving cows of the 
Cochno dairy farm (University of Glasgow) using ELISAs. A western 
immunoblotting procedure specific for milk Hp was also used. All cows 
calving between January and June, 2013 on the dairy farm were 
evaluated.  
 To determine quantitative and qualitative changes in milk proteins 
following parturition using one and then two dimensional gel 
electrophoresis (1DE and 2DE).  
 To characterize the source of milk Hp, during mastitis by 
immunohistochemical localization (IHC) of Hp in the bovine mammary 
gland.  
 
3.3 Materials and methods  
3.3.1 Acute phase proteins in post-calving milk 
3.3.1.1 Reagents  
General chemicals were obtained from Sigma-Aldrich, Poole, UK, except where 
otherwise stated. In all experiments, milli Q water was used.  
3.3.1.2  Samples  
Daily quarter milk samples were collected from the first to the tenth day 
(morning milking, 6:00 am daily) following parturition, from all calving-cows in 
Cochno dairy herd which calved between January and June, 2013. Approximately 
15 ml milk was collected after discarding the first strips of milk following teat 
disinfection. Three aliquots of ~5 ml each were prepared from each sample and 
stored at -20°C until analysed. 
In total twenty four (24) cows were sampled.  However 2 cows’ samples were 
excluded from further analyses because they became lethargic following an 
acute metritis infection in one cow and an undiagnosed illness in the other, 
therefore samples could not be collected after the 6th day post-calving. In all, 
575 quarter milk samples (functional quarters) obtained over ten days (average 
of 81 samples daily, from 22 cows) were analysed. All samples were thawed at 
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RT, thoroughly mixed by vortexing and diluted in the respective assay/wash 
buffer for Hp or M-SAA3 analysis. 
3.3.1.3 Haptoglobin in post-calving milk  
ELISA 
Haptoglobin was analysed in all quarter samples collected from the post calving 
cows. The analysis was carried out as described in Section 2.3.2. To obtain daily 
(composite) values for post calving milk Hp, the mean of Hp concentration from 
all daily quarters’ samples per cow was computed and designated daily 
composite Hp value of each cow. 
Western blotting for Hp in Post-calving milk 
An equal aliquot from daily quarter milk samples from 3 cows were pooled to 
obtain daily composite milk for each of the cows for the 10 days of sampling. 
These composite samples were then each subjected to a western blotting 
analysis for the characterization of Hp variation in daily milk. 10 µl of daily 
composite sample was diluted to a final concentration of 2 mg/ml µg first in 
milli Q water and then in Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 25 % (v/v) 
glycerol, 2 % (w/v) SDS, 0.01 % (w/v) bromophenol Blue) (1:1 with sample). 10 
µg of each sample (10 µl) was then loaded into separate wells of precast gels 
and the electrophoresis ran. After electrophoresis, the gels were carefully 
removed from cassettes and put onto a blotting sandwich comprising of suitably 
sized nitrocellulose membrane (NCM) (0.45 µm; Bio-Rad laboratories Inc., 
Germany), blotting pads and paper, fitted into a gel-holder cassette soaked with 
transfer buffer (6.06 g Tris-HCl, 28.8 g Glycine in 1600 ml milli Q water and 400 
ml methanol).This was then placed into the Blotter tank (Bio-Rad Criterion, USA) 
filled with an adequate volume of transfer buffer and a cooling block. Electro-
blotting was carried out at 70 V for 60 min.  NCM was removed and immersed in 
blocking solution (10 % non-fat dry milk) at RT on a rocker overnight. 
Membranes were then washed by gentle rocking in wash buffer (10 % Tween-20 
in Tris buffered saline (TTBS) for 10 min. Wash was discarded and washing was 
repeated two more times, before addition of the primary antibody (conjugate of 
a rabbit anti-bovine conjugated to alkaline phosphate) diluted in 10 % non-fat 
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dry milk (1:5,000) which was allowed to incubate for 60 min on a rocker at RT. 
Washing was repeated 3 times, after which membranes were incubated with an 
alkaline phosphatase chromogenic substrate (PIerce™ NBT/BCIP, Thermo 
Scientific, UK) solution for 10-15 min to allow for colour development on Hp 
bands. Western blot images were scanned on Umax powerlook III (Hamrick 
software, USA). Images were further analysed using ImageJ software (National 
Institute of Health, Maryland, USA). 
3.3.1.4 M-SAA3 in post-calving milk 
For analysis of M-SAA3, daily composite milk samples from cows were used. Ten 
cows were selected from the 22 calving cows, and from each quarter collected 
daily per cow, a pool of composite milk was made by mixing aliquots of 200 µl of 
each quarter milk samples together. This was done for each of the cows, for 10 
days. Daily composite samples were then assayed for M-SAA3 using ELISA as 
described in Section 2.3.3.  
3.3.1.5 CRP in post-calving milk  
For analysis of CRP, daily composite milk samples from ten cows were used. 
Aliquots (200 µl) of the daily samples (all quarters) were pooled to give a 
composite for each day per cow. Daily composite samples were then assayed for 
CRP using ELISA as described in Section 2.3.4. 
3.3.1.6 Proteomic analysis of post-calving milk 
1DE SDS-PAGE of post-calving milk 
As a first step to characterizing the protein changes in milk from the first to 
tenth day post calving, 1DE electrophoresis of daily (composite) milk was carried 
out. Prior to gel electrophoresis, protein concentration was determined in the 
daily composite (pooled daily quarters) milk samples (of 3 cows) using Bradford 
reagent (Sigma-Aldrich, USA) as described in Appendix Chapter 4. Bovine serum 
albumin (BSA) was used for the standard. Samples were diluted in milli Q water 
and then mixed at a ratio of 1:1 with Laemmli sample buffer to which 5 % (v/v) 
of β-mercaptoethanol had been added and thoroughly mixed, to achieve a final 
concentration of 2 mg/ml per sample (Appendix Chapter 4). This mixture was 
then heated at 95ºC for 4 min. After assembly of the 18-well comb precast gels 
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into the gel running tank (Bio-Rad, USA), and addition of sample loading buffer 
(1x Tris /Glycine/SDS buffer, Bio-Rad GmbH Ltd, UK) into the tank, 10 µl of 
heated samples (~10-25 µg protein/well) or pre-stained protein ladder (10-170 
kDa, PageRuler prestained protein ladder, Thermo Scientific Inc., USA) was 
pipetted into wells of precast gels. Gel electrophoresis was then run at 200 V for 
40-45 min. 
Gels were removed from the cassette and then stained for 1 hour in colloidal 
solution of Coomasie brilliant blue stain G-250 dye 0.1 % (w/v), 10 % (v/v) acetic 
acid, 40 % (v/v) ethanol; (Invitrogen, Manchester, UK) after which stain solution 
was discarded and de-staining carried out overnight using a solution of 10 % (v/v) 
acetic acid and 25 % (v/v) methanol. Image of gels were scanned using a UMAX 
Power Look III scanner and software (Hamrick software, USA). 
2DE SDS-PAGE of post-calving milk 
One representative day 1 and day 10 post-partum composite samples were 
subjected to 2DE SDS-PAGE in order to further identify key changes in the 
proteome of colostrum (day 1) compared to milk after 10 days post calving. 
After determination of protein concentration in each sample (using Bradford 
assay- Appendix Chapter 4), samples were diluted in rehydration buffer (RHB) 
(Bio-Rad ReadyPrep™ rehydration/sample buffer) containing 8 M Urea, 2 % (w/v) 
CHAPS, 50 mM DTT, 0.2 % (v/v) Bio-Lyte® 3/10 ampholyte, 0.001 % (w/v) 
bromophenol blue (BioRad, Hemel Hempstead, UK) so that 200 µg of sample was 
in a final volume of 200 µl for application to an 11 cm IPG strip (BioRad, Hemel 
Hempstead, UK) according to manufacturer’s instructions, of pH range 3-10. 
 
Rehydration and Isoelectric Focusing 
The prepared sample(s) was then applied on a gel focusing tray to a pH 3-10 IPG 
strip (11 cm, non-linear, Bio-Rad Lab, UK) and covered with 1 ml of mineral oil 
(Sigma-Aldrich, Dorset, UK). Active rehydration and then isoelectric focusing 
were carried out on a Bio-Rad Protean IEF cell using the protocol below; 
Focus temperature 20°C;  
Voltage intervals:  
500 V for 1 hour,  
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1000 V for 1 hour,  
2000 V for 2 hours,  
4000 V for 4 hours,  
8000 V for 12 hours. 
 
Focused IPG strips were then either stored with the gel side up in a well-covered 
IPG tray at -20ºC or used immediately for SDS-PAGE. 
Second Dimension SDS-PAGE 
Equilibration buffers (EB) I and II were prepared (Appendix Chapter 5). Focused 
IPG strips were then incubated for 15 min in EB I with gentle shaking, washed in 
running buffer and incubated in EB II for another 15 min. 
Equilibrated IPG strips were then carefully inserted horizontally on to the IPG 
well of the pre-cast IPG+1well comb which had been assembled in the gel 
running tank with added sample loading buffer. 10 µl of pre-stained protein 
ladder was added into the extra well. Electrophoresis was run at 200 V for 40-45 
min at RT. Gels were carefully removed from the gel cassette and then stained 
and de-stained as described for 1DE in section 3.3.1.6 above. 
3.3.2 Immunohistochemical localization of Hp in bovine mammary 
gland 
Samples 
Tissue sections from the mammary glands of two cows were examined 
histologically using H & E and Hp IHC. The cows were a 10 year old beef suckler 
cow with clinical mastitis and an age matched non-lactating beef suckler cow 
with no clinical or histological evidence of mastitis. Sections were supplied by 
VDS, University of Glasgow. 
Tissue Sectioning 
Tissues were fixed in 10 % neutral buffered formalin and embedded in paraffin 
wax (FFPE). They were then cut using a microtome to a thickness of 2.5microns 
and affixed onto a slide. Slides were baked at 57°C for 1 h prior to staining. 
H&E staining 
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Sections of both healthy and mastitis mammary gland were stained with the H&E 
stain as described below.  
First, the sections were brought to distilled water through graded alcohols and 
stained with Gill’s haematoxylin prepared in-house, for 5 min after which they 
were rinsed in running tap water. Differentiation was carried out briefly with 10 % 
acid alcohol and once again sections were rinsed in tap water. Sections were then 
counterstained with eosin for 5 min after which sections were dehydrated, cleared 
and mounted. 
Antibody Staining 
Prior to staining, tissue slides were completely deparaffinised and rehydrated by 
performing several incubation steps in xylene and different concentrations of 
ethanol solution and finally running under water. 
No antigen retrieval was required and the IHC was carried out using an 
automated immunohistochemistry system by Dako (Agilent technologies, UK). All 
procedures were carried out at RT. Tissue sections were placed on to a Dako 
autostainer and then rinsed with buffer (Tris buffer pH 7.5 + Tween) after which 
sections were blocked for 5 min with Dako REAL™ peroxidase blocking solution. 
Sections were buffer rinsed for 5 min and the primary antibody, rabbit anti-
bovine IgG (Life diagnostics, USA) diluted to an optimum of 1:800 (1.72 µg/ml) 
in Dako universal diluent was applied for 30 min. 
Subsequently two 5 min buffer washes were carried out and then sections were 
incubated with a secondary antibody (Dako Envision system HRP labelled 
polymer anti-rabbit (Dako UK Ltd, Cambridgeshire, UK). Two 5 min buffer 
washes were performed and the substrate, diaminobenzidine (DAB) (Dako DAB, 
K5007) was applied for 10 min. After 3 rinses with tap water, sections were 
counterstained for 27 seconds using Gills haematoxylin prepared in-house and 
finally sections were washed in water, dehydrated, cleared and mounted (DC&M) 
in synthetic resin.  
 
Image Capture 
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Images of slides were acquired and analysed using an Olympus™ BX51 microscope 
(Olympus Life Science, Hamburg Germany) and were processed using a Cell^D 
imaging software (Electro Optics, Cambridge, UK). The images were captured 
using an Olympus DP71 digital camera. Sections were examined at 
magnifications of x100 and x200. 
Histological sectioning and IHC staining for Hp was carried accomplished with 
the help of Ms Marion Lynn Stevenson of the Veterinary diagnostic services unit, 
University of Glasgow. Advice on interpretation of histological images was 
carried out by pathologists Dr. Pamela Johnston, Dr. Hayley Haining (Veterinary 
Diagnostic Services, School of Veterinary Medicine, University of Glasgow) and Dr 
Hal Thompson (formerly of the University of Glasgow). 
3.3.2.1 Statistical analysis 
Tests for normality were carried out on all APP data. A related samples 
Friedman’s two-way analysis of variance by ranks test was run on results of daily 
post-calving milk Hp, M-SAA3 and CRP. Non-parametric pair-wise comparisons 
(related samples Wilcoxon signed ranks test) of daily samples were carried to 
determined days where significant variation occurred. Non-parametric 
correlation test (Spearman’s rho) was used to assess the correlation of the daily 
APP in the same cows. P-value was considered significant at <0.05.  
3.4 Results 
3.4.1 Acute phase proteins in post-calving milk 
3.4.1.1 Milk haptoglobin in post-calving cows 
Milk Haptoglobin ELISA 
The mean Hp concentration in milk decreased with the days post-calving (Figure 
3-1) from a mean of 46.50 ± 7.94 (SEM) µg/ml on day 1 (colostrum) (n=83 
quarter-milk samples; n=22 cows) to a mean of 6.31 ± 4.01 µg/ml (SEM) on day 
10 (n=75 quarter-milk; n=22 cows). P-values to show pair-wise significant 
differences in Hp between days post-calving are shown in Table 3-1.   
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Figure 3-1: Histogram of mean± SEM of daily composite milk Hp from day 1 to 10 
(n=22 cows) 
 
Range of Hp in all samples (day 1-10) was <0.4 - >1250 µg/ml and median was 
4.86 µg/ml. 
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Table 3-1: P-values of differences in daily milk Hp across 10 days post-calving. 
Days of significant difference in Hp are highlighted in brown 
 
 
Haptoglobin P-value of significant difference with days post calving. 
 
 
Day 1 2 3 4 5 6 7 8 9 10 
1 * 0.170 0.008 0.000 0.000 0.001 0.000 0.000 0.000 0.000 
2 0.170 * 0.027 0.006 0.001 0.006 0.002 0.001 0.004 0.001 
3 0.008 0.027 * 0.002 0.002 0.014 0.001 0.001 0.001 0.002 
4 0.000 0.006 0.002 * 0.012 0.064 0.002 0.014 0.011 0.003 
5 0.000 0.001 0.002 0.012 * 0.117 0.064 0.044 0.059 0.048 
6 0.001 0.006 0.014 0.064 0.117 * 0.027 0.025 0.084 0.073 
7 0.000 0.002 0.001 0.002 0.064 0.027 * 0.748 0.184 0.057 
8 0.000 0.001 0.001 0.014 0.044 0.025 0.748 * 0.199 0.044 
9 0.000 0.004 0.001 0.011 0.059 0.084 0.184 0.199 * 0.013 
10 0.000 0.001 0.002 0.003 0.048 0.073 0.057 0.044 0.013 * 
Western blotting for Hp  
The Hp western blot of daily composite milk samples from one representative 
calving cow is shown in Figure 3-2 and shows the antibody reacting with the  
and   chains of bovine Hp at 15 kDa and 40 kDa respectively in milk from day 1 
to day 4 post-calving. This blot also shows non-specific reaction with higher Mw 
protein of 100 kDa and 70 kDa which are likely to be lactoferrin and albumin. 
The reaction to these proteins, which persisted till the day 10-sample varied 
between blots (compare to the blot in Figure 3-3) and are likely to be due to 
differences in the blocking reactions with normal dried milk. 
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Figure 3-2: Western blot for Hp in 1DE of post-calving milk from day 1 to 10. 
There is decreasing intensity of the Hp β by day 2, a very faint α-chain band on day 1 and both 







Figure 3-3: Example of irregular fluctuation in Hp concentration from day 1 to 10 a post-
calving cow’s milk. 
Greater intensity of Hp bands are seen on days 4 and 6, while days 2 and 9 had lower intensities, 
these intensity fluctuations agree with the measured Hp concentration for each day in the particular 
cow.  
 
3.4.1.2 M-SAA3 in post-calving milk 
A moderately high mean M-SAA3 concentration was observed for day 1 and 2 
post-calving (colostrum) samples (427 and 238 µg/ml respectively), which fell as 
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the days progressed reaching basal or undetectable levels (4.5 - <0.6 µg/ml) by 
day 4 to 5 (Figure 3-4). Range of M-SAA3 in all post calving samples was <0.6 
µg/ml (LOD) to >1500 µg/ml (highest limit of detection at 1:5000 dilution). P-
values to show pair-wise significant differences in M-SAA3 between days post-
calving are shown in Table 3-2.   
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Figure 3-4: Concentrations of daily M-SAA3 (mean ± SEM) from day 1-10 post-calving 
composite milk samples (n=10). 
 
 
Table 3-2: P-values of differences in daily milk M-SAA3 across 10 days post-calving. 
Days of significant difference in M-SAA3 are highlighted in brown. 
 
M-SAA3 P-value of significant differences between days post calving. 
Day 1 2 3 4 5 6 7 8 9 10 
1 * 0.012 0.025 0.038 0.025 0.036 0.036 0.012 0.017 0.012 
2 0.012 * 1 0.237 0.091 0.091 0.091 0.028 0.069 0.018 
3 0.025 0.012 * 0.091 0.043 0.069 0.093 0.018 0.028 0.018 
4 0.038 0.237 0.091 * 0.043 0.401 0.093 0.043 0.123 0.043 
5 0.025 0.091 0.043 0.043 * 0.08 0.345 0.465 0.5 0.465 
6 0.036 0.091 0.069 0.401 0.08 * 0.465 0.043 0.173 0.043 
7 0.036 0.091 0.093 0.093 0.345 0.465 * 0.225 0.463 0.043 
8 0.012 0.028 0.018 0.043 0.465 0.043 0.225 * 0.715 1 
9 0.017 0.069 0.028 0.123 0.5 0.173 0.463 0.715 * 1 
10 0.012 0.018 0.018 0.043 0.465 0.043 0.043 1 1 * 
 
 
3.4.1.3 CRP in post-calving milk 
Concentrations of CRP were moderately high in colostrum for 8 out of the 10 
composite samples of day 1 post-calving assayed, while 2 out of 10 composite 
colostrum samples had undetectable levels of CRP. In one cow, CRP was 
undetectable from day 1 (colostrum) up until day 10, except for day 4, which 
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same samples with undetectable CRP also had low or undetectable Hp and M-
SAA3 concentration across the 10 days. Furthermore, some irregular fluctuations 
were observed across the days in some samples for example in 2 samples, the 
highest CRP concentration occurred on day 2. In 2 cows, CRP had low to 
moderate concentrations from day 1 to 8, but spiked in concentrations on day 9, 
but dropped again on day 10.   
Figure 3-5 shows the mean and SEM of daily milk CRP concentrations in 
composite samples assayed for day 1 up until day 10 post calving. The range of 
CRP in all the post-calving milk was <1.8 to 607 ng/ml. Table 3-3 displays the P-
values of pair-wise significant difference in CRP values across the 10 days. 
The profile of Hp, M-SAA3 and CRP when compared in the ten cows (which were 
examined for the 3 APP) showed significant correlations (shown in Table 3-4). 
 
Figure 3-5: Concentrations of daily CRP (mean ± SEM) from day 1-10 post-calving 
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Table 3-3: P-values of differences in daily milk CRP across 10 days post-calving. 
Days of significant difference in CRP are highlighted in brown 
CRP P-value of significant difference with days post calving. 
Day 1 2 3 4 5 6 7 8 9 10 
1 * 0.594 0.401 0.021 0.012 0.051 0.021 0.011 0.086 0.012 
2 0.594 * 0.018 0.011 0.012 0.017 0.012 0.017 0.208 0.012 
3 0.401 0.018 * 0.401 0.091 0.263 0.017 0.069 0.208 0.018 
4 0.021 0.011 0.401 * 0.046 0.499 0.043 0.398 0.889 0.116 
5 0.012 0.012 0.091 0.046 * 0.6 0.753 0.6 0.463 0.715 
6 0.051 0.017 0.263 0.499 0.6 * 0.043 0.5 0.6 0.345 
7 0.021 0.012 0.017 0.043 0.753 0.043 * 0.345 0.173 0.893 
8 0.011 0.017 0.069 0.398 0.6 0.5 0.345 * 0.345 0.043 
9 0.086 0.208 0.208 0.889 0.463 0.6 0.173 0.345 * 0.043 
10 0.012 0.012 0.018 0.116 0.715 0.345 0.893 0.043 0.043 * 
 
 
Table 3-4: Correlation of Hp, M-SAA3 and CRP in the same cows (n=10) 
 





















Sig. (2-tailed) . .000 .000 








Sig. (2-tailed) .000 . .000 








Sig. (2-tailed) .000 .000 . 
N 100 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 
3.4.1.4 Proteomic analysis of post-calving milk 
1DE SDS-PAGE  
Figure 3-6 is the 1DE gel electrophoretogram of day 1 to 10 composite milk 
samples of a representative calving cow from Cochno Dairy farm. The labelling 
of bands and spots were carried out by inference using extrapolations from data 
obtained after MS identification of similar samples by Mansor (2012) (PhD thesis, 
University of Glasgow) and Henderson (2013) (MRes dissertation, University of 
Glasgow) see Appendix Chapter 3. 
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Between day 1 and day 10, there was a decrease in high abundance protein, 
especially IgG heavy and light chains while milk protein such as lactoferrin (Lf) 
or alpha-lactalbumin (α-LA) were more consistent between days. 
 
Figure 3-6: 1DE reducing gel electrophoretogram of immediate post-partum milk samples 
(day 1-10) pooled from healthy udder of cow A. 
Ig (immunoglobulin), Bovine Lf (bovine lactoferrin), αS2-CN (alpha S2 casein), β-CN (beta casein), 
κ-CN (kappa casein), β-LG (beta lactoglobulin), α-LA (alpha lactalbumin), DPC (days post-calving), 
kDa (kilo Dalton). Labelled by inference using data obtained from MS identification of similar 
samples by Mansor (2012) (PhD thesis, University of Glasgow) and Henderson (2013) (MRes 
dissertation, University of Glasgow); Appendix Chapter 3. 
 
2DE SDS-PAGE  
Figure 3-7 shows the 2DE gel image of colostrum sample (pooled from 4 
quarters) of a healthy calving cow from Cochno Dairy farm, while Figure 3-8 
shows the day 10 pooled milk 2DE of the same cow (pH 3-10). Spots on the gel 
were labelled by inference using extrapolations from reference 2DE gels 
described in Boehmer et al. (2008) and Mansor (2012) (PhD thesis, University of 
Glasgow). Comparing these 2DE gels, there is a reduction in the IgG heavy and 
light chains between day 1 and day 10 while the caseins, beta-lactoglobulin (β-
LG) and α-LA are more prominent at day 10. 
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Figure 3-7: 2DE reducing gel of pooled (quarters) colostrum (day 1 post-calving) sample. 
Isoelectric range pH 3-10, from one representative calving cow of Cochno Dairy farm. Abundant 
spots of Ig (heavy and light chain) are seen which is characteristic of colostrum. Ig 
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Figure 3-8: 2DE reducing gel of pooled (quarters) day 10 post-calving milk samples. 
On a pH 3-10 range strip. Less Ig spots are seen here compared to the colostrum samples 2DE. Ig 
(immunoglobulin), CN (caseins), κ-CN (kappa caseins), β-LG (beta lactoglobulin), α-LA (alpha 
lactalbumin), β-MG (beta-2 microglobulin). 
 
 
3.4.1.5 Immunohistochemical localization of Hp in bovine mammary gland 
Gross images of both mammary glands used for this study are shown in Figure 3-
9. Figure 3-10 shows a healthy mammary gland stained with H & E showing the 
normal architecture of bovine mammary gland, while Figure 3-11 depicts an H&E 
stained section of a mastitis mammary gland (x100). Overall, the mastitis gland 
showed a high infiltration of neutrophils in most areas of the gland while Hp 
staining was strong in the neutrophils and alveolar duct epithelium.






Figure 3-9: Gross images of the healthy involuted (A) and mastitic (B) mammary glands. 
These were used for the immunohistochemistry analysis of Haptoglobin.




Figure 3-10: Healthy (involuted) bovine mammary gland section, H&E, x200.  
Showing the normal mammary gland architecture, with occasional mononuclear cells infiltrating the 
periductular and perivascular stroma. Arrows indicate a blood vessel (1) and alveolar ducts (2). 
 
 
Figure 3-11: Mastitis bovine mammary gland section, H&E, x100.  
Arrows show duct epithelium (1), lamina propria (2), blood vessel (3), alveolar epithelium (4) and 
neutrophils within the alveolar duct (5). Moderate numbers of neutrophils as well as lower numbers 
of lymphocytes and plasma cells, macrophages infiltrate the lamina propria and extend into the 
mucosal lining of the duct cistern and alveoli in the mastitic glands. Moderate numbers of 
neutrophils are seen within the alveolar lumens.   
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Figure 3-12 displays the Hp IHC staining of healthy glands (1:800), x200 with 
occasional cytoplasmic activity of the ductal epithelial cells for Hp.                              
Figure 3-13 is the Hp IHC stained (1:800) sections showing strong positivity in Hp 
in the duct, alveolar epithelial cells and neutrophils at x100. 
  






Figure 3-12: Haptoglobin immunohistochemistry (titre 1:800) staining of a healthy 
(involuted) bovine mammary gland, x200: 
Very occasional ductal epithelial cells demonstrate minimal cytoplasmic positivity for Haptoglobin 
(brown staining). 
 
Figure 3-13: Haptoglobin immunohistochemistry (titre 1:800) staining of mastitic bovine 
mammary gland section, x100. 
Arrow showing intensely staining neutrophils in the duct lumen (1), duct epithelium (2), alveolar 
ducts with Hp stained neutrophils (3). The densely staining region comprising the neutrophils and 
mammary epithelial cells are indicative of Hp producing sites. Mammary stromal staining (lighter 
brown) is considered a non-specific staining. 






3.5.1 Acute phase proteins in post-calving milk 
3.5.1.1 Haptoglobin in post-calving milk 
In the study on milk samples obtained from calving cows, milk Hp was 
determined from the first milking after calving, and daily milking thereafter to 
the tenth day post calving. Cows were milked twice daily, mornings and 
afternoons and samples were collected for the Hp analysis during the morning 
milking. It is well accepted that the periparturient period is one of the most 
critical periods, health wise, in the productive life of a dairy cow (Trevisi et al., 
2010) and this has been attributed to the negative energy balance and its 
associated immune suppression at the puerperal period. The levels of serum Hp 
at this period can give a picture of the physiologic stress the cow is undergoing. 
Variations in milk Hp in this early post-partum period can help to assess the 
potential of milk Hp concentrations as a method of distinguishing between 
physiological increases and identifying new post-calving IMI. Previous studies 
have reported increases in APP in serum during the first week(s) post-calving 
(Humblet et al., 2006; Uchida et al., 1993; Alsemgeest et al., 1995), but few 
studies have demonstrated the effect of parturition on milk APP (McDonald et 
al., 2001; Ceciliani et al., 2005).  
It has previously been determined that very minimal variations exist (below 10 
%) in the APP (SAA and Hp) of healthy mid lactation (27 ± 9 weeks in lactation) 
cows over a course of 42 consecutive milkings (Åkerstedt et al., 2011). The 
results of this study indicate that Hp is moderately high in the first few days post 
calving milk (colostrum) and gradually drops back to basal levels within 3 to 5 
days after parturition. High individual variations exists, however by the fifth 
day, milk Hp had dropped to basal or non-detectable levels in over 80 % of 
quarter milk samples assayed in this study, which were considered healthy. In a 
few quarters, (~12 %), however, milk Hp increased beyond moderate or basal 
levels of the first few days of post-calving as days progressed. These quarters, 
can be suspected to be quarters developing new IMI or undergoing other forms of 
inflammatory stimulus that can influence the occurrence of an APR. 
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The major pattern of Hp in milk after parturition, followed a similar trend to 
those observed for SCC in the studies of Barkema (1999) and Sargeant et al., 
(2001). The high level of milk Hp in the first few days post-calving may suggest a 
role for Hp in colostrum of conferring maternal protection to the new-born. On 
the other hand, it may be purely due to the stress induced by parturition, and its 
effect extending to the mammary gland. 
Other APP that have been identified as being high in colostrum and shown to 
decrease in milk with days post calving are SAA (McDonald et al., 2001), alpha-1 
acid glycoprotein (Ceciliani et al., 2005), lactoferrin and transferrin (Sánchez et 
al., 1988). To the best of our knowledge this is the first report of daily variation 
in the levels of Hp from colostrum and milk over the first 10 days after 
parturition. 
That there was no correlation found between the concentrations of first day Hp 
with the position of the quarter or parity indicates that neither of these factors 
has an effect on Hp in milk.  
With the knowledge that Hp and other major APP are moderately high in 
colostrum in the first few days’ milk post calving, caution should be exercised in 
using them for confirming the presence of IMI at this period. Compared to Hp 
concentration in peak stages of mastitis, milk Hp concentrations in colostrum are 
moderately raised. However, since most dairy farms measure SCC on a monthly 
basis by samples submitted to a central laboratory, APP assay can still come in 
useful for detecting new IMI in the periparturient period, especially after the 
first few days when a drop in Hp would be expected in the absence of IMI and 
provided they can be adapted to a rapid measurement format. Indeed a rapid 
test for Hp may be a better test for IMI than CMT which has been evaluated for 
their usefulness in detecting major pathogen caused mastitis in the immediate 
post-partum period (Dingwell et al., 2003b). 
 
3.5.1.2 M-SAA3 in post-calving milk 
High levels of M-SAA3 observed in almost all composite colostrum samples are 
consistent with the first reports by McDonald et al. (2001) where high levels of 
MAA in bovine colostrum significantly dropped by day 4 post calving. 
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In this study it was observed that milk concentrations of M-SAA3 dropped faster 
than Hp levels post-partum, such that by the third day after calving values were 
almost all undetectable whereas milk Hp values were sustained in some animals 
to the 4-5th day. This suggests that M-SAA3 may have a critical role in 
conferment of innate immunity to the new born. Thus an M-SAA3 test may 
introduce spurious results if used for assessing for IMI at the first 4 to 5 days or 
first 6 milkings after calving, but it is therefore important that the natural levels 
of M-SAA3 in colostrum and early milk is recognized.  
3.5.1.3 CRP in post-calving milk 
Milk CRP was found to follow a similar trend as Hp and M-SAA3 in post calving 
milk, by being moderately high on the first 1 to 3 days and then gradually falling 
in concentration in healthy cows. This study confirms the reports of Schroedl et 
al. (2003) of the presence of CRP in bovine colostrum. In 2 cows, where CRP 
levels were low to moderate from day 1 to 8, but spiked in on day 9, and then 
dropped again on day 10, the spike in CRP on day 9 is not conclusively suggestive 
of a new IMI.  
According to Lee et al. (2003) serum CRP levels correlated with lactation status, 
being highest during peak lactation period (2-4 months of pregnancy). 
Furthermore in the study of Zimmermann et al. (1998) plasma CRP levels in cows 
were increased post-partum with the increase higher in the group of cows that 
had undergone a normal puerperium than in groups with delayed involution or 
puerperal endometritis. There has been no previous report of the daily variation 
of CRP in bovine milk from the day of parturition up to the 10th day post-partum. 
This pilot study should be extended in order to verify the observed pattern in 
milk CRP in the post-partum period. 
3.5.2 Proteomic analysis of post-calving Milk  
One dimensional gel electrophoresis is a robust and reproducible technique for 
protein separation. However, it has low resolution. From this study, 1DE of the 
daily milk samples displayed sufficient resolution to distinguish minor 
quantitative and qualitative variation of samples from first to tenth day post 
calving. The major milk proteins (caseins and whey proteins) as well as other 
high abundance proteins (for example immunoglobulins) have been identified 
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from similar studies by Henderson (MRes Dissertation, University of Glasgow, 
2013), such that protein identification by MS was redundant. 
As samples move from colostrum to milk, there is a decrease in immunological 
proteins such as Igs, bovine lactoferrin and serum albumin but the levels of 
major milk whey proteins; β-lactoglobulin and α-lactalbumin remain virtually the 
same. No bands of IgA and IgM were observed in milk samples from day 4 post 
calving although they were seen from day 0 to 3. These findings agree with the 
reports of Stelwagen et al. (2009) of colostrum containing higher amounts of Igs 
especially IgG and other immune related proteins than milk. It should be noted 
that bands on a reducing 1DE gel, such as examined in the present study, have a 
high probability of containing multiple proteins (of similar mass) since only 
molecular weight separation was achieved using a 1DE. Hence to obtain better 
protein resolution and additional separation dimension (isoelectric point) can be 
employed as obtainable in 2DE. 
Two dimensional gel electrophoresis of the milk samples from the first and tenth 
day post-calving had the additional advantage of being able to resolve proteins 
by both the isoelectric points and molecular mass.  Various spots corresponding 
to milk proteins as well as immunological proteins were observed upon staining 
of 2DE gels. Although no mass spectrometry of gels spots were carried out in this 
study, inferences on the constituents of each spot was made by comparing gels 
spots analyses of similar samples carried out previously (Henderson, MRes, 
dissertation, University of Glasgow, 2013) and in comparison to published 2DE 
gels of milk protein (Hogarth et al., 2004; Smolenski et al., 2007; Boehmer et 
al., 2008). 
Comparatively, visual examination of the 2DE gels of the day 1 and day 10 post-
calving milk showed clear distinctions in relation to the relative abundance of 
milk proteins and immunoglobulin spots, with Day 1 milk having greater 
abundance of both classes of proteins, consistent with the documented 
composition of colostrum of being rich in immunoglobulins and other immune 
proteins. The 2DE gel analysis gave increased separation of the high abundance 
proteins of milk which were largely the same as those on the 1DE apart from the 
β1-microglobulin, which with a high pi was well separated from other low Mw 
proteins such as α-LA. 
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Thus it can be concluded that 2DE provided a reasonable separation of high 
abundance proteins in milk and visual inspection of gels with comparison to 
previous results can identify protein for interpretation of the change in high 
abundance proteins of milk post calving. However 2DE does have limitations and 
more advanced proteomic technologies with greater sensitivity need to be 
applied to examine changes in lower abundant proteins and these issues are 
addressed in chapter 5 of this thesis. 
3.5.3 Immunohistochemical localization of Hp in the bovine 
mammary gland 
Immunohistochemistry is a technique that enables the localization of antigens or 
proteins in histological tissue sections by the use of labelled antibodies against 
the antigen of interest, which can then be visualized by staining with dyes.  
In this IHC study of normal and mastitic bovine mammary glands, it was found 
that Hp stains highly within the neutrophils and MEC during mastitis. This agrees 
with previous reports of the neutrophils and MECs as one of the major sources of 
milk Hp (Lai et al., 2009; Thielen et al., 2007). However in addition to the 
alveolar epithelia cells, strong Hp staining was also observed for the ductal 
epithelial cells in this study. Similar findings on IHC localization of Hp have been 
observed for porcine lungs (Hiss et al., 2007) and bovine female reproductive 
tract (Lavery et al., 2003). 
Furthermore, because MEC of both alveoli and ducts of the gland were found to 
stain highly for Hp, it can be inferred that the synthesis of Hp occurs in these 
sites of frequent communication between the body and the exterior lending 
further support to its possible role in the innate immune response. 
It has been demonstrated that Hp is stored in granules within neutrophils, and 
undergoes exocytosis at sites of infection or injury (Theilgaard-Mönch et al., 
2006). However there is no documented evidence of its storage in this form, 
within MEC, as no granules have been associated with the MEC. 
3.6 Conclusions 
The APP profile in milk in the immediate post calving period was evaluated and 
with the conclusion that moderate increases occur in the concentration of Hp, 
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M-SAA3 and CRP during this period. These increases in APP can be distinguished 
from mastitis related increases in APP from the 4th day post calving, beyond 
which any sustained high value of APP would be suggestive of a new or on-going 
intra mammary infection. The advantage of proteomic studies was shown in 
distinguishing changes in colostrum and milk during the periparturient period. 
Immunohistochemical studies have demonstrated the presence of Hp in 
neutrophil as well as the MEC, confirming these as possible origins of the source 
of milk Hp. 
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4 Proteins in milk from dairy cows with naturally 
occurring mastitis: effect of pathogen 
4.1 Overview 
This chapter discusses the analyses of milk samples from cows naturally affected 
by mastitis, which were submitted for diagnostic evaluation to a veterinary 
diagnostic laboratory in Scotland. Several analyses were carried out on these 
samples, ranging from quantitative assays, characterization of APP, as well as 
proteomic evaluations. The overall objective in this chapter was the 
identification of likely biomarkers of bovine mastitis from a panel of samples 
with a heterogeneous distribution of factors that relate to the occurrence of 
mastitis on dairy farms in the UK. In addition, milk collected, in these studies 
were subjected to a variant 2DE, to determine if milk isoforms of Hp correspond 
to the forms found in bovine serum during acute phase reaction. The milk 
protein was separated by a liquid phase isoelectric focusing and then 1DE SDS-
PAGE in order to identify change in low abundance proteins. 
4.2 Introduction  
4.2.1 Natural mastitis caused by different pathogens 
The incidence, types, aetiology, risk factors and distribution of mastitis has 
already been discussed in the introductory chapter of this thesis. A major 
determinant of the severity and course of a mastitis episode is the causative 
organism of the mastitis in a quarter at any given time. This can be further 
impacted by the presence of multiple species within the affected gland (Pyorälä 
et al., 2011). Other factors that can also create risks for bovine mastitis include 
farm hygiene or management system, seasonal variation and breeds of cows. 
In a number of studies, it has already been determined that different pathogens 
vary in the onset and level of release of inflammatory markers such as APP into 
milk during mastitis (Smolenski et al., 2007; Pyorälä et al., 2011; Kalmus et al., 
2013). Therefore the causative pathogen in any given mastitis condition could 
significantly affect biochemical composition of the milk and thus the findings 
during biomarker searches. Several studies have shown the variation of the APP 
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Hp and M-SAA3 in milk from mastitis caused by different pathogens. Furthermore 
Kruger and Neumann, (1999) have shown that significant variations exist in CRP 
levels of milk from mastitis caused by different pathogens. Having an in-house 
assay for milk Hp, as well as the hope of exploring the variation of APP from a 
wider spectrum of bacterial causes and comparing the dynamics of each APP 
with the other in the same samples, instigated further studies of APP dynamics 
in milk from mastitis caused by different pathogens. 
The traditional method for determination of causative pathogen of mastitis has 
been the bacterial culture and isolation and this method has been recommended 
by the NMC (NMC, 2004). This method has disadvantages particularly of the 
length of time it takes for testing as well as incidence of frequent ‘no growth’ 
cases in mastitis milk cultures. Nonetheless this method continues to be a 
popular method for confirming the aetiologies of IMI. 
In the search for markers for bovine mastitis, the use of samples from natural 
infections offer an added advantage over experimentally induced mastitis 
samples in that the disease takes its natural course as obtained in field or farm 
conditions. Indeed it would be part of validation of any commercial diagnostic 
test to ensure it can operate with samples from dairy farms with mastitis. Bovine 
mastitis is a ‘natural infection’ problem with high economic impact in most dairy 
farms across the world. Therefore, it was expected that exploring samples from 
natural infections from commercial dairy farms would give a better 
understanding of biomarker repertoires in naturally occurring mastitis affected 
milk. In addition, studying milk samples submitted from various dairy farms and 
locations in Scotland would help to understand the intricate contributions that 
other cow, farm or management factors have in the incidence, type and severity 
of mastitis. 
 
4.2.2 Objectives  
 
The objectives of this study were therefore to; 
Determine the profile of APP (Hp, M-SAA3 and CRP) in samples of milk from cows 
with natural mastitis submitted for bacteriological examination and assess how 
these APP vary by causative pathogens and other factors. 
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Investigate major differences in the proteome of a model of gram positive and 
gram negative bovine mastitis milk, compared to a healthy bovine milk 
proteome using a liquid phase isoelectric focusing sample fractionation step. 
4.3 Materials and methods 
4.3.1 Reagents  
General chemicals were obtained from Sigma-Aldrich, Poole, UK, except where 
otherwise stated. Reagents for polyacrylamide gel electrophoreses (PAGE) were 
obtained from Bio-Rad laboratories Ltd (Hemel Hempstead, UK). Buffers and 
stock solutions were prepared according to manufacturer’s instructions. A 4-15 % 
Criterion™ precast 18-well comb and 11 cm IPG+1 well comb gels (Bio-Rad Lab, 
Inc. USA) were used for the 1DE and 2DE respectively. Milli Q water was used 
throughout. 
4.3.2 Samples  
The milk samples (n=63) used in this study were obtained from the Veterinary 
Diagnostic Services (VDS) (School of Veterinary Medicine, University of Glasgow), 
these were samples which were submitted from 7 dairy farms across Scotland, to 
the Laboratory between August 2012 to December 2013, in order to undergo 
bacteriological culture for the causative pathogen of mastitis. All samples were 
aliquoted (5 ml) and stored at -20oC until analysed. The samples were obtained 
as part of collaborative study with Patricia Belinda Alves Simoes and Timothy 
Geraghty of the School of Veterinary Medicine, University of Glasgow. The 
results of bacterial isolation analyses performed by the VDS using bacteriological 
culture are presented along with APP results. Comparison of APP in milk caused 
by different mastitis pathogens was performed. 
 
4.3.3 Milk APP concentration in natural mastitis caused by 
different pathogens 
The APP, Hp, M-SAA3 and CRP were measured in the samples obtained from VDS 
(n=63, whose causative pathogens were determined by microbiology), using the 
in-house ELISA for Hp, the commercial ELISA kit from Tridelta development 
Company (Kildare, Ireland) for M-SAA3 and the commercial ELISA kit from Life 
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diagnostics (West Chester, USA) for CRP as described in Sections 2.3.2, 2.3.3 and 
2.3.4 respectively, with modifications carried out in the dilutions used for 
samples with high APP levels. A maximum dilution of 1:1600 was used for Hp, 
1:5000 for M-SAA3 and 1:2000 for CRP. An additional 12 samples with low SCC 
from Cochno dairy farm were analysed to provide a baseline for APP in milk from 
healthy cows.  
4.3.4 Proteomic analysis of a model of gram positive and gram 
negative bovine mastitis whey 
4.3.4.1 Sample preparation 
Milk samples submitted to the VDS for bacteriological diagnosis (section 4.3.2) 
were used for this study. Pools of all E. coli (n=9), S. aureus (n=9) and S. uberis 
(n=13) mastitis milk were made by adding equal volume of each sample (500 µl) 
together and mixing thoroughly. A pool of healthy (non-mastitic) milk samples 
was also made from 12 samples having low SCC obtained from the Cochno dairy 
farm (as described in section 2.3.5.2 of this thesis). 
Centrifugation was carried out in two steps to yield skimmed milk samples of 
each pool. First whole milk was centrifuged for 30-60 min at speed of 3,500 xg 
and 4°C temperature. Top layer (milk fat) was carefully removed and the 
supernatant (whey) decanted carefully into a new tube, while the bottom 
sediment (caseins) were discarded. The centrifugation step was repeated as 
above for the whey samples, and all residual fats and caseins removed. Once 
clear whey samples were obtained, they were dialyzed in milli Q water overnight 
at 4°C to remove salts. Samples were then filtered through a 0.45 µm Minisart® 
syringe filter (Sartorius, Epsom Surrey, UK).  
4.3.4.2 Total protein concentration 
Protein concentration in pooled whey samples for liquid phase preparative 
isoelectric focusing on the mini Rotofor™ cell was determined using 
spectrophotometric method (based on absorbance spectroscopy of proteins at 
280 nm and concentration calculated from the equation 4-1 (Grimsley and Pace, 
2004).  
Equation 4-1;  A = ε x l x c 




Solving for c, where A=absorbance; ε= extinction coefficient of bovine serum 
albumin (6.6); l=path length (1 cm) and c=concentration (allowing for the 
molecular weight of albumin). 
4.3.4.3 1DE SDS-PAGE   
The pools of E. coli, S. aureus, S. uberis mastitis and healthy whey samples were 
each resolved by 1DE SDS-PAGE in different wells on a precast gel as described in 
section 3.3.1.6 as an initial study. 
4.3.4.4 2DE: Rotofor™ and SDS-PAGE 
Isoelectric focusing 
Prior to the preparative isoelectric focusing on a Rotofor system (Bio-Rad 
Laboratories, Hemel Hempstead, UK), ampholyte concentration used in running 
the sample was calculated based on final protein concentration of each sample 
(>2 mg=2 %, 1 mg = 1.5 % and so on) and the final volume (18 ml) to be applied 
in the focusing chamber using the equation 4-2. 
Equation 4-2;  C1V1 = C2V2 
Solving for V1 where C1=starting Bio-Lyte® concentration; V1=unknown volume of 
Bio-Lyte®; C2= Desired concentration of Bio-Lyte®; V2=final volume for Rotofor 
(18 ml). 
A mini Rotofor® system (220/240 V, 18 ml sample volume; Bio-Rad Laboratories, 
Hemel Hempstead, UK) was used to fractionate whey samples from E. coli 
mastitis, S. aureus mastitis, S. uberis mastitis and healthy milk according to 
various pi of protein molecules. The preparative isoelectric focusing was carried 
out according to the manufacturer’s protocol;  
The mini Rotofor cell electrodes were using 0.1 M phosphoric acid (H3PO4) as the 
anode (+) electrode and 0.1 M sodium hydroxide (NaOH) as the cathode (-) 
electrode. The focusing chamber was assembled by first sliding the anode 
electrode through the ceramic cooling finger and membrane core followed by 
the focusing chamber over the membrane core and ensuring that the membrane 
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core ports were not blocked by the focusing chamber screen. Next the cathode 
electrode was inserted through the cooling finger. 
After covering the ports with sealing tape and cell-cover blocks, the focusing 
chamber was prepared by pre-running the cell with water at 5 watts constant 
power for 5 min. Next, a pre-sample solution of 1.5-2 % ampholyte (Bio-Lyte®; 
pH 3-10, 40 %; Bio-Rad laboratories, Hemel Hempstead, UK) in a solution of 5 M 
urea buffer (total volume 18 ml) was run at 12 watts constant power for 60 min. 
After discarding the pre-sample, 3 ml of whey sample in  an ampholyte (1.5-2 %); 
5 M urea solution  (to make a final volume of 18 ml) was loaded using a syringe 
and needle into the focusing chamber and run at 12 watts constant power for 3 
h. Fractions (n=20) were then collected by operating a vacuum pump through 
the harvest box, into pre-labelled culture tubes, and the pH of each fraction 
determined using a pH meter (Hanna instruments, Bedfordshire, UK). 
Gel electrophoresis 
Each whey fraction was then dialyzed in de-ionized water overnight to remove 
excess urea and concentrated using 0.5 ml centrifugal filter units (Merck 
Millipore, Germany), after which protein concentration of each fraction was 
determined and fractions were subjected to 1DE on SDS-PAGE to be resolved by 
molecular weight, as described in Section 3.3.1.6. 
Bands of interest (selected based on visual quantitative or qualitative 
differences between the different whey fractions’ 1DE) were carefully excised 
and placed in labelled 1.5 ml Eppendorf tube and taken for Trypsin digestion and 
further protein identification by liquid chromatography and mass spectrometry. 
Trypsin digestion 
The excised bands were placed in 1.5 ml Eppendorf tubes, cut into several 
pieces using pipette tips and washed for 30 min to 1 h by adding 500 μl of 100 
mM ammonium bicarbonate (NH4HCO3) into the tubes and placing on a shaker. 
The wash was discarded and the gel pieces were further washed in 50 % (v/v) 
acetonitrile (ACN)/100 mM NH4HCO3 for another 30 min to 1 h. The wash was 
again discarded. For reduction, 150 μl of 100 mM NH4HCO3 and 10 μl of 45 mM 
DTT were added and incubated at 37ºC for 30 min. For alkylation, 10 μl of 100 
mM iodoacetamide was added and incubated in the dark for 30 min. Solvent was 
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discarded and gel pieces were washed in 500 μl of 50 % (v/v) ACN/100 mM 
NH4HCO3 with shaking for 30 min to 1 h. The wash was discarded and 50 μl of 100 
% (v/v) ACN was added to shrink the gel pieces. After 10 min, the solvent was 
removed and gel pieces were dried completely in a vacuum centrifuge for 30 
min. Sequencing grade modified Porcine Trypsin (Promega #V111, Southampton 
UK) in 25 mM NH4HCO3, was then added to the dried gel pieces enough to 
rehydrate each gel piece. Additional Trypsin solution was added if Trypsin was 
completely absorbed so that the gel band became fully rehydrated. The gel 
pieces were then incubated overnight to allow protein digestion at 37ºC. 30 μl of 
100 % ACN was then added to the gel pieces and incubated for 20 min. Each 
solution in each tube was transferred to separate wells in a 96-well plate. 20 μl 
of 1 % (v/v) formic acid was added into each Eppendorf tube containing gel 
pieces and incubated for another 20 min. 40 μl of ACN (100 %) was added and 
further incubated for 20 min, after which the mixture was centrifuged briefly to 
sediment the gel and the solution was aspirated and transferred to the 
corresponding wells.  Samples in the 96-well plate were then dried in a vacuum 
centrifuge which was stored at -20°C prior to LC-MS/MS.  
LC-MS/MS 
A nanoflow HPLC electrospray tandem mass spectrometry (nLC-ESI-MS/MS) was 
employed. Peptides samples (obtained after Trypsin digest) were solubilised in 2 
% (v/v) acetonitrile with 0.1 % (v/v) trifluoroacetic acid and fractionated on a 
Thermo Scientific RSLCnano nanoflow uHPLC system (Thermo Scientific, Hemel 
Hempstead, UK). Peptide separation was performed on a Pepmap C18 reversed 
phase column (Thermo Scientific). Peptides are desalted and concentrated for 4 
min on trap column followed by an acetonitrile gradient (in 0.1 % v/v formic 
acid) (3.2 – 32 % v/v 4 - 27 min, 32 % to 80 % v/v 27 - 36 min, held at 80 % v/v 
36- 41 min and  re-equilibrium at 3.2 %) for a total time of 45 min. A fixed 
solvent flow rate of 0.3 l /min is used for the analytical column.  The trap 
column solvent flows at a fixed rate at 25 l/min using 2 % (v/v) ACN with 0.1 % 
(v/v) trifluoroacetic acid. 
Online analyses were then carried out by electrospray ionisation (ESI) mass 
spectrometry on an Amazon Speed ion trap MS/MS (Bruker Daltonics, Coventry, 
UK). MS analyses were performed using a continuous duty cycle of survey MS 
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scan followed by up to ten MS/MS analyses of the most abundant peptides, 
choosing the most intense multiply charged ions with dynamic exclusion for 120 
s. Mass spectra data were processed using Data Analysis software (Bruker, 
Coventry, UK) and the automated Matrix Science Mascot Daemon server (v2.4.1). 
Protein identifications were assigned using the Mascot search engine to 
interrogate protein sequences in the NCBI GenBank database, allowing a mass 
tolerance of 0.4 Da for both MS and MS/MS analyses (Burchmore, pers. comm., 
2014). LC-MS/MS analysis as well as data processing was carried out with the 
assistance of Ms Lorraine King under the supervision of Dr. Richard Burchmore 
(Glasgow Polyomics, University of Glasgow). 
4.3.5 Statistical analyses 
Tests for normal distribution were carried out on all data sets. Comparison of 
concentrations of the different APP in mastitis milk caused by different 
pathogens was carried out using an independent sample Kruskal-Wallis test. An 
independent Mann-Whitney’s test was employed to compare APP of pathogen 
groups, pair wise in order to determine which pathogen had significantly 
different APP values from the other. Among the samples from the VDS, APP 
values from clinical and subclinical mastitis and healthy samples (drawn from 
Cochno composite samples with SCC < 200,000 cells/ml) as well as from 
different farms were also compared. Cross tabulation analysis for significant 
associations between factors was also carried out between farms, pathogen type 
and clinical status levels using Pearson Chi-square test and non-parametric 
correlations (Spearman’s rho). P-value was considered significant at <0.05. 
4.4 Results 
4.4.1 Milk APP in natural mastitis caused by different pathogens  
The distribution of the APP; Hp, M-SAA3 and CRP in milk analysed by 
microbiological culture and isolation at the VDS, across the different pathogen 
groups are shown in Figures 4-1, 4-2 and 4-3 respectively. The distribution of Hp, 
M-SAA3 and CRP for the different pathogens groups were significantly different 
(P=0.000).  Similar and different pathogen groups are shown in Table 4-1. It was 
observed that E. coli had the greatest levels of each of the 3 APP among all the 
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pathogens. Next were the environmental pathogen S. uberis and S. dysgalactiae 
which also had APP significantly higher than that of other pathogens. 
The type of mastitis (clinical or subclinical) was determined by the Veterinarian 
on the farm by presence or absence of clots in milk and history of signs of udder 
inflammation and therefore it was possible to classify the milk samples assayed 
in this study into CM and SM along with healthy samples. Clinical condition of the 
cows had a significant effect on the concentrations of each of the 3 APP assayed 
(P=0.000). Figures 4-4, 4-5 and 4-6 show the distribution of each APP across the 
various clinical conditions of the quarter/udder (clinical mastitis, subclinical 
mastitis, healthy or unknown). When subclinical mastitis samples were compared 
specifically with healthy samples (using independent samples Mann-Whitney U 
test), the 3 APP distributions were significantly different between the two 
categories (P=000). Clinical mastitis samples were also significantly different 
from subclinical (Hp- P=0.004; M-SAA3-P=0.041 and CRP-P=0.039) as well as 
healthy (Hp, M-SAA3 and CRP-P=0.000) 
Farm of sample origin was another criteria used to categorise and compare the 
distribution of the APP in the milk samples. Figures 4-7, 4-8 and 4-9 displays the 
box plots showing median concentrations of Hp, M-SAA3 and CRP respectively, 
across the various farms of sample origin, which were also found to be 
significantly different across farms (P=0.000).   




Figure 4-1: Box plot showing the levels of Hp in milk samples, across specific pathogens 
groups  
* indicate extreme values, while º indicates outliers. 
 





Table 4-1: P-values showing significant differences of the Hp values between the different pathogen groups 
Significantly different P-values highlighted in light blue  
HAPTOGLOBIN 
Pathogen Other bacteria CNS Staph aureus Escherichia coli Strept uberis Strept dysgalactiae Healthy 
Other bacteria 1 0.431 0.186 0.000 0.013 0.002 0.000 
Coagulase negative 
staph 
0.431 1 0.014 0.000 0.009 0.001 0.000 
S  aureus 0.186 0.014 1 0.002 0.238 0.036 0.000 
Escherichia coli 0.000 0.000 0.002 1 0.155 0.541 0.000 
Strept uberis 0.013 0.009 0.238 0.155 1 0.357 0.000 
Strept dysgalactiae 0.002 0.001 0.036 0.541 0.357 1 0.000 
Healthy 0.000 0.000 0.000 0.000 0.000 0.000 1 
Other pathogens include:  
 -Staph warneri (n=2), Staph. scuiri (n=1), Staph. pseudintermedius (n=1), Staph. chromogenes (n=1), Enterococcus faecalis (n=2), Corynebacterium spp (n=3), 
Lactococcus lactis (n=1), Enterococcus faecium (n=1) and Aerococcus. viridians (n=1).  
 
CNS-coagulase negative Staphylococcus 








Figure 4-2: Box plot showing the levels of M-SAA3 in milk samples across specific pathogens 
groups 
* indicate extreme values, while º indicates outliers. 
 





Table 4-2: P-values showing significant differences of the M-SAA3 values between the different pathogen groups  
Significantly different P-values highlighted in light blue  
M-SAA3 
Pathogen Other bacteria CNS Staph aureus Escherichia coli Strept uberis Strept dysgalactiae Healthy 
Other bacteria 1 0.023 0.193 0.000 0.021 Sig.-0.025 0.000 
Coagulase negative 
staph 
0.023 1 0.863 0.000 0.238 0.481 0.000 
5 Staph aureus 0.193 0.863 1 0.000 0.174 0.200 0.002 
6 Escherichia 
coli 
0.000 0.000 0.000 1 0.108 0.046 0.000 
7 Strept uberis 0.021 0.238 0.174 0.108 1 0.776 0.000 
8 Strept 
dysgalactiae 
0.025 0.481 0.200 0.046 0.776 1 0.000 
Healthy 0.000 0.000 0.002 0.000 0.000 0.000 1 
Other pathogens include:  
 -Staph warneri (n=2), Staph. scuiri (n=1), Staph. pseudintermedius (n=1), Staph. chromogenes (n=1), Enterococcus faecalis (n=2), Corynebacterium spp (n=3), 
Lactococcus lactis (n=1), Enterococcus faecium (n=1) and Aerococcus. viridians (n=1).  
 










Figure 4-3: Box plot showing the levels of CRP in milk samples, across specific pathogens 
groups 
* indicate extreme values, while º indicates outliers. 
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Table 4-3: P-values showing significant differences of the CRP values between the different pathogen groups  
Significantly different P-values highlighted in light blue  
CRP 
Pathogen Other bacteria Coagulase negative 
staph 




Strept dysgalactiae Healthy 
Other bacteria 1 0.556 0.750 0.002 0.413 0.185 0.000 
Coagulasenegative staph 0.556 1  0.000 0.413 0.059 0.034 
9 Staph aureus 0.750 1.000 1 0.000 0.169 0.038 0.004 
10 Escherichia coli 0.002 0.000 0.000 1 0.035 0.015 0.000 
11 Strept uberis 0.413 0.413 0.169 0.035 1 0.875 0.001 
12 Strept dysgalactiae 0.185 0.059 0.038 0.015 0.875 1 0.000 
Healthy 0.000 0.034 0.004 0.000 0.001 0.000 1 
 
Other pathogens include:  
 -Staph warneri (n=2), Staph. scuiri (n=1), Staph. pseudintermedius (n=1), Staph. chromogenes (n=1), Enterococcus faecalis (n=2), Corynebacterium spp (n=3), 
Lactococcus lactis (n=1), Enterococcus faecium (n=1) and Aerococcus. viridians (n=1).  
 










Figure 4-4: Box plot showing Hp concentration across the various clinical conditions of 
sample-source quarter/udder 
* indicate extreme values, while º indicates outliers. 




Figure 4-5: Box plot showing M-SAA3 concentration across the various clinical conditions 
of sample source quarter/udder 
* indicate extreme values, while º indicates outliers. 
 
 




Figure 4-6: Box plot showing CRP concentration across the various clinical conditions of 
sample-source quarter/udder 
* indicate extreme values, while º indicates outliers. 






Figure 4-7: Box plot showing Hp concentration across the various farms from where the 
samples were obtained (Farm 1-7). 
* indicate extreme values, while º indicates outliers. 






Figure 4-8: Box plot showing M-SAA3 concentration across the various farms from where 
the samples were obtained (Farm 1-7) 
* indicate extreme values, while º indicates outliers. 






Figure 4-9: Box plot showing CRP concentration across the various farms from where the 
samples were obtained (Farm 1-7). 
* indicate extreme values, while º indicates outliers.




There was a significant association between the clinical status of quarter/udder 
sampled and the pathogen detected in such samples (P=0.000). Figure 4-10 
shows clustered bar charts of number of cases with different clinical statuses 
among the pathogens. There was also a significant association between 
pathogen-type detected and the farm of sample origin (P=0.013, shown in 
clustered bar charts in Figure 4-11). There was also significant associations 
between the clinical status and the farms (P=0.000, shown in clustered bar 
charts in Figure 4-12).  
A significant positive correlation was found between Hp and M-SAA3 (P=0.01, 
r=0.72), between Hp and CRP (P=0.01, r=0.76) and between M-SAA3 and CRP 
(P=0.01, r=0.66) in this study. 
 
Figure 4-10: Clustered bar chart showing number of pathogen-type (cases) found between 
each clinical status of quarters/udders of samples origin 
Pearson Chi-square test showed significant association between pathogens and clinical status 
(P=0.000), correlation between pathogen and clinical status (Spearman’s rho) was also significant 
(P=0.003). 
 









Figure 4-11: Clustered bar chart displaying the number of pathogen-type (cases) found in 
the different farms of sample origin 
Pearson Chi-square test showed significant association of pathogens with farm (P=0.013).  
 
 




Figure 4-12: Clustered bar charts displaying number of cases in the different clinical 
statuses categories found per farm of sample origin. 
Pearson Chi-square test showed significant association between clinical status and the farm of 
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12.1.1 Proteomic analysis of a model of gram positive and 
gram negative bovine bacterial mastitis 
12.1.1.1 1DE SDS-PAGE  
Figure 4-13 shows the 1DE gel image of the 3 pools (whey from E. coli (n=9), S. 
aureus (n=9) mastitis and healthy milk samples (n=9) loaded at a concentration 
of 2-3 mg/ml) per well. 
 
Figure 4-13: Skimmed samples from a pool of healthy (A), E. coli (B) and S. aureus (C) 
mastitis at concentration of ~2-3 mg/ml. 
Ig (immunoglobulin), Bovine Lf (bovine lactoferrin), αS2-CN (alpha S2 casein), β-CN (beta casein), 
κ-CN (kappa casein), β-LG (beta lactoglobulin), α-LA (alpha lactalbumin 
 
12.1.1.2 Two dimensional electrophoresis: Rotofor® and SDS-PAGE 
12.1.1.3 Rotofor® isoelectric focusing 
Each pooled sample was subjected to isoelectric focusing to yield 20 fractions 
with pH ranging from 3.0-10.0 on the mini Rotofor® cell system. Figure 4-14 
shows 1DE SDS-PAGE of 20 fractions with pH ranging from 2.71 to 9.92 for the 
healthy whey pool; Figure 4-15 shows E. coli pool fractions (pH 2.79 to 10.28) 
and the S. uberis fractions (pH 3.10 to 9.42) is shown in Figure 4-16. Bands 
excised for MS protein identification are indicated in circles. Table 4-4 gives a 
list of the bands and their corresponding proteins identified using the Mascot 
database search after LC-MS/MS analysis. 





Figure 4-14: 1DE reducing gel of fraction of healthy milk samples with different pIs 
(following isoelectric focusing on Rotofor®) 
Circled bands indicate bands excised for LC-MS/MS protein identification with the numbering 
corresponing to identifications listed on Table 4-4. Squared areas show bands representative of 





Figure 4-15: 1DE reducing gel of fractions of E. coli milk samples with different pIs 
(following isoelectric focusing using Rotofor®) 
Circled bands indicate bands excised for LC-MS/MS protein identification with the numbering 
corresponing to identifications listed on E. coli section of Table 4-5. 
 




Figure 4-16: 1DE reducing gel of fractions of S. uberis whey samples with different pI 
(following isoelectric focusing on Rotofor® 
Circled bands indicate bands excised for LC-MS/MS protein identification with the numbering 
corresponing to identifications listed on S. uberis section of Table 4-5.
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Table 4-4: Excised bands from 1DE of Rotofor® fractions of healthy whey pool (shown in Figure 4-14) and the protein(s) identification.  




Protein Ac. Number Calculated 
pi 
Mass (Da) MOWSE 
Score 
Matches % coverage 
1 Serum albumin P02769 5.82 71244 4423 259(163) 68 
2 Bovine Beta-Lactoglobulin 1BSO_A 4.76 18641 2588  97 
3 Alpha lactalbumin CAA44927 4.8 14603 1123 47(32) 40 
4 Bovine Beta-Lactoglobulin 1BEB_A 4.83 18583 121 14(6) 50 
5 Beta-casein A2 variant 
Lactoglobulin beta 




















6 Serum albumin P02769 5.82 71244 242 16(8) 11 
 Ig heavy chain AEY68824 6.1 51391 312 20(11) 10 
7 Lactoferrin AAA30610 8.73 80113 852 68(28) 46 
8 Immunoglobulin heavy chain 
variable region 
 
AEY68824 8.94 10127 39 3(1) 8 
9 Ig lambda light chain constant 
region 
AEM05851 8.49 11464 309 11(7) 47 
10 Beta-lactoglobulin AAA30412 4.6 6725 35 4(1) 56 
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Table 4-5: Excised bands from 1DE of Rotofor® fractions of the E. coli and S. uberis mastitis whey pools (gels shown in Figures 4-15 and 4-16) and the 
protein(s) identification. 
The number of band corresponds to the Band ID. This was following Mascot searches after Trypsin digestion and LC=MS/MS analysis 
E. coli whey pool 
Band 
ID 
Protein AC. Number calculated 
pi 
Mass (Da) MOWSE 
Score 
Matches % coverage 
1 Serum albumin 













2 IgG1 heavy chain constant region AAB37381 6.09 36510 452 33(16) 41 
3 Neutrophil gelatinase associated 
lipocalin (NGAL) 
XP_605012 9.35 22982 1174 75(36) 58 




9.35 22982 2191 97(72 65 
5 Neutrophil gelatinase-associated 
lipocalin isoformX2 (NGAL) 
XP_605012 
 
9.35 22982 2191 97(72 65 




















7 Apolipoprotein A-I preproprotein 
Bovine Beta-Lactoglobulin 
 Neutrophil gelatinase-associated 




































9 Beta 2-microglobulin BAC56416 7.08 11151 270 22(12) 35 
10 Serum albumin P02769 5.82 71244 1502 115 (63) 61 
S. uberis pool 
Band 
ID 
Protein Ac. Number Calculated 
pi 
Mass (Da) MOWSE 
Score 
Matches % coverage 
1a,b Serotransferrin precursor DAA33056 7.13 79783 2621 137(87) 57 
2 Serpin B3-like protein XP_001254421 
 
6.45 44318 1541 96(56) 41 
3 ß-2-microglobulin BAC56416 7.08 11151 284 19(14) 30 




12.2.1 Milk APP in mastitis caused by different pathogens  
12.2.1.1 Haptoglobin 
Since the extent of inflammatory signs and damage of udder tissue seen in any 
mastitis case depends on the pathogenicity of the mastitis causing bacteria 
(Pyörälä and Syväjärvi, 1987; Schukken et al., 2012), the degree of acute phase 
response in the mammary gland also depends on the causative bacterial 
pathogen (Kalmus et al., 2013). Wellnitz et al. (2013) also showed from their 
study that different bacterial endotoxins stimulated a variable panel of 
inflammatory cytokines.  
In the present study, E. coli, S. uberis and S. dysgalactiae mastitis milk had 
significantly higher values of Hp (P=0.00) than other bacterial mastitis. This is in 
agreement with the findings from the study of Kalmus et al. (2013) and findings 
from Pyörälä et al. (2011) as well as Wenz et al. (2010) and the experimental 
models of Suojala et al. (2008).  
Significantly lower milk Hp concentrations were observed for the CNS group of 
pathogens which are known to cause a mild form of mastitis (Pyörälä and 
Taponen, 2009; Simojoki et al., 2011). Similarly, S. aureus mastitis in this study, 
showed relatively low milk Hp on average. However 2 out of 9 samples assayed 
from this group had high levels of Hp (289 and 314 µg/ml) compared to a range 
of 16.8-96.9 µg/ml (mean= 39.94 µg/ml) for the remainder of the samples. It has 
been suggested that the clinical course of an S. aureus mastitis depends on the 
genotype isolated (Pyörälä et al., 2011) and consequently this could affect the 
level of APR detected in each case.  
In the study of Pyörälä et al. (2011), Hp was undetectable in a sizable proportion 
of mastitis milk samples, this may be due to a high detection limit of the assay 
used (7.8 mg/l), and this was anticipated as being a problem with the use of Hp 
in the diagnoses of mastitis. However in the present study, all samples from 
clinical mastitis cases assayed fell within the working range of the assay.   
Milk Hp concentration were found to be highest in samples from 
Arcanobacterium pyogenes mastitis compared with milk from other mastitis–
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causing bacteria, whereas SAA concentration in the same samples were very low 
(Pyörälä et al., 2011). A. pyogenes causes severe clinical mastitis (summer 
mastitis) characterized by purulent discharge and poor prognosis (NMC, 2001), 
therefore a high Hp value in A. pyogenes mastitic milk is more reflective of the 
inflammatory state of the gland than the low SAA values seen in milk isolated 
from this mastitis milk in the study of Pyörälä et al. (2011).  
In addition, Hp showed more association with inflammation than did MAA in the 
study by Kalmus et al. (2013), as it changed more to reflect infections by a more 
diverse range of pathogens than did MAA (for example as in A. pyogenes 
mastitis). This suggests that different pathogenic or host response mechanisms 
underlie the secretion of different APP in response to inflammatory stimuli, and 
Hp may be more useful for indication of inflammation to support the 
identification of different bacteria in milk (higher sensitivity for broader 
spectrum of mastitis-causing pathogens) than M-SAA3. 
In the study of Kim et al. (2011), different strains of S. aureus were used to 
induce mastitis and differences in serum cytokines (IL-8, IFN-γ, and TGF-β1) and 
milk cytokine (IFN-γ) were observed for the different strains. Strain typing of the 
various pathogens detected in the present study was not determined; however it 
would be interesting to determine the APP variation in milk from mastitis caused 
by different strains of the same pathogen.   
Significant variations seen in the clinical conditions of sampled udders, show 
that levels of APP can be computed to reference ranges for clinical mastitis, 
healthy and subclinical mastitis milk samples, which would further improve the 
value of APP for mastitis diagnosis.  
Significant associations were found between specific farms, clinical conditions of 
sampled udder/quarter and specific pathogens, with the environmental 
pathogens (E. coli and S. uberis) as well as S. dysgalactiae being more associated 
with CM and certain farms.  This would suggest the presence of environment-
related risk factors (e.g. poor milking hygiene, dirty pens etc.) in such farms 
that need to be addressed.  Variations in Hp across farms may also be indicative 
of presence of different strains of similar pathogens in different farms which 
may stimulate APR to different degrees (e.g. some S. aureus infected milk 
having very high Hp concentrations relative to the remaining majority with low 
Chapter 4, 197 
 
 
Hp). Although the sample-size per different-bacterial-mastitis milk in this study 
was small, conclusions can be drawn that different organisms are able to 
stimulate the APP response in the mammary gland during mastitis to varying 
degrees.  
12.2.1.2 M-SAA3 
Gram negative coliform, E. coli, and gram positive S. uberis and S. dysgalactiae 
mastitis milk samples had higher average M-SAA3 levels than any other bacteria-
mastitis samples assayed. E. coli and S. uberis have been described as 
environmental pathogens that have the ability to cause severe forms of mastitis; 
it was therefore not surprising that the APP response to mastitis by these 
pathogens were higher than for other pathogens. For contagious pathogens such 
as S. aureus and CNS, a milder M-SAA3 response was observed with low to 
moderate concentrations in samples. These findings also agree with the findings 
of Kalmus et al. (2013) and Pyorälä et al. (2011). Farm variations in M-SAA3 
levels from samples with the same pathogens may indicate differences in strains 
of the pathogens (on different farms) which could stimulate APP secretion to 
different extents. 
12.2.1.3 CRP 
C-reactive protein concentration was found to also vary significantly with the 
causative pathogen of mastitis indicating variable level of stimulation of its 
secretion by the virulence factors of different pathogens. The results from this 
study agrees with the findings of Kruger and Neumann, (1999), who observed 
variable levels of milk CRP in milk from mastitis caused by different pathogens, 
however, common mastitis causing pathogens such as E. coli, S. aureus and S. 
dysgalactiae were not examined in that study. The present results therefore 
represents the first report of the comparison of CRP levels in mastitis milk from 
E. coli, S. aureus, S. dysgalactiae and CNS organisms.  A similar pattern with the 
various pathogens of mastitis as observed for Hp and M-SAA3 was seen in the CRP 
analysis. This suggests that similar pathways of stimulation may be elicited for 
the secretion of the different APP secretion by the pathogens. This is further 
confirmed by the high positive correlation observed between the 3 APP. 
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All three APP examined in this first set of milk samples showed divergent levels 
that were able to distinguish clinical from subclinical mastitic samples. In 
addition, the values of the three APP were able to distinguish subclinical mastitis 
samples from healthy samples (SCC below 200,000 cells/ml) (P=0.00 for each 
APP). Hence it can be concluded that Hp, M-SAA3 or CRP can be applied to 
differentiate samples from healthy quarters from those with mastitis which are 
not showing any clinical signs of IMI (SM). 
Overall, from this study on milk of naturally occurring mastitis from commercial 
dairy farms, it can be seen that several factors can affect the APP variation, 
notably the causative pathogen of mastitis. However, this does not undermine 
the usefulness and sensitivity of APP in indicating on-going inflammatory 
processes in the sampled quarter/udder. Indeed the assay of APP can be used as 
a confirmatory test for active (on-going) mastitis infections, where a technique 
such as PCR has been employed and has detected several pathogens, in other to 
discriminate the presence of milk contaminants or mammary gland commensals 
(in samples with one or more detected pathogens but with low APP) from actual 
mastitis-causing pathogens (samples with high APP), and also indicate false 
negative PCR or microbiological culture results (where no pathogens have been 
detected by PCR or microbiology but the same samples have high APP).  
The level of the APP measured in milk samples could also give an indication as to 
the type or class of pathogen(s) responsible for the IMI; for example, as shown in 
this study and previous studies, environmental pathogens generally elicit a more 
pronounced APR with higher levels of APP than contagious pathogens. 
 
12.2.2 Proteomic analysis of a model of gram positive and 
gram negative bovine bacterial mastitis 
Sodium dodecyl sulphate- polyacrylamide gel electrophoresis following Rotofor 
preparative isoelectric focusing was able to resolve proteins into their isoelectric 
points with numerous bands being visible. Compared with using a gel based 
isoelectric focusing of proteins, it can be concluded that a liquid phase 
isoelectric focusing could offer an advantage of concentrating the low 
abundance proteins away from the high abundance proteins (caseins and major 
whey proteins) at their pi of 4-5, thus making these lower abundance proteins 
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easier to identify, for example apolipoprotein A precursor, serpin and α-2 
macroglobulin. 
Some of the proteins which were differentially expressed in the mastitis (E. coli) 
whey pool included NGAL, complement C3, α-2 macroglobulin and 
apolipoprotein A. Some of these proteins have already been reported in 
experimental E. coli mastitis milk proteomics (Boehmer et al., 2008; Boehmer, 
2011) and play a role in the innate immunity against mastitis. Neutrophil 
gelatinase associated lipocalin has been described in several human studies as a 
biomarker for kidney disease (Magnusson et al., 2012; Devarajan, 2008; Hinze et 
al., 2008; Wheeler et al., 2008; Suzuki et al., 2008).  
In bovine, NGAL was first isolated and purified from colostrum and an ELISA was 
developed for its measurement (van Veen et al., 2006). There have been no 
reports of its presence in normal milk or even its presence in mastitis milk from 
previous studies of milk proteomics in relation to bovine mastitis. Lipocalins are 
a group of proteins produced in several organs of the body notably the liver, 
kidney, uterus and the mammary gland. They are involved in transport of small 
hydrophobic molecules and play crucial role in inflammation; examples include 
alpha-1-microglobulin, alpha-1-acid glycoprotein, apolipoprotein D; beta-
lactoglobulin, complement component C8 and NGAL. Neutrophil gelatinase-
associated lipocalin are specifically localized in some granules of neutrophils. 
They have been suggested to function in defence against bacterial infections by 
limiting bacterial assess to iron as well as transport of iron, retinol and fatty 
acids (van Veen et al., 2006).  It can be speculated that the isolation of this 
protein from bovine colostrum by van Veen et al. (2006) may be related to its 
requirement for conferment of maternal protection to the new-born while its 
observation in E. coli mastitis milk in the present study may also relate to its 
functions in host defence against bacteria. A similar protein; Lipocalin-type 
prostaglandin D synthase has been reported in mastitis milk by Baeker et al. 
(2002).   
In the natural-infection S. uberis mastitis whey pool, fewer differential bands 
were seen from the healthy and E. coli pools thus only 4 bands were excised 
from the S. uberis gel.  Three out of the identified bands were also proteins not 
normally detected in healthy whey samples namely serotransferrin precursor and 
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serpin B3, which were also identified in mastitis milk (Boehmer, 2011). These 
two proteins are more commonly seen in the blood where serotransferrin acts in 
the binding and transportation of iron (Chung, 1984) and serpin B3, acts as a 
serine protease inhibitor (Villano et al., 2013). Therefore the presence of these 
proteins in the S. uberis infected whey samples is likely to be due to the seepage 
of blood constituents into milk from the damaged blood-milk barrier, which 
occurs during mastitis. In a recent study by Smolenski et al. (2014), a model of 
experimental S. uberis mastitis was subjected to a 2DE, MALDI-TOF MS and also a 
Gel LC-MS/MS proteomic analysis, and a large number of proteins (68) were 
identified in milk including a number of proteins related to host immune 
responses which were also identified for an E. coli challenge (Boehmer, 2011), 
and also serpins and serotransferrin as identified in the present study. In 
addition, four new proteins were identified including azurocidin 1, pancreatic 
adenocarcinoma up regulated factor (PAUF), common salivary protein BSP30b 
and serum amyloid P-component.  Due to the fact that limited number of bands 
from the S. uberis pool gel was selected for protein identification in this study, 
no new proteins other than those in similar bands on the E. coli gel were 
detected.  
12.3 Conclusions 
The conclusions that can be drawn from this chapter include the fact that 
different pathogens have the ability to stimulate the synthesis and secretion of 
milk APP to varying degrees, and these levels of milk APP are also related to the 
severity of mastitis caused by each pathogen. 
Furthermore, the use of a liquid phase first dimension fractionation of milk whey 
was observed to have an advantage of concentrating the high abundance milk 
proteins at their isoelectric points and therefore enabling the isolation of other 
les abundant milk proteins away from similar pi. Proteins of potential biomarker 
significance were observed in whey samples using this technique. 
. 
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13 Investigations of experimental Streptococcus 
uberis mastitis 
13.1 Overview 
In this chapter, the acute phase proteins profile and general proteomic studies 
of milk following an experimental mastitis challenge with a host adapted strain 
of Streptococcus uberis (S. uberis) is discussed. Proteomics technologies 
including 1DE, 2DE and difference gel electrophoresis (DiGE) as well as 
peptidomics analysis were employed in these studies. 
13.2 Introduction 
13.2.1 Streptococcus uberis mastitis 
Streptococcus uberis is one of the most prevalent causes of bovine mastitis in 
the UK (Zadoks, 2007) and other countries (Verbeke et al., 2014; Wang et al, 
2013; Katholm et al., 2012; Shima et al., 2004). Generally classified as an 
environmental pathogen, S. uberis has been determined to have a wide genetic 
diversity with the occurrence of several of strains having varying levels of 
virulence (Zadoks et al. 2013; Tassi et al., 2013; Wang et al., 2013). There have 
also been reports of strains capable of cow to cow transmission within herds 
(contagious pathogens) (Tassi et al., 2013). 
In addition to the high prevalence rates of S. uberis mastitis, mastitis caused by 
this pathogen has been known to have a high tendency to reoccur in the same 
cow (Abureema et al., 2014). This has been attributed mainly to reinfection of 
quarters with a new strain of the bacteria. In the study of Tassi et al. (2013), 
the immunological response of Holstein-Friesian cows to mastitis challenge with 
two separate strains of S. uberis; one, a host adapted one and the other non-
host adapted one, were studied. Clear differences were observed between the 
host responses to the strains. 
Numerous studies have attempted to elucidate the molecular properties of S. 
uberis in relation to bovine mastitis, several other studies have also been 
dedicated to understanding the host-pathogen responses to S. uberis, for 
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example Pedersen et al. (2003) studied the early inflammatory responses of the 
host to an experimental S. uberis infection showing the rise in milk APP. 
Bannerman et al. (2004) also explored the innate immune response to S. uberis 
mastitis in terms of the cytokines (IL-1 beta, IL-8, IL-10, IL-12, IFN-gamma and 
TNF-alpha) as well as CD14 and lipopolysaccharide binding protein (LBP).  
Since strain specific clinical, cellular and immunological responses have been 
shown to occur during S. uberis mastitis, it follows that earlier reports of the 
APP profile during S. uberis may not represent the general pattern for S. uberis 
mastitis due to particular strain characteristics. Adaptation to host has been 
shown to develop in strains that persist for long period in herds (Tassi et al., 
2013). It would therefore be useful to further explore the APR to a different 
strain than previously reported. 
In another study for by Smolenski et al. (2014), identification of suitable 
biomarkers for S. uberis mastitis in milk has been targeted. Utilizing a 2DE and 
gel electrophoresis liquid chromatography tandem mass spectrometry (GeLC-
MS/MS) proteomics approach, new proteins in milk were found, having specific 
biomarker potentials for S. uberis mastitis (strain O140J). It would also be useful 
to identify changes in the proteome with course of S. uberis mastitis challenge 
that may vary from strain to strain. 
13.2.2 Milk proteomics  
General aspects of proteomics have been discussed in Section 1.1.7.14. After, 
genomics and transcriptomics, proteomics was the next major technological 
approach to the study of biological systems. However proteomics is more 
complicated as proteins within a system are more dynamic and subject to post 
translational modifications.  
Milk is a major complex biological extracellular fluid that has been studied using 
proteomics. Caseins are the predominant milk proteins and the less abundant 
milk proteins are usually difficult to detect in proteomic analyses due to the 
masking effect of the high abundance milk proteins (Roncada et al., 2012). 
In the proteomic study of Hogarth et al. (2004), milk whey from mastitis cows 
was seen to have a composition nearing that of serum as a result of the 
compromised blood milk barrier, and subsequent leakage of serum proteins into 
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milk.  Smolenski et al., (2007) observed from their study the complexity of the 
milk proteome especially in relation to mastitis by using two different proteomic 
approaches 2DE-MALDI-TOF MS and LC-MS/MS. Several chaperonins which play a 
role in pathogen recognition were discovered, along with many other immune 
related proteins that had not been previously identified in milk, from that study. 
Boehmer et al. in a series of studies (2008, 2010 and 2011) used a coliform 
mastitis model to study several features of changes in the milk proteome during 
mastitis. Firstly, new proteins not previously reported were identified in both 
normal and mastitic whey and multiple isotypes of serum albumin in mastitis 
whey samples (Boehmer et al., 2008) and then a label free approach, 
specifically the number of peptides per identified protein, was employed for 
quantification of differentially expressed proteins (Boehmer et al., 2010). 
A similar study by Hinz et al. (2012) also identified several inflammatory markers 
and proteolytic products of casein hydrolysis in milk following an LPS challenge 
using a 2DE-MALDI-TOF MS approach. Using 2DE coupled to MALDI-TOF- MS/MS on 
normal and mastitic whey and serum samples, Alonso-Fauste et al. (2012), 
detected a panel of APP, antimicrobial proteins and other immune related 
proteins that were differentially expressed or regulated which have the 
potential to be used in diagnosing mammary infections.  
Bislev et al. (2012b) used a quantitative proteomic approach to differentially 
examine the expression of 20 selected host-response related proteins in healthy 
and S. uberis mastitis mammary glands, and was able to demonstrate multiple 
fold changes in some of the proteins. From the study of Smolenski et al. (2014), 
68 host defence proteins including 4 new proteins not previously seen in milk, 
and as many as 43 and 16 others identified in previous S. aureus (Reinhardt et 
al., 2013) and E. coli (Boehmer et al., 2008) studies respectively, were 
identified. Upon further validation of some of the proteins using western 
blotting technique, variable levels of response (of the proteins) were seen 
between milk from different quarters of individual cows and between quarters 
of separate cows. It was also observed that cathelicidins and S100 proteins 
showed relatively higher increases in response to mastitis than other proteins 
examined and were thus suggested as potential biomarkers of mastitis. Most 
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secretory products in milk were found to be decreased in response to mastitis 
(Smolenski et al., 2014).  
In all, these proteomic studies have contributed to the recognition of close to a 
hundred new proteins related to host immune response in milk in relation to 
mastitis. The application of milk proteomics continues to grow, particularly in 
the area of search for new mastitis biomarkers (Ceciliani et al., 2014) and in the 
characterization of milk from different species in order to detect possible inter 
species adulteration of milk or cheese (Hinz et al., 2012), as well as gaining a 
better understanding of systems biology of the mammary gland (Ferreira et al., 
2013). 
Typical limitation with proteomics studies involves the complexity of samples 
and the need for optimal preparation and the heterogeneity of protein 
molecules. In addition, a varying dynamic range of proteins is challenging with 
high abundance proteins that can mask the detection of low abundance proteins.  
13.2.3 Peptidomics 
13.2.3.1 General  
Peptidomics, which was first used in literature in the early 2000s, is another of 
the newly emerging and rapidly growing ‘omics’ technologies, has been 
described as an integrated analysis of the peptide content of an organism, body 
fluid, tissue or cell (Baggerman et al., 2004). It may be considered a subfield of 
proteomics. Peptidomics has proven successful and holds further promise in a 
number of areas including neuroendocrine research, biomarkers for diseases 
such as cancer (Eleftherios, 2006) and drug discovery. Peptides are chains of two 
or more amino acids linked by amide (peptide) bonds, having molecular weight 
of 20 kDa or less and which play crucial roles in many biological processes. 
Polypeptides comprise of longer continuous chains of peptides while proteins are 
distinguished from peptides by being composed of two or more polypeptides 
arranged in a functional way within the body. In a biological sample or system, 
peptides are either intact small peptide such as hormones, cytokines and growth 
factors, or peptides released during processing or proteolytic breakdown of 
protein molecules. The peptidome is therefore the collection of all peptide 
molecules within a given biologically system and these have the potential to 
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change with the physiological and pathological state of the system. Bioactive 
peptides include cytokines, hormones, neuropeptides involved in nervous system 
function such as neurotransmission. 
Peptidomic analyses of some biological samples such as serum and urine has led 
to the discovery of panel of biomarkers for several disease conditions such as 
cancers (Berry et al., 2013; Bauça et al., 2014), metabolic disorders such as 
diabetes (Budde et al., 2005), kidney disorders (Good et al., 2010) amongst 
others. 
13.2.3.2 Methodologies for peptidomics 
Peptides are too small to be visualized on 2D gels as they either run off the gels 
or do not pick up even the most sensitive stains (Clynen et al., 2008). 
Peptidomic analysis depends largely on mass spectrometry techniques such as 
MALDI-TOF or ESI combined with MS/MS, and usually requires identification of all 
available peptide molecule entities unlike in proteomics where not all digested 
peptide fragment needs be identified for protein recognition.  
Peptide analysis in many studies also entails their relative quantification, 
especially if such content would be assessed in relation to biomarkers discovery; 
and this is carried out by isotope affinity labelling such a iTRAQ or secondary 
antibodies (TMAB) which allow quantification using either the MS or MS/MS 
spectra (Clynen et al., 2008).  
Peptidomics also requires identification of all available peptide molecule 
entities, unlike proteomics where not all digested peptide fragments need to be 
identified for protein recognition. Concentration methods to enhance analysis of 
low abundance peptides in a complex biological matrix or solution include 
combinatorial and affinity peptidomics, where low abundance peptides are 
enriched and high abundance proteins or peptides in the samples are reduced 
(Soloviev and Finch, 2006). Tandem mass spectrometry (MS/MS) is often 
employed for identification of peptides or de novo sequencing can be applied to 
identify peptides based on their amino acid sequence from mass peaks as well as 
comparison of observed mass spectra to theoretical peaks obtainable from a 
genome (Costa et al., 2013). 
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A new identification tool for peptides after tandem mass spectrometry has been 
described by Costa et al. (2013), this analyses the 6 frame translation of a 
genome and is not limited to sets of de novo reconstruction sequences and 
search space and is specifically designed for peptidomics. Peptide analysis 
frequently also entails their relative quantification, especially if such data could 
be assessed in relation to biomarker discovery, and this can be carried out by 
isotope affinity labelling such  iTRAQ, secondary antibodies (TMAB) and so on, 
which are then quantified using either the MS or MS/MS spectra( Clynen et al., 
2008). 
Following mass detections, peptides can be identified by several methods 
including database searches, spectral matching algorithms, de novo sequencing 
or hybrid approaches; many of these tools can be accessed from the internet. 
Databases such as SwePep, PeptideDB, Peptidome and Erop-Moscow are a few 
examples of bioactive peptide databases, while more general peptide databases 
including X! Hunter and SpectraST, PeptideAtlas are available for peptides 
searches. A bovine specific peptide atlas has now been produced at ‘CowMilk2011-
https://db.systemsbiology.net/sbeams/cgi/PeptideAtlas/buildDeta-lsatlas_build_id=320’ 
(Bislev et al., 2012a). These databases can be searched based on peptide 
characteristics such as length, mass or amino acid sequence for data validation. 
Peptide identification is often validated by means of statistical tests including 
identification probabilities and false discovery rates (FDR) computation. 
Conventional separation technologies for peptides within complex mixtures 
comprise chromatographic techniques such as liquid chromatography, including 
reversed phase HPLC, and ion exchange chromatography (Schrader and Schulz-
Knappe, 2001).  
Combinatorial peptidomics is a modified method of peptidomic assay which has 
been described by Soloviev and Finch (2005). It is said to have the added 
advantage of being able to detect and quantify more proteins in an easier 
procedure which uses special functional groups contained within amino acids 
that make up the peptides, to affinity-purify the peptides in the complex protein 
mixtures (as obtainable in biological samples) (Soloviev and Finch, 2005). From 
the human diagnostics point of view, peptides within cerebrospinal fluid (CSF) 
and synovial fluid have been shown to have potential for use in diagnosis of 
Alzheimer’s disease, and osteoarthritis respectively (Clynen et al., 2008). A 
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specific panel of peptides in saliva have also been linked to diseases of the teeth 
in a recent study (Trindade et al., 2014). 
Peptidomics has also been used to elucidate proteolytic regulation of bioactive 
peptides as a key to understanding the physiology and identifying possible drug 
targets of these peptides (Kim YJ et al., 2013). 
13.2.3.3 Milk peptidomics  
Although several milk peptidomic studies have been carried out as reviewed in 
Section 1.1.7.15, most have been focussed on recognizing the patterns and 
contributors to proteolysis in milk during mastitis. Only a few studies have 
explored the possibility of the use of these proteolytic breakdown products in 
milk (peptides) as biomarkers that can differentiate mastitic from normal milk 
and even milk samples from mastitic quarters caused by one pathogen from 
those caused by a different pathogen. 
One such study was carried out by Mansor et al. (2013). In that study, a panel of 
peptides (n=154) that could differentiate milk of mastitic quarters from milk of 
normal (healthy) quarters,  and differentiate milk from S. aureus and E. coli 
mastitis (n=47) and serve as potential biomarker panel of peptides were 
recognized.  CE-MS as well as LC-MS/MS methods were used to characterize the 
peptides in milk from healthy and naturally occurring E. coli and S. aureus 
mastitis. Thus, the potentials of a peptidomic approach to biomarker discovery 
for bovine mastitis were highlighted in that study. Suggestions for further 
studies, which would additionally exploit the peptidomic tool, to resolve the 
critical need for biomarkers of bovine mastitis, were underscored.  
13.2.4 Objectives 
The objectives of this study were: 
 To explore the changing profile of milk APP following experimental 
challenge of six dairy cows’ quarters with a host-adapted strain of S. 
uberis. This was done in order to evaluate the usefulness of the APP; Hp, 
M-SAA3 and CRP for identifying new infections and in reflecting the stage 
of disease comprising the early, peak and resolution stages of the 
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infection, as well as to gain a better understanding of host response to S. 
uberis mastitis as it relates to secretion of these APP.  
 To utilize the different gel based proteomics approaches (1DE, 2DE and 
DiGE) as a pre-fractionation method prior to identification of qualitative 
and quantitative protein changes in the proteome of milk during the 
course of the experimental mastitis challenge. 
 To elucidate the changing peptide composition of milk during key time 
points of the S. uberis mastitis challenge using a capillary electrophoresis 
mass spectrometry-based peptidomics analysis of milk samples.  
These experiments, it is hoped, will offer insight into the course of proteolytic 
changes in milk and facilitate a better understanding in associating the changes 
caused by a specific pathogen, with time duration and host responses to 
mastitis. In addition it was anticipated that a valuable biomarker panel of 
peptides will be recognized in order to distinguish mastitic milk from healthy 
samples. 
13.3 Materials and methods 
13.3.1 Reagents 
Reagents for polyacrylamide gel electrophoreses (PAGE) were obtained from Bio-
Rad laboratories Ltd (Hemel Hempstead, UK). Buffers and stock solutions were 
prepared according to manufacturer’s instructions. A 4-15 % Criterion™ precast 
18-well comb and 11 cm IPG+1 well comb gels (Bio-Rad Lab, Inc. USA) were used 
for the 1DE and 2DE respectively. Milli Q water was used throughout. 
13.3.2 Experimental challenge  
For this investigation samples were provided by Dr Tom McNeilly and Professor 
Ruth Zadoks (Moredun Research Institute, Penicuik, Scotland) from a previous 
intramammary challenge study of six quarters from six cows using a putative 
host adapted strain of S. uberis, strain FSL Z1–048 carried out as described by 
Tassi et al. (2013). The intramammary challenge was carried out at the 
experimental unit of the Moredun Research Institute, Penicuik, Scotland. 
Samples were obtained at 19 time points from each challenge-positive quarter 
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(n=114) comprising 0, 6, 12, 18, 24, 30, 36, 42, 48, 57, 72, 81, 96, 120, 144, 168, 
192, 240 and 312 h post challenge and 7 time points (n=42) including 0, 12, 36, 
57, 96, 192 and 312 h post challenge, for the challenge control quarters  which 
were infused with 2 ml of sterile phosphate buffered saline (PBS). Skimmed milk 
was prepared by centrifuging 50 ml of milk at 2,800 x g at 4°C for 20 min. The 
fat layer was discarded and the supernatant was transferred to a new 50 ml 
Falcon tube. Centrifugation was repeated and the supernatant was stored at 
−20°C until analysed. Somatic cell counts (SCC), milk bacterial counts, clinical 
scoring and the cytokine profile for these samples were determined at the 
Moredun Research Institute and reported in Tassi et al. (2013). 
13.3.3 Acute phase proteins during experimental S. uberis 
mastitis  
13.3.3.1 Haptoglobin  
ELISA 
All samples collected from positive challenge (19 time points from each of the 6 
infected quarters, n=114) and challenge control quarters (7 time points from 
each of 6 quarters, n=42) during the course of the S. uberis mastitis challenge 
were analysed for Hp concentration using the in house Hp ELISA as earlier 
described (2.3.2.1.2), with modifications carried out in the dilutions used for 
samples with high Hp (maximum dilution of 1:1600 was used). 
Western immunoblotting analysis of milk Hp  
Samples from challenge positive quarters ranging from 0 to 192 h post challenge 
were subjected to western immunoblotting for Hp as described in Section 
3.3.1.3.2. 
13.3.3.2 M-SAA3 
The M-SAA3 was also measured in (skimmed) milk samples of challenge positive 
quarters (19 time points) (n=114). Analysis was carried out using the commercial 
ELISA kit as described in Section 2.3.3.3; with modifications carried out in the 
dilutions used for samples with high M-SAA3 (highest dilution used was 1:5000). 




Challenge positive samples from the infected quarters (n=114) were analysed for 
CRP concentration as described in details in Section 2.3.4, with modifications 
carried out in the dilutions used for samples with high CRP (maximum dilution of 
1:2000 used). 
13.3.4 Proteomics  
13.3.4.1 Total protein concentration 
The total protein concentration of whey samples used for the proteomics 
analyses were determined by Bradford method (Appendix Chapter 4) with bovine 
serum albumin (BSA) used as the standard.  
The Bicinchoninic acid assay (BCA) Uptima from interchim (Montluçon, France) 
was used to determine protein concentration in samples for peptidomic analysis 
prior to CE-MS investigation. About 25 μl of each standard and milk extracted 
samples were pipetted into microplate wells in duplicates. The BCA assay 
reagent was then added (200 μl) and mixed. The sample mixtures were 
incubated at 37°C for 30 min or 2 h at RT. The microplate was cooled to RT and 
absorbance read at wavelength of 562 nm. The protein concentrations of the 
samples were interpolated from a standard calibration curve of protein 
concentration using bovine serum albumin (BSA) (Sigma Aldrich, Dorset, UK). 
 
13.3.4.2 1DE SDS-PAGE 
The samples from 19 time points of one representative challenge quarter and 
the 7 time points of another representative control quarter were subjected to 
1DE SDS-PAGE. Protocol for this procedure has been described (3.3.1.5.1). 
13.3.4.3 2DE SDS-PAGE  
Whey samples from six time points selected across the duration of the 
intramammary challenge (including 0, 36, 42, 57, 81, 168 and 312 h post 
infection) were each subjected to a 2DE SDS-PAGE after pooling each time point 
together from all infected quarters. The 2DE SDS-PAGE procedure has been 
described in Section 3.3.1.5.2.   





Pooled samples of three selected time points; 0, 81 and 312 h post challenge 
following the S. uberis mastitis challenge were analysed using DiGE. These 
corresponded to samples from pre-infection, peak and resolution phase of the 
mastitis challenge, respectively. 
Sample Preparation 
Preliminary sample preparation was carried out by pooling 1 mg/ml of protein 
from each of the six samples from time points 0 h, 81 h and 312 h, to give a 
volume with a total protein content of 6 mg of each of the 3 time points.  
Acetone precipitation was then carried out on each of the pools by adding 4 
times the sample volume of ice cold 100 % acetone to the samples; this was 
mixed thoroughly and kept at -20°C overnight. Precipitate was separated from 
supernatant by centrifugation at 1400 xg for 30 min at 4°C. The pellets formed 
were then washed by mixing thoroughly with ice cold 80 % (v/v) acetone and 
then centrifuged at 1400 xg for 30 min once again. This step was repeated two 
more times. Finally all supernatant was separated from the pellet and the pellet 
allowed to air dry by exposing to air. Subsequently the pellet was re-suspended 
in 250 µl DiGE lysis buffer (Appendix Chapter 5). The total protein concentration 
of the re-suspended pellet was then determined by the Bradford method and 
adjusted to 5 mg/ml by addition of more DiGE lysis buffer.  
CyDye Labelling  
One μl of CyDye was added to 10 μl of sample and incubated in the dark at 4°C 
for 30 min. To stop the reaction, 1 μl of 10 mM lysine was added and further 
incubated in the dark for 10 min. The different dyes to sample mixtures that 
went into each DiGE gel are shown in Figure 5-1. 
 
 




Figure 13-1: Protocol of samples and corresponding dye labels, and pools used for each gel 
in the DiGE experiment. 
Red dye-cy3, blue dye-cy5, yellow dye-cy2 (pooled standard). 50µl of pooled samples were used 
for the preparatory gel. 
 
Isoelectric focusing  
The DiGE samples (labelled Cy3, Cy5 and pool standard labelled Cy2; ~12 μl of 
each) were mixed together and 424 μl of rehydration buffer (RHB) was added 
into the sample mixture and mixed thoroughly. 50 µl of the unlabelled pooled 
standard was added to 410 µl of the RHB. 450 μl of each DiGE pool and 
preparative gel pool was then pipetted along the length of each strip holder, 
avoiding any formation of bubbles. The IPG strip (24 cm pH 4-7, GE Healthcare, 
UK) was put onto the strip holder and covered and this was left for ~ 30 min for 
the gels on the strip to rehydrate passively. 1 ml of mineral oil was then applied 
over the top of the strip, just enough to cover it. The lid was placed back on and 
the strip holder was placed on the IPGphor system (GE Healthcare, UK). 
Isoelectric focussing was carried out on the IPGphor using the protocol in Table 
5-1. All aspects of the DiGE experiment were carried out with the assistance of 
Mr Alan Scott (Institute of Infection Immunity and Inflammation, University of 
Glasgow) and under the supervision of Dr. Richard Burchmore (Glasgow 
Polyomics, University of Glasgow). 




Table 13-1: Protocol for running isoelectric focusing of DiGE IPG strips 
 
Step Volts Time (h-hours) 
1 30 V       step and  hold    10 h 
2 300 V     step and hold      2 h 
3 600 V           gradient       2 h 
4 1000 V         gradient       2 h 
5 8000 V         gradient       1 h 
6 8000 V     step and hold    9 h 
7 1000 V     step and hold 1 h 
 
 
After isoelectric focussing, the strips were taken out of the holders, washed 
briefly in milli Q water to remove excess mineral oil and put into the plastic 
tubes. 10 ml of SDS EB I (see Appendix Chapter 5) were placed onto the strips 
and the plastic tubes were put on a large flat rocker desk for 15 min. The buffer 
was poured off and SDS EB II (see Appendix Chapter 5) was added and was 
rocked gently for another 15 min. The buffer was poured off and the strip(s) 
were inserted horizontally between then DiGE gel (precast Ettan DALT® gels; 26 
x 20 cm) cassettes and allowed to make contact with the gel. 1 ml of 0.5 % (w/v) 
agarose was added on top of the DiGE gel (before putting the gel in the 
electrophoresis running tank). Running buffer was added into the tank assembly 
and electrophoresis was carried overnight at 1W/gel.  
DiGE Gel Scanning  
DiGE gels were scanned on a 3 Laser Typhoon 9400 scanner (GE Healthcare life 
sciences, Buckinghamshire, UK). A preliminary scan was performed on each DiGE 
gel at a low resolution (1000 microns). Spot saturation was checked on each of 
the resulting images, and the photomultiplier tube voltage adjusted so that the 
most intense protein spots were not saturated (according to DiGE instruction 
manual, GE Healthcare). A high resolution (100 microns) scan of each DiGE gel 
was then done. Once satisfactory images were obtained, DiGE gels were stored 
in a wet tray and kept at 4°C for a maximum of one week. The preparative gel 
was fixed in 7 % (v/v) acetic acid + 10 % (v/v) methanol for 1-2 h and then rinsed 
in water and stained with Sypro orange (1/10, 000 dilution in 7 % (v/v) acetic 
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acid for 2 h. The prep gel was scanned using the green filter of the Typhoon 
scanner at high resolution (100 microns). The prep gel was wrapped and stored 
at 4°C until spot picking.  
Image manipulation  
DiGE images were cropped using ImageQuant software (GE Healthcare life 
Sciences, Buckinghamshire, UK) on the Typhoon scanner. The cropping removed 
all edges of the gel image (gel spacers, IPG strip and dye front). ImageJ software 
(National Institute of Health, Maryland, USA) was also used to obtain jpeg format 
images of each DiGE gel. Images were then loaded into DeCyder™ (GE Healthcare 
life sciences, Buckinghamshire, UK) 2-D differential analysis software for 
processing.  
DeCyder Biological Variation Analysis 
A DeCyder 2D (version 7.0) differential In-gel analysis (DIA) and biological 
variation analysis software (BVA) (GE Healthcare life sciences, Buckinghamshire, 
UK) were used to analyse the gels and create gel to gel matching of spots 
(qualitatively and quantitatively) within the three gels produced. The software 
produced statistical comparisons (one way ANOVA), after normalization of the 
ratio of spot volume between the spots of different dyes on a single gel using the 
internal standard (pool of all samples labelled with Cy2), between the 3 
different gels across the 3 time points (designated: before, peak and after for 0, 
81 ad 312 h post-infection times, respectively). It was therefore possible to 
identify spots which were quantitatively and qualitatively different across gels.  
A few of the significantly varying spots once identified, were then excised from 
the preparative gel (gel 4) using the Ettan spot picker (GE Healthcare life 
sciences, Buckinghamshire, UK) and processed by trypsin digestion for protein 
identification using LC-MS/MS as described in Sections 4.2.4.4.3 and 4.2.4.4.4 
respectively. 
13.3.5 Peptidomics 
13.3.5.1 Sample extraction for CE-MS 
Milk samples used for peptidomic analysis were from six time points in the 
course of the S. uberis mastitis challenge including 0 h (pre-challenge), 36, 42, 
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57, 81 and 312 h post challenge (n = 6 at each time point). Selection of these 
time points was based on the results from APP analysis and the published results 
for cytokine and SCC to represent stages of mastitis; pre-infection (0 h), initial 
infection (36/42 h), peak infection (57/81 h) and resolution (312 h). 
Skimmed milk samples were defrosted and 0.1 % phenylmethylsulfonyl fluoride 
(PMSF) was added to each milk sample to prevent further protease activity. An 
aliquot of 150 µl of sample was added to 150 µl of urea buffer (2 M urea, 100 mM 
sodium chloride (NaCl), 10 mM ammonium hydroxide (NH4OH) and 0.02 % (w/v) 
SDS) in a Centrisart ultrafiltration tube (Sartorius, Gottingen, Germany), and 
centrifuged for 60 min at 3,400 rpm, at 4°C in order to remove higher molecular 
weight (HMW) proteins with peptides being in the ultrafiltrate for peptidomic 
analysis. 
During this time, a NAP-5 column (GE Healthcare, Sweden) was placed onto a 50 
ml collecting tube, and equilibrated by rinsing with 15 ml of ammonium (NH4) 
buffer, in preparation for desalting, enrichment of the polypeptides and removal 
of urea (Mansor et al., 2013). After centrifugation, 200 µl of the Centrisart 
filtrate was passed through the column. 300 µl of NH4 buffer was further passed 
through the column. The columns were then placed in 2 ml Eppendorf tubes and 
eluted using 700 µl of the NH4 buffer. The eluate was frozen and later freeze-
dried.  
The protein concentrations of milk polypeptides samples extracted were 
determined using the BCA method as described in Section 5.3.4.1. A final 
concentration of 2 μg/μl was then achieved by re-suspending the freeze-dried 
samples in an appropriate volume of Milli Q water prior to CE-MS.  
13.3.5.2  CE-MS analysis 
Buffers and Solutions 
Buffers for CE-MS analysis are prepared freshly every week, these includes 1M 
sodium hydroxide (NaOH), NH4OH (prepared by adding 3.76 ml of NH4 solution 
(25%) to deionised water and the volume adjusted to 50 ml with deionised 
water), running buffer (prepared by adding 10 ml of ACN and 472 μl of formic 
acid to a final volume of 50 ml with deionised water),and the sheath flow liquid 
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(prepared by mixing 15 ml of 2-propanol and 200 μl of formic acid with the 
volume adjusted to 50 ml with deionised water).  
The standard protein/peptide solution (0.5 pmol/μl) for the calibration of CE-MS 
analysis contains lysozyme (14,303 Da, L4919, Sigma-Aldrich, Dorset, UK), 
ribonuclease (13,681 Da, R5500, Sigma-Aldrich, Dorset, UK), aprotinin (6,513 Da, 
A1153, Sigma-Aldrich, Dorset, UK) and 4 synthetic peptides including; 
ELMTGELPYSHINNRDQIIFMVGR (2,832 Da), TGSLPYSHIGSRDQIIFMVGR (2,333 Da), 
GIVLYELMTGELPYSHIN (2,048 Da) and REVQSKIGYGRQIIS (1,733 Da) (Method 
described in Mansor et al., 2013).  
Sample Analysis 
A Beckman Coulter P/ACE MDQ CE system (Fullerton, USA) was used for the CE-
MS analysis. A 90 cm 360 μm OD, 50 μm ID uncoated capillary with a tapered tip 
(New Objective, Woburn, USA) was used on-line and coupled to a microdot MS 
(Bruker Daltonics, Bremen, Germany). This (capillary) was first conditioned with 
NaOH (pressure 50 psi) for 15 min and then washed with NH4OH solution (50 psi) 
for 15 min and 20 min with running buffer (50 psi). The capillary was not 
connected to the MS until the conditioning procedure has been completed. The 
Beckman CE was set to run in reverse mode when connected to the MS system 
using the external detector adapter. Running buffer (pressure applied 50 psi) 
was used to rinse the capillary prior to each injection.  
Re-suspended samples were centrifuged at 14,000 xg for 10 min at 4ºC shortly 
before analysis. The samples were then injected at a pressure of 2.0 psi for 99 s 
resulting in a loading volume of 290 nl of sample. Separation was done with +25 
kV at the injection site for 30 min with a capillary set temperature of 35°C. 
Additional pressure to initial +25 kV was applied as follows; 0.1 psi for 1 min, 0.2 
psi for 1 min, 0.3 psi for 1 min, 0.4 psi for 1 min and 0.5 psi for 30 min. The 
sheath liquid was applied coaxially at a running speed of 0.02 ml/h. The 
capillary was rinsed with deionised water (50 psi) for 1 min after each run 
followed by a washing step with NH4OH solution (50 psi) for 3 min and lastly by a 
flushing step with deionised water (50 psi for 3 min). Electro-spray ionisation 
sprayer (Agilent Technologies, Palo Alto, CA, USA) was grounded to achieve 
electric potential of 0, and the electro-spray interface potential was set 
between -4 and -4.5 KV.   
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The mass calibration of the MS was performed on a weekly basis using the 
standard protein/peptide solution (0.5 pmol/μl) for CE-MS analysis. The 
acquisition of data and MS were automatically controlled by the CE via contact 
close-relays and MS spectra accumulated every 3 s, over a mass-to-charge range 
of 350 to 3000 for about 60 min depending on the analysis requirements. The CE-
MS analysis was performed with the assistance of Dr Angelique Stalmach and 
under supervision of Dr. William Mullen of the Institute of Cardiovascular and 
Medical Sciences, University of Glasgow, UK. 
13.3.5.3 CE-MS data analysis 
The Mosaiques Visu software (www.proteomiques.com) (Mosaiques Diagnostics, 
Hannover, Germany), was used to analyse the peptide mass spectra ion peaks, 
involving deisotoping and deconvolution along with spot picking. 
The Mosaiques Visu software examines all mass spectra from a CE–MS 
investigation for signals above the threshold (SNR^4) and uses a probabilistic 
clustering algorithm and both isotopic distribution and conjugated masses for 
charge-state determination of the entities (Kolch et al., 2005). This resulted into 
a list in which all signals that are interpretable were defined by mass/charge, 
charge, migration time and single intensity (ion counts). Only signals observed in 
a minimum of 3 consecutive spectra with a signal-to-noise ratio of at least 4 
were considered. Signals with a calculated charge of +1 were automatically 
excluded to minimize interference with matrix compounds or drugs. 
Capillary electrophoresis migration time and ion signal intensities were 
normalized. Reference signals of over 380 milk entities or milk “housekeeping 
polypeptides” were used for CE-time calibration by local regression. The same 
peptides were used for ion signal intensity normalization by a applying a global 
linear regression. The resulting peak list contained the molecular mass (Da) and 
normalized CE migration time (min) for each feature. Normalized signal intensity 
can be used as a measure of relative abundance. Data sets were accepted only if 
the following quality control criteria were met: A minimum of 950 
chromatographic features (mean number of features minus one standard 
deviation) must be detected with a minimal MS resolution of 8000 (required 
resolution to resolve ion signals with z = 6) in a minimal migration time interval 
(the time window, in which separated signals can be detected) of 10 min. After 
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calibration, the mean deviation of migration time (compared to reference 
standards) must be below 0.35 min. Control and disease-specific polypeptide 
patterns were generated using support vector machine (SVM)-based MosaCluster 
software.  
13.3.5.4  LC-MS/MS peptide sequencing 
In order to determine the sequences of significant biomarker polypeptides, an 
LC-MS/MS peptide sequencing was carried out using a Dionex Ultimate 3000 RSLS 
nanoflow system (Dionex, Camberley UK). 5 μl of each sample were loaded onto a 
Dionex 100 μm x 2 cm 5 μm C18 nano trap column at a flow rate of 5 μl/min by an 
Ultimate 3000 RS auto sampler (Dionex, Camberley UK). This was then separated on 
a C18 reverse phase column (75 μm ID × 150 mm, 100 Å, Acclaim PepMap RSLC C18, 
Dionex). Eluting of peptides was carried out with gradient of 1-5-40 % B (80 % ACN, 
0.2 % formic acid) in 0-5-60 min at a flow rate of 300 nl/min. The eluent from the 
column was directed to a Proxeon nano spray ESI source (Thermo Fisher, Hemel, UK) 
operating in positive ion mode then into an Orbitrap Velos Fourier transform mass 
spectrometer (FTMS). The ionisation voltage was 2.5 kV and the capillary 
temperature was 200ºC. The mass spectrometer was operated in MS/MS mode 
scanning from 380 to 2000 atomic mass unit (amu). The top 20 multiply charged ions 
were selected from each full scan for MS/MS analysis, the fragmentation method 
was CID at 35 % collision energy. The ions selected for MS2 using data dependent 
method with a repeat count of 1 and repeat and exclusion time of 15 s. Precursor 
ions with a charge state of 1 were rejected. The resolution of ions in MS1 was 60,000 
and 7,500 for HCD MS2. LC-MS/MS analysis was performed by Dr. William Mullen of 
the Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK. 
13.3.5.5 LC-MS/MS data analysis 
Raw spectral data from LC-MS/MS analysis of the samples were uploaded to 
Thermo Proteome Discoverer 1.3. Peak picking was performed under default 
settings for Fourier transform mass analysers (FTMS) analysis i.e. only >+2 
peptides were considered with signal to noise ratio higher than 1.5 and 
belonging to precursor peptides between 380 – 6000 Da. Peptide and protein 
identification was performed with SEQUEST algorithm. An in house compiled 
database containing proteins from the latest version UniProt SwissProt database 
was compiled to include only Bos taurus and S. uberis entries. No enzyme 
cleavage was selected and oxidation of methionine and proline were chosen as 
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variable modifications. Precursor mass tolerance was set at 5 parts per million 
(ppm) and 0.1 Da for MS/MS fragment ions. Resulting peptides and protein hits 
were further screened by excluding peptides with an error tolerance higher than 
10 ppm and by accepting only those hits listed as high confidence by Proteome 
Discoverer software.  Target FDR was 0.01 (strict) and 0.05 (relaxed). 
13.3.6 Statistical analyses 
Acute phase proteins 
Test for normality of data were run on each APP set of data per time point. The 
concentration of each APP across time points were compared using related 
samples Friedman’s two-way analysis by ranks test (non-parametric ANOVA). For 
pair wise (time point) comparison of APP values, a related sample Wilcoxon’s 
signed rank test was utilized. P-value was considered significant at < 0.05.  
DiGE 
A one way ANOVA test was carried out by the BVA module of the DeCyder 
software following normalization and ratio matching of spots, to determine the 
spots that changed across the 3 time points in each of the gels. A student T-test 
was also used to determine differences in spot intensities at pre-infection (0 h) 
and peak infection time (81 h). 
 CE-MS  
Only polypeptides that were found in more than 70 % of the samples in at least 
one of the groups were considered for biomarker definition. The pre-defined 
sets of polypeptides were further validated by randomly excluding 30 % of 
available samples. This was repeated (bootstrapping procedure) up to 10 times. 
For multiple testing corrections, P-values were corrected using the stringent 
maxT test or using false discovery rate adjustments of Benjamini-Hochberg (BH).  
A model was generated for the classification of the samples depending on their 
CE-MS profile. In the model, 6 samples from time 0 (control) and 6 samples from 
time 81 (peak infection) were used as training cohort (n=12).  For the validation 
of the model, samples from 36 h, 42 h, 57 h and 312 h (n=23) were used to 
discriminate the time points of progression and resolution of infection. A non-
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parametric Wilcoxon test was carried out to analyse the significant peptides 
(significant adjusted BH p-value) in the training set. From the significant 
peptides, those with AUC of 1 were selected and a model based in these was 
used to score the validation set and box-plots to find visually possible changes 
per time were plotted. 
13.4 Results 




The profile of Hp over time during an S. uberis mastitis challenge is shown in 
Figure 5-2. The earliest significant rise in Hp levels was seen between 36 h post 
challenge (PC) (P=0.028). Peak values of Hp was achieved at 42 h in one cow, 57 
h in another, 72 h in two others, 81 h and 96 h in last two respectively. In all the 
average time of peaking in Hp was at 57 h.  
At the final time point sampled (312 h) which corresponded to the time of 
resolution of the infection, two cow-quarters still had high Hp concentration 
relative to basal values; one these two quarters was shown to still be positive for 
S. uberis colony forming units (CFU) at this time point whereas the others were 
negative. The remaining four cow-quarters’ Hp had lowered significantly, 
however there was still a significant difference in the total median values of Hp 
at 312 h and at 0 h (possibly due to the two quarters still having high Hp at 312 
h). Time 0 h milk Hp ranged from <0.4 - 3.21 µg/ml in the infected quarters 
whereas in milk from controls range was <0.4 - 2.25 µg/ml. In control quarters 
milk the overall range of Hp in milk from 0 h to 312 h was <0.4 - 6.38 µg/ml.  
 
 




Figure 13-2: Concentrations of Haptoglobin (mean ± SEM) during the course of an 
experimental S. uberis infection. 
Host adapted strain of Streptococcus uberis was used; challenge positive samples (blue line) and 
challenge controls (red line) over several time points from 0 to 312 h. 
 
Hp western immunoblotting 
Haptoglobin bands became visible on the western blotted NCM first at the 36 h 
post challenge (β-chain) and the intensity of the bands increased to a peak at 57 
and 72 h post challenge (Figure 5-3). Bands were once again absent by 120 h 
post challenge. This is in agreement with the results of ELISA on the milk 
samples that showed an average peak at 57 h post challenge.  




Figure 13-3: Western blot of pooled S. uberis challenge whey samples. 
Lanes represent time 0 to 192 h post infusion samples, showing bands of the β and α chain of Hp 




The profile of M-SAA3 over time during an S. uberis mastitis challenge is shown 
in Figure 5-4. The earliest significant rise in M-SAA3 levels was seen between 36-
48h PC in 2 quarters, however in all quarters, 57 h PC was the time when a 
significant change was observed in M-SAA3 concentrations from the 0 h. Peak 
values of M-SAA3 were achieved at 96 h in 5 out of six cows and 81 h in the last 
cow. At the final time point sampled (312 h) which corresponded to the time of 
resolution, two cow-quarters still had high M-SAA3 concentrations relative to 
basal values; these two quarters were the ones which also showed high Hp 
concentrations at 312 h one of which had not cleared the bacteria from milk 
samples by 312 h.   
.




Figure 13-4: Concentrations of M-SAA3 (mean ± SEM) during the course of an experimental infection with host-adapted strain of S. uberis. 
 




The changing profile of milk CRP through the course of the mastitis challenge is 
shown as a plot of mean ± SEM in Figure 5-5. CRP was first noticed to rise from 
baseline levels at 30 h PC two peaks of mean CRP concentration were observed 
during the course of the infection, one at 42 h and the other at 120 h PC. 
Concentrations of CRP at 240 h were still significantly higher than at 0 h, but at 
312 h, the CRP levels had dropped back to similar values as at 0 h. A related 
samples Friedman’s two way analysis of variance by ranks showed that 
distribution of CRP across the various time points were significantly different 
(P=000).  
 






Figure 13-5: Concentrations of CRP (mean ± SEM) during the course of an experimental infection with host-adapted strain of S. uberis.




13.4.2.1 1DE-SDS PAGE 
The 1DE electrophoretogram image of challenge positive samples is shown in 
Figure 5-6 while that from control quarters infused with PBS at seven of the time 
points is shown in Figure 5-7. Bands on the gels were identified by inference 
from results of MALDI-MS identification of 1DE bands of clinical mastitis milk 




Figure 13-6: 1DE reducing gel image of S. uberis challenge positive skimmed samples at 19 
time points during course of challenge. 
Ig (immunoglobulin), Bovine Lf (bovine lactoferrin), αS2-CN (alpha S2 casein), β-CN (beta casein), 
κ-CN (kappa casein), β-LG (beta lactoglobulin), α-LA (alpha lactalbumin 
 
 




Figure 13-7: 1DE reducing gel image of pooled samples from S. uberis control-challenge 
quarters  
Including the 7 time points sampled during the course of the control-challenge (PBS). αS2-CN 




13.4.2.2 2DE-SDS PAGE 
Pooled samples from six time points of the S. uberis challenge positive quarters, 
were resolved with a 2DE SDS-PAGE (pH 4-7), and the gel images of the time 
points 0 h, 36 h, 57 h, 81 h, 168 h and 312 h are shown in Figures 5-8, 5-9, 5-10, 
5-11, 5-12 and 5-13 respectively. Spots were identified by inference to spots 
analysed from 2DE of normal and mastitis milk whey as described in Boehmer et 
al. (2008), Smolenski et al.(2007) and Hogarth et al. (2004).  
 




Figure 13-8: 2DE reducing gel image of pooled skimmed milk samples positive for S. uberis 
challenge at 0 h 




Figure 13-9: 2DE reducing gel image of pooled skimmed milk samples positive for S. uberis 
challenge at 36 h 
Isoelectric range pH 4-7, Ig (immunoglobulin), CN (casein), β-LG (beta lactoglobulin), α-LA (alpha 
lactalbumin). 
 






Figure 13-10: 2DE reducing gel image of pooled skimmed milk samples positive for S. 
uberis challenge at 57 h 
Isoelectric range-pH 4-7 
 
 
Figure 13-11: 2DE reducing gel of pooled skimmed milk samples positive for S. uberis 
challenge at 81 h. 
Isoelectric range- pH 4-7 





Figure 13-12: 2DE reducing gel image of pooled skimmed milk samples positive for S. 
uberis challenge at 168 h 




Figure 13-13: 2DE reducing gel image of pooled skimmed milk samples positive for S. 
uberis challenge at 312 h 
Isoelectric range- pH 4-7. Ig (immunoglobulin), CN (casein), β-LG (beta lactoglobulin), α-LA (alpha 
lactalbumin) 






Different combinations of three time-points’ samples from the S. uberis mastitis 
challenge (time 0, 81 and 312 h post infection) were run on 3 DiGE gels. The 
ImageQuant software images of the 3 different DiGE gels are shown in Figures 5-
14 to 5-16. Numerous new protein spots were seen at 81 h which were not 
present at 0 h.  Also, some major differences in the intensity of spots present at 
0 h and 312 h were observed at 81 h. There were no appreciable differences 
between spots at 0 h and at 312 h (Figure 5-15). The Preparative (prep) gel 
image is shown in Figure 5-17. This gel comprised of a pool of the 3 time points 
considered for the DiGE experiment, from which spots of interest were excised 
(spots indicated as numbers on the image). 
 




Figure 13-14: Difference gel electrophoresis (DiGE gel 1) on bovine whey from experimental S. uberis mastitis showing juxtaposed ImageQuant image (1), 
DeCyder differential scans of Cy3 (2) and Cy5 (3) spots.  








Figure 13-15: Difference gel electrophoresis (DiGE gel 2) on bovine whey from experimental S uberis mastitis, showing juxtaposed ImageQuant image (1), 
DeCyder differential scans of Cy3 (2) and Cy5 (3) spots.  
Pool of time point 0 labelled with Cy5/blue (appearing green) fluorescent dye and pool of time point 312 labelled with Cy3/red (appearing purple) on ImageQuant. 
 




Figure 13-16: Difference gel electrophoresis (DiGE gel 3) on bovine whey from experimental S uberis mastitis, showing juxtaposed ImageQuant image (1), 
DeCyder differential scans of Cy3 (2) and Cy5 (3) spots.  
Pool of time point 81 labelled with Cy3/red (appearing bluish/purple) fluorescent dye and pool of time point 312 labelled with Cy5/blue (appearing green) on 
ImageQuant. 




Figure 13-17: DiGE preparative gel comprising of the pool of 3 time points (0, 81 and 312 h).  
Spots of interest (selected based on changing profile during the course of the 3 time points) (n=29) 
excised for LC-MS/MS analysis are shown numbered and identified as listed in Table 5-2. 
 
A total of 2154 spots were identified in the first DiGE gel (0 h + 81 h) by the 
DeCyder software and 1077 of these were matched on the prep gel.  While 2577 
and 2358 spots were seen in second and third DiGE gels respectively (0 h + 312 h 
and 81 h+312 h).  A total of 2577 spots were matched in the preparatory gel in 
the second DiGE gel while 1077 matched to the prep gel on the third DiGE gel. 
Therefore because the second DiGE gel had the higher number of matches in the 
preparatory gel, it was selected for matched-spots picking to detect proteins of 
interest (spots varying significantly across the 3 time points and in the three 
gels). After the BVA test, 728 showed differences across the pre-infection, peak-
infection and resolution phase of the challenge study. A total of 521 of these 
spots had a statistically significant variation (ANOVA, P<0.05) with time, while 
the variation in 207 spots were not statistically significant (P=0.05-0.97). Out of 
the significantly varying spots, 29 were selected based on level of change, for 
protein identification. Table 5-2 shows the 29 spots picked from the prep gel for 
LC-MS/MS analysis and their protein identifications.  
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Table 13-2: Protein identification of spots excised from the DiGE preparative gel (Figure 5-17). 




Spot ID Protein Ac. Number Calculated pi Mass (Da) MOWSE 
Score 
Characteristics at 
 peak infection 
1 78 Poor protein quality hCG1811380-like DAA33614 9.03 169671 23 up regulated 
2 132 Benzodiazepine receptor (peripheral) associated protein 1 
Poor protein quality 
DAA19201 5.55 173983 22 up regulated 
3 141 Ankyrin repeat and sterile alpha motif domain-containing 
protein 1B 
XP_005198370 5.41 90486 18 Down regulated 
4 156 ND     Down regulated 
5 495 Albumin 754920A 5.76 68083 51 up regulated 
6 562 Albumin 754920A 5.76 68083 51 up regulated 
7 607 Serotransferrin  Q29443 6.75 79870  81 up regulated 
8 636 IQ motif containing E-like DAA15162 8.43 88179 21 up regulated 
9 689 Albumin 754920A 5.76 68083 55 ND 
10 960 Albumin 754920A 5.76 68083 74 up regulated 
11 962 Albumin 754920A 5.76 68083 48 up regulated 
12 1042 Refeldin A-inhibited guanine nucleotide-exchange protein 3  XP_871474 5.54 245336 16 Down regulated 
13 1117 Factor XIIa inhibitor precursor  NP_777246 6.19 51919 16 Up regulated 
14 1137 Centromere protein A-like DAA25906 11.19 52963 16 Up regulated 
15 1140 Leucine-rich repeat flightless-interacting protein 2   DAA17146 5.37 45494 28 ND 
16 1155 RAC-beta serine/threonine protein kinase isoform x4 
 
 5.98 55905 20 Up regulated 
17 1170 ND     Up regulated 
18 1209 ND     Up regulated 
19 1236 SH2 domain-containing adapter protein B NP_001179863 
XP_618475 
9.07 55667 21 Up regulated 
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20 1336 RAC-beta serine/threonine-protein kinase NP_001193075 
XP_870006 
5.98 56004 23 Up regulated 
21 1370 ND     Up regulated 
22 1375 Albumin 754920A 5.76 68083 76 Up regulated 
2 1429 ND     Down regulated 
24 1457 ND     Down regulated 
25 1701 Immunoglobulin heavy chain variable region CAA10182 8.62 12561 19 Down regulated 
26 1960 ND     Down regulated 
27 2023 ND     Down regulated 
28 2236 Beta-lactoglobulin  CAA32835 4.85 20307 25 Down regulated 
29 2402 Poor  protein quality; zinc finger protein XP_003587295 9.32 64407 17 Down regulated 
*ND-not determined due to poor protein quality 
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13.4.3 Milk peptidomics  
13.4.3.1 CE-MS analysis 
Model for infected milk biomarkers 
Using a non-parametric Wilcoxon test to compare peptides identified at 0 h and 
81 h, 460 polypeptides were detected to have significant Benjamini-Hochberg 
(BH) p–value, and used to train the SVM algorithm. Out of these, 205 had an AUC 
of 1 (specificity-100 %, sensitivity-100 %, cut off ≤-0.915 and interval of 
confidence 0.805 to 1) and were thus selected as discriminatory polypeptides 
with prospective biomarker significance and assessed in a validation set of 
samples (n=23). 
Model of pre-infection (n=6) versus peak-infection (n=6) polypeptides is shown in 
box-and-whisker plots used as training sets for validation are shown in Figures 5-
18 and 5-19. The Y-axis in these box plots represents the biomarker score, the 
case (disease) is scored as 1 and the control is scored as -1. So on the Y-axis it is 
possible to determine how much or how little of the disease is present based on 
the scores. A cut off point between healthy and diseased is somewhere between 
-1.0 and 1.0 and for biological samples it is not always zero. 
 
Figure 13-18: Box plot of non-total cross validation of the CE-MS polypeptides training set  
Biomarker scores; Control= -1.0, Diseased= 1.0 
 




Figure 13-19: Box plot of total cross validation of the CE-MS polypeptides training set  
Biomarker scores; Control= -1.0, Diseased= 1.0 
 
Figure 5-20, displays the box plot of the validation using the test (training) set 
and shows control obtained from training set used for the validation. 
 
 
Figure 13-20: Box plot of test set validation of polypeptides using the training set model  
Biomarker scores; Control= -1.0, Diseased= 1.0 
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 There was little discrimination between the biomarker sets of 36 h and 81 h 
samples, therefore to gain a better biomarker model, CE-MS profile of the 
highest level of infection seen (81 h post infection) was used to establish a 
biomarker panel and this was tested against all the other time points. Figure 5-
21, shows the box plot of the of test set used for validation. A total of 205 




Figure 13-21: Box plot of training and validation set using CE-MS profile of control time and 
81 h post-infection. 
This was used to identify polypeptide biomarker panel (205 polypeptides); Biomarker scores; 
Control= -1.0, Diseased= 1.0 
    
The panel of 205 polypeptides obtained were further matched from multi-
consensus file of 3 reports of CE-MS carried out on milk samples including results 
obtained from Mansor et al. (2013). Out of the total number, seventy seven 
peptides were obtained (criteria used was number of basic amino acids + less 
than 100 ppm allowed). A model was then created using the training set 
described above and the 77 polypeptides. Thus a box plot (Figure 5-22) was 
plotted to show the different scores in progression of infection based on this 
model (training set plus 77 matched polypeptides). Time point 312 h presents 
scores closer to the beginning of the infection. 





Figure 13-22: Box plot of training and validation set using CE-MS profile of control time and 
81 h post-infection 
Used to identify polypeptide biomarker panel (77 polypeptides); Biomarker scores; Control= -1.0, 
Diseased= 1.0 
 
The peptide maps (CE/LS/MS peptide peaks) following the peptidomic analysis of 
6 time points during the course of the mastitis challenge are shown in Figures 5-
23, 5-24 and 5-25. It can be seen from the peptide maps, that as infection 
progressed there was a slight shift in peptides from higher to lower molecular 
weight and from earlier to later migration time upon capillary electrophoresis.




Figure 13-23: Composite peptide maps of CE/LC/MS peaks of milk at time points 0 h (A) and 36 h (B) h post infection respectively.  
Z –axis represents the mean signal intensity. 
  




Figure 13-24:  Composite peptide maps of CE/LC/MS peaks of milk at time points 42 h (C) and 57 h (D)  post infection respectively. 
Z –axis represents the mean signal intensity. 
  




Figure 13-25: Composite peptide maps of CE/LC/MS peaks of milk at time points 81 (E) and 312 (F) h post infection respectively.  
Z –axis represents the mean signal intensity. 
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Peptide maps (CE/LC/MS peaks) of potential biomarkers of S. uberis mastitis 
which were up-regulated or down regulated during infection time (36, 42, 57 and 





Figure 13-26: Differential peptide maps (CE/LC/MS peaks) 
Showing peptides which were up-regulated (1) and down-regulated (2) during infection time (36 h, 
42 h, 57 h and 81 h) relative to pre-infection time (0 h). Z –axis represents the mean signal 
intensity.
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13.4.3.2 LC-MS/MS analysis 
Liquid chromatography-tandem mass spectrometry sequences of the first 40 
polypeptides in serial order out of 77 which were matched with 3 multi-
consensus reports and also from report of Mansor et al. (2013), along with some 
of their characteristics, are listed in Table 5-4. Mass to charge ratio (m/z) range 
of the sequenced peptides was from 498.93 to 1008.88 Da and mass range from 
1016.5 to 3610.74. Most of the sequenced peptides arose from cleavages of 
alpha-S1-casein and other caseins. A few were from SAA and glycosylation-
dependent cell adhesion molecule (GDCAM) proteins. Some of the peptides 
derived from SAA protein were up regulated to several thousand folds during 
peak of infection, for example; GADKYFHARGNYDAA, GADKYFHARGNYDAAQRGPGGAWAA 
and SGKDPNHFRPAGLPDKY. 
The greatest fold change occurred with the polypeptide 
GWRLPEYTVTQESGPAHRKEFTMTCRVERF which had sequences matching into the RISC-
loading complex subunit protein. This peptide was the most up regulated 
peptide identified followed by SGKDPNHFRPAGLPDKY derived from SAA protein. 
There were 22 peptides which were down regulated among the total 77 
sequenced and these were derived mainly from alpha-caseins and GDCAM 
proteins.
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Table 13-3: Amino acid sequences of the first 50 polypeptides showing biomarker value and their protein characteristics 
Peptide rows highlighted in green were identified in the present study, in 3 multi-consensus reports and also in report by Mansor et al. (2013) while the purple highlighted row 





time Freq 0h Freq 81h 
Direction (peak 
infection) Sequence Charge Protein Source 
11 1177.6 30.25 1 0 down-regulated NELSKDIGSES 2 Alpha-S1-casein 
17 1250.74 31.01 1 0 down-regulated TKVIPYVRYL 3 Alpha-S2-casein  
29 1493.79 33.04 1 0 down-regulated FVAPFPEVFGKEK 3 Alpha-S1-casein  
68 1768.84 40.46 1 0 down-regulated LYQGPIVLNPWDQVK 2 Alpha-S2-casein  
102 2149.18 31.66 1 0 down-regulated SSRQPQSQNPKLPLSILKE 4 
Glycosylation-dependent 
 cell adhesion molecule 
104 2153.17 24.53 1 0 down-regulated RGSKASADESLALGKPGKEPR 6 
Fibroblast growth factor 
-binding protein 1  




 cell adhesion molecule 1  
123 2298.2 37.31 1 0 down-regulated KNTMEHVSSSEESIISQETY 3 Alpha-S2-casein  
135 2429.24 32.95 1 0 down-regulated HIQKEDVPSERYLGYLEQLL 4 Alpha-S1-casein  
140 2453.18 38.12 1 0 down-regulated ILNKPEDETHLEAQPTDASAQF 3 
Glycosylation-dependent 
 cell adhesion molecule 1  




cell adhesion molecule 1  
162 2708.46 26.6 1 0 down-regulated LKKYKVPQLEIVPNSAEERLHSM 6 Alpha-S1-casein  
163 2765.34 29.82 1 0 down-regulated RTPEVDDEALEKFDKALKALPMHI 6 Beta-lactoglobulin  
165 2788.43 30.64 1 0 down-regulated EERLHSMKEGIHAQQKEPMIGVNQ 6 Alpha-S1-casein  
118 2234.22 27.51 1 0.17 down-regulated HPIKHQGLPQEVLNENLLR 5 Alpha-S1-casein  
168 2826.54 25.95 1 0.17 down-regulated HIQKEDVPSERYLGYLEQLLRLK 6 Alpha-S1-casein  
22 1384.71 37.93 1 0.33 down-regulated IPNPIGSENSEKT 2 Alpha-S1-casein  
116 2233.23 24.72 1 0.33 down-regulated RPKHPIKHQGLPQEVLNEN 6 Alpha-S1-casein  
62 1744.99 24.67 1 0.67 down-regulated HKEMPFPKYPVEPF 4 Beta-casein  
126 2346.3 25.22 1 0.67 down-regulated RPKHPIKHQGLPQEVLNENL 6 Alpha-S1-casein  
158 2615.5 23.84 1 0.83 down-regulated RPKHPIKHQGLPQEVLNENLLR 7 Alpha-S1-casein  
141 2459.39 25.81 1 0.83 down-regulated RPKHPIKHQGLPQEVLNENLL 6 Alpha-S1-casein  
112 2215.06 43.52 1 1 up-regulated SDIPNPIGSENSEKTTMPLW 2 Alpha-S1-casein  
41 1560.77 39.33 0.17 1 up-regulated GNYDAAQRGPGGAWAA 2 Serum amyloid A protein  
33 1499.76 27.43 0.17 1 up-regulated HIQKEDVPSERY 4 Alpha-S1-casein  
21 1381.74 26.16 0.33 1 up-regulated HPIKHQGLPQEV 4 Alpha-S1-casein  
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25 1456.75 39.53 0.17 1 up-regulated YKVPQLEIVPNSA 2 Alpha-S1-casein  
23 1445.8 32.42 0.17 1 up-regulated VAPFPEVFGKEKV 3 Alpha-S1-casein  
44 1595.83 27.76 0.5 1 up-regulated SEETKENERFTVK 4 Complement C3  
174 2989.64 35.25 0.17 1 up-regulated LSLSQSKVLPVPQKAVPYPQRDMPIQA 4 Beta-casein  
67 1767.84 40.66 0.17 1 up-regulated FPKYPVEPFTESQSL 2 Beta-casein  
85 1961.95 34.68 0 1 up-regulated SRYPSYGLNYYQQKPV 3 Kappa-casein  
13 1217.62 37.27 0.17 1 up-regulated YPQRDMPIQA 2 Beta-casein  
99 2125.03 42.81 0.33 1 up-regulated GIHAQQKEPMIGVNQELAY 3 Alpha-S1-casein  
3 1016.54 29.63 0.33 1 up-regulated SHAFEVVKT 3 
Glycosylation-dependent 
 cell adhesion molecule 1  
167 2823.44 34.41 0 1 up-regulated SQSKVLPVPQKAVPYPQRDMPIQAF 4 Beta-casein  
77 1887.97 34.79 0 1 up-regulated QKAVPYPQRDMPIQAF 3 Beta-casein  
32 1499.73 39.75 0 1 up-regulated DIPNPIGSENSEKT 2 Alpha-S1-casein  





















13.5.1 Acute phase proteins during a Streptococcus uberis 
challenge  
13.5.1.1 Haptoglobin 
In this study milk Hp was first noticed to increase slightly from basal values at 30 
h post challenge in 4 cows and at 36 h in two cows. The peak of the mean Hp in 
6 cows was at time 57 h. The time of increase Hp coincided with the times of 
increasing SCC, peak bacteria CFU, and increases in most cytokines as previously 
described (Tassi et al., 2013), thus Hp levels can be said to reflect the stage of 
inflammation.  
In comparison with other experimental mastitis challenge studies, for example 
that of Hiss et al. (2004) who induced an intramammary endotoxin challenge 
using LPS in dairy cows, Hp levels increased as early as 3 h in milk suggesting 
that the virulence or pathogenic factor of invading pathogens can play a crucial 
role on the onset and possible magnitude of Hp secretion into milk. In that 
study, the amount of pathogenic virulence factors injected may also have played 
a role in the quicker onset of rise in milk Hp. Following the experimental 
challenge of mammary glands with LPS, with an increase in Hp after 3 h in milk, 
and a rise at 9 h in serum, it was apparent that Hp in milk was not from seepage 
from serum. However the source(s) of Hp in mastitic and healthy milk samples 
has been subject of subsequent investigations mainly by RT-PCR (Lai et al., 
2009). In the study of Pedersen et al. (2003), the same organism, S. uberis, was 
used for a mastitis challenge and earlier increases in milk Hp (10 h PC) were also 
observed compared to that in this study. Since that study only measured APP in 
milk following a short duration after experimental infection 0-12 h PC, the 
maximum increase from pre-challenge levels (tenfold) was observed at the 12th 
hour PC. The discrepancy observed in the onset of milk Hp increase in the 
present study and that reported by Pedersen et al. (2003) may be due to 
differences in strains of S. uberis used i.e. U103 used in the Pedersen et al. 
(2003) study whereas FSL Z1-048 was used in this study. The U1O3 was isolated 
from a case of clinical mastitis, while the FSL Z1-048 is a host adapted strain 
known to evade the host immune response and survive in the host causing 
chronic subclinical infections (Tassi et al., 2013). However following the 
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experimental challenge, clinical mastitis resulted. Therefore it can be concluded 
that, as suggested in the study of Kim et al. (2011), strain differences can 
influence the innate immune response and specifically APR and APP secretion 
patterns. 
Up to a thousand fold increase in milk Hp was observed at the peak infection 
time in this study, highlighting the sensitivity of milk Hp to severity of infection. 
13.5.1.2 M-SAA3 
The response of M-SAA3 to the mammary challenge was more pronounced (in 
terms of total level of increase by µg/ml than Hp (~8000 µg/ml for M-SAA3 and 
~500 µg/ml for Hp), although these changes occurred slightly later for M-SAA3 
than Hp. There have been reports that SAA is a more sensitive APP to 
inflammation than Hp (Alsemgeest et al., 1994; Humblet et al., 2006), this has 
not been confirmed in the present study. M-SAA3 values were seen to increase to 
several thousand folds above basal levels at the period of peak infection (96 h). 
The profile of M-SAA3 in the present S. uberis mastitis challenge study can be 
said to reflect the severity and stage of the infection.  Similar to the findings for 
Hp, M-SAA3 in two cows remained high at the last sampled time point (312 h), 
which indicated the presence of on-going infection, as confirmed by the positive 
detection of bacterial CFU in milk, from those quarters. 
Unlike earlier observations, in this model of mastitis challenge, the APP response 
was slightly delayed, with the earliest noticeable increase in M-SAA3 occurring at 
36 h as against previous reports of 6 h PC (Pedersen et al., 2003). In the study of 
Pedersen et al. (2003), SAA increased earlier than Hp whereas in the present 
study, Hp tended to raise earlier (average 36 h) than M-SAA3 (average 48 h) and 
also peaked earlier. The study of Pedersen et al. (2003) also reported that SAA 
increased in milk before SCC and also preceded onset of clinical signs. The 
variance in APP response under the same pathogen mastitis may be explained by 
strain differences. In a similar study, this time in challenged heifers, SAA 
increased slightly in milk at 24 h post challenge, but more appreciably at 42 h PC 
(de Greeff et al., 2013). 
During an E. coli experimental infection study, various isoforms of SAA were 
detected in milk and appeared as early as 12 h post infection (Jacobsen et al., 
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2005). In that study S. uberis mastitis milk expressed about 4 different isoforms 
of SAA ranging from 5.8-7.4 in pI.  
Following a Staphylococcus chromogenes experimental infection, a CNS organism 
which is known to cause milk mastitis infections, MAA increased to peak levels at 
54 h post challenge (Simojoki et al., 2009), but the milking interval was reported 
to affect M-SAA3 levels.  
Pedersen et al. (2003) and Jacobsen et al. (2005) demonstrated an earlier rise in 
M-SAA3 than Hp suggesting that M-SAA3 may be more useful in early mastitis 
diagnosis. However other studies have not found M-SAA3 to be useful in relation 
to mastitis; Petersen et al. (2005) observed no significant correlation. In a 
recent study, Kalmus et al. (2013) did not find milk amyloid A (M-SAA3) as useful 
in indicating inflammation as Hp in mastitis caused by A. pyogenes. Although, 
Petersen et al. (2005), found that M-SAA3 was not correlated to SCC in mastitis 
milk, it can be inferred from the observations in the present study, that stage of 
infection when milk samples are collected for assay can significantly influence 
findings on both APP response and that of other innate immunity indices. 
13.5.1.3 CRP 
In this study, the first reports of milk CRP dynamics during the course of an 
experimental mastitis challenge have been presented. There was an initial 
noticeable increase in milk CRP at 30 h post infection in 4 out of 6 quarter-milk 
samples examined. These first increases were in the order of a 100 fold although 
rising from the undetectable (<1.8 ng/ml; LOD) concentration to an average of 
about 500 ng/ml in 3 samples, but was as high as a 4000 fold in one sample being 
undetectable at 24 h, but 4530 ng/ml by 30 h. However the maximum CRP at 
this level was less than that of Hp at ~500 µg/ml or M-SAA3 at ~8000 µg/ml. 
The CRP concentration first peaked at 48 h post infection; however a biphasic 
pattern was seen, resulting in a second (slightly higher) peak of CRP 
concentration at 120  h post infection. The cause or significance of this biphasic 
pattern is not clear, but it may indicate changing phases in the bacterial growth 
and/or stimulation of cytokine response. The values of CRP, as was 
characteristic of the other two major APP in bovine milk, fell with the time 
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course of infection but remained significantly high at 312 h in all but one quarter 
sample which became undetectable. 
Concentration increases as high as above 20,000 times the LOD were achieved at 
the peak of CRP levels. This level of increase in CRP in milk following a mastitis 
challenge clearly corresponds to the dynamics expected of a major acute phase 
protein and confirms the manufacturer’s data (Life Diagnostics Inc.), of high CRP 
levels from mastitic milk samples. However, due to the presence of relatively 
small quantity of CRP in milk compared to the other APP (Hp and M-SAA3), which 
were measured in µg/ml, Hp and M-SAA3 have had more importance as 
indicators of inflammation in bovine milk. Nonetheless, using a proportionately 
sensitive assay with a sufficiently lower LOD may help to uncover potential of 
CRP in detecting mastitis. 
From this study, CRP was found to rise earlier, than the other two APP and this 
could portend a potential advantage of CRP over Hp and M-SAA3 in the diagnosis 
of bovine mastitis. Other factors, such as the mastitis causing bacterial species, 
and the experimental model of the disease may however influence the rate of 
APP secretions, hence the behaviour of CRP in this study would require further 
validation using various disease models (natural and experimental) and mastitis 
causing pathogens.  
Combinations of APP results into a mastitis diagnosis algorithm may add value to 
the use of these biomarkers, and would be suitable for future investigation. 
13.5.2 Proteomics of milk during an S. uberis mastitis 
challenge  
13.5.2.1 1DE SDS-PAGE 
One dimensional gel electrophoresis is a robust and reproducible technique for 
protein separation of especially samples of simple mixture. However, it has low 
resolution. From the 1DE gel image, it was possible to identify visual differences 
in milk samples across the time points during the challenge period. Bands 
representing the major milk proteins (caseins) were observed to be absent at 36 
h and 48 h, and only slightly visible at 42 h and 57 h, and then gradually increase 
in intensity towards resolution. In addition there was the gradual increase in 
intensity of bands identified as bovine lactoferrin with infection from 42 h up 
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until 312 h. There were also changes in serum albumin and immunoglobulin 
bands. Compared to the 1DE gel image of samples from control quarters, no 
obvious changes in protein bands could be observed across the time points 
spanning the entire challenge period. These changes in the high abundance 
proteins of milk have been documented previously (Hogarth et al., 2004; 
Smolenski et al., 2007), but here there is a clear demonstration of the transition 
of milk protein production from health to mastitis and resolution. It can 
therefore be inferred that 1DE is a good pre-fractionation method that can be 
employed for identifying broad changes in milk proteins during mastitis. 
13.5.2.2 2DE: IEF and SDS-PAGE 
Samples from 6 time points (0, 36, 57, 81, 168 and 312 h) during the course of 
the S. uberis mastitis challenge were further investigated to resolve proteins by 
both the isoelectric points and molecular mass. Spots corresponding to milk 
proteins as well as serum proteins were observed upon staining of 2DE gels. 
Although no mass spectrometry of gels spots were carried out in this study, 
inferences on the constituents of each spot was made by comparing gels spots 
analyses of similar whey samples carried out by Henderson (2013) and Mansor 
(2012) (Appendix Chapter 5). 
The 2DE electrophoretogram of the various time points clearly delineated the 
stages of the infection through to abundance levels of milk proteins and Igs spots 
as well as presence and abundance of bovine serum albumin spots. Pre-infection 
samples (0 h), had abundant milk proteins spots and sparse Igs and BSA spots. 
During peak of infection (81 h), milk protein spots (caseins and whey proteins) 
were depleted, and BSA and Igs spots became abundant as samples came closer 
to the composition of blood (Hogarth et al., 2004). Expectedly, as resolution of 
infection commenced (from 168 h), milk proteins spots began to increase while 
Igs and BSA spots diminished in size.  
The 2DE methodology can be used for quantification of protein (spots) changes 
between different samples by the application of 2D gel analysis software such as 
SameSpots® (Totallab Ltd) and PDQuest analysis software package (Bio-Rad 
laboratories, Hemel Hempstead, UK), but would require duplicate or even 
replicate gels to allow statistical analysis. However, a more robust method for 
determining quantitative changes in proteins between gels is the DiGE method 
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which employs the comparison of spots of different samples run in the same gel, 
hence it eliminates technical errors (between gel variation) that may arise from 
running separate gels (Minden, 2007). 
13.5.2.3 DiGE 
In this study, 3 time points representing pre-infection, peak infection and 
resolution phase of the experimental mastitis model were analysed using the 
DiGE technique. The DiGE procedure provides a platform for comparison of 
similar samples and in this study it was possible to identify small changes in 
protein spots from different samples run on a single gel. 
Using the Decyder™ 2-D image analysis software (DIA), it was possible to match 
and recognize differing spots across the three time points considered within the 
same gel using the internal pooled standard. In particular, quantitative changes 
in protein across the pre-infection, peak infection and resolution of infection 
stages were recognizable. The BVA module of the Decyder software also made it 
possible to reproducibly compare the spots and their variation across the 3 
different gels, thus improving the robustness of the DiGE proteomic 
methodology. 
From this study however, there were a number of spots observed in the DiGE 
gels which were not detected in the preparative gel possibly due to the relative 
lower protein concentration of each time point sample in the prep gel.  This may 
pose a problem for identification of key proteins which are relevant to the 
diagnosis of IMI, as they cannot be picked for further MS analysis. 
The technique enabled the detection of up to 728 protein spots which changed 
across the pre-infection, peak infection and resolution phase of the challenge 
course. Two hundred and thirty eight protein spots were up regulated during the 
course of infection while 283 protein spots were down regulated as the infection 
progressed. Among the 29 spots selected for LC-MS/MS identification 19 spots 
were of proteins up regulated during infection and were identified as serum 
related proteins such as albumin and serotransferrin which is known to increase 
in milk during mastitis. One other up regulated protein, benzodiazepine receptor 
(peripheral) associated protein 1, represents a rare finding in mastitic milk. It 
has been reported to have roles in steriodogenesis, apoptosis and oxidative 
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processes and being localized in the mitochondria (Casellas et al., 2002), and 
this suggests the reason for its detection and up regulation in mastitic milk as 
probably being because of the part it plays in the phagocytic process and also as 
a consequence of seepage from serum into milk. Factor XIIa inhibitor precursor, 
a serine–type endopeptidase inhibitor with molecular roles in regulating 
important physiological pathways including complement activation, blood 
coagulation, fibrinolysis and the generation of kinins 
(www.uniprot.org/uniprot/P50448), was also identified as up regulated, likely as 
a results of seepage of from serum into milk. Acyl-protein thioesterase 1 isoform 
X1, leucine-rich repeat flightless-interacting protein 2, RAC-beta 
serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase and 
glial fibrillary acidic protein were all up regulated, are also likely related to the 
compromise of the blood milk barrier (Hogarth et al., 2004). 
Some of the down regulated proteins identified such as nuclear receptor ROR-
alpha, thyroid receptor-interacting protein 6 and zinc finger protein have no 
clear significance in milk during mastitis. 
Generally, DiGE is a proven useful and robust quantitative method for analysing 
protein differences between samples; however, this method is limited by the 
number of samples that can be compared per experiment, due to the number of 
dyes available for labelling samples. Newer approaches for quantitative 
proteomics studies are being developed to overcome these limitations, for 
example, label-free quantification proteomics, which does not require labelling 
of proteins prior to MS analysis but is rather based on precursor signal intensity 
or on spectral counting. This label-free method has been applied to study the 
proteomic changes in milk samples following this experimental S. uberis mastitis 
challenge (Dr Manikhandan Mudaliar, pers. comm.). 
13.5.3 Peptidomics 
The CE-MS analysis of bovine milk during the course of experimental mastitis 
revealed diverse changes in the milk peptidome across the time points spanning 
the mastitis challenge. This method of peptide analysis has been described as a 
powerful hyphenated technique for the study of peptidomic profiles (Herrero et 
al., 2008), and has been exploited for the generation of biomarker panel of 
peptides for conditions such as renal (Good et al., 2010) and cardiovascular 
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(Delles et al., 2010) disorders. As observed in the study of Mansor et al. (2013), 
the technique was sensitive enough to detect peptide differences between milk 
samples from control and infected udders (31 polypeptides) and between milk 
from mastitic udders caused by two separate pathogens (14 polypeptides). 
In order to identify potential biomarkers, a model that utilized training set from 
the pre-infection samples (0 h, with SCC levels <200,000 cells/ml reported in 
Tassi et al., 2013) and from the time of peak of infection and greatest 
biochemical changes in milk (81 h post infection) was created. Statistical 
parameters such as significant BH p-value (0.01) and AUC=1 and correction for 
multiple testing were employed to screen polypeptides in order to determine 
those with biomarker potentials. The training set generated was then validated 
using the test set.  
Overall, 205 peptides with significantly changing profile were detected, 77 
peptides were able to be sequenced using an LC-MS/MS platform, using the 
peptide mass and number of basic amino acids link the peptides from the two 
separate systems (CE-MS and LC-MS/MS).  
A majority of the successfully sequenced changing peptides arose from cleavages 
of alpha-S1-casein (n=31) and beta-casein (22 milk proteins confirming the 
reports of Dallas et al. (2014), Mansor et al. (2013) and Larsen et al. (2010b). 
This further explains the general decrease in milk caseins associated with 
clinical mastitis (Hogarth et al., 2004).  
A few of the peptides were from glycosylation-dependent cell adhesion molecule 
(GlyCAM-1) protein, (mainly down regulated), and serum amyloid A (SAA) protein 
(up regulated) cleavages. These two proteins have been identified as immune 
related proteins (Rocanda et al., 2012; Boehmer et al., 2010: Danielsen et al., 
2010). Proteases play a central role in the type and amounts of peptides 
detected in milk during mastitis and endogenous peptides such as plasmin, 
cathepsins, elastase, and amino- and carboxypeptidases have been suggested as 
the as crucial during the IMI as they are increased in milk due to release from 
the influx of neutrophils (PMNs) and other phagocytic cells (SCC) that occurs 
during mastitis (Larsen et al., 2010b; Moussaoui et al., 2003). These proteases 
were also reported to have specificities towards alpha-S1 and beta caseins. 
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Pathogen related proteases have also been suggested to contribute to the 
proteolysis observed in milk during mastitis (Larsen et al., 2010b).  
As reported in the study of Wedholm et al. (2008), peptides from alpha-S1, 
alpha-S2 and beta-caseins were identified in this study, additionally in the 
present study; two kappa-caseins fragments (sequenced) were seen during 
infection (absent at pre-infection samples). This followed the trend seen in the 
study of Moussaoui et al. (2003) who utilized LPS infusion to generate an 
experimental mastitis and studied the proteolytic changes of milk over time. 
Out of the 77 peptides sequenced, 55 were increased in abundance (since they 
are mostly casein breakdown products) at peak infection time pointing to the 
increased proteolysis that occurs in milk during mastitis (Larsen et al., 2010b). 
Fifty polypeptides showed qualitative differences between the 0 and 81 h post 
infection (being totally absent at one time as against the other), 27 peptides 
displayed quantitative changes with the course of infection.  
Three polypeptides sequenced in this study, were similarly identified in both the 
multi-consensus and Mansor et al. (2013) reports. Two of these peptides were 
fragments from GlyCAM-1 protein and one was from cleavage of fibroblast 
growth factor-binding protein (FGFBP). All of these three polypeptides were 
found in pre-infection samples and absent during infection, and in the study of 
Mansor et al. (2013), these polypeptides only differentiated between healthy 
and mastitic samples and not between the two different mastitis pathogen 
species studied (i.e. E. coli and S. aureus). The matching of these peptides from 
the present study, the study of Mansor et al. (2013) and with reports from 
previous CE-MS milk analysis substantiates their probability as peptide markers 
of mastitis irrespective of the causal agent of mastitis.  
As a time-point-based peptidomic study of mastitis progression, this study offers 
additional advantage over other previous peptidomic analysis of milk samples in 
relation to bovine mastitis, of detecting and identifying peptide(s), showing 
significant difference from pre-infection controls, as early as 36 h post infection. 
The probability exists that the peptidomic profile at an earlier time (before 36 
h) may significantly differentiate pre-infection samples from commencement of 
infection, however, 36 h was the earliest post infection time assayed in this 
study. As an objective for future studies, it would be useful to determine the 
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earliest time point during which peptide changes are able to significantly 
differentiate healthy form infected samples.  
In respect of peptide panel that differentiate mastitis caused by S. uberis from 
other pathogens, 72 of the polypeptides which were sequenced in this study, did 
not match any of the polypeptides detected in Mansor et al’s study or any of the 
multi-consensus reports. Therefore, these 72 peptides could represent a panel of 
peptides specific to S. uberis mastitis. Validation of this claim would be required 
using other S. uberis mastitis models such as natural infection and infections by 
different strains of S. uberis.  
13.6 Conclusion 
In this chapter, the APP profile of milk during an experimental mastitis challenge 
was studied and results clearly indicate the value of the 3 APP, Hp, M-SAA3 and 
CRP in diagnosing and monitoring the stage of mastitis infections. 
Gel based proteomic studies, further carried out on the samples, gave clearer 
understanding on protein pattern variation with course of infection and 
resolution. 
Analysis of the peptide profile in milk across selected time points of the 
experimental challenge, showed a panel of peptides, cross matched with reports 
from previous studies, which as early as 36 h post infection could significantly 
differentiate infected from non-infected milk, thus suggesting potential as 






Chapter 6, 259 
 
 
14 Metabolomic investigation of milk following an 
experimental Streptococcus uberis mastitis 
challenge 
14.1 Overview 
In this chapter, a metabolomics approach to biomarker identification for bovine 
mastitis is described. The S. uberis experimental mastitis challenge discussed in 
the proceeding chapter is used as the time point based model of mastitis. 
14.2 Introduction  
14.2.1 Bovine milk metabolomics 
Following the advances in instrumentation for metabolomic analyses, 
metabolomics of milk samples have been applied in a growing number of studies 
for increased understanding of the physiology of the mammary gland and 
lactation. This has included studies on the associations of milk metabolites with 
technological properties of different milk (traits), relationship with disease 
conditions (somatic cell counts), nutritional quality and composition, as well as 
authentication and screening for adulteration or detection of the origin of milk 
samples (Lamanna et al., 2011; Lachenmeier et al., 2009) and even for 
recognizing the association of blood with milk metabolites (Maher et al., 2013). 
In bovine milk, metabolomics experiments by Belloque and Ramos, (2002) used 
an NMR based approach for a targeted analysis of caseins in commercial milk 
samples while Hu et al. (2007) successfully used NMR (1H 1D and 1H-13C HSQC 
2D) to quantify organic compounds in milk including the low quantity milk N-
acetyl carbohydrate compounds which had rarely been quantified in commercial 
milk, before that study. Milk volatile constituents were identified and 
differentiated based on ration composition using GC-MS and discriminant analysis 
by Toso et al. (2002). 
 
Likewise, Hettinga et al., 2008 employed a solid phase micro extraction (SPME) 
GC-MS approach for the elucidation of volatile metabolites in milk in relation to 
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five common causative organisms of bovine mastitis. In order to confirm the 
origin of the volatile metabolites in mastitis milk, a further study was carried 
out by inoculating milk from healthy quarters with selected bacteria. Results 
from these studies not only demonstrated the specificity of the milk metabolome 
for intramammary infections, but also pathogen specific mastitis. 
Furthermore, studies by Boudonck et al. (2009) showed the capability of a 
metabolomics approach using GC-MS and LC-MS in differentiating milk samples 
based on ten different characteristics that were sources of variability. 
Consequently, it was possible to differentiate milk samples coming from 
different farming systems. This study also highlighted metabolite differences 
that are present in various processed milks. 
Another metabolomics experiment on milk by Klein et al. (2010) identified 
Acetone and β-hydroxybutyric acid (BHBA) as indicators of metabolic status for 
cows, and also classified stage of lactation based on the milk metabolome. In 
that study NMR and GC-MS data were combined for further statistical analysis 
after confirmation of agreement of the analysis by the two methods, 
demonstrating the versatility that could be achieved with a combined approach 
to the study of the metabolome.  
Metabolomic experiments in bovine milk have encompassed the identification of 
a diverse range of metabolites and compounds from different pathways. For 
example, phosphorylated saccharides accounted for the most significant changes 
in metabolites of milk with days of lactation in studies by Ilves et al. (2012), who 
utilized a global untargeted metabolomics approach in order to study the 
variation in milk and blood metabolome in different lactation stages of dairy 
cows. Changes in citrate and lactose were also observed to be significant with 
days in milk (DIM) and the duration of the current lactation. Harzia et al. (2013) 
were able to identify several marker compounds that indicated different 
coagulation abilities in milk through a metabolic profiling using LC-MS. 
The ratio of glycerophosphocholine to phosphocholine was recognized as a 
prognostic marker for determining the risk of development of ketosis in cows 
using milk metabolomics (Klein et al., 2012), thus highlighting another area of 
use of milk metabolomics as not just in diagnosis, but also having prognostic 
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value. Similarly BHBA was recognized as one of the metabolites that had a 
significant increase in milk with high SCC (Sundekilde et al., 2013). 
An untargeted metabolomics (and proteomics) technique was used to analyse 
the profile of milk samples from dairy cows with different energy balances and 
at different stages of lactation by Lu et al. (2013). They found a correlation 
between acute phase response proteins, unsaturated fatty acids, and galactose-
1-phosphate and negative energy balance. Since negative energy balance is a 
stress inducing condition especially in lactating dairy cows, the positive 
association with acute phase proteins (APP) is expected as the latter are 
normally induced in response to inflammation, infection or stress. Stomatin, a 
hormone that influences body growth, was also found to be strongly associated 
with a positive energy balance status of the cows as  were cholesterol and other  
proteins. 
Compounds shown to have antimicrobial properties, including N-alky 
diethanolamines, N-2-alkoxyethyl diethanolamines and N-alkyl ethanolamine 
were also elucidated in milk in up to 2.3-30 ppm using an electrospray ionisation 
MS procedure directly following protein precipitation (Vadla et al., 2013). Melzer 
et al. (2013) have also shown a relationship between metabolite profile and 
specific milk traits, for instance lactic acid, uracil and nine other major 
metabolites were demonstrated to be correlated to high SCC, this agreed with 
findings of Sundekilde et al. (2013) who also uncovered the significant 
association of lactate to high SCC. Melzer et al., 2013 have also used the tool of 
metabolomics to relate genetics to milk traits. Metabolite profiles of three 
specific milk traits were first determined as his was used to identify single 
nucleotide polymorphism (SNP) that could be used to predict these metabolic 
traits..  
The use of metabolomics in order to detect viable biomarkers for mastitis has 
been explored by a number of researchers. Mansor et al. (2013) studied the 
metabolite profiles of milk samples from E. coli and S. aureus infected udder 
quarters in natural cases of clinical mastitis and compared these profiles to 
those from healthy milk samples. Fifteen metabolites, mostly tripeptides and 
dipeptides were found to be differentially expressed in infected samples 
compared to healthy samples. In particular, 3- nitrotyrosine, deoxyguanosine 
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and 3-methoxy-4-hydroxylphenyl were significantly increased in E. coli 
infections, while Leu-Arg, Ser-His and Lys-Ala-Gly were significantly increased in 
S aureus infections as against healthy. Pathway analysis showed that the lipids, 
protein and carbohydrate metabolism pathways were altered through the 
arachidonic acid, arginine and galactose metabolites, respectively. These 
metabolites were significantly increased in mastitis samples. 
Sundekilde et al. (2013) using NMR spectroscopy of milk elucidated differences 
in metabolite profile between samples with high and low SCC. Multivariate data 
analysis techniques revealed distinct differences in the metabolite profiles of 
milk with low or high SCC (with lactate, butyrate, isoleucine, acetate and BHBA 
being increased in high and decreased in low SCC groups, while hippurate and 
fumarate decreased in high and increased in low respectively). In an earlier 
study by Hettinga et al (2009), some metabolites such as acetic acid (acetate), 
butyric acid (butyrate), were detected in milk samples from udders with mastitis 
caused by different pathogens. These studies have so far demonstrated that 
evaluating the metabolome of milk, can, if further explored and properly 
validated, be used to identify markers of metabolic-disease risks, mammary 
inflammation and outcomes of mastitis. 
More work, therefore needs to be carried out in order to comprehensively 
elucidate the metabolome of milk during an IMI. Especially important is the 
relation to a time course of such an intramammary disease, which would enable 
the capturing and recognition of metabolite profile in the critical stages during a 
typical mastitis episode, such as the early, peak and the resolution phases of the 
infection.  
14.3 Objectives of study 
The aim of this study was to assess the variation in the metabolome in bovine 
milk samples following progression of experimental intramammary challenge 
with a host-adapted strain of Streptococcus uberis (FSL Z1–048).  
Streptococcus uberis represents an important cause of mastitis in dairies in the 
UK and it has been shown to cause severe disease which is often difficult to 
control (Zadoks, 2007). 
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The ultimate goal of this experiment is to identify metabolites or compounds, 
having the potential for use as biomarkers of general mammary inflammation or 
infection specific to the S. uberis pathogen and strain, using a time course from 
infection free to resolution of infection. This will help to gain a better 
understanding of metabolic pathways altered with this infection and provide 
valuable information on the nature of the bacterial infection and host response.  
14.4 Materials and methods 
14.4.1 Samples 
Milk samples used for this study were obtained following an experimental 
challenge of six udder quarters in six different cows with a host adapted strain 
of Streptococcus uberis (strain FSL Z1–048) as described in section 2.3.4.5. 
Samples collected at time 0, 36, 42, 57, 81 and 312 h after intramammary 
challenge from each infected quarter (n=36) were used for metabolomic studies.  
APP profiles of the milk samples were determined as described in sections 
2.3.4.5 and 3.3.6.4 and results reported in sections 2.4.5 and 3.4.4 respectively. 
14.4.2 Sample extraction 
The skimmed milk samples were extracted using chloroform: methanol (1:3 v/v) 
mixture (Canelas et al., 2009; Beltran et al., 2012) by adding 400 µl of this 
mixture to 100 µl of skimmed milk sample and mixing vigorously for 2 h at 4ºC 
(on a vortex). After this, the samples were centrifuged at 13 000 g,  4ºC for 5 
min, then the supernatant was separated and stored at -80ºC until analysed.  
14.4.3 Separation and detection 
Liquid chromatography mass spectrometry (LC-MS) was carried out using a 
Dionex UltiMate 3000 RSLCnano in-line HPLC coupled to a Thermo Scientific Q 
Exactive hybrid quadrupole-Orbitrap mass spectrometer. The separation of 
metabolites was performed using a 4.6 x 150 mm SeQuant ZIC-pHILIC (Merck 
KGaA, 6427 Darmstadt, Germany) column at 300 μl/min. The mobile phase 
consisted of (A) 20 mM Ammonium Acetate, pH 9.9 and (B) 80 % acetonitrile 
(ACN). Gradient B: 80 % ACN to 5 % ACN in 15 min then held at 5 % for 3 min, 
returned to 80 % in 1 min, equilibrated for 6 min. The total run time was 25 min. 
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Samples were prepared in H2O: ACN (1:3) and 10 µl was injected in every run. 
The MS acquisition was performed in both negative and positive ionisation modes 
with full scan. The MS was set at 50,000 resolutions with the scan range from 70-
1400 amu. The LC-MS analysis was performed with the assistance of Dr 
Manikhandan Mudaliar under the supervision of Dr. Karl Burgess at Glasgow 
Polyomics, College of Medical, Veterinary and Life Sciences, University of 
Glasgow, UK. 
14.4.4 Data processing and statistical analysis 
The data generated after the LC-MS analysis was processed using Ideom software 
version 18 (http://mzmatch.sourceforge.net/ideom.php). Briefly, the raw data 
was manually sorted into folders according to study groups and using the 
automated peak picking, grouping and filtering option in Ideom, the raw data 
was converted from ‘RAW’ file format to mzXML file format, peaks were 
identified and converted to peakML files using XCMS and peaks from all samples 
were combined and annotated into one peakML file using mzMatch imported into 
Ideom for metabolite identification, data from positive and negative modes were 
combined and comparison between the groups was performed using unpaired t-
test (Darren et al., 2012). Settings and thresholds used in the analysis is given in 
the Table 6-1. Table 6-2 shows the identification confidence for the LC-MS data 
used.  
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Table 14-1: Settings and threshold values used for running the LC-MS metabolomics 
experiment on milk 
IDEOM SETTINGS 
Polarity: Combined  
XCMS (Centwave) 
Method (file type): mzXML  
Parts per million (ppm): 2  
Peak width (min): 5 seconds 
Peak width (max): 100 seconds 
S/N threshold: 3  
Prefilter (# points): 3  
Prefilter (intensity): 1000  
Mzdiff: 0.001  
mzMatch   
Mzmatch grouping RT window: 0.5 min 
Mzmatch grouping m/z ppm: 5 ppm 
Relative Standard Deviation (RSD) filter: 0.80 GENEROUS 
Noise filter (coded): 0.80  
Intensity filter (LOQ): 1000  
Minimum detections # 3  
Retention time (RT) window for related 
peaks: 
0.10 min 
IDEOM   
RT for id of authentic standards: 5.0 % 
RT for id for calculated RT: 50.0 % 
PPM for mass identification: 3.0 ppm 
Ignore related peaks before RT: 0.0 min 
RT window for complex adducts: 0.50 min 
RT window for Duplicate peaks: 1.00 min 
RT window for Shoulder peaks: 2.0 min 
Intensity ratio for Shoulder peaks: 5 to 1 
Intensity limit duplicate peaks: 1 % 
r
2 
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Table 14-2: Identification confidence for LC-MS data 
IDENTIFICATION CONFIDENCE: 
Confidence levels Arbitrary 
Standard RT within 5% 9 
Calculated RT within 50% 7 
ID-dependent rejection   
Xenobiotics 4.5 
RT outside window 3 
Peak-dependent rejection   
Below intensity filter 0.5 
RSD filter 0.4 
Shoulder/duplicate peak 0.2 
common adducts/fragments/isotopes 0.1 
not more than blank control 0 
Confidence modifiers add 
Preferred DB 1 
Related peak (mzMatch) -2 




14.4.5 Metabolite analysis 
A spread sheet of metabolite mass, retention time (RT), formula, isomers, 
putative metabolite, pathway, map, max intensity and confidence obtained for 
each time point was obtained and is provided as supplementary information 
data. The mass spectra data were normalized and descriptive statistics including 
mean, standard deviation of metabolites in each time point for the 6 infected 
quarters as well as relative standard deviation, Fisher test and P-values of t-test 
of means at point 0, compared with other time points were also displayed on the 
excel spread sheet (supplementary information). 
Structure, chemical and physical properties of all identified metabolites were 
assessed by linking to the Chemspider website that displays these details on the 
webpage (http://www.chemspider.com/Chemical-Structure). To further 
differentiate and quantify the changes to metabolites at different times and 
based on pathways, false discovery rate (FDR)-adjusted P≤0.05 log2 fold (at 
specific time points) was computed.  
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14.4.6 Pathway assignment 
Pathway assignment of metabolites was carried out by following the link of the 
putative metabolite to the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
map available on http://www.genome.jp/kegg-bin/show_pathway identifying 
pathways in which each metabolite is involved. 
14.4.7 Advanced data analysis 
The large data generated is to be also analysed by advanced stratified and 
bioinformatics methodologies but is beyond the scope of this thesis and will be 
reported elsewhere (Thomas and Mudaliar, in preparation). 
14.5 Results 
14.5.1  General 
A total of 9681 different metabolites were detected over all 36 samples 
analysed, 5545 metabolites were in the positive ionisation mode while 4136 were 
in the negative ionisation mode. Of all the compounds detected, 3164 were 
provisionally identified (shown in supplementary data) and 1109 of these showed 
variation with time during the course of experimental challenge and were thus 
used for the comparison between time points. Six hundred and forty (640) of 
these varying metabolites were identified with a confidence score of ≥ 7. The 
confidence score (CS) of metabolites identification is based on the minimum 
reporting standards for metabolomics (Sumner et al., 2007). Metabolites 
identified by mass and retention time (RT) with authentic standards are 
highlighted yellow in the following Tables and given a CS of 10 (n=57, 
supplementary data), all others are putative identifications. Putative 
identification is by an untargeted method whereby high-resolution LC-MS signals 
are matched to a database of theoretical masses and predicted retention times. 
It is recognized that a CS of 7 upwards is acceptable for biochemical 
interpretation (Sumner et al., 2007), therefore all results presented and 
discussed, were based on metabolites having CS of ≥ 7 that changed over time.  
A total of 57 metabolites were identified with a CS of 10, 3 with CS of 9, 152 
with 8 and 428 with 7 making the total 640 metabolites. A summary of the 
number of metabolites detected and identified is presented in table 6-3. Figure 
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6-1 shows the proportion (percentage) of metabolites identified with CS of 7-10 
from each of the different metabolic pathways, while Figure 6-2 shows the 
proportion of the metabolites which were identified using authentic standards 
with a CS of 10 (n=57) from the different pathways. In tables some metabolites 
are highlighted in yellow. The metabolites highlighted in yellow signify those 





Table 14-3: Summary of the number of metabolites in different categories 
(CS-Confidence score; IM-ionisation mode) 










Peaks Annotated 1849 1315 3164 
Peaks non-annotated 3696 2821 6517 
Metabolites Identified 628 481 1109 
All metabolites compared across time points 628 481 1109 
 
Metabolites compared across time points with CS of ≥ 7 373 267 640 
















Figure 14-1: Percentage of metabolites in specific pathways identified with confidence score 







Figure 14-2: Percentage of metabolites in specific pathways identified with confidence score 
of 10 (n=57). 
 
 
Altogether, the mass of metabolites identified that showed variation across 
time, ranged from 75 to 886 Da, whilst a retention time range of 0.29 to 21.6 s 
was seen. Metabolites were further examined based on their m/z intensity levels 
and level of change (increase or decrease) based on log2 intensity fold change 
(P-value of <0.05). Trends of specific metabolites with time were also 
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infection are given in the supplementary data. The focus of this chapter is on 
the metabolites which showed the greatest change following infection. Table 6-4 
shows the first 20 metabolites from the highest m/z intensity that changed in 
intensity with time. 
 
Table 14-4: First 20 metabolites with highest m/z intensity (20/640) 
Showing their associated pathways and ionisation mode (IM): AAs-amino acids and related 
metabolites; PP-small peptides; C/E-carbohydrate and energy metabolites; LL-lipids and lipid 
related metabolites; 0-unknown pathway; VC-vitamins, co-factors and related metabolites; NT-
nucleotides and related metabolites; p-positive, n-negative. Compounds highlighted in yellow are 












number Creatine C4H9N3O2 AAs 1.92E+09 p7 
Betaine C5H11NO2 AAs 1.61E+09 p24 
L-Carnitine C7H15NO3 AAs  1.36E+09 p78 
sn-glycero-3-Phosphocholine C8H20NO6P LLs 1.33E+09 p91 
Choline C5H13NO AAs 1.08E+09 p112 
L-Proline C5H9NO2 AAs  6.05E+08 p68 
Citrate C6H8O7 C/E 5.99E+08 n6 
Creatinine C4H7N3O AAs  5.08E+08 p125 
Hexadecanoic acid C16H32O2 LL  5.03E+08 n85 
2-Dehydro-3-deoxy-L-rhamnonate C6H10O5 C/E  4.04E+08 n162 
Orotate C5H4N2O4 NT  3.53E+08 n205 
Choline phosphate C5H14NO4P LL 3.24E+08 p270 
Hippurate C9H9NO3 AAs 2.77E+08 n332 
(S)-Malate C4H6O5 C/E 2.64E+08 n139 
L-Leucine C6H13NO2 AAs 2.4E+08 p153 
8-keto-7-aminoperlagonate C9H15NO3 0 1.84E+08 n345 
4-Trimethylammoniobutanoate C7H15NO2 AA  1.84E+08 p1 
Methyloxaloacetate C5H6O5 CE 1.69E+08 n368 
(R)-3-Hydroxybutanoate C4H8O3 LL  1.62E+08 n393 
Asp-Cys-Ser-Tyr C19H26N4O9S PP 1.59E+08 p372 
 
 
There were four distinct trends observed among metabolites as the infection 
progressed;  
Trend A; decline in intensity from 0 h with the lowest levels at one of the points 
between 0 and 312 h (coinciding with peak clinical disease) and a restoration 
back to normal levels (as at 0 h; control/healthy samples), at the resolution time 
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312 h. Examples of metabolites showing this trend are creatine, betaine and sn-
glycero-3-Phosphocholine which were lowest at 81 h, while others such as L-
carnitine, pyridoxal and L-glutamine were lowest at 57 h. 
Trend B; an increase in m/z intensity of compound(s) present at 0 h, from initial 
levels (0 h) rising to a maximum during the peak periods of clinical mastitis and 
then dropping back at 312 h. Examples are hexadecanoic acid (peaked at 57 h 
and then drops), (R)-3-hydroxybutanoate (peaked at 57 h) and decanoic acid 
(peak at 57 h). N-acetyl-L-aspartate (peaked at 42 h) and then drops almost to 
levels recorded at 0 h by 312 h. This occurred with a total of 73 metabolites. 
Trend C; Metabolites that were initially absent in healthy samples (0 h), 
appearing after 0 h and peaking at some point between 42-81 h, while 
disappearing (or almost) again at 312 h. Examples are thiomorpholine 3-
carboxylate, Leu-Ala-Gln and L-ala-L-glu. 
Trend D; Metabolites in which the levels fluctuated irregularly and in no specific 
pattern in relation to progression of disease. This occurred with urate, N-
ethylmaleimide and D-ornithine. 
The specific metabolites with the most fold increase or decrease at different 
time points after 0 h are listed in Table 6-5. 
 
Table 14-5: List of metabolites that showed the greatest changes at different time points. 
The changes were based on Log2 (fold) and were of two types; increasing (up regulation) or 
decreasing (down regulation). 
Time point Highest  fold decrease Highest  fold increase 
36 h Deoxycytidine (-5.43) 7-methyladenine (10.27) 




57 h Choline phosphate (-9.54) Leu-Ala-Gln (12.24) 
81 h Choline phosphate (-10.83) Puromycin (10.92) 




14.5.2  Time points analysis of metabolites 
The metabolites were assessed by comparing mean m/z intensities at the five 
different time points to their mean intensities at 0 hour (0 h) which was used as 
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the control time.  Student’s T-test was carried out to compare means of the 
different time points with mean at time 0 h. Frequency distributions of 
metabolites at specific time points relative to control time (0 h) are shown in 
Figures below 6-3 to 6-8.  
At each time point, the tables show metabolites with significant change from 0 h 
(first twenty), trend of metabolites and metabolites with the highest m/z 
intensity (first twenty) are listed with their major characteristics (Table 6-6 to 
6-26). In these tables metabolites are listed in descending order of m/z intensity 
and metabolites with a yellow highlight are those that were identified using 
authentic standards and given confidence score of 10. Figures 6-1 to 6-12 also 
show the distribution of metabolites present and absent in samples at various 
time points relative to the 0 h time point sample. 
14.5.2.1 Thirty six hours post infection 
At this time point some substantial changes had occurred in the milk 
metabolome. Details of the distribution of changes relative to time 0 h and lists 
of first 20 metabolites with most significant changes in m/z intensity are shown 
in Figure 6-3 and tables 6-6 to 6-9. 
 
. 
Figure 14-3: Proportion of metabolites present at 0 h, which have either increased or 
decreased in m/z intensity by 36 h. 
Of 640 metabolites identified, 581 were present at 0 h, histogram shows how many increased (149) 
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Table 14-6: Two compounds that were present at time 0 h but absent at 36 h 


































Table 14-7: The 20 Metabolites with highest m/z intensities of n=433, present at 0 h, and 
reduced at 36 h. 
In descending m/z intensity, (Trend A) showing their associated pathways and ionisation mode 
(IM): AAs-amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; p-positive, n-negative (ion 
detection).  
Metabolite Mass Formula 15 Path
way 
m/z Intensity 16 IM/p
eak 
ID 
Creatine 131.07 C4H9N3O2 AAs 1919896320 p7 
Betaine 117.08 C5H11NO2 AAs 1610266496 p24 
L-Carnitine 161.11 7H15NO3 AAs 1356191488 p78 
sn-glycero-3-Phosphocholine 257.1 C8H20NO6P LL  1331854592 p91 
Choline 103.1 C5H13NO AAs 1080505600 p112 
Citrate 192.03 C6H8O7 C/E 598937344 n6 
Creatinine 113.06 C4H7N3O AAs  507809600 p125 
2-Dehydro-3-deoxy-L-
rhamnonate 
162.05 C6H10O5 C/E 403872448 n162 
 
Orotate 
156.02 C5H4N2O4 NT 352815456 n205 
Choline phosphate 183.07 C5H14NO4P LL 324032768 p270 
Hippurate 179.06 C9H9NO3 AAs  276560320 n332 
(S)-Malate 134.02 C4H6O5 C/E 263881568 n139 
8-keto-7-aminoperlagonate 185.11 C9H15NO3 0 184082784 n345 
4Trimethylammoniobutanoate 145.11 C7H15NO2 AAs  184079424 p1 
Methyloxaloacetate 146.02 C5H6O5 C/E 168854336 n368 
Asp-Cys-Ser-Tyr 243.07 C19H26N4O9S PP 158657744 p372 
Lactose 342.12 C12H22O11 C/E  152418496 n396 
N-(octanoyl)-L-homoserine 245.16 C12H23NO4 0 147646064 p410 
cis-Aconitate 174.02 C6H6O6 C/E  145240640 n339 
N-Acetyl-D-glucosamine 221.09 C8H15NO6 AAs 143361424 p373 
 




Table 14-8: The 20 Metabolites with highest m/z intensities out of 148, present at 0 h, 
increased by 36 h 
 In descending m/z intensity, (Trend B) showing their associated pathways and ionisation mode 
(IM): AAs-amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; p-positive; n-negative 




peak ID L-Proline 115.06 C5H9NO2 AAs 605189696 p68 
Hexadecanoic acid 256.24 C16H32O2 LL 502962240 n85 
L-Leucine 131.09 C6H13NO2 AAs 239876032 p153 
(R)-3-Hydroxybutanoate 104.05 C4H8O3 LL 162329008 n393 
Decanoic acid 172.15 C10H20O2 LL 150188064 n484 
L-Phenylalanine 165.08 C9H11NO2 AAs 134699168 p418 
N-Acetyl-L-aspartate 175.05 C6H9NO5 AAs 134420832 n518 
L-1-Pyrroline-3-hydroxy-5-carboxylate 129.04 C5H7NO3 AAs 108133304 n224 
Leu-Leu-Val 343.25 C17H33N3O4 PP 106793240 n543 
5-Hydroxypentanoate 118.06 C5H10O3 LL 95705432 n556 
L-Tyrosine 181.07 C9H11NO3 AAs 73216184 p541 
L-Methionine 149.05 C5H11NO2S AAs 64114592 p412 
2-C-Methyl-D-erythritol 4-phosphate 216.04 C5H13O7P LL 59665204 n572 
D-Lysine 146.11 C6H14N2O2 AAs 50868420 p594 
5,6-Dihydroxy-3-methyl-2-oxo-1,2,5,6-
tetrahydroquinoline 
193.07 C10H11NO3 0 50290708 n671 
Leu-Val 230.16 C11H22N2O3 PP 46736928 p623 
(9Z)-Tetradecenoic acid 226.19 C14H26O2 LL 44001420 n776 
Ala-Val-Val-Pro 384.24 C18H32N4O5 PP 42998740 p651 
Ethyl 3-oxobutanoate 130.06 C6H10O3 0 42456888 n784 
[ST] (5Z,7E)-9,10-seco-5,7,10(19)-
cholestatriene 














Table 14-9: The 20 Metabolites with highest m/z intensities out of 44, absent at 0 h but 
present at 36 h. 
In descending m/z intensity, (Trend A) showing their associated pathways and ionisation mode 
(IM): AAs-amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites: SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 
Metabolite Mass Formula Pathway m/z Intensity IM/peak ID 
Thiomorpholine3 
-carboxylate 
147.04 C5H9NO2S 0 23337922 p880 
Leu-Val-Gly 287.18 C13H25N3O4 PP 12892019 n1341 
Leu-Ala-Gln 330.19 C14H26N4O5 PP 11301985 p1536 
L-Ala-L-Glu 218.09 C8H14N2O5 PP 6445378 p2019 
gamma-L-Glutamyl 
putrescine 
217.14 C9H19N3O3 AAs 4641422 p2259 
7-Methyladenine 149.07 C6H7N5 NT 4261534 p1948 
Puromycin 471.22 C22H29N7O5 SM 3969427 p2546 
Ile-Met-Met-Val 492.24 C21H40N4O5S2 PP 3730136 p2617 
Leu-Leu-Ser 331.21 C15H29N3O5 PP 2811824 n2295 
ZAPA 146.01 C4H6N2O2S 0 2713729 p2843 
Ala-His 226.11 C9H14N4O3 PP 2673113 p2858 
Ala-Leu-Ser-Ser 376.2 C15H28N4O7 PP 2541258 n2336 
Glu-Lys-Lys-Gln 265.65 C22H41N7O8 PP 2335129 p3005 
Ser-Arg 261.14 C9H19N5O4 PP 2331511 p3010 
N2-(D-1-Carboxyethyl) 
-L-arginine 
246.13 C9H18N4O4 AAs  2257569 p3042 
Ala-Leu-Asn-Ser 403.21 C16H29N5O7 PP 2019028 p3162 
Taurodeoxycholate 499.3 C26H45NO6S LL 1970903 n2494 
Lys-Val-Ser 332.21 C14H28N4O5 PP 1530063 p3506 
Convolvine 291.15 C16H21NO4 0 1434941 p3577 
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18.1.1.1 Forty two hours post-infection 
One compound was found present at 0 h but absent at 42 h; N-
ethylethanolamine phosphate (a lipid metabolism intermediate detected in 
negative ionisation mode). Pattern of changes in metabolites relative to 0 h and 
a list of the first 20 metabolites with most changing m/z intensity at this point 
are shown in Figure 6-4 and Tables 6-10 to 6-13 respectively. 
 
. 
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Table 14-10: The 20 Metabolites with highest m/z intensities out of 366 present at 0 h having 
decreased m/z intensity at 42 h (Trend A) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; p-positive; n-negative 
Metabolite Mass Formula Pathway m/z Intensity IM/peak ID 
Creatine 131.07 C4H9N3O2 AAs 1919896320 p7 
Betaine 117.08 C5H11NO2 AAs 1610266496 p24 
L-Carnitine 161.11 C7H15NO3 AAs 1356191488 p78 
sn-glycero-3-Phosphocholine 257.1 C8H20NO6P LL 1331854592 p91 
Choline 103.1 C5H13NO AAs 1080505600 p112 
Citrate 192.03 C6H8O7 C/E 598937344 n6 
Creatinine 113.06 C4H7N3O AAs 507809600 p125 
2-Dehydro-3-deoxy-L-rhamnonate 162.05 C6H10O5 C/E 403872448 n162 
Orotate 156.02 C5H4N2O4 NT 352815456 n205 
Choline phosphate 183.07 C5H14NO4P LL 324032768 p270 
Hippurate 179.06 C9H9NO3 AAs 276560320 n332 
(S)-Malate 134.02 C4H6O5 C/E 263881568 n139 
8-keto-7-aminoperlagonate 185.11 C9H15NO3 0 184082784 n345 
4-Trimethylammoniobutanoate 145.11 C7H15NO2 AAs 184079424 p1 
Methyloxaloacetate 146.02 C5H6O5 C/E 168854336 n368 
Asp-Cys-Ser-Tyr 243.07 C19H26N4O9S PP 158657744 p372 
Lactose 342.12 C12H22O11 C/E 152418496 n396 
N-(octanoyl)-L-homoserine 245.16 C12H23NO4 0 147646064 p410 
cis-Aconitate 174.02 C6H6O6 C/E 145240640 n339 
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Table 14-11: The 20 Metabolites with highest m/z intensities out of 215 present at time 0 h 
having increased m/z intensity  by time 42 h (Trend B) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; p-positive; n-negative 
Metabolite Mass Formula Pathway m/z 
Intensity 
IM/peak ID 
L-Proline 115.06 C5H9NO2 AAs 605189696 p68 
Hexadecanoic acid 256.24 C16H32O2 LL 502962240 n85 
L-Leucine 131.09 C6H13NO2 AAs 239876032 p153 
(R)-3-Hydroxybutanoate 104.05 C4H8O3 LL 162329008 n393 
Decanoic acid 172.15 C10H20O2 LL 150188064 n484 
L-Phenylalanine 165.08 C9H11NO2 AAs 134699168 p418 
N-Acetyl-L-aspartate 175.05 C6H9NO5 AAs 134420832 n518 
L-1-Pyrroline-3-hydroxy-5-
carboxylate 
129.04 C5H7NO3 AAs 108133304 n224 
Leu-Leu-Val 343.25 C17H33N3O4 PP 106793240 n543 
5-Hydroxypentanoate 118.06 C5H10O3 LL 95705432 n556 
L-Histidine 155.07 C6H9N3O2 AAs 79849448 p512 
Hexanoic acid 116.08 C6H12O2 LL 77407704 n604 
L-Tyrosine 181.07 C9H11NO3 AAs 73216184 p541 
L-Arginine 174.11 C6H14N4O2 AAs 68342504 p529 
L-Methionine 149.05 C5H11NO2S AAs 64114592 p412 
2-C-Methyl-D-erythritol4-
phosphate 
216.04 C5H13O7P LL 59665204 n572 
D-Lysine 146.11 C6H14N2O2 AAs 50868420 p594 
5,6-Dihydroxy-3-methyl-2-oxo-
1,2,5,6-tetrahydroquinoline 
193.07 C10H11NO3 0 50290708 n671 
Leu-Val 230.16 C11H22N2O3 PP 46736928 p623 
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Table 14-12: The 20 Metabolites with highest m/z intensities out of 54, that were absent at 0 
h but present at 42 h (Trend C) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative. 
Metabolite Mass Formula Pathway m/z 
Intensity 
IM/peak ID 
Thiomorpholine 3-carboxylate 147.04 C5H9NO2S 0 23337922 p880 
Leu-Val-Gly 287.18 C13H25N3O4 PP 12892019 n1341 
Leu-Ala-Gln 330.19 C14H26N4O5 PP 11301985 p1536 
L-Ala-L-Glu 218.09 C8H14N2O5 PP 6445378 p2019 
Leu-Val-Val 329.23 C16H31N3O4 PP 6164059 n1852 
Gamma-L-Glutamylputrescine 217.14 C9H19N3O3 AAs 4641422 p2259 
7-Methyladenine 149.07 C6H7N5 NT 4261534 p1948 
Puromycin 471.22 C22H29N7O5 SM 3969427 p2546 
Ile-Met-Met-Val 492.24 C21H40N4O5S2 PP 3730136 p2617 
beta-Alanyl-L-arginine 245.15 C9H19N5O3 AAs 2845797 p2788 
Leu-Leu-Ser 331.21 C15H29N3O5 PP 2811824 n2295 
ZAPA 146.01 C4H6N2O2S 0 2713729 p2843 
Ala-His 226.11 C9H14N4O3 PP 2673113 p2858 
Ala-Leu-Ser-Ser 376.2 C15H28N4O7 PP 2541258 n2336 
Glu-Lys-Lys-Gln 265.65 C22H41N7O8 PP 2335129 p3005 
Ser-Arg 261.14 C9H19N5O4 PP 2331511 p3010 
N2-(D-1-Carboxyethyl)-L-arginine 246.13 C9H18N4O4 AAs 2257569 p3042 
Lys-Tyr 309.17 C15H23N3O4 PP 2213790 p3059 
Glu-Arg 303.15 C11H21N5O5 PP 2065376 p3157 
Ala-Leu-Asn-Ser 403.21 C16H29N5O7 PP 2019028 p3162 
 
  




Table 14-13: Ten metabolites absent at 0 h and 36 h, but present at 42 h (Trend C-2) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 
Metabolite Mass Formula Pathway m/z intensity IM/peak ID 
Leu-Val-Val 329.23 C16H31N3O4 PP 6164059 n1852 
beta-Alanyl-L-arginine 245.15 C21H35N5O6 AAs 2845797 n2899 
Lys-Tyr 309.17 C7H10N2O4 PP 2213790 n2470 
Glu-Arg 303.15 C22H28N4O10 PP 2065376 n4029 
Lys-Lys-Tyr 218.63 C15H23N3O4 PP 1229814 p3059 
Gln-Leu-Pro-Pro 453.26 C21H35N5O5 PP 999610 p3812 
Leu-Thr 232.14 C9H19N5O3 PP 972397 p2788 
Ala-Asp-Pro 301.13 C10H20N2O4 PP 336479 p2124 
(S)-AMPA 186.06 C11H21N5O5 0 320437 p3157 





18.1.1.2 Fifty seven hours post infection 
Choline phosphate was the metabolite with the highest fold (log2 fold change) 
decrease at this time point (-9.54) while Leu-Ala-Gln had the highest fold 
increase (12.24). Other significantly decreasing compounds at this time include 
(S)-dihydroorotate propanoyl phosphate and pyridoxal. Furcatin was another 
metabolite which at 57 h decreased very significantly (3.43 fold decrease with p-
value of 3.38 X 10-8) from 0 h levels, but was being restored by 312 h, trend A.  
Leu-Ala-Gln, Puromycin, beta-Alanyl-L-arginine, Ala-His and Ala-Leu-Ser-Ser has 
the highest fold increase (in decreasing order) among all changing metabolites at 
57 h. Thr-Tyr (L-Threonyl-L-tyrosine) was also significantly increased (6.43 fold) 
at 57 h following a trend C. A hydrophobic dipeptide, peaked at 57 h, and was 
absent again at 312 h, just as it was at 0 h. Details of distribution of metabolites  
and listings of metabolites with significant changes at this time are shown in 
Figures 6-5 and Tables 6-14 to 6-17. 
 
 





Figure 14-5: Proportion of metabolites present at 0h, decreasing or increasing at 57 h 
 
 
Table 14-14: The 20 Metabolites with highest m/z intensities out of 348 which were present 
at 0 h and decreased in m/z intensity by 57 h (Trend A) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 
Metabolite Mass Formula Pathway 19 m/z 
Intensity 
IM/peak ID 
Creatine 131.07 C4H9N3O2 AAs 1919896320 p7 
Betaine 117.08 C5H11NO2 AAs 1610266496 p24 
L-Carnitine 161.11 C7H15NO3 AAs 1356191488 p78 
sn-glycero-3-Phosphocholine 257.1 C8H20NO6P LL 1331854592 p91 
Choline 103.1 C5H13NO AAs 1080505600 p112 
Citrate 192.03 C6H8O7 C/E 598937344 n6 
Creatinine 113.06 C4H7N3O AAs 507809600 p125 
2-Dehydro-3-deoxy-L-rhamnonate 162.05 C6H10O5 C/E 403872448 n162 
Orotate 156.02 C5H4N2O4 NT 352815456 n205 
Choline phosphate 183.07 C5H14NO4P LL 324032768 p270 
Hippurate 179.06 C9H9NO3 AAs 276560320 n332 
(S)-Malate 134.02 C4H6O5 C/E 263881568 n139 
8-keto-7-aminoperlagonate 185.11 C9H15NO3 0 184082784 n345 
4-Trimethylammoniobutanoate 145.11 C7H15NO2 AAs 184079424 p1 
Methyloxaloacetate 146.02 C5H6O5 C/E 168854336 n368 
Asp-Cys-Ser-Tyr 243.07 C19H26N4O9S PP 158657744 p372 
Lactose 342.12 C12H22O11 C/E 152418496 n396 
N-(octanoyl)-L-homoserine 245.16 C12H23NO4 0 147646064 p410 
cis-Aconitate 174.02 C6H6O6 C/E 145240640 n339 


































Table 14-15: The 20 Metabolites with highest m/z intensities out of 233 present at 0 h and 
increasing in m/z intensity at 57 h (Trend B) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 




ID L-Proline 115.06 C5H9NO2 AAs 605189696 p68 
Hexadecanoic acid 256.24 C16H32O2 LL 502962240 n85 
L-Leucine 131.09 C6H13NO2 AAs 239876032 p153 
(R)-3-Hydroxybutanoate 104.05 C4H8O3 LL 162329008 n393 
Decanoic acid 172.15 C10H20O2 LL 150188064 n484 
L-Phenylalanine 165.08 C9H11NO2 AAs 134699168 p418 
N-Acetyl-L-aspartate 175.05 C6H9NO5 AAs 134420832 n518 
L-1-Pyrroline-3-hydroxy-5-carboxylate 129.04 C5H7NO3 AAs 108133304 n224 
Leu-Leu-Val 343.25 C17H33N3O4 PP 106793240 n543 
5-Hydroxypentanoate 118.06 C5H10O3 LL 95705432 n556 
L-Histidine 155.07 C6H9N3O2 AAs 79849448 p512 
Hexanoic acid 116.08 C6H12O2 LL 77407704 n604 
L-Tyrosine 181.07 C9H11NO3 AAs 73216184 p541 
L-Arginine 174.11 C6H14N4O2 AAs 68342504 p529 
3-Methyleneoxindole 145.05 C9H7NO 0 66962672 n611 
L-Methionine 149.05 C5H11NO2S AAs 64114592 p412 
2-C-Methyl-D-erythritol 4-phosphate 216.04 C5H13O7P LL 59665204 n572 
D-Lysine 146.11 C6H14N2O2 AAs 50868420 p594 
5,6-Dihydroxy-3-methyl-2-oxo-1,2,5,6-
tetrahydroquinoline 
193.07 C10H11NO3 0 50290708 n671 
Orthophosphate 97.977 H3O4P C/E 48464996 n685 
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Table 14-16: The 20 Metabolites with highest m/z intensities out of 59, absent at 0 h but present at 57 h (Trend C). 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-amino acids and related metabolites; PP-small peptides; C/E-
carbohydrate and energy metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors and related metabolites; NT-nucleotides and 
related metabolites; SM-biosynthesis of secondary metabolites; p-positive; n-negative 
Metabolite Mass Formula Pathway m/z Intensity IM/peak ID 
Thiomorpholine 3-carboxylate 147.04 C5H9NO2S 0 23337922 p880 
Leu-Val-Gly 287.18 C13H25N3O4 PP 12892019 n1341 
Leu-Ala-Gln 330.19 C14H26N4O5 PP 11301985 p1536 
L-Ala-L-Glu 218.09 C8H14N2O5 PP 6445378 p2019 
Leu-Val-Val 329.23 C16H31N3O4 PP 6164059 n1852 
gamma-L-Glutamylputrescine 217.14 C9H19N3O3 AAs 4641422 p2259 
7-Methyladenine 149.07 C6H7N5 NT 4261534 p1948 
Puromycin 471.22 C22H29N7O5 SM 3969427 p2546 
Ile-Met-Met-Val 492.24 C21H40N4O5S2 PP 3730136 p2617 
beta-Alanyl-L-arginine 245.15 C9H19N5O3 AAs 2845797 p2788 
Leu-Leu-Ser 331.21 C15H29N3O5 PP 2811824 n2295 
ZAPA 146.01 C4H6N2O2S 0 2713729 p2843 
Ala-His 226.11 C9H14N4O3 PP 2673113 p2858 
Ala-Leu-Ser-Ser 376.2 C15H28N4O7 PP 2541258 n2336 
Glu-Lys-Lys-Gln 265.65 C22H41N7O8 PP 2335129 p3005 
Ser-Arg 261.14 C9H19N5O4 PP 2331511 p3010 
N2-(D-1-Carboxyethyl)-L-arginine 246.13 C9H18N4O4 AAs 2257569 p3042 
Lys-Tyr 309.17 C15H23N3O4 PP 2213790 p3059 
Glu-Arg 303.15 C11H21N5O5 PP 2065376 p3157 
Ala-Leu-Asn-Ser 403.21 C16H29N5O7 PP 2019028 p3162 
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Table 14-17: The 20 Metabolites with highest m/z intensities out of 20 present at 0 h but absent at 57 h listed by m/z intensity. 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-amino acids and related metabolites; PP-small peptides; C/E-
carbohydrate and energy metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors and related metabolites; NT-nucleotides and 
related metabolites; SM-biosynthesis of secondary metabolites; LG-Lipids Glycerophospholipids; LP-Lipids: Polyketides; p-postive; n-negative 
Metabolite Mass Formula Pathway m/z Intensity IM/peak ID 
Choline phosphate 183.07 C5H14NO4P LL 324032768 p270 
N-Acetyl-D-glucosamine 6-phosphate 301.06 C8H16NO9P AAs 61189868 n622 
D-Glucose 6-phosphate 260.03 C6H13O9P C/E 17423838 n1193 
(S)-Dihydroorotate 158.03 C5H6N2O4 NT 8641255 n1688 
Ethanolamine phosphate 141.02 C2H8NO4P AAs 4438335 n1194 
CMP 323.05 C9H14N3O8P NT 828210 p3851 
[PC ethyl,acety] 1-ethyl-2-acetyl-sn-glycero-3-phosphocholine 327.14 C12H26NO7P LG 702942 p4232 
Oxaloacetate 132.01 C4H4O5 C/E 475359 n3324 
[Fv] Kurzichalcolactone 263.1 C32H30O7 LP 453875 p4544 
U 50488 368.14 C19H26N2OCl2 0 429468 n3395 
3',5'-Cyclic AMP 329.05 C10H12N5O6P NT 313534 p617 
Glu-Asp-Asp 377.11 C13H19N3O10 PP 308783 n3573 
4-Nitrophenylsulfate 218.98 C6H5NO6S 0 213780 n3747 
4-Hydroxyaminoquinoline N-oxide 176.06 C9H8N2O2 0 154301 p5256 
Malvin 327.09 C29H34O17 0 150250 n3882 
Fexaramine 248.14 C32H36N2O3 0 145077 p4542 
3-Methoxy-4-hydroxyphenylethyleneglycolsulfate 264.03 C9H12O7S 0 122686 n3946 
N-Methylethanolamine phosphate 155.03 C3H10NO4P LL 104954 n3997 
5-Carboxy-2-oxohept-3-enedioate 216.03 C8H8O7 AAs 77691 n4057 
ubiquinone-1 250.12 C14H18O4 0 48992 p5099 
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20.1.1.1  Eighty one hours post infection 
Lactose a disaccharide, which is involved in the galactose metabolism pathway 
and the major milk sugar, was one of the major milk metabolites most 
significantly reduced at 81 h. It had a 4 fold decrease while other metabolites 
such as choline phosphate, alpha-D-Galactosyl-1, 3-beta-D-galactosyl-1, 4-N-
acetyl-D-glucosamine, 3-Dehydrocarnitine, and sn-Glycerol 3-phosphate had the 
highest fold decreases (10, 7, 6 and 5 folds) respectively.  D-glucose also 
decreased by about 5 fold at this time. Overall, more metabolites were 
significantly decreased at this time point (having up to 5 fold change) than at 
other time points showing trend A, (reducing gradually up to 81 h) and by 312 h, 
it was almost back to levels recorded at 0 h. Puromycin, beta-Alanyl-L-arginine, 
Ala-His, [ST hydrox] N-(3alpha, 7alpha-dihydroxy-5beta-cholan-24-oyl)-taurine, 
Arg-Lys-Asp-Gln, Ala-Trp-Gln-Gln and Leu-Thr increased from point 0 h. N-
Acetyl-beta-alanine was one other metabolite that increased in several folds 
above its concentration recorded at 0 h but showed irregular fluctuations not 
consistent with infection course. N-Acetyl-beta-alanine is involved in amino acid 
metabolism as a precursor of alanine.  Distributions of metabolites at this time 
point relative to 0 h are shown in Figures 6-6 while Tables 6-18 to 6-21 shows 






































Table 14-18: The 20 Metabolites with highest m/z intensities out of 376 present at 0 h with 
decreased m/z intensity at 81 h (Trend A). 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative. 
Metabolite Mass Formula Pathway m/z Intensity IM/peak 
ID Creatine 131.07 C4H9N3O2 AAs 1919896320 p7 
Betaine 117.08 C5H11NO2 AAs 1610266496 p24 
L-Carnitine 161.11 C7H15NO3 AAs 1356191488 p78 
sn-glycero-3-Phosphocholine 257.1 C8H20NO6P LL 1331854592 p91 
Choline 103.1 C5H13NO AAs 1080505600 p112 
Citrate 192.03 C6H8O7 C/E 598937344 n6 
Creatinine 113.06 C4H7N3O AAs 507809600 p125 
2-Dehydro-3-deoxy-L-rhamnonate 162.05 C6H10O5 C/E 403872448 n162 
Orotate 156.02 C5H4N2O4 NT 352815456 n205 
Choline phosphate 183.07 C5H14NO4P LL 324032768 p270 
Hippurate 179.06 C9H9NO3 AAs 276560320 n332 
(S)-Malate 134.02 C4H6O5 C/E 263881568 n139 
8-keto-7-aminoperlagonate 185.11 C9H15NO3 0 184082784 n345 
4-Trimethylammoniobutanoate 145.11 C7H15NO2 AAs 184079424 p1 
Methyloxaloacetate 146.02 C5H6O5 C/E 168854336 n368 
Asp-Cys-Ser-Tyr 243.07 C19H26N4O9S PP 158657744 p372 
Lactose 342.12 C12H22O11 C/E 152418496 n396 
N-(octanoyl)-L-homoserine 245.16 C12H23NO4 0 147646064 p410 
cis-Aconitate 174.02 C6H6O6 C/E 145240640 n339 
N-Acetyl-D-glucosamine 221.09 C8H15NO6 AAs 143361424 p373 
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Table 14-19: The 20 Metabolites with highest m/z intensities out of 205, present at 0 h with 
increased m/z intensity at 81 h (Trend B) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 
 
Metabolite Mass Formula Pathway m/z Intensity IM/peak 
ID L-Proline 115.06 C5H9NO2 AAs 605189696 p68 
Hexadecanoic acid 256.24 C16H32O2 LL 502962240 n85 
L-Leucine 131.09 C6H13NO2 AAs 239876032 p153 
(R)-3-Hydroxybutanoate 104.05 C4H8O3 LL 162329008 n393 
Decanoic acid 172.15 C10H20O2 LL 150188064 n484 
L-Phenylalanine 165.08 C9H11NO2 AAs 134699168 p418 
N-Acetyl-L-aspartate 175.05 C6H9NO5 AAs 134420832 n518 
L-1-Pyrroline-3-hydroxy-5-carboxylate 129.04 C5H7NO3 AAs 108133304 n224 
Leu-Leu-Val 343.25 C17H33N3O4 PP 106793240 n543 
5-Hydroxypentanoate 118.06 C5H10O3 LL 95705432 n556 
L-Histidine 155.07 C6H9N3O2 AAs 79849448 p512 
Hexanoic acid 116.08 C6H12O2 LL 77407704 n604 
L-Tyrosine 181.07 C9H11NO3 AAs 73216184 p541 
L-Arginine 174.11 C6H14N4O2 AAs 68342504 p529 
L-Methionine 149.05 C5H11NO2S AAs 64114592 p412 
D-Lysine 146.11 C6H14N2O2 AAs 50868420 p594 
5,6-Dihydroxy-3-methyl-2-oxo-1,2,5,6-
tetrahydroquinoline 
193.07 C10H11NO3 0 50290708 n671 
L u-Val 230.16 C11H22N2O3 PP 46736928 p623 
(9Z)-Tetradecenoic acid 226.19 C14H26O2 LL 44001420 n776 
Ala-Val-Val-Pro 384.24 C18H32N4O5 PP 42998740 p651 
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Table 14-20: The 20 Metabolites with highest m/z intensities out of 58, absent at 0 h present 
at 81 h (Trend C) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative. 
Metabolite Mass Formula Pathway M/z Intensity IM/peak ID 
Thiomorpholine 3-
carboxylate 
147.04 C5H9NO2S 0 23337922 p880 
Leu-Val-Gly 287.18 C13H25N3O4 PP 12892019 n1341 
Leu-Ala-Gln 330.19 C14H26N4O5 PP 11301985 p1536 
L-Ala-L-Glu 218.09 C8H14N2O5 PP 6445378 p2019 
Leu-Val-Val 329.23 C16H31N3O4 PP 6164059 n1852 
gamma-L-
Glutamylputrescine 
217.14 C9H19N3O3 AAs 4641422 p2259 
7-Meth ladenine 149.07 C6H7N5 NT 4261534 p1948 
Puromycin 471.22 C22H29N7O5 SM 3969427 p2546 
Ile-Met-Met-Val 492.24 C21H40N4O5S2 PP 3730136 p2617 
beta-Alanyl-L-arginine 245.15 C9H19N5O3 AAs 2845797 p2788 
Leu-Leu-Ser 331.21 C15H29N3O5 PP 2811824 n2295 
ZAPA 146.01 C4H6N2O2S 0 2713729 p2843 
Ala-His 226.11 C9H14N4O3 PP 2673113 p2858 
Ala-Leu-Ser-Ser 376.2 C15H28N4O7 PP 2541258 n2336 
Glu-Lys-Lys-Gln 265.65 C22H41N7O8 PP 2335129 p3005 
Ser-Arg 261.14 C9H19N5O4 PP 2331511 p3010 
N2-(D-1-Carboxyethyl)-L-
arginine 
246.13 C9H18N4O4 AAs 2257569 p3042 
Lys-Tyr 309.17 C15H23N3O4 PP 2213790 p3059 
Glu-Arg 303.15 C11H21N5O5 PP 2065376 p3157 
Ala-Leu-Asn-Ser 403.21 C16H29N5O7 PP 2019028 p3162 
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Table 14-21: The 20 Metabolites with highest m/z intensities out of 29, present at 0 h and 
absent at 81 h (Trend A-2) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 
 Metabolite Mass Formula Pathway M/z 
Intensity 
IM/peak 
ID  Choline phosphate 183.07 C5H14NO4P LL 324032768 p270 
 N-Acetyl-D-glucosamine 6-phosphate 301.06 C8H16NO9P AAs 61189868 n622 
 D-Glucose 6-phosphate 260.03 C6H13O9P C/E 17423838 n1193 
 (S)-Dihydroorotate 158.03 C5H6N2O4 NT 8641255 n1688 
 Propanoyl phosphate 154 C3H7O5P C/E 5321211 n1914 
 Ethanolamine phosphate 141.02 C2H8NO4P AAs 4438335 n1194 
 CMP 323.05 C9H14N3O8P NT 828210 p3851 
 D-Ribose 5-phosphate 230.02 C5H11O8P C/E 726186 n3070 
 [PC ethyl,acety] 1-ethyl-2-acetyl-sn-glycero-3-
phosphocholine 
327.14 C12H26NO7P LG 702942 p4232 
 Oxaloacetate 132.01 C4H4O5 C/E 475359 n3324 
 [Fv] Kurzichalcolactone 263.1 C32H30O7 LP 453875 p4544 
 U 50488 368.14 C19H26N2OCl2 0 429468 n3395 
 [PC acetyl(4:2)] 1-butyryl-2-acetyl-sn-glycero-3osphocholine 355.18 C14H30NO7P LG 375129 p4664 
 P-DPD 212.01 C5H9O7P 0 369553 n3480 
 2-Deoxy-D-ribose 5-phosphate 214.02 C5H11O7P C/E 323946 n2843 
 3',5'-Cyclic AMP 329.05 C10H12N5O6P NT 313534 p617 
 Glu-Asp-Asp 377.11 C13H19N3O10 PP 308783 n3573 
 4-Nitrophenylsulfate 218.98 C6H5NO6S 0 213780 n3747 
 urate-3-ribonucleoside 300.07 C10H12N4O7 NT 213725 n3749 
 4-Hydroxy-3-nitrosobenzamide 166.04 C7H6N2O3 0 196354 n3219 
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20.1.1.2 Three hundred and twelve hours post infection 
5-Methyl-2'-deoxycytidine has the greatest fold decrease at 312 h. 3, 5/4-
Trihydroxycyclohexa-1, 2-dione, an intermediary of inositol phosphate 
metabolism (carbohydrate metabolism), was also found to have significant fold 
reduction. Thiomorpholine 3-carboxylate, Puromycin, [FA] O-Palmitoyl-R-
carnitine and tetradecanoylcarnitine were most significantly increased 
metabolites. Ala-Gly-Tyr, a hydrophobic tripeptide was one metabolite which 
also increased from 0 h levels in a significant order of folds. Distribution of 
metabolites present and absent at this time point relative to 0 h are shown in 
Figures 6-7 while Tables 6-22 to 6-26 gives a list of the metabolites in with m/z 
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Table 14-22: The 20 Metabolites with highest m/z intensities of 27 present at 0 h, reduced 
during infection going back to normal levels at 312 h (trend A) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative. 
Metabolites Mass Formula Pathway m/z intensity IM/peak ID 
Creatine 131.0694 C4H9N3O2 AAs 1919896320 p7 
Choline 103.0996 C5H13NO AAs 1080505600 p112 
Hippurate 179.0583 C9H9NO3 AAs 276560320 n332 
Asp-Cys-Ser-Tyr 243.0716 C19H26N4O9S PP 158657744 p372 
D-Glycerate 106.0266 C3H6O4 C/E 32857964 n895 
Ecgonine 185.1052 C9H15NO3 SM 10426968 p1634 
2-Ethylhexyl phthalate 278.1515 C16H22O4 0 2596841 p1707 
L-Formylkynurenine 236.0794 C11H12N2O4 AAs 1750220 p3371 
Ala-Met-Ala-Pro 388.1771 C16H28N4O5S PP 1317536 p3751 
Imidazol-5-yl-pyruvate 77.01912 C6H6N2O3 AAs 1295559 n2720 
Asp-Phe-Cys-Pro 240.0846 C21H28N4O7S PP 1180533 n2784 
Lactosamine 341.1323 C12H23NO10 C/E 1028320 n2882 
Formylpyruvate 116.0109 C4H4O4 0 727474 n3059 
Leu-Pro-Tyr 391.2102 C20H29N3O5 PP 641105 p4296 
Nalpha-Dimethyl-L-histidine 183.1008 C8H13N3O2 0 524394 p4447 
Ginsenoside Rh2 311.2222 C36H62O8 0 289180 p4878 
3-Hydroxy-2-methylpyridine-4,5-dicarboxylate 197.0325 C8H7NO5 VC 285486 n2192 
Phenethylamineglucuronide 297.1213 C14H19NO6 0 271261 n3614 
Trimethylaminoacetone 115.0997 C6H13NO 0 221264 p4867 
21 4,5-dihydro-5,5-dimethyl-4-(3-
oxobutyl)furan-2(3H)-one 
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Table 14-23: All (19) metabolites present at 0 h, increased during infection and falling back 
to 0 h levels at 312 h (trend B)  
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 




ID (L-Seryl)adenylate C13H21N6O9P 0 19214912 n1082 
[FA trihydroxy(4:0)] 2,3,4-trihydroxy-butanoic acid C4H8O5 C/E 18440210 n1047 
Nonanoic acid C9H18O2 LL 11126324 n1442 
Ile-Tyr C15H22N2O4 PP 8091055 p1795 
Ala-Pro C8H14N2O3 PP 5502632 p2145 
[FA hydroxy(18:2)] 9S-hydroxy-10E,12Z-octadecadienoic acid C18H32O3 LL 5268704 n1920 
5,6-Dihydrothymine C5H8N2O2 NT 5194296 p528 
N,N-Dimethylglycine C4H9NO2 AAs 3219889 n2211 
Glycine C2H5NO2 AAs 1850985 p2260 
Ethyl (R)-3-hydroxyhexanoate C8H16O3 0 1087381 n2841 
Pro-Pro C10H16N2O3 PP 1042433 p3381 
Maleamate C4H5NO3 VC 722413 n2887 
Phenylacetic acid C8H8O2 AAs 648813 n774 
2-Aminophenol C6H7NO AAs 633281 p2047 
Caffeic aldehyde C9H8O3 SM 441880 n2946 
2-Hydroxyethanesulfonate C2H6O4S AAs 344144 n3529 
di-n-Undecylamine C22H47N  0 197438 p5140 
[FA (9:2)] 2,6-nonadienoic acid C9H14O2 LL 191842 n3792 
Suberic acid C8H14O4 LL 179402 n3824 
3-Dehydroteasterone C28H46O4 SM 125943 p4479 
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Table 14-24: All (18) metabolites which were absent at 0 h, present during infection (36-81 h) 
and then absent again at 312 h (Trend C) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 
 
Metabolite Mass Formula Pathway m/z 
Intensity 
24 IM/pea
k ID Leu-Val-Gly 287.184
5 
C13H25N3O4 PP 12892019 n1341 
Leu-Ala-Gln 330.19 C14H26N4O5 PP 11301985 p1536 
gamma-L-Glutamylputrescine 217.142
5 
C9H19N3O3 AAs 4641422 p2259 
7-Methyladenine 149.070
1 
C6H7N5 NT 4261534 p1948 
Glu-Lys-Lys-Gln 265.650
5 
C22H41N7O8 PP 2335129 p3005 
Lys-Val-Ser 332.205
8 
C14H28N4O5 PP 1530063 p3506 
Convolvine 291.146
9 
C16H21NO4 0 1434941 p3577 
Asp-Leu-Gln-Gln 502.238
1 
C20H34N6O9 PP 1340881 p3739 
Ala-Thr-Thr-Tyr 454.206
7 
C20H30N4O8 PP 1180278 n2786 
N-Formimino-L-glutamate 174.064
1 





PP 1059106 n2859 
Arg-Leu-Lys-Asn 264.666
5 





PP 994687 n2901 
Guanosine 283.091
3 
C10H13N5O5 NT 677377 p1097 
Ala-Lys-Ala-Pro 385.231
9 
C17H31N5O5 PP 540860 p4425 
Ala-Asn-Gly 260.111
9 
C9H16N4O5 PP 530324 n3256 
Asp-Leu-Leu-Gln 487.264 C21H37N5O8 PP 283327 n3604 
Thr-Tyr 282.121
5 
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Table 14-25: Metabolites present at 0 h but absent at 312 h 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): 0-
unknown pathway; NT-nucleotides and related metabolites; p-positive; n-negative 
Metabolite Mass Formula Pathway m/z Intensity IM/peak ID 
CMP 323.05 C9H14N3O8P NT 828210 p3851 
25 N1,N8-
diacetylspermidine 
229.18 C11H23N3O2 0 356028 p4706 





Table 14-26: The 20 Metabolites with highest m/z intensities out of 31 absent at 0 h but 
present at 312 h (Trend C) 
In descending m/z intensity, showing their associated pathways and ionisation mode (IM): AAs-
amino acids and related metabolites; PP-small peptides; C/E-carbohydrate and energy 
metabolites; LL-lipids and lipid related metabolites; 0-unknown pathway; VC-vitamins, co-factors 
and related metabolites; NT-nucleotides and related metabolites; SM-biosynthesis of secondary 
metabolites; p-positive; n-negative 
 
Metabolite Mass Formula Pathway m/z 
Intensity 
IM/peak 
ID Thiomorpholine 3-carboxylate 147.04 C5H9NO2S 0 23337922 p880 
L-Ala-L-Glu 218.09 C8H14N2O5 PP 6445378 p2019 
Puromycin 471.22 C22H29N7O5 SM 3969427 p2546 
Ile-Met-Met-Val 492.24 C21H40N4O5S2 PP 3730136 p2617 
beta-Alanyl-L-arginine 245.15 C9H19N5O3 AAs 2845797 p2788 
Leu-Leu-Ser 331.21 C15H29N3O5 PP 2811824 n2295 
ZAPA 146.01 C4H6N2O2S 0 2713729 p2843 
Ala-His 226.11 C9H14N4O3 PP 2673113 p2858 
Ala-Leu-Ser-Ser 376.2 C15H28N4O7 PP 2541258 n2336 
Ser-Arg 261.14 C9H19N5O4 PP 2331511 p3010 
N2-(D-1-Carboxyethyl)-L-arginine 246.13 C9H18N4O4 AAs 2257569 p3042 
Lys-Tyr 309.17 C15H23N3O4 PP 2213790 p3059 
Glu-Arg 303.15 C11H21N5O5 PP 2065376 p3157 
Ala-Leu-Asn-Ser 403.21 C16H29N5O7 PP 2019028 p3162 
Taurodeoxycholate 499.3 C26H45NO6S LL 1970903 n2494 
Lys-Lys-Tyr 218.63 C21H35N5O5 PP 1229814 p3812 
Glu-Lys-Asn-Arg 272.65 C21H39N9O8 PP 1087936 p3903 
Ovothiol A-cysteine disulfide 160.03 C10H16N4O4S2 0 776263 p4157 
Ala-Gly-Ser 233.1 C8H15N3O5 PP 756449 p4166 
Ala-Gly-Arg 302.17 C11H22N6O4 PP 718070 p4219 
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25.1.1 The changes in metabolites in relation to pathways of 
metabolism 
Overall, there were more compounds which significantly reduced with time from 
the control time (0 h) than compounds which increased or newly emerge, at all-
time points considered. Specifically, most carbohydrate metabolism compounds 
showed a trend of reducing with time as infection progressed (trend A), while 
most peptide molecules increased with time (trend C). 
25.1.1.1 Carbohydrate and energy metabolism   
A total of thirty nine (39) carbohydrate and energy metabolites changed with 
time and all were present at 0 h. Having the peak intensity among these was 
citrate. Figure 6-8 shows the proportion of metabolites and their changes with 
time. Fold change in carbohydrate and energy metabolites during the course of 
infection were computed and Table  6-27 shows a list of first 10 metabolites, 
having greatest fold change, type of change (up or down regulation) and the 
corresponding time when it occurred (P<0.05).  Examples of carbohydrate and 
energy metabolism metabolites displaying the various trends are listed in table 
6-28. 
 
Figure 14-8: Carbohydrates and energy metabolism metabolites and their changes at 
different time points  
Showing total metabolites present at 0 h, and proportion of the metabolites absent (green); 
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Table 14-27: First 10 carbohydrate and energy metabolites having significant fold change in time (P<0.05) in order of decreasing fold change.  
Time of the highest fold change (THFC), the value of fold change (FC) log2 and type of change that occurred are also depicted in the table, P-value (at that time point) 
Metabolites Mass Formula Specific Pathway m/z intensity P-value THFC 
Log2 FC(Fold 
change) 
Type of change 
2-Dehydro-3-deoxy-L-rhamnonate 162.05283 C6H10O5 Fructose & mannose 403872448 7.805E-07 81 -5.01 Down regulation 
Methyloxaloacetate 134.02151 C5H6O5 C5-Branched dibasic acid  168854336 0.0001349 81 -5.53 Down regulation 
cis-Aconitate 146.0215 C6H6O6 Citrate cycle (TCA cycle) 145240640 9.434E-05 81 -5.84 Down regulation 
D-Glucose 342.11621 C6H12O6 Glycolysis / Gluconeogenesis 112635952 8.567E-08 81 4.93 Down regulation 
D-Glucuronolactone 176.03209 C6H8O6 Ascorbate & aldarate metabolism 10795787 0.0226727 36 4.85 Up regulation 
D-Glucuronolactone 176.03209 C6H8O6 Ascorbate and aldarate metabolism 10795787 0.0226727 42 4.81 Up regulation 
N-Acetylneuraminate 309.10615 C11H19NO9 Amino sugars metabolism 13092637 0.0007315 81 -4.65 Down regulation 
2-Deoxy-D-ribose 5-phosphate 214.02436 C5H11O7P Pentose phosphate pathway 323946 0.00 57 -4.13 Down regulation 
Lactose 342.11621 C12H22O11 Galactose metabolism 152418496 6.107E-09 81 -4.18 Down regulation 
2-Dehydro-3-deoxy-D-gluconate 174.01641 C6H10O6 Pentose phosphate pathway 1487273 4.064E-07 81 -4.09 Down regulation 
 
 
 Table 14-28: Examples of Carbohydrate and Energy metabolites displaying different trends during the course of infection 
Trend A Trend B Trend C Trend D 
Lactose Pyruvate N/A Orthophosphate 
2-Dehydro-3-deoxy-L-rhamnonate [FA trihydroxy(4:0)] 2,3,4-trihydroxy-
butanoic acid 
N/A D-Gluconic acid 
(S)-Malate D-Glucuronolactone N/A Succinate 
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25.1.1.2  Protein metabolism  
Amino acids and Related Metabolites 
A total of 117 compounds differed in intensity with time course in this study. 
The compound with the highest intensity of this pathway was creatine, however 
the metabolite with the greatest fold change was N-Acetyl-D-glucosamine 6-
phosphate which had an approximately 13 fold decrease at 57 h from its 
concentration at 0 h. Beta-Alanyl-L-arginine on the other hand was up regulated 
by the most folds (10.5) at 81 h post infection. 
Fold changes in the first ten highest altered amino acids and related metabolites 
are presented and Table 6-29 while Table 6-30 displays examples of metabolites 
with different trends in this metabolic pathway. Figure 6-9 shows proportion of 





Figure 14-9: Amino acids and related metabolites and their changes at different time points  
Showing total metabolites present at 0 h (purple), and proportion of the metabolites absent (green); 
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Table 14-29: First 10 amino acids and related metabolites with significant change in time (P<0.05) in order of decreasing fold change. 
Metabolites Mass Formula Pathway m/z intensity P-value THFC Log2 Fold 
change 












2845797 0.03 57 10.03 Up regulation 
N2-(D-1-Carboxyethyl)-L-arginine 
246.13269 C9H18N4O4 
Arginine and proline  
2257569 0.010944 57 7.97 Up regulation 
N-Acetyl-L-aspartate 
175.04804 C6H9NO5 
Alanine and aspartate  




















386711 0.0085574 81 -5.57 Down regulation 
 
 
Table 14-30: Examples of amino acid related metabolites displaying the various trends with course of infection. 
 (Trend A-decline in intensity with infection and rise at resolution; Trend B-increase in intensity with infection and drop at resolution; Trend C-absent from pre-infection, 
present at peak infection and absent at resolution; Trend D-irregular fluctuations from pre-infection to resolution).  
 
Trend A Trend B Trend C Trend D 
Creatine L-Proline gamma-L-Glutamylputrescine N-Acetyl-beta-alanine 




Choline N-Acetyl-L-aspartate N-Formimino-L-glutamate S-Methyl-L-methionine 
L-Threonine L-1-Pyrroline-3-hydroxy-5-carboxylate - Gentisate aldehyde 




One hundred and twelve (112) peptides having 2 to 4 amino acid residues were 
identified, varying in concentration with time. The highest intensity metabolite 
in this group is the tetra-peptide Asp-Cys-Ser-Tyr, followed by Leu-Leu-Val and 
Leu-Val. The greatest fold change occurred with tri-peptide Leu-Ala-Gln (~12 
fold) at the 57 h point. 
Fold change in small peptides during the course of infection were computed and 
Table 6-31 shows a list of first 10 peptides, having greatest fold change, type of 
change (up or down regulation) and the corresponding time when it occurred 
(P<0.05), Table 6-32 displays examples of different trending peptides and Figure 




Figure 14-10: Peptides and related metabolites and their changes at different time points  
Showing total metabolites present at 0 h (green), and proportion of the metabolites absent (purple); 
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14-31: First 10 Peptides and related metabolites with significant change in time (P<0.05) in order of decreasing fold change.  
Metabolites Mass Formula Pathway m/z intensity P-value THFC Fold change Type of change 
Leu-Ala-Gln 330.19 C14H26N4O5 Hydrophobic peptide 11301985 0.03354 57 12.25 Up regulation 
Ala-His 226.1064 C9H14N4O3 Basic peptide 2673113 0.015318 57 10.45 Up regulation 
Ala-Leu-Ser-Ser 376.1959 C15H28N4O7 Hydrophobic peptide 2541258 0.023883 57 10.12 Up regulation 
Val-Gly-Pro 271.1529 C12H21N3O4 Hydrophobic peptide 8562357 0.047323 57 9.64 Up regulation 
Ile-Met-Met-Val 492.2426 C21H40N4O5S2 Hydrophobic peptide 3730136 0.045738 57 9.58 Up regulation 
Leu-Phe 278.163 C15H22N2O3 Hydrophobic peptide 12801995 0.011838 57 9.35 Up regulation 
Lys-Val-Ser 332.2058 C14H28N4O5 Basic peptide 1530063 0.027428 57 9.30 Up regulation 
Arg-Lys-Asp-Gln 272.6457 C21H39N9O8 Basic peptide 1375922 0.04312 57 9.16 Up regulation 
Ala-His 226.1064 C9H14N4O3 Basic peptide 2673113 0.024157 81 9.16 Up regulation 
Ala-Trp-Gln-Gln 531.244 C24H33N7O7 Hydrophobic peptide 1096478 0.049699 81 8.95 Up regulation 
  
 
Table 14-32: Examples of peptides displaying the various trends during the course of infection 
(Trend A-decline in intensity with infection and rise at resolution; Trend B-increase in intensity with infection and drop at resolution; Trend C-absent from pre-infection, 
present at peak infection and absent at resolution; Trend D-irregular fluctuations from pre-infection to resolution). 
Trend A Trend B Trend C Trend D 
Asp-Cys-Ser-Tyr Leu-Leu-Val Leu-Val-Gly Ala-Val-Val-Pro 
Lys-Val Leu-Val Leu-Ala-Gln Leu-Pro 
Ile-Phe-Thr-Pro Ile-Val L-Ala-L-Glu Lys-His 
Asp-Phe-Cys-Pro Leucyl-leucine Leu-Val-Val Asp-Asp-Pro-Ser 
Leu-Lys-Asp Leu-Phe Ile-Met-Met-Val Ala-Tyr 
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25.1.1.3 Lipids and lipid metabolism Metabolites 
A total of one hundred and four (104) compounds were identified in these 
pathways. Three of these were absent at 0 h, while all others were present. The 
metabolite with highest intensity in this group was sn-glycero-3-Phosphocholine. 
Figure 6-11 shows the frequency distribution of metabolites in this pathway with 
time points. Fold change in lipids during the course of infection were computed 
and Table 6-33 shows a list of first 10 metabolites, having greatest fold change, 
type of change (up or down regulation) and the corresponding time when it 
occurred (P<0.05) and Table 6-34 gives examples of metabolites in this pathway 
following different trends. 
. 
Figure 14-11: Lipids and lipid metabolites and their changes at different time points  
Showing total metabolites present at 0 h (green), and proportion of the metabolites absent (purple); 
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Table 14-33: First 10 Lipids, Lipid metabolism and related metabolites having significant fold change in time (P<0.05) in order of decreasing fold change.  
Metabolites Mass Formula Pathway m/z 
intensity 
P-value THFC Fold 
change 
Type of change 
Choline phosphate 183.065955 C5H14NO4P Glycerophospholipid metabolism 324032768 0.0015 81 10.83 Down regulation 
[ST hydrox] N-(3alpha,7alpha-dihydroxy-5beta-cholan-24-oyl)-taurine 499.296836 C26H45NO6S Bile acid biosynthesis 1970903 0.035 57 9.54 Up regulation 
[FA] O-Palmitoyl-R-carnitine 399.334472 C23H45NO4 Fatty acyl carnitine 490806 0.0189 81 7.60 Up regulation 
[PE (18:1/18:1)] 1-(1Z-octadecenyl)-2-(9Z- otadecenoyl)-sn-glycero-3-osphoethanolamine 729.567453 C41H80NO7P Glycerophospho-ethanolamines 265814 0.0116 81 6.98 Up regulation 
[FA (22:0)] 13Z-docosenoic acid 338.318825 C22H42O2 Biosynthesis of unsaturated FA 
  
829085 0.0136 57 6.61 Up regulation 
[FA] O-Palmitoyl-R-carnitine 399.334472 C23H45NO4 Fatty acyl carnitines 490806 0.0409 57 6.35 Up regulation 
sn-Glycerol 3-phosphate 172.013729 C3H9O6P Glycerolipid metabolism 18743178 0.0021 81 5.82 Down regulation 
[FA (16:0/2:0)] Hexadecanedioic acid 143.107179 C16H30O4 Fatty Acids and Conjugates 569451 0.0163 57 5.58 Up regulation 
L-Serine-phosphoethanolamine 228.050985 C5H13N2O6P Glycerophospholipid metabolism 366023 0.0114 81 5.27 Down regulation 
sn-glycero-3-Phosphoethanolamine 215.056024 C5H14NO6P Glycerophospholipid metabolism 48044336 0.0028 81 5.26 Down regulation 
  
 
Table 14-34: Examples of Lipid metabolites displaying the various trends in the course of infection. 
(Trend A-decline in intensity with infection and rise at resolution; Trend B-increase in intensity with infection and drop at resolution; Trend C-absent from pre-infection, 
present at peak infection and absent at resolution; Trend D-irregular fluctuations from pre-infection to resolution). 
Trend A Trend B Trend C Trend D 















[SP (17:0)] heptadecasphinganine - - N-Butyryl-L-homoserine lactone 
[Fv] Kurzichalcolactone - - [FA oxo(16:0)] 3-oxo-hexadecanoic acid 
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25.1.1.4 Nucleotide metabolism 
There were a total of 23 compounds in this category. 20 were present at 0h 
while 3 were not. Orotate had the highest m/z intensity of all metabolites in this 
pathway. Figure 6-12 shows the frequency distribution of metabolites these 
pathways. Fold change in nucleotides and related metabolites during the course 
of infection were computed and Table 6-35 shows a list of first 10 metabolites, 
having greatest fold change, type of change (up or down regulation) and the 
corresponding time when it occurred (P<0.05) and Table 6-36 shows examples of 
compounds displaying different trends with course of infection belonging to this 
group of metabolites. 
Only two compounds were significantly increased (from 0 h) at times 57 h and 81 
h respectively which were 5,6-dihydrothymine and trimetaphosphate.  
 
. 
Figure 14-12: Nucleotides and related metabolites and their changes at different time points  
Showing total metabolites present at 0 h (green), and proportion of the metabolites absent (purple); 
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Table 14-35: First 10 nucleotides and related metabolites having significant fold change in time (P<0.05) in order of decreasing fold change. 
THFC-time of highest fold change 
  
Metabolites Mass Formula Pathway m/z intensity P-value THFC Fold change Type of change 
7-Methyladenine 149.0701 C6H7N5 Base excision repair 4261534 0.032 36 10.27 Up regulation 
Inosine 268.0804 C10H12N4O5 Purine metabolism 598516 0.005 57 8.29 Up regulation 
(S)-Dihydroorotate 158.0327 C5H6N2O4 Pyrimidine metabolism 8641255 0.002 57 -8.24 Down regulation 
Guanosine 283.0913 C10H13N5O5 Purine metabolism 677377 0.003 57 8.19 Up regulation 
7-Methyladenine 149.0701 C6H7N5 Base excision repair 4261534 0.023 57 7.73 Up regulation 
Inosine 268.0804 C10H12N4O5 Purine metabolism 598516 0.038 81 7.26 Up regulation 
Deoxycytidine 227.0903 C9H13N3O4 Pyrimidine metabolism 3535116 0.015 57 -5.79 Down regulation 
Orotate 156.0171 C5H4N2O4 Pyrimidine metabolism 352815456 0.000 81 -5.57 Down regulation 
Deoxycytidine 227.0903 C9H13N3O4 Pyrimidine metabolism 3535116 0.015 36 -5.43 Down regulation 





Table 14-36: Examples of Nucleotides and related metabolites displaying the various trends with course of infection 
(Trend A-decline in intensity with infection and rise at resolution; Trend B-increase in intensity with infection and drop at resolution; Trend C-absent from pre-infection, 
present at peak infection and absent at resolution; Trend D-irregular fluctuations from pre-infection to resolution). 















25.1.1.5 Vitamins and Co-factors metabolism 
The total number of compounds that changed in the course of infection in this 
metabolic group was 22. All these were present at 0 h. Nicotinamide had the 
highest m/z intensity. Fold (level of) change in vitamins, co-factors and related 
metabolites during the course of infection were computed and Table 6-37 and 
shows a list of the six metabolites, with significant fold change with time, type 
of change (up or down regulation) and the corresponding time when it occurred 
(P<0.05) while Table 6-38 is a list of metabolites showing different trends in this 
group. 
Figure 6-13 shows the distribution trends of metabolites in this pathway with 
time. 
. 
Figure 14-13: Vitamins, cofactors and related metabolites and their changes at different time 
points.  
Showing total metabolites present at 0 h (green), and proportion of the metabolites absent (purple); 
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Table 14-37: First 7 Vitamins and Co-factors and related metabolites with significant change in time (P<0.05) in order of decreasing fold change. 
Some metabolites displayed most significant fold change at different time points and are displayed at the different time points when the fold change occurred. THFC-
time of highest fold change. 
 
Metabolites Mass Formula Pathway/Metabolism m/z intensity P-value THFC Fold change Type of change 
Pyridoxal 167.0583106 C8H9NO3 Vitamin B6  6655131 0.0005 57 -6.32 Down regulation 
Pyridoxal 167.0583106 C8H9NO3 Vitamin B6  6655131 0.0005 81 -5.45 Down regulation 
3-Hydroxy-2-ethylpyridine-4,5-dicarboxylate 197.032485 C8H7NO5 Vitamin B6  285486 0.0000 81 -5.14 Down regulation 
Pyridoxal 167.0583106 C8H9NO3 Vitamin B6  6655131 0.0005 42 -4.59 Down regulation 
Nicotinamide 122.047965 C6H6N2O Nicotinate & nicotinamide  116364936 0.0013 42 -3.74 Down regulation 
Pyridoxal 167.0583106 C8H9NO3 Vitamin B6  6655131 0.0005 312 -3.21 Down regulation 
Nicotinamide 122.047965 C6H6N2O Nicotinate & nicotinamide  116364936 0.0013 81 -3.09 Down regulation 
Thiamin 264.10418 C12H16N4O
S 
Thiamine  1124829 8.42E-06 81 -2.74 Down regulation 
Pyridoxine 169.073852 C8H11NO3 Vitamin B6  658731 0.0041 57 -2.65 Down regulation 
Pyridoxamine 168.089827 C8H12N2O2 Vitamin B6  1129846 0.0152 57 -2.56 Down regulation 
1-Methylpyrrolinium 83.0734422 C5H9N Nicotinate & nicotinamide  676540 0.0126 57 2.25 Up regulation 
6-ydroxypseudooxynicotine 97.0527639 C10H14N2O
2 





Table 14-38: Examples of vitamins, co-factors and related metabolites displaying various trends during the course of infection 
(Trend A-decline in intensity with infection and rise at resolution; Trend B-increase in intensity with infection and drop at resolution; Trend C-absent from pre-infection, 
present at peak infection and absent at resolution; Trend D-irregular fluctuations from pre-infection to resolution). 
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25.1.1.6 All other minor pathways  
Other pathways whose metabolites were represented in different time points of 
infection include metabolites of biosynthesis of polyketides and non-ribosomal 
peptides, biosynthesis of secondary metabolites, medium components, xenobiotic 
biodegradation and metabolism as well as unspecified pathways compounds. 
Compounds in all these categories totalled 223.  
The compound with highest intensity of all other pathways metabolites is 8-keto-7-
aminoperlagonate, belonging to the group of compounds with unknown metabolic 
map or pathway but it displayed a Trend A. Fold change in a combination of all 
other remaining groups of metabolite pathways during the course of infection were 
computed and Table 6-39 shows a list of first 10 metabolites, having greatest fold 
change, type of change (up or down regulation) and the corresponding time when 
it occurred (P<0.05) and Table 6-40 shows different trend metabolites. 
Proportional changes of metabolites with time are shown in Figure 6-14. 
 
. 
Figure 14-14: All other metabolites in different and unknown pathways and their changes at 
different time points  
Showing total metabolites present at 0 h (green), and proportion of the metabolites absent (purple); 
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Table 14-39: First 10 metabolites from all other pathways having significant fold change in time (P<0.05) in order of decreasing fold change 
Some metabolites displayed most significant fold change at different time points and are displayed at the different time points when the fold change occurred. * Other minor or 
unspecified pathways metabolites include metabolites involved in biosynthesis of secondary metabolites
b
















Type of change 
Puromycin 471.22247 C22H29N7O5 Puromycin 
b
 3969427 0.02479 81 10.92 Up regulation 
Thiomorpholine 3-carboxylate 147.03534 C5H9NO2S 0
0 
23337922 0.049398 312 10.87 Up regulation 
Puromycin 471.22247 C22H29N7O6 Puromycin 
b
 3969427 0.024614 57 10.47 Up regulation 
Convolvine 291.14693 C16H21NO4 0
0 
1434941 0.036735 57 9.35 Up regulation 
ZAPA 146.01494 C4H6N2O2S 0
0 
2713729 0.016248 57 9.01 Up regulation 
Thiomorpholine 3-carboxylate 147.03534 C5H9NO2S 0
0 
23337922 0.00363 57 8.93 Up regulation 
Puromycin 471.22247 C22H29N7O5 Puromycin
b 
3969427 0.010308 312 8.20 Up regulation 
Ovothiol A-cysteine disulfide 160.03059 C10H16N4O4S2 0
0 
776263 0.022443 57 7.73 Up regulation 
Convolvine 291.14693 C16H21NO4 0
0 





15667663 0.000164 81 -7.40 Down regulation 




Table 14-40: Examples of all other metabolites pathways displaying the various trends with course of infection 
(Trend A-decline in intensity with infection and rise at resolution; Trend B-increase in intensity with infection and drop at resolution; Trend C-absent from pre-infection, present 
at peak infection and absent at resolution; Trend D-irregular fluctuations from pre-infection to resolution). 








PIperidine - Capryloylglycine 





















This study was an untargeted global metabolomics study of milk, carried out to 
investigate and describe the metabolite profile of milk and its changes with time 
during the course of an intramammary challenge with a host-adapted strain of S. 
uberis, an important environmental pathogen of mastitis. 
A major goal was to identify potential biomarker candidates for mastitis in 
general and specifically for S. uberis mastitis. In addition, it was hoped that this 
study will provide information on metabolic pathways that change during the 
course of IMIs and possible measures that could be exploited for the 
enhancement of animal management, diagnosis, therapeutics and welfare of 
dairy cows. 
Metabolomics produces ‘big data’ which can be analysed by sophisticated 
statistical and bioinformatics approaches. These are beyond the scope of this 
thesis but are to be addressed in the future. Here a molecular and biochemical 
approach was taken to identify the key metabolites and metabolic pathways 
altered during mastitis. 
Clinical mastitis developed in all quarters challenged with this host adapted 
strain of S. uberis (Tassi et al., 2013). This was unexpected as the host adapted 
strains were thought to be characterized by a more subclinical and persistent 
mammary infection (Zadoks, 2007). There was also a considerable cellular and 
cytokine response by the host to this challenge (Tassi et al., 2013)  
The time 0 (0 h) was the control time, which corresponded to absence of 
infection, as confirmed by SCC and bacteriology (Tassi et al., 2013). Hence all 
data obtained from other time points were statistically compared with values of 
0 h. Metabolites identified with a CS of 7 to 10 were selected to ensure that data 
were reliable. The method used for the analysis was found to be specific and the 
Ideom software was able to give provide a comparison of time points. 
It is expected that metabolomics experiments yield a high number of 
metabolites (Sundekilde et al., 2013; Leichtle et al., 2013) so it was not 
surprising that in this analysis over 9000 metabolites were detected. Moreover 




the methodology used, LC-MS, is known to be of higher sensitivity than other 
metabolomics techniques such as H-NMR spectroscopy, although having its own 
disadvantages (Boudonck et al., 2009; Sundekilde et al., 2011). Wang et al. 
(2012) constructed a metabolic network for the bovine mammary tissue using 
bovine genome information and uncovered up to 1,743 metabolites and 657 
enzymes. They also identified 11 crucial enzymes whose expression changed in 
condition of mastitis by integrating the array from healthy and clinical mastitis. 
About a third of the detected metabolites were recognised and identified using 
the KEGG maps associated with the programme, while in the comparison 
interface, a third of the identified metabolites showed variation with the course 
of infection. Previously, in a study by Mansor (University of Glasgow PhD thesis) 
over 15000 metabolites were detected and only 1356 of these were identified. 
The higher number of metabolites detected in Mansor’s study may be by virtue 
of the fact that mastitis samples studied were from natural cases of mastitis, 
caused by more than one organism.  
In studies of milk metabolomics using NMR spectroscopy, compounds found to be 
potential biomarkers for mastitis through correlation with elevated SCC such as 
lactose (Sundekilde et al., 2013) were also found in this study.  
Pathways represented by the metabolites detected and identified in this 
metabolomics experiment ranged from protein metabolism (amino acids, 
peptides), carbohydrate and energy metabolism, vitamins and cofactors 
metabolism, nucleotides, biosynthesis of secondary metabolites, as well as 
xenobiotic degradation intermediates. These findings were similar to those of 
Boudonck et al., (2009).  
Other metabolites found belonged to biochemical classes of medium 
components, polyketides and non-ribosomal peptides as well as compounds with 
unknown pathway groups. 
Metabolites were classified in their super and sub pathways, retention times, 
intensity, ionisation modes, formula and number of isomers. In this study, 
creatine, betaine, L-carnitine and sn-glycero-3-phosphocholine were the 
metabolites with highest m/z intensity in that order.  




Overall, in the comparisons of metabolites between time points, N-Acetyl-D-
glucosamine 6-phosphate was the most significantly changed (fold log2) 
compound, from the level it was at in time 0 h (trend A) and its most significant 
change (decrease) occurred at 57 h. Similarly, Leu-Ala-Gln was the most up 
regulated metabolite observed in the entire experiment. 
Lactose (m/z intensity=152418496, negative ionisation mode) which was 
identified by the Ideom software with 42 different isomers including maltose and 
lactulose was also among the highly down regulated metabolites during the 
course of infection. In all the major metabolic pathways (carbohydrate, protein, 
lipid, nucleotide, vitamin and co-factor metabolism), metabolites showed 
greatest changes (fold levels) at times 57 h and 81 h. This suggests that peak 
inflammatory changes in this challenge study occurred at this period, hence the 
most profound metabolite changes milk are seen at this period. Whether this is 
true for natural infections as well and how this differs or reflects infections by 
other species or strains of S. uberis cannot be inferred from this study. The 
earliest (36 h) significant changes in metabolites were seen among the 
nucleotide group rather than in metabolites from any other metabolic pathway.  
Compounds seen at 0 h are hypothetically metabolites which are normal 
constituents of healthy milk from normal mammary gland metabolism but 
become depleted, damaged or are no longer synthesized as a result of the 
presence and activities of pathogens and the body’s reaction to get rid of the 
pathogens.  
During mastitis (or other inflammatory conditions), physiological metabolic 
pathways are disrupted to accommodate the need to fight invading organisms. 
Pathways that enhance bacterial cell lysis such as production of free radicals are 
enhanced.  
25.2.2  Time points comparisons 
25.2.2.1 Thirty Six Hours (36 h) post infection 
Thirty six h post infection (36 h) corresponds to the time of the maximum 
average bacteria colony forming units (CFU) isolated from milk samples in 
challenged quarters during the challenge study (Tassi et al., 2013). Thus, 




metabolites that appeared or increased at this time may relate to products or 
intermediates of peak bacterial activities and metabolism or the host’s reaction 
to bacteria invasion. At 36 h, the earliest changes related to infection were 
noticed in clinical signs, APP and cytokine levels. Clinical signs of mastitis were 
first observed between 30-48 h PC, appearing first at 36 h for two of the six 
challenge cows (Tassi et al., 2013). Other changes first seen at this time in some 
cows include increase in temperature for one cow, detection of high SCC in one 
cow and appearance of most cytokines in most cows. The APP Hp was also first 
increased from baseline values at 36 h in two cows. 
Several metabolites were also found to have become significantly different at 
this time from their initial levels at 0 h.  Some of these compounds which 
displayed fluctuation with the course of infection similar to bacterial count, SCC 
and clinical scores, suggests possible early markers of this S. uberis infection. 
4-Hydroxy-3-nitrosobenzamide was one very significantly decreased metabolite 
from 0 h at this time (36 h), however, an irregular fluctuation in the level of this 
metabolite was observed between 42 to 312 h, and thus it may not be accurately 
predictive of the on-going IMI. Also, the pathway of this metabolite was 
unidentified by the KEGG software (denoted as 0), making it difficult to relate 
its biochemical significance to its presence and dynamics during the disease. 
Deoxycytidine had the highest fold down regulation. Deoxycytidine is a 
nucleotide related compound and as was observed for most nucleotides, there 
was a general decrease  in these compounds with course of infection. On the 
contrary and unlike other nucleotides and related compounds, the methylated 
nucleotide; 7-methyladenine was the most up-regulated metabolite of all 
identified compounds in this experiment, at 36 h; however it was a ‘newly 
appearing’ metabolite which was not present at 0 h but was detected first at 36 
h. It is a compound involved in base excision DNA repair, indicating that while 
rapid decreases in nucleotides occurs at the early stages of mastitis in milk 
samples, a possible fate of the metabolites is the addition of substituent groups 
such as alkyl group. The presence of this compound in urine of rats has been 
shown to be indicative of exposure to methylating agents (Mandel et al., 1994).  




Ovothiol A-cysteine disulfide was another compound found with a high fold 
increase at 36 h compared to 0 h. It was also absent at 0 h and was not 
associated with any known pathway using the KEGG map. It peaked at 57 h but 
still remained significantly high at 312 h although the trend suggests levels were 
returning back to baseline as recorded for 0 h. The course of this compound with 
time post-infection, which has been designated trend C in this study, 
corresponds to the pattern of the IMI clinical signs and other indicators of 
inflammation such as APP (Hp which also peaked at 57 h), bacterial counts and 
to an extent SCC. Nothing is known of ovothiol A-cysteine disulfide’s role in milk 
but it may be a by-product of bacterial or endogenous protease degradation of 
proteins or amino acids, or the use of sulphur from dithiotreol for the formation 
of cysteine (Ryan et al., 2001).  
Potential biomarker candidates, that appear early in the course of an infection 
can be early indicators of such mastitis inflammation, therefore a compound 
such as ovothiol A-cysteine can offer that advantage, if proven and validated.  
Two compounds (Glu-Leu-Lys-Lys and alpha-N-Acetylneuraminyl-2, 6-beta-D-
galactosyl-1, 4-N-acetyl-beta-D- glucosamine) were present at 0 h but absent at 
36 h. However, these compounds reappeared again at 42 h and thereafter, 
suggesting a fluctuation that may not be related to infection course. Many other 
compounds showed significant variations in intensity between 0 h and 36 h, some 
being present at 0 h and absent at 36 h, or being absent at 36 h but present at 
36 h, the basis of which mastitis biomarkers could be sourced.  
 
25.2.2.2  Forty two hours post infection 
The forty second hour post infection corresponded to the time of the highest 
mean SCC in challenged quarters as reported by Tassi et al. (2013). Somatic cells 
are increased in milk during mastitis as a result of the increased migration of 
leukocytes into the udder. SCC has thus been used as the ‘gold standard’ in 
many countries, for the recognition of subclinical mastitis in dairy farms. 
Deoxycytidine was also the most down regulated metabolite at 42 h. It is a 
ribonucleoside involved in the metabolism of DNA. Although this metabolite 
followed trend A, it however still remained very significantly low at the 




resolution time point thus may not be a sensitive gauge of reversal of 
inflammatory signs. 
Another example of a down-regulated compound at this time is 4, 5-dihydro-5, 
and 5-dimethyl-4-(3-oxobutyl) furan-2(3H)-one, it displayed a distinct trend A 
and was almost back to normal (0 h levels) at 312 h. It was identified in the 
positive ionisation mode and is an intermediate in the terpenoid biosynthesis 
pathway with 9 isomers, many of which were non-esterified unsaturated fatty 
acids (C10).  
Terpenoids are precursors of sterols and steroids in animals, and these are useful 
mediators of inflammation, and it is likely that a reduction in this compound as 
infection progressed is related to its massive recruitment for the formation of 
terpenoids and consequently, steroids. 
Out of all metabolites, the dipeptide Trp-Ala was the most up regulated at 42 h 
from 0 h. There were ten metabolites that appeared for the first time at 42 h 
(absent at 0 h and 36 h).  These compounds were mainly di- and tripeptides (8 
out of 10)  and are a reflection of metabolites released into milk as a result of 
the peak activities and presence of somatic cells (mainly neutrophils), which are 
known to release proteolytic enzymes such as cathepsins and amino peptidases 
(Urech et al., 1999). On the other hand, there was one compound present at 
time 0 and 36 h, but undetectable at time 42, N-Methyl ethanolamine 
phosphate. Many compounds were noticed to be present at 0 h and 36 h, but 
became either increasing (213) or decreasing (365); at 42 h. L-proline had 
highest intensity among such increasing metabolites with creatine, in the 
decreasing group. 
25.2.2.3 Fifty seven hours post infection 
This time point corresponds to time when peak average Hp levels in milk were 
recorded. Choline phosphate was the most down regulated compound and it is 
involved in the lipid metabolism (glycerophospholipid metabolism) and 
specifically in the formation of membrane lipid phosphatidylcholine, which is its 
inverse form and has been described as a universal biomembrane adhesive 
because of its peculiar properties (Yu et al., 2012). The trend observed for this 




metabolite may be due to it being used by pathogens in milk for formation of 
cell membranes as they multiply. 
The compound Furcatin (m/z intensity = 479125), taken as one example of 
significantly down-regulated metabolites at 57 h, had an unknown pathway and 
displayed a trend A. It was detected in the negative ionisation mode and is a 
disaccharide which is a structural derivative of ß-D-apiofuranosyl-(1→6)-D-
glucopyranose. Its role in milk is not known and the reasons for its decrease with 
time in course of infection may be related to the general decline in 
carbohydrate metabolites encountered during the course of the IMI, noticed in 
this study.  A few other compounds (n=20) which were present in control 
samples became totally absent at 57 h, N-Acetyl-D-glucosamine 6-phosphate, D-
Glucose 6-phosphate, (S)-Dihydroorotate Ethanolamine phosphate, CMP [PC 
ethyl, acetyl] 1-ethyl-2-acetyl-sn-glycero-3-phosphocholine and Oxaloacetate. 
Pyridoxal and Propanoyl phosphate also showed great reductions in intensity (but 
not complete absence). These metabolites constitute important co-factors that 
are essential for biochemical processes in the cell (for example transamination 
reactions), thus their depletion corresponds to their rapid conversion for use by 
invading bacteria. 
The amino acid, glycine which was present at control time, was one of the most 
significantly increased compounds at 57 h (trend B). Among compounds not 
present at 0 h, the hydrophobic di-peptide, Thr-Tyr, greatly increased (trend C), 
first appearing at 36 h, peaking at 57 h and absent again at resolution time at 
312 h, but the tri-peptide, Leu-Ala-Gln had the most fold increase among these 
newly emerging compounds. The appearance and rapid surge of these small 
peptides during the period of peak infective changes, is a pointer to enormous 
proteolytic changes going on in milk during an IMI. Proteolysis of milk proteins 
that occurs in mastitis, results in the rise in levels of small peptides in milk 
(Larsen et al., 2010b). 
25.2.2.4 Eighty one hours post infection  
The cytokine, interleukin 17A (IL-17A) was first noticed by immunoassay to 
increase between 72 h and 144 h, with a peak of  average at 81 h in 4/6 cows. At 
the same time, there was also a temporary increase in lymphocyte levels in 




milk. IL-17A displayed a pattern unlike other interleukins such as IL-6, which 
showed earlier average peak and displayed a progression similar to APP (Tassi et 
al., 2013). The detection of IL-17A was also associated with a decrease in 
bacteria CFU and spontaneous clearing of infections, which was observed in the 
cows with detectable IL-17A. Thus the metabolomic analysis carried out for this 
time point could determine if metabolites reflect a status of metabolism 
indicative of resolution. 
Many of the metabolites identified with variation with time showed the highest 
levels of fold change (especially decrease) at this time point (in addition to 57 
h). It can therefore be inferred that 81 h post infection, in this experimental 
mastitis model, matches the period of greatest alteration impacted by mastitis 
on milk metabolites and by extension the mammary gland. 
Choline phosphate was the most ‘fold reduced’ metabolite at 81 h, lactose too 
was also very significantly reduced at this time compared to control time 
samples. It is the major product of galactose metabolism and the main sugar 
found in milk; a disaccharide of galactose and glucose. 
Among metabolites present from the 0 h, Val-Gly-Pro had the greatest fold 
increase.  Creatine had the highest intensity among initially present compounds. 
Betaine which is an oxidative product of choline involved in the glycine and 
serine metabolism has been shown to play a crucial role in the synthesis of milk 
fat, and in this experiment it had the highest m/z intensity (from pre-infection 
time) after creatine. Studies have shown its ability to increase milk yield when 
administered in feed to cows, without significantly altering milk composition 
(Peterson et al., 2012). There is a possibility that betaine formed a component 
of the cows’ feed, which was secreted into milk.  
 
25.2.2.5  Three hundred and twelve hours post infection  
This time corresponds to the stage of resolution of infection. Five out of six cows 
had cleared the infection at this time. This time point was generally 
characterized by restoration of levels of carbohydrate and energy metabolites to 
values as at 0 h and the disappearance of small peptides noticed in abundance 
during the peak periods of the infection (36 h to 81 h). Features consistent with 




a molecule being a good biomarker include its ability to also correctly indicate 
the resolution stage of infection by reverting back to the level of characteristic 
at normal or healthy state. Many compounds were observed to show parallel at 
312 h with 0 h after eitherincreasing, decreasing or disappearing at points 
between these two time points. 
A few compounds, however still retained differences at this time from 0 h. It 
was observed that though some of these compounds differed significantly from 0 
h at this point, their levels of fold change were not as high as seen during the 
peak infection periods (36-81 h).  
5-Methyl-2'-deoxycytidine and thiomorpholine 3-carboxylate (newly emerging) 
had the highest fold decrease and increase respectively at this time point, while 
another hydrophobic dipeptide; Leu-Asn was the most (fold) increased amongst 
previously present compounds.   
For instance, 3, 5/4-Trihydroxycyclohexa-1, 2-dione was one metabolite, a 
carbohydrate of the inositol phosphate pathway with 5 isomers, including one 
involved in the xenobiotic degradation pathway (3-oxadipate) and another in the 
metabolism of vitamins and co factors (2-formylglutarate), which had a high fold 
decrease.  It was characterized by being reduced as infection progressed having 
lowest levels at 81 h, and then beginning to rise at 312 h (trend A). 
25.2.3  Metabolic pathways 
25.2.3.1 Carbohydrate metabolism 
Milk is a secretion of the mammary gland whose components represents the end 
product of mammary gland metabolism, although milk itself does not normally 
contain metabolically active cells. Therefore, compositions of milk can reflect 
the metabolic/biochemical status of the gland and can thus be used to make 
inferences on the systems biology of the mammary gland cells in different 
physiological and pathological conditions. 
In all, metabolites of carbohydrate and energy metabolism were most 
significantly different from 0 h levels (reduced) at time 81 h. Hence it may be 
deduced that the changes in these pathway metabolites, occur late in the course 




of infection and as such may not offer good potentials for an early mastitis 
marker. The general trend with the carbohydrate and energy metabolome in 
milk observed during mastitis is a gradual decrease in concentration as infection 
progresses. This could be because they are used up by bacteria for energy during 
the course of infection, or their production may be inhibited as part of host 
response.  
Lactose 
Lactose is synthesized in the Golgi apparatus of the mammary epithelial 
secretory cells in a reaction catalysed by lactose synthetase complex, using 
glucose and galactose as substrates (DeWitt, 2010). Many bacteria utilize lactose 
as a source of their energy, especially the Streptococcus group, hence the trend 
observed for lactose (becoming depleted) with the peak of infection in this 
study. The lactose trend is discussed further under the carbohydrate metabolism 
section below, but lactose which is the main milk sugar and in addition plays a 
crucial role in the osmotic maintenance of milk volume, was found present at 0 
h (healthy samples) but significantly reduced with time of infection but restored 
to normal levels at 312 h. 
In a recent study of the milk metabolome during the first few months of 
lactation, it was discovered that lactose and citrate were the metabolites that 
contributed the most to changes observed in the milk metabolites between early 
lactation and other stages, decreasing with days in milk (Ilves et al., 2012). 
Previous studies had highlighted the existence of lactose in milk within a narrow 
concentration range (Klein et al., 2012), therefore, the marked decrease in 
lactose with time of infection is a significant but expected finding that is now 
well accepted (Bruckmaier et al., 2004; Shuster et al., 1991; Pyorälä, 2003).  
Apart from the fact that many bacteria utilize lactose as source of energy 
(especially the Streptococcus spp), there could be pathogen induced damage to 
lactose synthesizing mammary gland cells, resulting in a lack of or diminished 
synthesis of lactose. Hence the progressive lactose depletion observed with time 
of infection and its restoration back to normal levels at time of low bacteria 
CFU. A number of studies have already described the correlation of lactose with 
mastitis or SCC levels in milk (Pyorälä, 2003; Berglund et al., 2007; Malek dos 




Reis et al., 2013). Lactose level in milk is often measured as a quality trait of 
milk and an indicator of milk composition (Wittenburg et al., 2013; Melzer et 
al., 2013). In the study of Melzer et al. (2013), lactose (along with other milk 
traits) was found to be associated with specific metabolic profile of milk, and 
was thus identified as a characteristic that could be used to the represent the 
interrelations that occur between milk traits and the milk metabolome. Lactose 
was found to be correlated significantly to mostly carbohydrate metabolism 
compounds such as 1, 3-Dihydroxyacetone and Glucaric acid-1, 4-lactone. In that 
study, it was also observed that a negative correlation existed between somatic 
cell scores and lactose. This is congruent to findings in this study ofsignificant 
decreases in lactose levels at the time points with the peak SCC. 
Lactose fluctuations in milk are so important that Bittante and Cecchinato 
(2013) demonstrated by the use of the milk lactose trait, the breeding values of 
cows. 
Citrate 
Citrate showed a very significant decrease from normal levels throughout the 
course of the IMC.  By the time of remission of infection, levels of this compound 
were still very significantly lower than at 0 h. Citrate is an intermediate of the 
tricarboxylic acid cycle (TCA) formed from the condensation of oxaloacetate and 
acetyl Co A. Acetyl Co A is the product of the reaction catalysed by the enzyme 
complex pyruvate dehydrogenase on pyruvate. In the study by Klein et al. 
(2010), citrate did not show any significant variation throughout the lactation 
period studied, however previous studies have reported wide variation with 
lactation stage (Garnsworthy et al., 2006) and based on other factors such as 
nutrition. Though variation was observed in citrate levels with disease in this 
study, a specific pattern that can be matched with the disease trend was not 
followed. 
Pyruvate 
In this study, pyruvate was found to be increased as the infection peaked, 
suggesting a correlation between pyruvate and SCC as reported by Chagunda et 
al. (2006a).  These findings were in contrast to those of Klein et al. (2012) who 
found no association between pyruvate or lactate and SCC. Chagunda et al. 




(2006b) had also reported an increase in activity of lactate dehydrogenase (LDH) 
with mastitis. The enzyme LDH, converts lactate to pyruvate in a reversible 
reaction. Pyruvate was the only intermediate of the glycolytic pathway which 
increased as infection peaked and this may be due to conversion of lactate 
produced by bacteria into pyruvate by LDH. This may explain the spiking of 
pyruvate levels, observed in their study and also in this investigation.  
Fumarate 
Another energy metabolite of the TCA cycle, fumarate showed a significant 
decrease from control levels as infection peaked, corroborating the findings of 
Sundekilde et al. (2013), who identified that fumarate (and hippurate) were 
significantly decreased in milk having high SCC. The lowest point for fumarate 
was at 81 h, and at 312 h, although beginning to increase was still highly 
significantly different from 0 h levels (P= 0.0006). Fumarate also takes part in 
the TCA and the significance of its decrease in milk during mammary infection is 
that energy synthesizing precursors are deficient.  
Other energy metabolites 
Other intermediates of the TCA such as oxaloacetate, cis–aconitate, succinate, 
S-malate and oxoglutarate were also observed to be significantly reduced as 
infection peaked, thus it can be concluded that the IMI generally leads to a down 
regulation of the TCA cycle. It was found that some intermediates of the pentose 
phosphate pathway, such as ribose, were up regulated during the peak of 
mastitis. As observed in the study of Mansor (2012), D-glucose levels also 
decreased at the peak of infection. It has been suggested that this occurs in 
order to maintain the osmotic balance in the mammary gland, following a loss of 
balance that occurs after leakage of ions such as Na+ and Cl- during 
inflammation-induced disruption of blood milk barrier (Marschke & Kitchen 
1984). In addition, it was suggested that blood perfusion of the mammary gland 
is markedly reduced during mastitis; consequently uptake of glucose by the 
mammary gland is hampered (Mansor, 2012). The decrease in glucose 
concentration could also explain the drop in lactose during mastitis, given that 
glucose is a major substrate for the formation of lactose.  Glucose-6-phospate 
was also found to be absent at peak infection time but high during pre-infection. 




Lactate is one end product of energy metabolism in bacteria and it has been 
reported to correlate with mastitis. It also displayed a trend B, which is 
consistent with previous reports of lactate fluctuation with mastitis. 
Hydroxybutyrate 
Hydroxybutyrate (BHBA) was found to show an increasing trend with infection 
agreeing with many previous studies that have indicated that this metabolite is 
an indicator not only of mastitis or high SCC but also of metabolic status and 
ketosis in dairy cattle (Moyes et al., 2009a; Klein et al., 2012; Sundekilde et al. 
2013). It was most significantly increased by 57 h, and then dropped slightly at 
81 h. Levels at other times were not found to be significantly different from 
control time levels. 
25.2.3.2  Proteins and peptides metabolism 
It has been demonstrated that mastitis results in an increased concentration of 
soluble proteins of milk (whey) while there is reduction in the insoluble (caseins) 
fractions (Urech et al., 1999). Many of the compounds that were absent at 0 h, 
present at 36 h, 42 h, 57 h and 81 h and absent again at 312 h were peptides and 
intermediates of protein metabolism. This observation is similar to findings of 
Mansor (2012) who noticed an increase of di- and tri-peptides in mastitic milk 
samples compared to healthy samples. In that study, it was also observed that 
certain di and tri-peptides were associated with one specific causative organism, 
more than another.  S. aureus mastitis milk showed more small peptides than in 
milk from cows with E. coli mastitis.  
It has also been proposed that the increase in small molecular weight peptides is 
due to the activities of plasma proteases such as plasmin, leukocyte associated 
proteases and cathepsins, as well as bacterial proteases (Haddadi et al., 2005; 
Larsen et al., 2010b). It has also been suggested that both endogenous proteases 
and bacterial proteases have different specificities in their cleavage of milk 
proteins (Napoli et al., 2007; Haddadi et al., 2005). 
Amino acids 
Amino acids (AAs) and related nitrogenous compounds in milk are obtained via 
direct absorption from the blood or protein degradation in the mammary gland 




and are important for the synthesis of milk proteins in the gland. Methionine and 
lysine have been described as limiting AAs for milk protein synthesis. Glutamine 
(and glutamate) has also been hypothesized to be limiting AAs for milk 
production in dairy cows (Meijer et al., 1993). Significant changes occurred in 
intensities of AAs and their related metabolites during the course of the IMI. 
These findings are in agreement with observations of Wang et al. (2012), who 
used a systems biology approach to study the bovine mammary tissue 
metabolism, and ascertained that enzymes related to amino acid metabolism 
were very significantly altered during mastitis.  This leads to a compromise in 
the synthesis of milk proteins which makes up the major nutrient composition of 
milk, hence the reduced milk yield commonly associated with mastitis. 
Creatine had the highest intensity out of all 117 AAs and related nitrogen 
containing compounds identified and among all 640 metabolites with a 7-10 CS. 
It followed a trend A; being most abundant at control time but decreased post 
challenge, to the lowest levels at 57 h. It was detected in the positive ionisation 
mode and was related to the glycine, serine and threonine metabolism pathway 
on the KEGG map. Even at 36 h, creatine had showed a highly significant 
reduction from 0 h levels and continued to reduce to lowest level at 81 h, but by 
the resolution time 312 h, it had almost returned back to same as at 0 h. The P-
value between the mean of Creatine concentration at 0 h and at 312 h was not 
significant at P<0.1. Creatine is an energy metabolite (in form of energy 
releasing creatine phosphate) found in muscle and a product of amino acid 
degradation. 
Another AA related molecule which reduced significantly starting from 36 h, but 
regained intensity to become almost the same as at 0 h levels was hippurate (0 h 
vs. 312 h ; P=0.9). Its lowest point was at 42 h. Hippurate is formed from the 
conjugation of benzoic acid with glycine, to facilitate the excretion of the 
former from the body. Hippurate was found by Sundekilde et al. (2013) to be 
significantly reduced in association with high milk SCC levels. Its reduction with 
time even as glycine increased in milk, is a pointer to a diversion of the glycine 
conjugation pathway of benzoic acid, whose antibacterial properties, as 
suggested by Sundekilde et al. (2013), is exploited to combat invading bacteria 
in the mammary gland. The trend of creatine and hippurate is consistent with 




molecules that can be used to identify new infection while also indicating 
resolution at the appropriate time that corresponds to observations of clinical 
scores and bacteriological examination. An added advantage of creatine is its 
very high intensity at 0 h, as such making decreases during infection time(s) easy 
to recognize. 
Betaine, the amino acid related metabolite which was next in peak intensity, is 
an oxidative product of choline which can ultimately be used for the synthesis of 
fatty acids in milk (Peterson et al., 2012).  Showing a similar trend to creatine in 
milk during mastitis, its high presence in healthy milk samples may be due to the 
secretion into milk from dietary sources in the rumen. Although reasons for its 
progressive reduction during intramammary infection and restoration in 
resolution of infection is unknown, but it can be speculated that the pathogens 
responsible for mastitis and present in milk, may possess enzymatic systems 
similar to the rumen microbes that can convert betaine to more useful energy 
deriving intermediates such as acetate (Peterson et al., 2012). Thus, as bacterial 
counts peak, betaine levels decline and then begin to increase as the infection is 
resolved. This corresponds to time of fall in bacterial counts or absence of 
bacteria (Tassi et al., 2013). Milk betaine levels have been reported to correlate 
with milk N-acetyl carbohydrate levels (Klein et al., 2012). Supplementation of 
betaine in diet has been observed to cause an increase in milk yield in dairy 
cows (Peterson et al., 2012). 
N-Acetyl-D-glucosamine which is a normal constituent of milk was found to 
decrease with infection and increase back at 312 h (trend A), it can be suggested 
that since it is a substrate for NAGase, which increases in milk during IMI and has 
been recognized as an enzyme indicator of mastitis (Chagunda et al., 2006b), 
decreased levels may be due to increased activity of the NAGase on this 
metabolite. Among all the AAs metabolites that changed throughout all the 
examined time points, the most significantly altered (lowered from control 
levels) was p-Benzenediol at 57 h. It is involved in the tyrosine metabolism 
pathway and has 5 isomers. 3-Methoxy-4-hydroxyphenylglycolaldehyde and 2-
Methylglutaric acid were the next most significantly changing compounds, the 
former being also involved in the tyrosine metabolism pathway having 13 isomers 
with 182.06 Da MW, and the latter with 16 isomers and Mw of 146.02 Da. All 




three metabolites named above, had the greatest changes at time 57 h and were 
detected in the negative mode. 
Amongst the 22 standard amino acids (that can be encoded for by the genetic 
codons), L-Proline had the highest intensity followed by L-Leucine, L-
Phenylalanine, L-Histidine and L-Glutamate in that order. All these amino acids 
except L-glutamate had a trend of increasing post challenge, which is a different 
trend from that observed for most of the non-standard AAs (standard AAs are the 
20 AAs encoded directly by the codons of the universal genetic code and used for 
synthesis of proteins). Other standard amino acids found to decrease with time 
of infection included L-threonine and L-aspartate.  
In the study of Csapó et al. (1995), most significantly increased free amino acids 
milk during mastitis included Ile, Ala, Pro, Leu and Asp. However, Asp was 
observed to decrease with infection in the present study, although the trend was 
somewhat irregular. L-Methionine was observed to increase with mastitis in this 
study; this confirms the findings of Mansor (University of Glasgow PhD thesis, 
2012) who observed increased methionine in mastitis milk from E. coli and S. 
aureus infected quarters compared to controls. This increase in free methionine 
may arise from breakdown of proteins to small peptides and even amino acids as 
it is an important limiting amino acid required for metabolic reactions in the 
body. 
At 36 h PC, the most significantly changed amino acid related compound was N-
gamma-acetyldiaminobutyrate (NADA), which decreased to the lowest point at 
that 57 h. This metabolite was the earliest most significantly changed 
metabolite associated with progress of infection. By 312 h the intensity had 
returned towards control values, although there was still a very significant 
difference compared to 0 h levels, (P=0.0001). Studies by Wang et al. (2012) on 
the systems biology of mammary tissue demonstrated that an enzyme, glycine-C-
acetyltransferase (GCAT) involved in glycine, serine and threonine metabolism 
was significantly affected in mastitis. NADA has been reported to be involved in 
the osmotic adaptation of bacteria through the action of one of its derivatives, 
ectoine, which helps organisms survive extremes of osmotic stress. It was also 
found to stabilize rabbit muscle LDH against inactivation by heat (Cánovas et al., 
1999). Fluctuating levels of NADA observed in this study probably occurred due 




to its conversion to ectoine or hydroxyectoine, by bacterial biosynthetic 
enzymes. Ectoine itself was identified in this experiment, and showed a similar 
trend to NADA. 
Contrary to findings of Mansor’s study (University of Glasgow PhD thesis, 2012), 
phosphocholine levels did not increase as infection peaked in this study, even 
while glycine levels were increasing. Isoleucine and tyrosine were also found to 
increase with infection as observed by Mansor. Tyrosine levels have been 
associated with marked casein proteolysis (Murphy et al., 1989). 
Peptides 
The major proteins of milk (caseins) and to a lesser extent α-lactalbumin, β-
lactoglobulin, immunoglobulins, bovine serum albumin as well as the minor ones 
such as lactoperoxidase, lysozyme and lactoferrin are a rich source of peptides 
upon hydrolysis. Peptide hydrolysates of milk proteins have been studied and 
established to have various bioactive properties (Ammendolia et al., 2012) 
(Arruda et al., 2012; Artym and Zimecki, 2013; Barzyk et al., 2009; Cadee et al., 
2007). Mastitis causes an increase in the presence of peptides in milk due to the 
release of proteases from the blood somatic cells and or bacteria (Larsen et al., 
2010b; Lindmark-Mansson et al., 2005; Moussaoui et al., 2002; Wedholm et al., 
2008). 
Although only small peptides of less than or equal to four amino acid residues in 
length were targeted in this study, there were 112 peptides that showed changes 
across time points assessed in the course of IMC study. The peptide with greatest 
fold change was Leu-Ala-Gln followed by Ala-His and Ala-Leu-Ser-Ser, all of 
these showed an increase in intensity from 0 h.  
Asp-Cys-Ser-Tyr was present in healthy samples (0 h) and showed a trend A 
(lowest point at 81 h and almost restored to control levels at 312 h). Other 
peptides that showed a similar pattern include Ile-Phe-Thr-Pro, Asp-Phe-Cys-Pro 
and Leu-Lys-Asp, Asp-Cys-Ser-Tyr and Leu-Leu-Val. 
Irregular fluctuations between time points were observed for most of the 
peptides that were initially present at 0 h. Some however, for example, Ile-Val, 




Val-Gly-Pro and Cys-Lys-Pro-Pro distinctly increased with progress of infection, 
and decreased again by the resolution time. 
The peptide most significantly different from 0 h was Glu-Met-Phe-His (at 81 h), 
and this peptide still remained significantly low at 312 h. In Mansor (2012)’s 
study, S. aureus milk also had a high peptide profile; however, the most 
abundant peptides observed were Gln-Ser-Ser, Leu-Asn-Tyr and Leu-Thr. This 
was different from the observation in the present study. This difference in 
peptide profiles of mastitis milk may indicate that pathogens could be crucial in 
the proteolysis of milk proteins during mastitis.  Different varieties of proteases 
existing in different organisms (pathogens) may explain the varying specificities 
of cleavage sites on the proteins, hence the detection of different high intensity 
(small) peptides in milk from mastitis by different pathogens. Although studies 
by Dufour et al.(2009) was not able to attribute mastitis related caseinolysis, to 
the proteases of a mammopathogenic E. coli P4 strain, several other studies 
have suggested the role of bacterial proteases (Andrew, 1983; Grieve and 
Kitchen, 1985; Haddadi et al., 2005; Johansson et al., 2013). Moreover, in the 
study of Weldholm et al. (2008), several peptides with unknown enzyme specific 
cleavage sites were identified, and could probably result from bacterial protease 
cleavage. On the other hand, peptide variation in mastitis milk may be due to 
stage of the infection or as a result of the variation in level of SCC in the course 
of an infection of the mammary gland, as somatic cells are a major source of 
proteases which act on milk proteins. Weldholm et al. (2008) studied the 
peptides in milk resulting at different levels of SCC and observed that different 
proteases dominated in activity at different levels of SCC. 
The finding that 39 peptides were present in milk during infection as observed in 
this metabolomic study, confirms the high level of milk protein proteolysis that 
occurs during an IMI. Out of these peptides, 22 had completely disappeared 
again at the resolution (312 h). All these mastitis related peptides showed a 
trend C and declined or were absent at 312 h.  When the entire experimental 
data was assessed, of all compounds which were not detected at 0h (absent from 
controls), the most significantly enhanced in intensity was the tri-peptide Leu-
Ala-Gln. These findings corroborated the observation of Mansor (2012), where 




metabolites showing the largest variation from control time were also found to 
be peptides.  
Whilst there is a general increase in peptide levels in milk during mastitis due to 
the increased presence and activity of proteolytic enzymes, there was an 
observation, in this study, that some peptides increased with mastitis (trend C) 
while others decreased (trend A). This may be explained by the fact that after 
the rapid hydrolysis of milk proteins to yield small peptides, some of these 
peptides become used by the bacteria as a source of substrates for essential life 
processes. They undergo further hydrolysis to yield AAs that become 
incorporated into the bacteria’s metabolic pathways (Kitt and Leigh, 1997), 
while other peptides are not. The choice of peptides removed by bacterial 
metabolism may be based on the specificity of the sequence of the peptides for 
the cleavage sites peculiar to proteases of the bacteria involved. Therefore, 
other peptides (products of milk proteins hydrolysis) which do not contain the 
specific cleavage sequences remain abundant in the mastitic milk. 
In a study by Varhimo et al. (2011), mastitis causing Strep Uberis were shown to 
utilize proteolytic break down products of α-caseins and β-caseins for biofilm 
formation. These biofilms were reported to enhance the survival of these 
pathogens, thus facilitating persistent infections by these bacteria. Proteolysis 
of the milk proteins were also described to be enhanced by the bacterial 
proteases.    
25.2.3.3  Lipids and related compounds metabolism 
Lipids are a very important constituent of bovine milk that play a crucial role of 
supplying the new-born with energy. The various classes of lipids that can be 
found in bovine milk include; triacylglycerols, diacylglycerols, 
monoacylglycerols, free (non-esterified) fatty acids, phospholipids and sterols 
(MacGibbon and Taylor, 2006). Mastitis is associated with increased lipolysis (Ma 
et al., 2000) and hence an increased level of free fatty acids in milk (Hunt et 
al., 2013). Increased fat content has been shown to be associated with 
mammary infections (Bruckmaier et al., 2004; Ogola et al., 2007;  Shuster et al., 
1991). Different classes of lipids were identified in this experiment.  They were 
classified as lipid metabolism compounds (14), fatty acyls (46), glycerolipids (2), 




glycerophospholipids (19), flavonoids (4), prenols (2), sphingolipids (10, with 
more decreasing) and sterol lipids (7). Except for the flavonoid and glycerolipids 
subclass which showed a clear trend A, decreasing with infection, other classes 
of lipids did not show a clear course among the metabolites, although more 
sphingolipids tended to decrease with infection. 
Chloroform-methanol sample extraction used is a standard method in lipid 
biochemistry called Folch’s method which may significantly affect the lipid 
constituents of samples (Karl Burgess, pers. comm; Prasad and Ferenci, 2003), 
therefore the overall interpretation of results of this metabolomics study is 
subjective to the effects of this extraction. It is difficult to draw a conclusion on 
the general trend of fat content during this mastitis challenge; however more of 
the lipids were reduced with time from 0 h levels than increased. 
Notwithstanding the glycerophospholipids group had a slightly higher number of 
compounds with intensity increasing as infection progressed.  
Based on the overall pattern observed for the lipid pathway, it can be suggested 
that mastitis causes a reduction in the fat content of milk, although variant 
views exist on the effect of mastitis on fat content of bovine milk (Malek dos 
Reis et al., 2013).  
Closely related to the controversy on the fat content of milk during mastitis, 
Hunt et al. (2013) observed an increase in the free fatty acid contents of milk 
from human mastitis compared to that of healthy ones, suggesting the effect of 
mastitis was only on lipolysis and not on lipid synthesis in milk. 
Lipoprotein lipase (LPL) is the major lipase in milk that is involved in milk fat 
synthesis in the mammary gland, but may be transferred into milk where it 
causes the hydrolysis of milk fat, leading to the release of free fatty acids and 
triglycerides (Deeth, 2006). It has also been suggested that high NEFA that occur 
in mastitic milk samples are a result of disruption of the milk fat biosynthesis 
pathways due to inflammatory changes and not just as a result of increased 
spontaneous lipolysis (Deeth, 2006). Bacterial lipases have also been suggested 
to play a role in the increase of FA into milk. 
Apart from fatty acyls, 46 lipid metabolites were found in the milk samples. 
Among these 6 were short-chain FA, 22 medium-chains, 15 long-chains and 3 




very-long-chains FA. In the study of Mansor, 2012, high amounts of long-chain FA 
were observed, conflicting with the reports of Kisza & Batura (1959) and 
Randolph & Erwin (1974) that long chains C:18 were only present in early 
lactation milk and not in mastitis. In the present study, long-chain FA (of C:18, 
C:19, C:20 and C:21) as well as very-long-chain FA (lengths of C:22 and C:23) 
were identified. 10 out of the 46 FA were unsaturated. Out of these, 11 showed 
a distinguishable pattern of increase with infection (by 42 h), while the 
remainder had levels that varied from slight to profound reduction with infection 
time or minor irregular fluctuations around the basal levels.  
There was not a clear trend of variation in levels, unique to the FA type (chain 
length or saturation number) with course of infection, although studies by 
Massart-Leën et al. (1994) showed a trend of the long-chain FA decreasing with 
mastitis. In the study of (Atroshi et al., 1989), both short and long chain FA were 
seen to be increased in milk during mastitis.  
Furthermore reports by Murphy et al. (1989) and Mansor (2012), suggest that 
there is an increase in milk FA during mastitis. The significance of an increase in 
fatty acids in mastitis milk could be beneficial to the immunity of the host since 
fatty acids have an established role as precursors to eicosanoids that have 
significant roles in inflammatory response, thus it would be expected that their 
levels increase as infection progresses (Atroshi et al., 1989; Mansor, 2012).  
Sources of increased FA during mastitis could be through the action of bile salts 
lipases as well as lipoprotein lipases (LPL) which are released from blood into 
milk (Jensen and Pitas, 1976). Fatty acyls are broken down to FAs and this can 
be reflected as increased FA in milk during infection. FA are also rapidly 
mobilized from tissues during episodes of negative energy balance (NEB) and the 
increase of non-esterified fatty acids (NEFA) in blood in late term has been 
associated with a greater incidence of developing mastitis at the periparturient 
period (Moyes et al., 2009b). It has also been suggested that FA increase during 
inflammation as a result of lipid peroxidation by free radicals which are released 
to kill bacteria (Atroshi et al., 1989). 
Three metabolites in the general lipid metabolism pathway were found to be 
totally absent at the 0 h, but appear and increase greatly in intensity as the 




infection peaked, these were; Taurodeoxycholate (two isomers; 
Tauroursodeoxycholic acid and a sterol lipid N-(3alpha,7alpha-dihydroxy-5beta-
cholan-24-oyl)-taurine) which plays a role in bile acid biosynthesis, the fatty acid 
; O-Palmitoyl-R-carnitine and a phosphoethanolamine [PE (18:1/18:1)] 1-(1Z-
octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine. All these 
complied with a trend C. While Taurodeoxycholate peaked at 57 h, the 
remaining two compounds did so at 81 h. Phosphoethanolamine (18:1/18:1); 1-
(1Z-octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine was 
the most significantly increased newly appearing lipid metabolite at time (81 h) 
a glycerophospholipid involved in the glycerophospho-ethanolamine pathway, 
detected in negative ionisation mode. 
This increase in the intermediates of bile acid biosynthesis is consistent with the 
expectation of the increase in the activity of bile salts leading to increases in 
lipolysis, as the presence of the bile salts is needed to activate the lipases (Wang 
et al., 1999). Although it has been established that bile salt activated lipases are 
present in human milk as well as milk from a number of other mammals (Wang 
et al., 1999), it has not been shown to be secreted into the colostrum and early 
post-partum milk of cows. Also taurine, which was present at 0 h, increased 
significantly with infection and peaked at 57 h.  
At all the time points evaluated, the most significantly reduced compound in the 
lipid pathway was choline phosphate, its greatest reduction occurred at 81 h. It 
also showed a trend A, restoring back to normal by 312 h.  
N-Heptanoylhomoserine lactone a fatty amine is another metabolite displaying 
this trend although its biological importance in milk during mastitis is not 
ascertained. What is known about it is that it can be produced by a bacterium 
Erwinia psidii and other gram negative endobacteria for bacterial cell-to-cell 
communication commonly referred to as quorum sensing (Kai et al., 2012). The 
earliest (36 h) most significant changes in lipid metabolism occurred with [FA 
hydroxy (10:0)] N-(3S-hydroxydecanoyl)-L-serine-N-(3-Oxooctanoyl) homoserine 
lactone another compound which changed significantly early in the infection also 
followed a similar trend as the homoserine lactone above. This compound is also 
found in bacteria (A. tumefaciens), where it acts as a transcription promoter 
(Cayman Chemical, 2012). Phospholipids, regardless of the class, generally 




showed a trend of decreasing with infection as would be expected since they are 
constituents of membranes which are destroyed during mastitis and acted upon 
by phospholipases and carboxylesterases. Sn-glycero-3-Phosphocholine, the lipid 
metabolite with the highest intensity, showed a decreasing trend with infection 
and rises almost back to control level at infection resolved. Hexadecanoic acid, 
the next highest intensity on the other hand showed a trend of increasing, 
peaking at 57 h and dropping to similar levels of 0 h by 312 h. In the study of 
Klein et al. (2012), the ratio of glycerophosphocholine to phosphocholine in the 
first few weeks of lactation was suggested to be indicative of metabolic status, 
while high glycerophosphocholine was said to be indicative of healthy animals at 
mid lactation. The cows used in this challenge study were mid-lactation cows 
and from the metabolomics experiment, glycerol- phosphocholine was found to 
have very high intensity at control (healthy) time. It decreased with progress of 
infection, and by resolution time, it had risen back almost to levels recorded at 
0 h. This observation supports the finding that high glycerophosphocholine levels 
may be indicative of healthy animals. 
In this study phosphocholine (identified as choline phosphate) was seen 
decreasing (by the most fold change) with mastitis and becoming totally absent 
at 57 h and 81 h, then showing reappearance of minimal relative amounts at 
312h. Free choline itself, which is a precursor of most of the membrane 
phospholipids highlighted above, was observed with high levels at controls but 
reduced very significantly with infection, in the present study. It has previously 
been demonstrated that choline levels are fairly constant in milk throughout 
lactation (Zeisel et al., 1986). 
On the other hand, a greater number of all (glycerol) phospholipids (PL) 
metabolites showed a tendency of decreasing with infection. This is an expected 
finding as damage to the cell membrane of mammary cells as well as milk fat 
globule membrane (MFGM) would cause a release of membrane structural 
constituents, chiefly phospholipids into milk during inflammation. Also the 
activity of phospholipases have been shown to increase during mastitis (Fitz-
Gerald et al., 1981) however these findings did not agree with observations of 
Hunt et al. (2013), of no change in PL levels in mastitis as compared to non-
mastitic human mammary glands. 




In this study, eicosanoic acid (C: 20) was identified and observed to increase 
with infection, and this is the precursor of the eicosanoids that include 
thromboxanes (TXA), prostacyclins (PGI), prostaglandins (PG), leukotrienes (LT) 
and lipoxins (LX) which play role in signalling of inflammatory mediators, and 
may have arisen as a result of the increase in the activity of phospholipases that 
release arachidonic acids from acylglycerols. The increase in Eicosanoids in 
mastitis is generally accepted and regulation of this increase by Selenium has 
been demonstrated (Maddox et al., 1991) 
Leukotriene B4 (LTB4) was identified in the KEGG map under the arachidonic 
acid pathway with a formula of C20H32O5. This is similar to the chemical 
formula of many other metabolites under the eicosanoid group. The metabolites 
were identified with 48 different isomers all of which fall under the class of 
eicosanoids. These compounds had a trend of increasing in intensity from control 
levels as infection progressed (Trend B). The specific role of LTB4 in 
inflammation is the recruitment of leucocytes to sites of inflammation (Maddox 
et al., 1991) and has been attributed the most potent endogenous 
chemoattractant (Bannerman, 2009). It also plays a significant role in activation 
and degranulation of PMN cells. The increased concentration of LTB4 is thus in 
accordance with the need for the influx into the mammary gland of PMN cells, 
where they are classified as somatic cells for the SCC, in order to kill invading 
bacteria during mastitis. In a closely related observation, metabolites of linoleic 
acid metabolism were increased during the peak periods of infection although 
not significantly, in this study. 
From the studies of Sundekilde et al. (2013), other major metabolites that had 
significant correlations with high SCC included, lactate, acetate, butyrate, β-
hydroxybutyric acid (BHBA) and isoleucine. In the present study D-2-
hydroxybutyrate was the closest compound in chemical formula to BHBA that 
was identified and it showed an increasing trend that was significant at 57 h 
(P<0.01) and 81 h (P<0.05). (s)-2-aminobutanoate (α-aminobutyric acid) showed 
a significant increase with infection with peak significant level at 57 h, and 
dropping back to normal at 312 h. Breed has been shown to be a possible cause 
of variation in its levels in milk (Klein et al., 2012).  




25.2.3.4   Nucleotide metabolism 
Most of the nucleotide metabolites detected in this study showed trend A. Only 3 
compounds that were not present in normal (control) samples appeared 
following infection, 7-Methyladenine, guanosine and inosine, reaching maximum 
levels at 42 h, 57 h and 57 h respectively. 7-Methyladenine is involved in the 
base excision repair pathway and its increase during mastitis may be related to 
the destruction of cellular and nuclear membranes with the release of 
intracellular and nuclear contents.  
Uracil-5-carboxylate (orotate) was the nucleotide metabolite with the highest 
peak intensity and it showed a trend A (decrease with infection progress with 
lowest point at 81 h, and rising at 312 h). The presence of orotate in bovine milk 
at levels of 30-70 µg/ml has been previously reported (Indyk and Woollard, 
2004), although it is absent in non-ruminant milk. In the study of Melzer et al. 
(2013), uracil, a related compound to orotate, was found to be highly correlated 
to the milk trait, SCC, the major indicator of mastitis in milk. In the present 
study, however, uracil was not identified as such, only the carboxylated form 
(orotate) was detected.  
A closely related compound to uracil, cytosine changed the most of all 
nucleotides and was seen to follow a typical trend A also, with a lowest intensity 
at 57 h and was very significantly different from control levels at all time points 
except 312 h. It also showed the greatest change earliest in this metabolic 
pathway. Nucleotides are normal constituents of milk (Schlimme et al., 2000). 
Bovine milk typically has less nucleotides  than that found in human milk hence 
the hence the practice of supplementing calf-infant formula with nucleotides 
and nucleosides (Gill et al., 2010; Ren et al., 2011). Therefore it can be said 
that mastitis further disrupts the nutritional value of bovine milk by causing a 
depletion of the major nucleotides.  
Urate, a breakdown product of purine metabolism also involved in microbial 
metabolism and bile secretion was found showing a trend A during the challenge. 




25.2.3.5 Vitamins and co-factors 
Vitamins and co-factors play a very crucial role in mammalian metabolism. 
Nicotinamide followed close to a trend A, but still remained very low at 312 h 
compared to 0 h. The implication of this is that its response to resolution is not 
rapid enough for it to be a good marker of infection resolution. The decrease in 
nicotinamide levels in milk as the infection advanced may be due to the 
conversion of nicotinamide to nicotinic acid by activities of enzyme 
nicotinamidase. This enzyme is present in many bacteria including Streptococcus 
species and is a major regulator of intracellular nicotinamide concentrations in 
prokaryotic organisms (French et al., 2010). Nicotinamide is a precursor to 
nicotinamide adenine dinucleotide (NAD+) and its phosphorylated and reduced 
forms (NADP and NADH) which are central to energy production metabolic 
pathways.  
Dethiobiotin, a high intensity metabolite, showed a trend B and peaked at 57 h, 
although increases were mostly not statistically significant. It is an intermediate 
in biotin metabolism, detected in the positive ionisation mode. Its increase 
during infection may relate to proteolysis of biotin synthetase which catalyses 
the conversion of dethiobiotin to biotin, resulting from bacterial damage to 
mammary gland cells and the action of neutrophilic proteases.  
Pyridoxal, nicotinamide, 3-Hydroxy-2-methylpyridine-4,5-dicarboxylate and then 
thiamine were the most significantly changed (fold decrease) vitamin related 
metabolites after time 0 at 81 h. Thiamine is a water soluble vitamin obtained 
from grains and other plant sources of feed and involved in the catabolism of 
sugars and amino acids as well as the biosynthesis of neurotransmitters 
acetylcholine and gamma amino butyric acid (GABA). 
Thiamine is normally secreted into milk as a means of excretion of excess 
quantities obtained from the cows’ diet, explaining its high intensity in healthy 
milk samples; it is also found in high concentration in colostrum (Echols et al., 
1986; Kehoe et al., 2007). The decreasing quantities observed during the peak of 
infection in this analysis, may be due to the presence of thiaminase factors 
associated with bacterial causing mastitis. The implication of this is that milk 
samples from mastitic udders are less able to supply nutritional thiamine. Rumen 




bacteria have been suggested to be able to produce thiaminase factors that 
could affect the effects of dietary supplementation with thiamine on milk 
production (Shaver and Bal, 2000). 1-Methylpyrrolinium was the only 
significantly up regulated metabolite belonging to this pathway and the most 
fold increase occurred at 57 h. The majority of metabolites in the vitamin and co 
factors pathway displayed an overall D trend, fluctuating irregularly between 
control and resolution time, but with more tendency towards a trend A, implying 
that the vitamin nutritional composition of milk during mastitis is profoundly 
compromised (by their reduced presence in milk). 
25.2.3.6 Minor pathways 
Puromycin, Dihydroclavaminic acid and Taxa-4(20),11(12)-dien-5alpha-yl acetate 
were the only metabolites of biosynthesis of secondary metabolites that 
increased with time of infection peaking at 81 h (trend B) and dropping 
significantly by 312 h. Overall, in the category of all other metabolites, 
puromycin was the most increased in folds. 
Furcatin was one of the metabolites that decreased significantly at 57 h, 
following a trend A and had the greatest level of significance in difference. 
Alpha-D-Galactosyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosamine and 3-
Dehydrocarnitine were the two most significantly up-regulated metabolites in 
terms of fold increase, both highest at 81 h. Phthalate was the only metabolite 
of xenobiotic degradation that was identified changing across time points. It is 
involved in Toluene degradation pathway. 
25.3 Conclusion 
In this chapter, the potentials of analysis of the milk metabolome as it changes 
during an experimental S. uberis mastitis challenge is investigated with the aim 
of recognizing new biomarker candidates for bovine mastitis and for 
understanding mastitis induced metabolic change. Numerous compounds were 
found to vary in milk in the presence of and during different time points of 
infection. While confirming previous reports on possible markers of mastitis such 
as lactose, lactate and hydroybutyrate, new metabolites showing a high 
correlation in trend with mastitis course and having high intensity such as 




betaine, L-carnitine, sn-glycerophosphocholine and choline were identified and 
are suggested for further scrutiny and validation in relation to mastitis diagnosis. 
Others such as 7-methlyadenine and tauroxycholate, compounds otherwise not 
detected in normal milk, also project a possible potential (as newly appearing 
compounds) that could be used to detect and monitor the course of mastitis. 
In addition, small peptides such as Leu-Ala-Gln, Ala-His and Ala-Leu-Ser-Ser may 
also be useful in understanding the proteolytic changes in milk during mastitis 
and show promise in being able to distinguish S. uberis mastitis from mastitis 
caused by other pathogens, thus such small peptides may be explored for ability 
to differentiate various causative organisms.  
 




26 General Discussion 
26.1 Milk acute phase proteins in the diagnosis of bovine 
mastitis 
A major setback in the management of mastitis in dairy herds is the lack of 
adequate and sensitive measure(s) of the presence of mastitis in milk, which can 
be tested by a rapid on-farm format discussed previously (Chapter 1). Somatic 
cell counts remain the most widely used parameter for predicting the mastitis 
status of cows in dairy farms globally. However, pertinent problems continue to 
arise with the use of this measure and others such as the enzymes NAGase, LDH 
and electrical conductivity for diagnosis and monitoring of mastitis. The 
economic impact of bovine mastitis is growing, and with new technological 
innovations in dairy management, an added challenge is posed to the prompt 
recognition of IMIs by the increasingly popular use of automatic milking systems 
in dairy farming. There is a growing need for more sensitive and reliable markers 
of mastitis. 
Since the first reports of the detection of the major bovine APP in milk over a 
decade ago (Eckersall et al., 2001), a number of studies have come up to 
determine the potential for use of these APP for mastitis detection, not just as a 
laboratory measure, but also to have a on farm rapid format application. In the 
studies carried out in this PhD research, the usefulness of two major bovine APP 
(Hp and M-SAA3) and one other APP hitherto considered minor in bovines (CRP) 
was assessed in relation to diagnosing mastitis. Several types of samples ranging 
from quarter and composite milk from a herd of newly calved cows, natural 
infections of mastitis from several dairy farms and from experimental mastitis 
challenge on otherwise healthy udders were used in the assessment of these 
APP.  
First, the development of an assay to measure APP was instigated and resulted 
in the successful development of an ELISA for measuring milk Hp. Several 
attempts were made to develop an ELISA for M-SAA3, these were however not 
successful, so a commercial kit was used for its measurement.  




In order to further validate the Hp assay and determine the reference range of 
these APP in milk in a field condition, the profile of Hp, M-SAA3 and CRP in 
healthy and mastitis milk in relation to the SCC and in the periparturient period 
milk samples were explored in a dairy herd. The Cochno farm dairy herd 
(University of Glasgow) was used for this study. It was not however possible to 
obtain reference values for M-SAA3 due to many of the samples having 
undetectable amounts of M-SAA3 even at low dilutions (1:50) using the 
commercial assay available. 
In addition, sets of samples submitted to a veterinary diagnostic laboratory for 
mastitis diagnosis, from several farms across Scotland and from an experimental 
model of mastitis were examined for APP. The results of these studies indicated 
that these APP in milk can reliably be used to discriminate healthy from clinical 
mastitis milk samples and subclinical mastitis from healthy. However some level 
of variability was observed between the three APP in bovine milk in relation to 
IMI, with Hp proving more specific to indicate mastitis from a wider variety of 
pathogens than M-SAA3. However, M-SAA3 showed higher response to a 
mammary inflammation (reaching a higher peak with peak of infection) during 
an experimental model mastitis study. Also it was observed that CRP tended to 
rise earlier than other APP during the course of the experimental mastitis, 
signifying a possible higher sensitivity of CRP than Hp and M-SAA3. This 
observation requires further validation using different models of mastitis and 
pathogens. It was also determined that Hp correlated more to SCC than M-SAA3 
and CRP in samples of both healthy and mastitis milk, this presumably due to 
their (Hp and SCC) common source of origin in the neutrophils/somatic cells 
(Hiss et al., 2004; Lai et al., 2009). 
Bovine CRP has been known as a minor APP due to its characteristics in serum of 
having very minimal variation in response to inflammation or infections 
(Eckersall and Conner, 1988), although, a few reports have pointed to a possible 
usefulness of CRP for mastitis recognition (Schrodl et al., 1995; Kruger and 
Neumann, 1999 and Lee et al., 2003).  In this thesis, it was found that CRP 
concentration in milk varied considerably with presence of mastitis and even 
began to rise slightly earlier than the two major APP during the course of an 
experimental infection. Further studies are required to ascertain the origin and 




detailed dynamics of CRP in bovine milk and the mammary gland under 
physiological and pathological conditions. 
All three APP proved sensitive enough to indicate the presence of mammary 
infection but showed variable levels with SCC lower than 200,000 cells/ml and 
with some minor or mild mastitis causing pathogens such as CNS.  
In further studies the properties of Hp including its localization in the bovine 
mammary gland was examined. Since no functional antibody for M-SAA3 was 
available for IHC or western blotting, similar studies were not possible for M-
SAA3. However, results of the Hp characterization studies confirm that Hp is 
synthesized in neutrophils and MEC and possibly undergoes PTMs that gives Hp a 
range of pi. 
From the findings in these studies, it is  recommended that these APP should be 
assayed or assessed together to complement each other in making a diagnosis or 
prognosis for mastitis, as host response or pathogen virulence factors have the 
ability to alter trends in any specific APP response under different disease 
models. Reference values for Hp in milk using SCC cut off value of 200,000 
cells/ml was established using the Hp profile of composite milk samples of a 
dairy herd (Chapter 2) and it was possible to use this reference cut off of Hp 
concentration to determine the acute phase response level/stage in the 
immediate post calving milk (Chapter 3), in natural mastitis milk samples 
(Chapter 4) and samples from an experimental mastitis challenge (Chapter 5). 
The results presented in this thesis have lent further credence to the potential 
usefulness of Hp and M-SAA3 in bovine mastitis diagnosis. It can be concluded 
that these APP have the specificity, sensitivity and precision to be used for 
diagnosis of bovine mastitis in milk, either alone or in combination with other 
traditional indicators of mastitis in milk.  
26.2 Milk proteomics in the diagnosis of bovine mastitis  
Proteomics has developed as a promising tool for the identification of disease 
biomarkers in recent years, thanks to advances in mass spectrometry and 
bioinformatics (reviewed in Chapter 1 and Chapter of 5). This necessitated the 
use of the proteomics platform in order to explore potential biomarkers of 




mastitis in both natural and experimental models of the disease. Whilst gel 
based proteomics approaches (1DE, 2DE and DiGE) offered insight into 
quantitative variation of mostly high abundance proteins present in healthy and 
mastitis milk and also gave fractionation advantage to milk proteomics, 
characterization of mastitis discriminatory proteins was only possible using mass 
spectrometry. 
Other fractionation methods employed in the study of milk proteins included a 
non-gel liquid phase isoelectric focusing which yielded a protein separation with 
an advantage of better resolution of lower molecular weight proteins away from 
the isoelectric point of the higher abundance milk proteins (Chapter 4). Overall, 
a few of the important proteins that became highlighted as potential biomarkers 
of mastitis from the proteomics studies of milk in this research included serpins, 
serotransferrin, NGAL, apolipoproteins and complement C3.  Most of these 
proteins have already been identified in previous milk proteomic studies and 
would require further validation studies before becoming useful in detecting 
mastitis.  
Going further into an area commonly considered a sub-field of proteomics, 
peptidomic analysis on bovine milk was able to offer more insight into the 
common proteolytic changes that occurs in milk, specifically during a S. uberis 
mastitis challenge model. Being an experimental model of mastitis, an added 
advantage of time point based changes in the milk peptidome was gained. 
Noteworthy peptidomic findings included the identification of 77 polypeptides 
which significantly (P=0.01) differentiated pre-infection samples from infected 
ones. Hence they represent a panel of peptides that can be considered as 
biomarkers of mastitis. Three to four of these polypeptides showed a possibility 
to be general polypeptide markers of mastitis, having been identified in previous 
peptidomic studies of milk from mastitis of different pathogen origin. It is 
possible that in the not too far distant future, the cost of MS could come down 
and mastitis diagnosis could use this technology on a routine basis especially if 
differing pathogen infection causes different patterns of peptides. 




26.3 Milk metabolomics in the diagnosis of bovine 
mastitis  
Metabolomics aims to quantitatively and qualitatively identify all small 
metabolites within a given biological sample. This was the aim in the study of 
milk metabolomics during the course of an S. uberis mastitis which was 
investigated in this research. As would be expected, a lot of significant 
differences in metabolite profiles were observed across the different time points 
of the mastitis challenge. More prominent changes were seen in the small 
peptides (up to four amino acid residues), carbohydrate, vitamins and co-factor 
metabolites composition across infection times. Numerous metabolites with 
unassigned metabolic pathways also showed wide deviations at the peak of 
mastitis, from pre-infection and resolution phase. 
Numerous compounds were found to vary in milk in the presence of and during 
different time points of infection. While confirming previous reports on possible 
markers of mastitis such as lactose, lactate and hydroxybutyrate, new 
metabolites showed a high correlation with the course of mastitis and had high 
intensity. Thus betaine, L-carnitine, sn-glycerophosphocholine and choline were 
identified and are suggested for further scrutiny and validation in relation to 
mastitis diagnosis. Others such as 7-methlyadenine and tauroxycholate, which 
are compounds otherwise not detected in normal milk, also point to possible 
markers (as newly appearing compounds) that could be used to detect and 
monitor the course of mastitis. In addition, small peptides such as Leu-Ala-Gln, 
Ala-His and Ala-Leu-Ser-Ser may also be useful in understanding the proteolytic 
changes in milk during mastitis and show promise in being able to distinguish S. 
uberis mastitis from mastitis caused by other pathogens, thus such small 
peptides may be explored for ability to differentiate various causative 
organisms.  
26.4 General conclusions and future direction 
In this thesis, biomarker candidates for bovine mastitis in milk have been 
explored using the tools of immunoassays of acute phase proteins, proteomics, 
and metabolomics. The findings from this research form a platform from which 
future studies for potential biomarkers of bovine mastitis can be launched.  




The use of APP as mastitis biomarkers would require their adaptation to rapid 
measurement formats. Other identified proteins, peptides and small metabolites 
need to be further experimentally and clinically validated as specific and 
sensitive markers of mastitis and would also require measurement (on farm) in 






Appendix Chapter 2  
 
Table 1: M-SAA3 concentrations in two QC samples in 5 different assays.  
This was used to determine the inter assay precision of the SAA ELISA; Mean % CV=33 % 
                                                M-SAA3 (µg/ml) 




 2 625.00 5.40 
3 1122.00 6.20 
4 1072.50 8.76 




SD 222.50 4.18 
CV 0.22 0.46 
 
  
Table 2: CRP ELISA repeats of two quality control samples in 5 different assays. 
This was used to determine the inter-assay precision (CV) to be 7 %. 
Test Low QC High QC 
Plate 1 1.90 6.80 
Plate 2 2.00 8.50 
Plate 3 2.18 8.66 
Plate 4 2.04 8.33 
Plate 5 2.20 7.13 
Mean 2.06 7.88 
SD 0.11 0.76 
CV 0.05 0.09 
 






Appendix Chapter 3 
 
Day 1-10 post calving milk 1DE MS analysis results (Henderson, 2013, MRes. 
Dissertation, University of Glasgow) 
 
 
Figure 1: 1-D SDS PAGE Coomasie stained gel of bovine colostrum and milk for Cow 1, day 
1-10. 
Adapted from Henderson C.L (2013). University of Glasgow  MRes Infection and Immunobiology 
Project (Title; Proteomics investigation of bovine colostrum for molecules of innate immunity). 
Letters running horizontally across the top indicate the day number (Day 1 to Day 10), and letters 






Table 3: Proteins found in bovine colostrum and milk in both healthy and unhealthy cows, 
with corresponding letters to those of Figures 1.  Expected Molecular Weights (MW) are 
taken from Malcata, 2007.  Observed MWs are measured from 1-D SDS PAGE gels.  
LC=Light Chain, HC = Heavy Chain. 
Adapted from Henderson C.L (2013). University of Glasgow MRes Infection and Immunobiology 
Project (Title; Proteomics investigation of bovine colostrum for molecules of innate immunity). 
Band ID 
letter 
Expected MW (kDa) Observed MW 
(kDa) 
Protein Name Column1 
a 25 (each LC) + 50-70 (each 
HC)  
130.0-150.0 Immunoglobulins (A, M and 
G) b 25 (each LC) + 50-70 (each 
HC) 
82 Immunoglobulins (A, M and 
G) c 80 78.0-80.0 Lactoferrin  
d 66.2 70.0 - 72.0 Bovine Serum Albumin 
e 25 (each LC) + 50-70 (each 
HC) 
55.0 - 57.0 Immunoglobulin (G) 
f 22.1 (α-s1) – 25.2 (α-s2) 35.0 - 37.0 Alpha-casein  
g 24 33.0 - 36.0 Beta-casein  
h 19 29.0 - 34.0 Kappa-casein  
i 25 (each LC) + 50-70 (each 
HC) 
25.0 -27.0 Immunoglobulins (G) 
j 25 (each LC) + 50-70 (each 
HC) 
20.0 - 22.0 Immunoglobulins (A, M and 
G) k 18.2 18 Beta-lactoglobulin 




Figure 2: 2 dimensional electrophoresis gel for Day 1 (colostrum) sample.   
Protein spots chosen for LC-MS/MS are circled and numbered, with numbers corresponding to 
Table 4. Adapted from Henderson C.L (2013). University of Glasgow MRes Infection and 








Table 4: LC-MS/MS results for Day 1 bovine colostrum protein spots 2DE gel, with spot number corresponding to Figure 2.  
Spot number, protein name from Mascot database, Mass, isoelectric point (pi), score, sequence (Sqnce), protein sequence coverage (PSC) and emPAT are listed. 
Adapted from Henderson C.L (2013). University of Glasgow MRes Infection and Immunobiology Project (Title; Proteomics investigation of bovine colostrum for 
molecules of innate immunity). 
 
 
Spot Protein Name Mass pI Score Sqnce PSC emPAT 
1 Alpha-lactalbumin  14603 4.8 580 11(11) 0.6 41.91 
 Chain A, 12-Bromododecanoic Acid 
that Binds Inside The Calyx Of Bovine 
Beta-Lactoglobulin 
18641 4.76 371 13(5) - 6.35 
2 Immunoglobulin heavy chain 
precursor 
51391 6.1 643 12(9) 0.24 1.39 
 Alpha-S1-casein precursor  24570 4.98 229 8(5) 0.39 2.16 
 Immunogl bulin gamma-2 chain C 
region  
36590 8.04 191 10(2) 0.33 1 
 Alpha-1-antiproteinase precursor  46417 6.05 190 9(4) 0.19 0.51 
3 Alpha-S1-casein precursor  24570 4.98 124 8(4) - 0.89 
 Immunoglobulin lambda locus 24910 5.84 116 5(4) 0.22 0.88 
 Immunoglobulin light chain, lambda 
gene cluster  
24863 7.53 103 4(3) 0.2 0.66 
4 Immunoglobulin heavy chain 
precursor  
51391 6.1 631 14(9) 0.34 1.54 
 Alpha-S1-casein precursor  24570 4.98 182 8(4) - 1.45 
 Glycoprotein antigen MGP57/53, 
bovine mammary gland 
45704 7.1 140 5(3) 0.13 0.32 
5 Immunoglobulin lambda light chain  25032 5.84 2020 9(7) 0.31 2.49 
 Unknown (protein for MGC:159378)  25059  7.52 1999 13(9) 0.53 4.08 
 Immunoglobulin light chain, lambda 
gene cluster  
24863 7.53 1986 11(8) 0.46 3 
6 Chain A, Bovine Beta-Lactoglobulin, 
Lattice X 
18583 4.83 180 7(5) 0.38 3.5 
 Beta-lactoglobulin 18641 4.76 168 7(5) 0.38 3.46 
7 Chain A, 12-Bromododecanoic Acid 
that Binds Inside The Calyx Of Bovine 
Beta-Lactoglobulin 
18641 4.76 501  14(8) - 9.24 
 Chain A, Bovine Beta-Lactoglobulin, 
Lattice X 
18583 4.83 501 13(8) 0.64 7.78 
 Beta-lactoglobulin  18641  4.76 457 14(8) 0.64 9.24 
8 Chain A, 12-Bromododecanoic Acid 
that Binds Inside The Calyx Of Bovine 
Beta-Lactoglobulin 
18641 4.76 485 13(9) - 7.67 
 Beta-lactoglobulin 18641 4.76 470 13(9) 0.61 7.67 
9 Chain A, Bovine Beta-Lactoglobulin, 
Lattice X 





Spot Protein Name Mass pI Score Sqnce PSC emPAT 
 Beta-lactoglobulin 18641 4.76 265 11(5) 0.54 3.46 
10 Chain A, 12-Bromododecanoic Acid 
that Binds Inside The Calyx Of Bovine 
Beta-Lactoglobulin 
18641 4.76 772 16(10) - 18.91 
 Chain A, Bovine Beta-Lactoglobulin, 
Lattice X 
18583 4.83 757 16(9) 0.69 13.5 
 Chain A, Structural And Functional 
Consequences Of Point Mutations Of 
Variants A And B Of Bovine Beta-
Lactoglobulin 
18555 4.83 742 16(8) - 13.5 
        
11 Chain A, Crystal Structure Of Bovine 
Beta2-Microglobulin 
11742 7.96 969 9(7) 0.42 9.05 
 Ant -te tosterone antibody  24786 7.53 501 6(3) 0.31 0.88 
 Immunoglobulin lambda locus 24910 5.84 487 7(3) 0.33 1.13 
12 Immunoglobulin light chain, lambda 
gene cluster  
 24863  7.53 1117 10(6) 0.36 2.11 
 Immunoglobulin lambda light chain 11464 8.49 1104 8(5) 0.51 7.22 








Figure 3: 2 DE reducing gel for bovine milk from Day 10.   
Protein spots chosen for LC-MS/MS are circled and numbered, with numbers corresponding to 
Table 5. Adapted from Henderson C.L (2013). University of Glasgow MRes Infection and 







Table 5: LC-MS/MS results for Day 10 bovine milk protein spots from a 2DE gel, with spot 
number corresponding to Figure 3. 
Spot number, protein name from Mascot database, Mass, isoelectric point (pI), score, sequence 
(Sqnce), protein sequence coverage (PSC) and emPAT are listed. Adapted from Henderson C.L 
(2013). University of Glasgow MRes Infection and Immunobiology Project (Title; Proteomics 
investigation of bovine colostrum for molecules of innate immunity). 
 
Spot Protein Name Mass pI Score Sqnce PSC emPAT 
13 Alpha lactalbumin  14603 4.8 1019 12(10) 0.62 51.88 
 Chain A, Bovine Beta-Lactoglobulin, Lattice X 18583 4.83 348 10(6) 0.46 5.29 
 Beta-lactoglobulin 18641 4.76 346 10(5) 0.46 4.27 
14 Chain A, Bovine Beta-Lactoglobulin, Lattice X 18583 4.83 233 7(4) 0.42 2.81 
 Beta-lactoglobulin 18641 4.76 207 7(4) 0.42 2.78 
 Alpha-S1 casein 24477 4.85 189 4(2) 0.18 0.29 
15 Chain A, Bovine Beta-Lactoglobulin, Lattice X 18583 4.83 464 12(8) 0.6 5.29 
 Beta-lactoglobulin 18641  4.76 452 12(8) 0.6 5.22 
 Alpha S1 casein  22442 4.71 449 9(4) 0.45 3.63 
16 Kappa-casein precursor  21326 6.82 933  7(6) 0.34 6.75 
17 Chain A, 12-Bromododecanoic Acid Binds Inside The Calyx Of Bovine Beta-
Lactoglobulin 
18641 4.76 2783 15(13) - 37.7 
 Chain A, Structural And Functional Consequences Of Point Mutations Of 
Variants A And B Of Bovine Beta-Lactoglobulin 
18555 4.83 2773 14(13) - 32.44 
18 Chain A, 12-Bromododecanoic Acid Binds Inside The Calyx Of Bovine Beta-
Lactoglobulin 
18641 4.76 2943  15(13) - 26.76 
 Chain A, Bovine Beta-Lactoglobulin, Lattice X 18583 4.83 2869 14(11) 0.78 22.94 
19 Chain A, Bovine Beta-Lactoglobulin, Lattice X 18583 4.83 442 12(9) 0.58 7.78 
 Beta-lactoglobulin 18641 4.76 386 12(9) 0.58 7.67 
20 Kappa-casein precursor  21326 6.82 1743 8(7) 0.34 9.38 
 Kappa-casein precursor  10620 5.16 1323 4(4) 0.42 28.13 
 Kappa-casein 12393 8.92 701 7(5) 0.55 6.02 
21 Serum albumin precursor  71274 5.82 2253  64(42) 0.85 16.07 
 Albumin 68083 5.76 2073 60(38) 0.81 14.4 
22 Chain A, Bovine Beta-Lactoglobulin, Lattice X 18583 4.83 125 9(3) 0.58 1.73 
 Beta-lactoglobulin 18641 4.76 114 9(3) 0.58 1.71 
23 Beta-casein 25148 5.26 136 7(3) 0.21 0.86 
24 Immunoglobulin light chain, lambda gene cluster  24863 7.53 486 8(4) 0.33 1.42 
 Immunoglobulin lambda light chain  25032 5.84 470 9(3) 0.39 1.72 
 Immunoglobulin lambda light chain constant region 3  11464 8.49 414 7(4) 0.61 5.32 
 Anti-testosterone antibody  24786 7.53 386 8(3) 0.34 1.43 
 Immunoglobulin lambda locus 24910 5.84 384 9(4) 0.36 1.74 
25 Chain A, Crystal Structure Of Bovine Beta2-Microglobulin 11742 7.96 482 9(6) 0.42 6.78 







Appendix Chapter 4 
 
1) Bradford Assay:  
a) Bradford reagent; Brilliant blue G, phosphoric acid and methanol 
 
b) Protein standard; Bovine serum albumin at 2 mg/ml (Sigma-Aldrich, 
Dorset, UK), double diluted from 2 mg/ml to 1 mg/ml, 0.5 mg/ml, 0.25 
mg/ml and 0.125 mg/ml to make standards. 
 
c) Assay Procedure: Milk samples were diluted to 1:20 or 1:40 in milli Q 
water. 5 µl of diluted samples  and standards were added in duplicates 
into wells of a Costar™ 96-well ELISA plate (Fisher scientific, UK) and 250 
µl of Bradford reagent added per well. The mixture was left to stand for 
few minutes at RT after which absorbance were read at 595 nm using a 
FLUOstar Optima plate reader. A linear regression standard curve was 
plotted from value of standards and concentrations of proteins in each 
well were interpolated from the curve. 
 
2) 1DE 
a) Laemmli Buffer (2x); was made up  of 65.8 mM Tris-HCl, pH 6.8, 2.1 % 
SDS, 26.3 % (w/v) glycerol, 0.01 % bromophenol blue  (Bio-Rad, Hemel 
Hempstead, UK). 2x Sample buffer was prepared by addition of 50 µl of β-
mercaptoethanol (BME) to 950 µl of 2x Laemmli buffer. Pre-diluted 
protein samples were further diluted 1:1 in sample buffer and heated at 








Figure 4: 1D gel electrophoresis of a subclinical mastitic and a healthy milk sample. 
Showing all the proteins identified by the MS based on the Mascot database 
Adapted from Mansor, R (2012), University of Glasgow PhD thesis (Titled; Proteomic and 
Metabolomic Studies on Milk during Bovine Mastitis) 
 
Appendix Chapter 5 
 
1. DiGE and 2DE 
a) Lysis buffer; made up of 6 M urea, 2 M thiourea 4 % CHAPS and 25 mM Tris 
base. 
a) DiGE lysis buffer; 7 M urea, 2 M Thiourea, 4 % CHAPS, 25 mM Tris HCl 
b) Equilibration buffer I; pH8.8, 1.5M Tris HCl, 216.21 g urea ,180 ml glycerol 
12 g SDS  and 100 mg DTT 
c) Equilibration buffer II; pH8.8, 1.5 M Tris HCl, 216.21 g urea, 180 ml 
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